The Psychopharmacology of Novel Synthetic Cannabinoids by Kevin, Richard Charles
    
 
 
The Psychopharmacology of Novel 
Synthetic Cannabinoids 
 
 
Richard C. Kevin 
A thesis submitted in fulfilment of the requirements for the degree of  
Doctor of Philosophy 
 
 
 
 
School of Psychology 
Faculty of Science 
The University of Sydney 
2017 
 
 
 
 
Table of contents 
 
Acknowledgements .............................................................................................................V 
List of figures ..................................................................................................................... VI 
List of tables ...................................................................................................................... IX 
Statement of originality ...................................................................................................... X 
Authorship attribution statement .................................................................................... XI 
Publications ...................................................................................................................... XII 
Additional publications .................................................................................................. XIII 
List of abbreviations........................................................................................................ XIV 
Thesis abstract .............................................................................................................. XVII 
Chapter 1. General introduction and literature review ...................................................... 1 
1.1 Preface ......................................................................................................................... 2 
1.2 A brief history of Cannabis sativa and cannabinoid pharmacology ........................ 5 
1.2.1 The discovery and classification of cannabinoids............................................... 5 
1.2.2 The endocannabinoid system ............................................................................. 7 
1.2.3 ∆9-tetrahydrocannabinol, the prototypical CB1 receptor agonist ................... 10 
1.2.4 Interactions between ∆9-tetrahydrocannabinol and cannabidiol ................... 15 
1.2.5 Interactions between ∆9-tetrahydrocannabinol and other 
phytochemicals in Cannabis sativa ............................................................................ 17 
1.3 The discovery and evolution of synthetic cannabinoids ......................................... 19 
1.3.1 Early bicyclic synthetic cannabinoids................................................................. 19 
1.3.2 Pravadoline and the aminoalkylindoles ............................................................ 21 
1.3.3 Synthetic cannabinoids as recreational drugs .................................................. 23 
1.3.4 Common structures and modifications ............................................................ 26 
1.3.5 Structure-activity relationships ......................................................................... 29 
1.4 The psychopharmacology of synthetic cannabinoids ............................................ 32 
1.4.1 Acute effects ....................................................................................................... 32 
1.4.2 Acute toxicity ..................................................................................................... 35 
1.4.3 Metabolism ........................................................................................................ 37 
1.4.4 Thermal degradation ......................................................................................... 39 
1.4.5 Long-term effects and toxicity ........................................................................... 41 
1.5 Legislation, forensics, and treatments .................................................................... 43 
Table of contents I
 
 
1.5.1 Reasons for synthetic cannabinoid use/abuse .................................................. 43 
1.5.2 Legislation and the “chemical arms race” ........................................................ 45 
1.5.3 Forensic detection and identification of synthetic cannabinoids ................... 48 
1.5.4 Treatments for synthetic cannabinoid toxicity and dependence ................... 50 
1.6 Thesis overview ........................................................................................................ 53 
1.7 References ................................................................................................................. 55 
Chapter 2. Physiological effects of synthetic cannabinoids as measured by 
biotelemetry ...................................................................................................................... 76 
2.1 Effects of biosteric fluorine in synthetic cannabinoid designer drugs JWH-
018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135 ..................... 77 
2.1.1 Abstract ............................................................................................................... 77 
2.1.2 Introduction ....................................................................................................... 77 
2.1.3 Results and discussion ....................................................................................... 79 
2.1.4 Conclusion ......................................................................................................... 84 
2.1.5 Methods ............................................................................................................. 85 
2.1.6 References .......................................................................................................... 88 
2.2 Pharmacology of indole and indazole synthetic cannabinoid designer drugs 
AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 
5F-ADB-PINACA, ADBICA, and 5F-ADBICA ............................................................... 91 
2.2.1 Abstract ............................................................................................................... 91 
2.2.2 Introduction ....................................................................................................... 91 
2.2.3 Results and discussion ...................................................................................... 93 
2.2.4 Conclusions ....................................................................................................... 96 
2.2.5 Methods ............................................................................................................. 98 
2.2.6 References ........................................................................................................ 103 
2.3 Pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-
AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-
CHMICA, and their analogues .....................................................................................105 
2.3.1 Abstract .............................................................................................................105 
2.3.2 Introduction .....................................................................................................105 
2.3.3 Results and discussion .................................................................................... 106 
2.3.4 Conclusion ........................................................................................................ 110 
2.3.5 Methods ............................................................................................................ 110 
2.3.6 References ........................................................................................................ 116 
Table of contents II
 
 
Chapter 3. In vitro and in vivo pharmacokinetics and metabolism of synthetic 
cannabinoids CUMYL-PICA and 5F-CUMYL-PICA ....................................................... 119 
3.1 Abstract ................................................................................................................... 120 
3.2 Introduction ........................................................................................................... 120 
3.3 Materials and methods ............................................................................................121 
3.4 Results ..................................................................................................................... 123 
3.5 Discussion ............................................................................................................... 132 
3.6 Conclusions ............................................................................................................. 133 
3.7 References ............................................................................................................... 133 
Chapter 4. Acute and residual effects in adolescent rats resulting from exposure 
to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA ........................ 135 
4.1 Abstract ................................................................................................................... 136 
4.2 Introduction ........................................................................................................... 136 
4.3 Materials and methods ........................................................................................... 138 
4.4 Results .................................................................................................................... 140 
4.5 Discussion ............................................................................................................... 143 
4.6 Conclusion .............................................................................................................. 146 
4.7 References ............................................................................................................... 146 
Chapter 5. Urinary cannabinoid levels during nabiximols (Sativex®)-medicated 
inpatient cannabis withdrawal ........................................................................................ 149 
5.1 Abstract ....................................................................................................................150 
5.2 Introduction ............................................................................................................150 
5.3 Materials and methods ............................................................................................ 151 
5.4 Results ..................................................................................................................... 153 
5.5 Discussion ............................................................................................................... 156 
5.6 Conclusions ............................................................................................................ 159 
5.7 References ............................................................................................................... 159 
Chapter 6. General Discussion ........................................................................................ 162 
6.1 Chapter overview .................................................................................................... 163 
6.2 Summary of findings .............................................................................................. 164 
6.2.1 Chapter 2: Physiological effects of synthetic cannabinoids as measured 
by biotelemetry ......................................................................................................... 164 
6.2.2 Chapter 3: In vitro and in vivo pharmacokinetics and metabolism of 
synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA ................................. 171 
Table of contents III
 
 
6.2.3 Chapter 4: Acute and residual effects in adolescent rats resulting from 
exposure to the novel synthetic cannabinoids AB-PINACA and AB-
FUBINACA ................................................................................................................ 174 
6.2.4 Chapter 5: Urinary cannabinoid levels during nabiximols (Sativex®)-
medicated inpatient cannabis withdrawal .............................................................. 178 
6.3 Wider implications and future directions ............................................................. 181 
6.3.1 Potency and metabolism prediction based on molecular structure .............. 181 
6.3.2 Implications of chronic use of synthetic cannabinoids ................................ 188 
6.3.3 Agonist substitution therapy for synthetic cannabinoid withdrawal .......... 190 
6.4 Conclusions ............................................................................................................ 194 
6.5 References ............................................................................................................... 197 
Appendix 1. Supplementary information for Chapter 2 ................................................ 205 
A1.1 Supplementary information for Chapter 2.1 ....................................................... 206 
A1.2 Supplementary information for Chapter 2.2 ...................................................... 225 
A1.3 Supplementary information for Chapter 2.3 ...................................................... 242 
Appendix 2. Supplementary information for Chapter 5 ................................................ 281 
 
 
Table of contents IV
 
 
Acknowledgements 
 
Science is a fundamentally collaborative effort, and there are a great many people 
without whom this thesis could never have happened. 
 
First and foremost, I need to thank my PhD supervisor, Iain McGregor, for his 
unwavering and amazing support throughout my time as a research student. It is a 
rare thing to find a supervisor who is not only passionate about his student’s work, but 
also fully prepared to support them in all endeavours, from harebrained schemes to 
international travel for conferences or visits to other research groups. More than that, 
the bravery required to let an untrained student loose on expensive analytical 
instruments is certainly worthy of acknowledgement! 
 
The support of my lab colleagues (formerly the McGregor psychopharmacology lab, 
now the Lambert Initiative) has been crucial over the past four years. There are too 
many wonderful people to mention individually, although I feel it necessary to give 
special thanks to Jordyn Stuart, my analytical chemistry buddy and fellow hater of O-
rings, and to Katie Wood, for her excellent work as a research assistant.  
 
To Brian Thomas and the folks over at the Research Triangle Institute, thank you for 
your generosity, your hard work, and incredible hospitality during my visit. I am 
certain that the skills and friendships I developed during my visit will be invaluable 
moving forward, and I hope to continue our collaboration in the years ahead. Speaking 
of collaborations, I also need to thank Samuel Banister for his scientific expertise, 
synthesis of many of the compounds in this thesis, and valuable advice at key 
moments. 
 
A very special thanks goes to my parents, Christine and Peter Kevin, who have done so 
much for me over the years. They have supported me throughout my entire life and 
have encouraged me in all endeavours, academic or otherwise, and I cannot thank 
them enough for that. And thanks also to my grandmother Shirley Page for her 
financial support, home-cooked meals, and tasty biscuits. 
 
And finally, my endless thanks and gratitude go to Peter Wylie, my ever-patient and 
amazing partner in all things. You mean everything to me. 
Acknowledgements V
 List of figures 
Chapter 1 
Figure 1. Molecular structures of ∆9-THC and early synthetic cannabinoids ............ 21  
Figure 2. Front and back of a typical synthetic cannabinoid product “Banana 
Cream Nuke”, as published by Schneir, Cullen, and Ly (2011) .................................. 25 
Figure 3. Molecular structures of synthetic cannabinoids JWH-018, AM-2201, 
AB-001, THJ-018, SDB-001, and CUMYL-PICA .......................................................... 28  
Figure 4. Structure-activity relationships for aminoalkylindoles, with AM-2201 
as an example, and bicyclic synthetic cannabinoids, with CP-55,940 as an 
example .......................................................................................................................... 31  
Figure 5. UR-144 and UR-144 thermal degradant formed after heating to 800 
°C ................................................................................................................................... 40  
Figure 6. Self-reported reasons for first using synthetic cannabinoids ..................... 44 
Chapter 2 
Chapter 2.1  
Figure 1. Selected natural and synthetic cannabinoids .......................................... 78 
Scheme 1. Synthesis of synthetic cannabinoids ...................................................... 79 
Figure 2. ORTEP diagram of the crystal structure of UR-144 with thermal  
ellipsoids at the 50 % probability level ...................................................................80 
Figure 3. Hyperpolarization of CB1 receptors induced by JWH-018, AM-
2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-145 ................................ 81 
Figure 4. Effects of JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, 
APICA, and STS-145 on rat body temperature ....................................................... 82 
Figure 5. Effects of JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, 
APICA, and STS-145 on rat heart rate ..................................................................... 83 
Chapter 2.2  
Figure 1. Selected phytocannabinoids and synthetic cannabinoids ...................... 92 
Figure 2. Indole- and indazole-3-carboxamide synthetic cannabinoid 
designer drugs .......................................................................................................... 92 
Figure 3. Amino acid derivatives L-valinamide and L-tert-leucinamide ................ 93 
Scheme 1. Synthesis of L-tert-leucinamide .............................................................. 93 
Scheme 2. Synthesis of indazole synthetic cannabinoids ...................................... 94 
Scheme 3. Synthesis of indole synthetic cannabinoids .......................................... 94 
Figure 4. Hyperpolarization of CB1 receptors induced by AB-PINACA, ADB-
PINACA, AB-PICA, and ADBICA ............................................................................ 95 
List of figures VI
 Figure 5. Effects of AB-FUBINACA and AB-PINACA on rat body 
temperature .............................................................................................................. 96 
Figure 6. Effects of AB-FUBINACA and AB-PINACA on rat heart rate ................ 97 
Figure 7. Structures of selective CB1 receptor antagonist rimonabant and 
selective CB2 receptor antagonist SR144528 .......................................................... 98 
Figure 8. Effects of AB-FUBINACA or AB-PINACA on rat body temperature 
following pretreatment with vehicle, rimonabant, or SR144528 .......................... 99 
Chapter 2.3  
Figure 1. Selected synthetic cannabinoids ............................................................ 106 
Figure 2. Emergent indole and indazole synthetic cannabinoids featuring 
pendant methyl valinate and methyl tert-leucinate functional groups .............. 106 
Scheme 1. Synthesis of indole synthetic cannabinoids .........................................107 
Scheme 2. Synthesis of indazole synthetic cannabinoids .....................................107 
Figure 3. Hyperpolarization mediated by CB1 receptors induced by 
differently 1-substituted indoles and the corresponding indazoles .................... 108 
Figure 4. Effects of 5F-AMB and MDMB-FUBINACA on rat body 
temperature ............................................................................................................ 109 
Figure 5. Effects of 5F-AMB and MDMB-FUBINACA on rat heart rate .............. 109 
Figure 6. Effects of 5F-AMB and MDMB-FUBINACA on rat body 
temperature following pretreatment with vehicle, rimonabant, or SR144528 .... 110 
Chapter 3 
Figure 1. Structures of CUMYL-PICA and 5F-CUMYL-PICA .................................... 121 
Figure 2. Mean rectal body temperature of male rats following intraperitoneal 
injections of 3 mg/kg CUMYL-PICA or 5F-CUMYL-PICA ........................................ 124 
Figure 3. Chromatographic peak areas of CUMYL-PICA and 5F-CUMYL-PICA 
following incubation with rat and human liver microsomes and plasma 
concentrations of CUMYL-PICA and 5F-CUMYL-PICA following 3 mg/kg 
intraperitoneal injection in rats .................................................................................. 125 
Figure 4. Combined extracted ion chromatograms of CUMYL-PICA and 5F-
CUMYL-PICA metabolites .......................................................................................... 127 
Figure 5. Proposed metabolic pathways for CUMYL-PICA ....................................... 128 
Figure 6. Proposed metabolic pathways for 5F-CUMYL-PICA ................................. 130 
Chapter 4 
Figure 1. Schematic of behavioural assessment over the entire experiment ............ 138 
Figure 2. Place conditioning following six low then six high doses of ∆9-THC, 
AB-PINACA, and AB-FUBINACA ............................................................................... 142 
List of figures VII
 Figure 3. Novel object recognition 2-weeks post dosing with AB-PINACA and 
AB-FUBINACA............................................................................................................. 142 
Chapter 5 
Figure 1. Mean CBD, ∆9-THC, THC-COOH, and 11-OH-THC in plasma and 
urine of patients treated with placebo or nabiximols ............................................... 154 
Figure 2. Effect of hydrolysis with red abalone β-glucuronidase on urinary 
CBD, ∆9-THC, THC-COOH, and 11-OH-THC in a single nabiximols-treated 
patient .......................................................................................................................... 156 
Figure 3. Scatter plots of plasma and urine concentrations of CBD, ∆9-THC, 
THC-COOH, and 11-OH-THC .................................................................................... 157 
Chapter 6 
Figure 1. Complex metabolic interactions in carboxamide synthetic 
cannabinoids ................................................................................................................ 185 
Figure 2. Flow chart for the streamlined testing of novel synthetic 
cannabinoids ................................................................................................................ 187 
 
List of figures VIII
 List of tables 
Chapter 2 
Chapter 2.1 
Table 1. Functional activity of ∆9-THC and indole synthetic cannabinoids at 
CB1 and CB2 receptors ..............................................................................................80 
Chapter 2.2 
Table 1. Functional activity of ∆9-THC, CP-55,940, JWH-018, and novel 
synthetic cannabinoids at CB1 and CB2 receptors .................................................. 94 
Chapter 2.3 
Table 1. Functional activity of ∆9-THC, CP-55,940, and novel synthetic 
cannabinoids at CB1 and CB2 receptors .................................................................107 
Chapter 3 
Table 1. Pharmacokinetic parameters for CUMYL-PICA and 5F-CUMYL-PICA ...... 126 
Table 2. CUMYL-PICA metabolites ............................................................................ 129 
Table 3. 5F-CUMYL-PICA metabolites ........................................................................ 131 
Chapter 4 
Table 1. Locomotor and emergence results for all experimental phases .................. 141 
Table 2. Behaviour in the social interaction test 19 days post drug 
administration ............................................................................................................. 143 
Table 3. Effects of chronic administration of ∆9-THC, AB-PINACA, and AB-
FUBINACA on body weight ........................................................................................ 143 
Table 4. Plasma steroids, cytokines, and ethanolamides with cerebellar 
ethanolamides 6 weeks post drug administration .................................................... 144 
Chapter 5 
Table 1. Demographic and substance use history by treatment group ..................... 153 
Table 2. Urinary and plasma analyte ratios in nabiximols-treated patients at 
peak dosing .................................................................................................................. 158 
Chapter 6 
Table 1. Comparison of in vitro CB1 receptor binding and hypothermic effects 
of compounds assessed via biotelemetry in Chapter 2 ............................................. 167 
Table 2. Proposed structure-metabolism relationships based on common 
structural elements found in synthetic cannabinoids ............................................... 183 
List of tables IX
 Statement of originality 
 
This thesis is submitted to the University of Sydney in fulfilment of the requirement 
for the Degree of Doctor of Philosophy. 
 
The work presented in this thesis is, to the best of my knowledge and belief, original 
except as acknowledged in the text. I hereby declare that I have not submitted this 
material, either in full or in part, for a degree at this or any other institution. 
 
Richard C. Kevin 
 
Signature:          Date: 30/03/2017 
 
Statement of originality X
 Authorship attribution statement 
 
I, Mr. Richard C. Kevin, was the primary author of the publications featured in 
Chapters 3, 4, and 5. For these publications, I took the lead role in the conception and 
design of the research, conducting the research, data analysis and interpretation, and 
the writing and appraisal of manuscripts. 
 
I made a substantial contribution to each of the three publications featured in Chapter 
2. In each publication, I performed the experiment concerned with in vivo evaluation 
of synthetic cannabinoids in rats using biotelemetry. For this part of each publication, 
I took the lead role in experimental design, conducting the experiment, data analysis 
and interpretation, and writing and appraising the parts of the manuscript concerning 
biotelemetric assessment. The other experiments concerning compound synthesis and 
in vitro evaluation were designed and carried out by the co-authors of these 
publications. 
 
In addition to the statements above, in cases where I am not the corresponding author 
of a published item, permission to include the published material has been granted by 
the corresponding author.  
 
Richard C. Kevin 
 
Signature:         Date: 30/03/2017 
 
 
 
As supervisor for the candidature upon which this thesis is based, I can confirm that 
the authorship attribution statements above are correct. 
 
Prof. Iain S. Mcgregor 
 
Signature:          Date: 30/03/2017 
Author attribution statement XI
 Publications 
The following publications form the main content of this thesis: 
 
Kevin, R. C., Lefever, T. W., Patel, P., Synder, R., Fennel, T. R., Wiley, J. L., McGregor, 
I. S., & Thomas, B. F. (2017). In vitro and in vivo pharmacokinetics and 
metabolism of synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. 
Forensic Toxicology, doi:10.1007/s11419-017-0361-1 
 (Chapter 3) 
Kevin, R. C., Wood, K. E., Stuart, J., Mitchell, A. J., Moir, M., Banister, S. D., Kassiou, 
M., & McGregor, I. S. (2017). Acute and lasting residual effects resulting from 
exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA 
in adolescent rats. Journal of Psychopharmacology, doi: 
10.1177/0269881116684336 
 (Chapter 4) 
Kevin, R. C., Allsop, D. J., Lintzeris, N., Dunlop, A. J., Booth, J., & McGregor, I. S. 
(2017). Urinary cannabinoid levels during Nabiximols (Sativex™)-medicated 
inpatient cannabis withdrawal. Forensic Toxicology, 35, 33-44. 
(Chapter 5) 
Banister, S. D., Longworth, M., Kevin, R. C., Shivani, S., Santiago, M., Stuart, J., Mack, 
J., Glass, M., McGregor, I. S., Connor, M., & Kassiou, M. (2016). The 
pharmacology of valinate and tert-leucinate synthetic cannabinoids 5F-
AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-
CHMICA, and their analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. 
 (Part of Chapter 2) 
Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E., Wilkinson, S. M., 
Longworth, M., Beinat, C., Buchanan, A., Glass, M., Connor, M., McGregor, I. S., 
& Kassiou, M. (2015). The pharmacology of indole and indazole synthetic 
cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, 
ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA. 
ACS Chemical Neuroscience, 6(9), 1546-1559. 
(Part of Chapter 2) 
Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth, M., Wilkinson, S. M., 
Beinat, C., Buchanan, A. S., Hibbs, D. E., Glass, M., Connor, M., McGregor, I. S., 
& Kassiou, M. (2015). The effects of bioisosteric fluorine in synthetic 
cannabinoid designer drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-
22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. 
 (Part of Chapter 2) 
Publications XII
 Additional publications 
During my PhD candidature, I contributed to the following publications which are 
complimentary to this thesis, but do not form part of its content: 
 
Book Chapters 
Allsop, D. J., Kevin, R. C., & Arnold, J. (2016). Cannabis:  The pharmacokinetics and 
pharmacodynamics of recreational and medicinal cannabis.  In Wolff, K., 
White, J., & Karch S. (Eds.) The SAGE Handbook of Drug & Alcohol Studies: 
Biological Approaches, 194-212. 
 
Original Research 
Banister, S. D., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., 
Wilkinson, S. M., Kevin, R. C., Hibbs, D. E., Glass, M., Connor, M., McGregor, 
I. S., & Kassiou, M. (2015). Structure-activity relationships (SARs) of synthetic 
cannabinoid designer drug RCS-4 and its regioisomers and C4-homologs. 
Forensic Toxicology, 33(2), 355-366. 
Lefever, T. W., Marusich, J. A., Thomas, B. F., Barrus, D. G., Peiper, N. C., Kevin, R. C., 
& Wiley, J. L. (2017). Vaping synthetic cannabinoids: A novel preclinical model 
of E-cigarette use in mice. Substance Abuse: Research and Treatment. 
Thomas, B. F., Lefever, T. W., Cortes, R. A., Kovach, A. L., Cox, A. O., Patel, P. R., 
Pollard, G. T., Marusich, J. A., Kevin, R. C., Gamage, T. F., & Wiley, J. L. (2017). 
Thermolytic degradation of synthetic cannabinoids: Chemical exposures and 
pharmacological consequences. The Journal of Pharmacology and Experimental 
Therapeutics. 
 
Additional publications XIII
 List of abbreviations 
11-OH-THC  11-hydroxy-Δ9-tetrahydrocannabinol 
5F-AB-PINACA N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(5-fluoropentyl)-1H-
indazole-3-carboxamide 
5F-ADB-PINACA N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(5-fluoropentyl)-1H-
indazole-3-carboxamide 
5F-ADB N-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-3-methyl-D-
valine, methyl ester 
5F-ADBICA N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-(5-fluoropentyl)-1H-
indole-3-carboxamide 
5F-AMB N-[(1-(5-fluoropentyl)-1H-indazol-3-yl)carbonyl]-L-valine, methyl 
ester 
5F-AMBICA N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-
indol-3-carboxamide 
5F-CUMYL-PICA 1-(5-Fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide 
5F-PB-22  1-fluoropentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester 
7-OH-CBD  7-hydroxy-cannabidiol 
∆9-THC  (-)-trans-Δ9-tetrahydrocannabinol 
AB-001  1-pentyl-3-(1-adamantoyl)indole 
AB-CHMINACA N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-
1H-indazole-3-carboxamide 
AB-FUBINACA N-[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]-1-[(4-fluorophenyl) 
methyl]indazole-3-carboxamide 
AB-PINACA N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-pentyl-1H-indazole-
3-carboxamide 
ACN acetonitrile 
ADB-FUBINACA N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-[(4-
fluorophenyl)methyl]-1H-indazole-3-carboxamide 
ADB-PINACA N-[1-(aminocarbonyl)-2,2-dimethylpropyl]-1-pentyl-1H-indazole-
3-carboxamide 
ADBICA N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-
carboxamide 
AEA   N-arachidonoylethanolamine; anandamide 
AM-2201  1-(5-fluoropentyl)-3-(1-naphthoyl)indole 
List of abbreviations XIV
 AMB-FUBINACA methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate 
ANOVA  analysis of variance 
APICA  see SDB-001 
CB1   cannabinoid 1 (receptor) 
CB2   cannabinoid 2 (receptor) 
CBD   cannabidiol 
CBDA   cannabidiolic acid 
CBG   cannabigerol 
CBN   cannabinol 
CP-47,497 2[(1S,3R)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-yl)phenol 
CP-55,940 2-[(1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl) cyclohexyl]-5-(2-
methyloctan-2-yl)phenol 
CPP   conditioned place preference 
CUMYL-PICA 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide 
EG-018  naphthalen-1-yl(9-pentyl-9H-carbazol-3-yl)methanone 
EPM   elevated plus maze 
EtOH   ethanol 
FA   formic acid 
FAAH   fatty acid amide hydrolase 
FUBIMINA (1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-1-
yl)methanone 
GC-MS  gas chromatrography-mass spectrometry 
GM-CSF  granulocyte macrophage colony-stimulating factor 
GPR55  G-protein coupled receptor 55 
HU-210  1,1-dimethylheptyl- 11-hydroxytetrahydrocannabinol 
IFNγ   interferon gamma 
IL   interleukin 
i.p.   intraperitoneal 
JWH-018 1-pentyl-3-(1-naphthoyl)indole 
JWH-073 1-butyl-3-(1-naphthoyl)indole 
JWH-200 [1-[2-(4-morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-
methanone 
LC-MS/MS liquid chromatography-tandem mass spectrometry 
List of abbreviations XV
 MDMB-CHMINACA N-[[1-(cyclohexylmethyl)-1H-indazol-3-yl]carbonyl]-3-methyl-L-
valine, methyl ester 
MDMB-FUBINACA N-[[1-[(4-fluorophenyl)methyl]-1H-indazol-3-yl]carbonyl]-3- 
methyl-L-valine, methyl ester 
MeOH methanol 
NOR   novel object recognition 
NPS   novel psychoactive substance 
OF   open field 
SAR   structure-activity relationship 
SC   synthetic cannabinoid 
SDB-001  N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide 
SI   social interaction 
STS-135  N-(1-adamantyl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide 
PB-22   1-pentyl-1H-indole-3-carboxylic acid 8-quinolinyl ester 
THCA   tetrahydrocannabinolic acid 
THC-COOH  11-nor-9-carboxy-Δ9-tetrahydrocannabinol 
THCV   tetrahydrocannabivarin 
TNFα   tumor necrosis factor alpha  
THJ-018  1-naphthalenyl(1-pentyl-1H-indazol-3-yl)-methanone 
TRP   transient receptor potential channel 
UR-144 1-(pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-
methanone  
VEH   vehicle 
WIN-48,098 pravadoline; (4-methoxyphenyl)[2-methyl]-1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl]-methanone 
XLR-11 1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone 
WIN-55,212-2 [(3R)-2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-
naphthalenyl-methanone 
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Thesis abstract 
Over recent years, the rapid proliferation of novel psychoactive substances 
(NPS) has presented significant challenges to health professionals, regulators, and 
forensic scientists alike. Of the many different classes of NPS, synthetic cannabinoids 
comprise an increasingly prevalent and diverse class of compounds that are used by 
many people around the world for recreational purposes. These compounds act on CBͱ 
and CBͲ cannabinoid receptors, similar to endogenous cannabinoid receptor ligands 
and to the prototypical cannabis‐derived receptor agonist ∆͹‐tetrahydrocannabinol 
(∆͹‐THC). Recreationally used synthetic cannabinoids tend to produce psychoactive 
effects similar to, but stronger than, those of ∆͹‐THC. The majority of modern 
synthetic cannabinoids have never been systematically assessed for their effects in 
humans, meaning that their psychopharmacological and toxicological effects remain 
largely uncharacterised. Unfortunately, but perhaps not surprisingly, these 
compounds are implicated in scores of toxic and fatal episodes worldwide. 
This thesis presents a series of studies aimed at building new knowledge 
regarding the behavioural and physiological effects of specific synthetic cannabinoids, 
their potency and metabolism, their long‐term effects on cognitive function and brain 
neurochemistry, and analytical techniques that may be useful in the development of 
agonist substitution therapies to assist with synthetic cannabinoid withdrawal.  
Chapter ͱ consists of a comprehensive review of what is currently known and 
unknown about modern synthetic cannabinoids. It presents an outline of general 
cannabinoid pharmacology and reviews the acute effects and toxicity of synthetic 
cannabinoids, their metabolism, potential for thermal degradation, and the limited 
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data available regarding their long‐tern health‐related effects. This review introduces 
the rationale for the studies presented in the subsequent chapters. 
Chapter Ͳ presents three studies that describe the synthesis of twelve novel 
synthetic cannabinoids, the affinity and efficacy of these compounds at CBͱ and CBͲ 
receptors, and their in vivo effects on body temperature and heart rate across specific 
dose ranges. These in vivo dose‐response relationships were used to inform dosing in 
subsequent chapters. Radiotelemetric probes were surgically implanted into adult 
male rats to enable the real‐time monitoring of body temperature and heart rate 
following synthetic cannabinoid administration. All of the tested compounds 
produced hypothermic effects, although the required dose, magnitude of effect, and 
duration of effect varied as a function of molecular structure. In some cases, in vivo 
potency exceeded or fell short of predictions derived from in vitro cannabinoid 
receptor binding assays and user reports. These findings suggest that while 
cannabinoid receptor binding is an important determinant of in vivo efficacy of 
synthetic cannabinoids, metabolic transformation and thermolytic degradation into 
cannabinoid receptor active compounds most likely play additional important roles in 
determining in vivo potency.  
Accordingly, Chapter ͳ focuses on the metabolism of the two recently identified 
synthetic cannabinoids CUMYL‐PICA and ͵F‐CUMYL‐PICA, aiming to establish 
pharmacokinetic parameters and metabolic pathways for these compounds. A total of 
͵Ͷ novel metabolites were described. Major and minor metabolic pathways were 
postulated, and useful analytical targets were identified as putative markers of 
consumption. Additionally, this study compared in vitro pharmacokinetic parameters, 
obtained with in vitro microsomal and hepatocyte assays, to data collected in vivo in 
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rats, finding that in vitro clearance estimates greatly exceeded actual in vivo 
elimination rates. It is argued that lipid solubility and protein binding are factors that 
may require consideration during interpretation of similar in vitro estimates in the 
wider literature. 
Given the dearth of information regarding the long‐term consequences of 
synthetic cannabinoid use, Chapter ʹ investigates the acute and long‐term effects of 
repeated administration of synthetic cannabinoids AB‐PINACA and AB‐FUBINACA to 
adolescent male rats. These effects were compared to those of ∆͹‐THC.  Acute effects 
included dose‐dependent reductions in locomotor activity, increases in anxiety and an 
absence of conditioned place preference or aversion. Weeks after the cessation of 
dosing, long‐term residual deficits in recognition memory are described, as well as 
complex ligand‐specific effects on cerebellar endocannabinoids and plasma cytokines. 
Interestingly, most effects caused by either synthetic cannabinoid were similar to 
those of ∆͹‐THC, and no unusual toxidrome was observed in Chapters Ͳ, ͳ or ʹ with 
synthetic cannabinoid administration. The inability of rodent models to capture the 
human toxicity described in numerous case studies in puzzling, and may reflect 
factors specific to human use, such as product contamination, use of extreme doses, or 
species differences in pharmacokinetics. 
Reports of synthetic cannabinoid withdrawal and addiction are increasingly 
found in media reports and case studies, suggesting a need for novel clinical 
treatments for these conditions. One option is agonist substitution therapy, which 
might involve products such as nabiximols (Sativex™), a buccal spray consisting of 
equal parts ∆͹‐THC and cannabidiol (CBD). CBD is a non‐psychoactive constituent of 
cannabis with anxiolytic and neuroprotective properties.  The viability of this 
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approach depends on being able to administer the treatment at appropriate 
concentrations, and being able to accurately monitor patient pharmacokinetics. 
Chapter ͵ reports use of a novel method of cannabinoid urinalysis in a population of 
cannabis‐dependent treatment‐seeking users treated with nabiximols during inpatient 
withdrawal. β‐glucuronidase hydrolysis was used to increase the concentrations of key 
cannabinoids and metabolites in urine samples, allowing for enhanced detection of 
∆͹‐THC and CBD. The study provides evidence that cannabinoid urinalysis can 
substitute for plasma analysis, which may provide a less invasive sampling method for 
future studies. Moreover, this study showed that after hydrolysis cannabinoid 
concentrations were greater in urine than in plasma, such that cannabinoid urinalysis 
could be used for analysis of trace cannabinoids that may go undetected in blood. This 
technique might also prove useful for the analysis of urinary synthetic cannabinoid 
metabolites in future studies.  
Chapter Ͷ provides a general discussion of the results obtained in this thesis 
and describes how the results represent an advance in several areas of cannabinoid 
research. The results obtained from Chapters Ͳ, ͳ, and the wider literature are 
combined to identify in vivo structure‐activity and structure‐metabolism relationships 
for a wide variety of synthetic cannabinoids. These relationships may prove useful for 
the prediction of the psychopharmacological properties and metabolic pathways of 
future novel synthetic cannabinoids that are detected by authorities, reducing the 
burden involved in testing large numbers of novel compounds individually. Second, 
potential implications of chronic synthetic cannabinoid use in humans are discussed. 
Specifically, long‐lasting cognitive impairments and subtle biochemical modulations 
are predicted in chronic synthetic cannabinoid users. Finally, analytical techniques for 
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evaluating and monitoring agonist replacement therapy for synthetic cannabinoid 
withdrawal are established. Taken together, the research presented in this thesis sheds 
light on the physiological, psychopharmacological, and pharmacokinetic properties of 
several recreationally used synthetic cannabinoids, and establishes key methodology 
for future research into specific and efficacious treatments for synthetic cannabinoid 
withdrawal. 
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Chapter 1. General introduction and literature review 
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1.1 Preface 
As our understanding of pharmacological processes evolves, so do the tools 
used to carry out pharmacological investigations. For example, we can design more 
targeted and efficacious agonists, antagonists, and modulators of systems of interest. 
These tools may further boost our pharmacological understanding and even provide 
superior therapeutics for injuries or diseases. Sometimes, these new discoveries 
involve systems that can produce psychoactive effects. And sometimes, the syntheses 
of novel, targeted, ultra-potent compounds are published for the world to see. And 
sometimes, chemists get creative with their business practices. 
Thus it comes as little surprise that recent decades have seen the emergence of 
vast numbers of novel psychoactive substances – compounds that are specifically 
designed to act on neural systems to produce psychoactive effects (Power, 2014). 
Scientists, health professionals, and  legislators are faced with the emergence of 
hundreds of such drugs, each possessing largely uncharacterised psychopharmalogical 
and toxicological properties (EMCDDA, 2015). From “bath salts” to “fake weed” to the 
misnomer “synthetic LSD”, recent evolutions in psychoactive drugs have challenged 
health systems, drug legislation, and our understanding of recreational drug use. 
Novel drugs are nothing new – improved medications, for example, are 
introduced all the time. But the typical modern therapeutic has years of research 
behind it: in vitro screening, controlled trials in animals, extensive toxicological and 
metabolic studies, and often long-term follow-ups (Balunas & Kinghorn, 2005). Each 
drug, barring exceptional circumstances, has undergone extensive screening before 
ever being used by a person. For emerging novel psychoactive substances, this process 
is reversed – the first major discovery is that people are using the substance. From 
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there, researchers must work backwards, deriving the basic pharmacological 
properties of the substance after the fact. 
Of the many classes of novel psychoactive substances, this thesis focuses on 
synthetic cannabinoids – compounds designed to act on cannabinoid receptors. In 
particular, it focuses on a range of synthetic cannabinoids that produce psychoactive 
effects and that are frequently used recreationally for that purpose. While these drugs 
are superficially innocuous compared to other novel psychoactive substances like 
synthetic opiates or designer cathinones, some compounds (but intriguingly, not all) 
have nevertheless produced toxic and even fatal outcomes worldwide (Louh & 
Freeman, 2014; Schwartz et al., 2015; Trecki, Gerona, & Schwartz, 2015). 
When a novel synthetic cannabinoid is first detected in recreational products, 
there exist a number of very important but unanswered questions. How does this 
compound produce its effects? Is there a safe dose, and what is it? Is it inherently 
toxic? If so, what is the mechanism underlying that toxicity? How is it metabolised? 
How can it be identified forensically? Does it degrade when heated? How long do the 
effects last, and are they harmful in the long term? Is it addictive, and if so, can that 
addiction be treated? The work presented in this thesis is designed to answer some of 
these questions. 
Synthetic cannabinoids exert their effects - at least partially - via mimicry of the 
action of exogenous phytocannabinoids found in Cannabis sativa and the endogenous 
cannabinoids (“endocannabinoids”) occurring naturally throughout the body. 
Therefore, this introductory chapter begins with a brief review of the history of 
cannabinoid science, endocannabinoid science and general cannabinoid 
pharmacology. Following this, the emergence of synthetic cannabinoids as 
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recreationally used and abused novel psychoactive substances is explored. The 
chemical structures, structure-activity relationships, and recreational use of synthetic 
cannabinoids are discussed, before moving to a review of what is currently understood 
about the psychopharmacology of synthetic cannabinoids. This discussion focuses on 
their acute physiological and behavioural effects, their toxicity, metabolism and 
thermal stability, and the limited data concerning their long-term effects. The chapter 
then moves to a discussion of legislative and forensic responses to the emergence of 
synthetic cannabinoids, and possible treatments for those burdened with their 
multifarious adverse effects. Finally, a variety of research is introduced, which is 
designed to answer important questions surrounding the psychopharmacology and 
toxicity of synthetic cannabinoids. 
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1.2 A brief history of Cannabis sativa and cannabinoid 
pharmacology 
 
1.2.1 The discovery and classification of cannabinoids 
Cannabis sativa (cannabis; marijuana) is a robust dioecious annual plant that 
has been utilised for a range of human purposes. It has seen use as a textile (i.e. 
hemp), as herbal medicine, in religious ceremonies, and as a psychoactive drug. The 
plant’s origins can be traced to Central Asia, wherefrom it spread via trade to India, 
Western Asia, and eventually Europe and beyond (Zuardi, 2006). It was used in Egypt 
for pain relief around 1500 BC and in China for recreational purposes as early as 2737 
BC (Russo, 2007). The success of the plant, which can now be found growing in every 
inhabited continent, speaks to the historical value of cannabis to human populations. 
It is therefore somewhat surprising that a basic pharmacological understanding of 
cannabis has only been achieved recently compared to other psychoactive plants such 
as the opium poppy (Papaverus somniferum) or coca bush (Erthoxylum coca). 
The delayed development of cannabis pharmacology is underpinned by the 
chemical properties of the “cannabinoids”, which were first defined as a “group of 
oxygen containing C21 aromatic hydrocarbon compounds typical of and present in 
Cannabis sativa” (Mechoulam & Gaoni, 1967, p. 177). Compared to opium or coca 
constituents like morphine and cocaine, respectively, cannabinoids are difficult to 
purify and separate. Cannabinoids are numerous and structurally similar, and 
generally lack distinct functional groups which are easily manipulated in order to 
chemically separate them from one another (ElSohly & Slade, 2005; Mechoulam et al., 
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2014). While opium and coca constituents and derivatives were isolated, purified, and 
medically studied (e.g. codeine, an opioid medication used as for pain relief; or 
lignocaine, a local anaesthetic, structurally related to cocaine), cannabis could only be 
classed as a “drug” with unknown pharmacology for most of the 20th century.  It took 
until the 1960s for analytical techniques to advance sufficiently to correctly identify 
the psychoactive components of cannabis, and until the 1990s to identify the 
molecular targets of exogenous cannabinoids and endocannabinoids within the brain 
and body (Devane et al., 1992; Gaoni & Mechoulam, 1964). It was only then that the 
pharmacological properties of cannabinoids could be studied directly.  
Cannabidiol (CBD) and cannabinol (CBN) were the first cannabinoids isolated 
from Cannabis sativa (Wollner et al., 1942). However, the molecular structures of 
these cannabinoids could not be accurately elucidated at the time, and they were 
mistakenly thought to be the psychoactive components of cannabis. The synthetic 
compound Δ6a,10a-tetrahydrocannabinol possessed pharmacological activity similar to 
cannabis extracts, so it was assumed that it must be structurally related to the true 
psychoactive compound(s) (Mechoulam et al., 2014). Finally, in 1964, ∆9-
tetrahydrocannabinol (∆9-THC) was correctly identified as the primary psychoactive 
component of cannabis, and the correct structures of ∆9-THC and CBD were 
elucidated (Gaoni & Mechoulam, 1964).  
Since this early work, growing understanding of cannabinoid pharmacology has 
necessitated a broadening of the definition of cannabinoids to include several 
additional chemical classes beyond the components first identified in the cannabis 
plant. Cannabinoids now include the carboxylic acid precursors of THC, CBD, and 
other cannabis-derived cannabinoids (together termed “phytocannabinoids”), 
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cannabinoid metabolites, synthetic cannabinoids, and endogenous cannabinoids 
(endocannabinoids). Of these, discovery of the endocannabinoids was a particularly 
significant breakthrough in cannabinoid pharmacology. 
  
1.2.2 The endocannabinoid system  
When ∆9-THC was first isolated, it had no established molecular target or 
mechanism of action, although it was clear that phytocannabinoids must act on some 
endogenous system in order to produce their effects. The basic components of the 
endocannabinoid system - cannabinoid receptors and their endogenous ligands – were 
subsequently discovered in the early 1990s (Devane et al., 1992; Matsuda et al., 1990). 
The endocannabinoid system is comprised of two G-protein coupled receptors termed 
cannabinoid 1 (CB1) and 2 (CB2) receptors, and the endocannabinoids that act on those 
receptors (Matsuda et al., 1990). The CB1 receptor was first cloned in 1990 followed 
shortly by CB2 receptors in 1993 (Matsuda et al., 1990; Munro, Thomas, & Abu-Shaar, 
1993). Both proved resistant to crystallisation, such that the crystal structure of the 
human CB1 receptor was only obtained in 2016 (Hua et al., 2016).  The 
endocannabinoid system can be further expanded to include enzymes that synthesise 
or degrade endocannabinoids (e.g. monoacylglyceral lipase, diacylglycerol lipase) and 
membrane transporters (Reggio, 2010). G-protein coupled receptor 55 (GPR55) is also 
activated by some exogenous and endogenous cannabinoid ligands and can be 
considered a putative cannabinoid receptor (Ryberg et al., 2007).  
The first endocannabinoid to be discovered was N-arachidonoylethanolamide 
(AEA; anandamide)(Devane et al., 1992). AEA is a fatty acid neurotransmitter that is a 
partial agonist for CB1 and CB2 receptors, and is primarily degraded by fatty acid amide 
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hydrolase (FAAH) (Deutsch & Chin, 1993; Mechoulam et al., 2014). A second 
endocannabinoid, 2-arachidonoylglycerol (2-AG), was identified shortly after the 
discovery of AEA (Mechoulam et al., 1995; Sugiura et al., 1995). 2-AG acts as a full 
agonist at CB1 and CB2 receptors, and has been found at brain concentrations 170 times 
that of AEA (Gonsiorek et al., 2000; Stella, Schweitzer, & Piomelli, 1997). 
CB1 receptors are highly expressed throughout the central nervous system, such 
that CB1 is one of the most abundantly expressed receptors identified in mammalian 
brain (Mackie, 2005). It is also found less abundantly in peripheral tissues (Tsou et al., 
1998). CB1 receptor expression is particularly dense in the hippocampus, amygdala, 
molecular layer of the cerebellum, periaqueductal gray, and dorsal horn of the spinal 
cord (Farquhar-Smith et al., 2000; Glass, Faull, & Dragunow, 1997; Herkenham et al., 
1991; Westlake et al., 1994).  
In neural systems, endocannabinoids (particularly 2-AG) activate CB1 receptors 
via retrograde (post-synaptic to pre-synaptic) transmission (Freund, Katona, & 
Piomelli, 2003; Wilson & Nicoll, 2001). Endocannabinoids are synthesised and 
released when intracellular calcium concentrations rise, such that synaptic 
endocannabinoid concentrations increase alongside neuronal activation (Mechoulam 
et al., 2014; Wilson & Nicoll, 2001). Endocannabinoids then bind to presynaptic CB1 
receptors, which inhibit presynaptic firing. Accordingly, the endocannabinoid system 
appears to be important for maintaining homeostasis across a number of physiological 
systems. These include appetite (Colombo et al., 1998; Mattes et al., 1994), pain 
regulation (Guindon & Hohmann, 2009), anxiety (Hill & Tasker, 2012), memory 
formation and learning (Marsicano & Lafenetre, 2009), mood (Witkin, Tzavara, & 
Nomikos, 2005), and sleep (Gates, Albertella, & Copeland, 2014; Mechoulam et al., 
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1997). However, it should be noted that presynaptic CB1 receptor activation does not 
necessarily produce net inhibition across a neural system – for example, inhibition of 
GABAergic neurons could produce net excitation. 
The endocannabinoid system is probably involved in such a plethora of 
physiological functions because cannabinoid receptors are abundantly distributed 
(Malfitano et al., 2014; Svizenska, Dubovy, & Sulcova, 2008). It should also be noted 
that AEA and 2-AG may also act on non-cannabinoid receptors, including transient 
receptor potential (TRP) channels (Di Marzo & De Petrocellis, 2010), specifically 
TRPV1 (Ross et al., 2001), peroxisome proliferator-activated receptors (Rockwell et al., 
2006), and GPR55 (Ryberg et al., 2007). Consequently the total “footprint” of the 
endocannabinoid system may extend beyond that of systems presently known to 
express cannabinoid receptors. 
Crucially, CB1 receptor activation produces the psychoactive effects associated 
with cannabis. Frequently reported effects of CB1 receptor agonists in humans are 
lethargy, increased appetite, xerostomia, and mild euphoria (Heishman et al., 1990; 
Wachtel et al., 2002). In rodents, CB1 receptor agonists produce a well-defined 
behavioural “tetrad”: catalepsy, analgesia, hypomotility, and hypothermia (Martin et 
al., 1991). Tetrad effects can typically be blocked by CB1 receptor antagonists (Huestis 
et al., 2001; Rinaldi-Carmona et al., 1995), and are largely absent in CB1 genetic 
knockout models (Zimmer et al., 1999). Thus CB1 receptors are well established as the 
molecular target underlying these effects. These effects are further reviewed in 
Sections 1.2.3 and 1.4.1. 
CB2 receptor-mediated effects are less well established than those of CB1, but 
nevertheless CB2 receptors may be involved in the regulation of  a large number of 
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bodily systems and disease states (Malfitano et al., 2014). CB2 receptors have been 
found in microglial cells within the CNS, and somewhat controversially, in neuronal 
tissue (Onaivi, 2011; Stempel et al., 2016). However, CB2 receptors are generally found 
in peripheral immune tissues (Svizenska et al., 2008). In particular, CB2 receptors are 
highly expressed in tonsils, spleen, and thymus. Although CB2 receptor activation 
could theoretically be problematic for immune responses against infectious diseases, 
some researchers have found evidence for a therapeutic role for CB2 receptor agonists 
in treating autoimmune disorders or injury where inflammation plays a major role 
(Maresz et al., 2007; Zhang et al., 2007). For example, selective CB2 receptor agonists 
O-3853 and O-1966 can decrease cerebral infarction following ischemic stroke in mice 
(Zhang et al., 2007). The therapeutic potential of CB2 receptors remains an emerging 
and active area of research. 
 
1.2.3 ∆9-tetrahydrocannabinol, the prototypical CB1 receptor agonist 
Since its discovery in 1964, the effects of ∆9-THC (psychoactive or otherwise) 
have been extensively studied. It was first identified in a hexane extract of hashish, 
from which it was chromatographically separated from other phytocannabinoids, 
purified and tested for psychoactivity in dogs (Gaoni & Mechoulam, 1964). Similar 
assessments revealed that ∆8-tetrahydrocannabinol is also psychoactive, but that ∆9-
THC is more potent in vivo and more prevalent in cannabis (Pertwee, 1988). ∆9-THC is 
therefore generally considered the principle psychoactive component of cannabis. 
The complete biosynthesis of ∆9-THC and other phytocannabinoids in the 
plant is complex and beyond the scope of this thesis (for review see Flores-Sanchez 
and Verpoorte (2008)), but briefly, the carboxylic acid precursor to ∆9-THC, 
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tetrahydrocannabinolic acid (THCA), is biosynthesised from cannabigerolic acid 
(CBGA) by THCA synthase, and concentrated in the glandular trichomes of cannabis 
(Flores-Sanchez & Verpoorte, 2008; Taura et al., 2007). THCA, which is not 
psychoactive, is readily converted by light and heat to ∆9-THC, and this typically 
occurs when cannabis or cannabis extracts are smoked, vaporised, or baked 
(McPartland et al., 2015).  
∆9-THC content (including THCA) typically ranges from 0 - 35 % of dry plant 
weight (Bruci et al., 2012; Burgdorf, Kilmer, & Pacula, 2011; Swift et al., 2013). This 
variance is a result of plant genetics (including plant gender), growing conditions, and 
the portion of the plant analysed. Repeated selection of plant strains with high ∆9-
THC content for recreational purposes has produced an increase in cannabis potency 
(i.e. ∆9-THC content) in Europe, the US, the UK, New Zealand, and Australia (Cascini, 
Aiello, & Di Tanna, 2012; Swift et al., 2013).  
After intake of ∆9-THC via smoking, vaporisation, or ingestion, ∆9-THC 
circulates in blood, crosses the blood-brain-barrier and activates CB1 receptors, 
producing the classic cannabis “high”. As reviewed in the previous section, CB1 
receptor activation affects a variety of physiological systems, such that ∆9-THC can 
increase appetite, reduce pain, modulate anxiety, impair memory formation and 
learning, and alter mood (Pertwee & Cascio, 2014). It also produces “tetrad” effects in 
rodents (Compton et al., 1993; Martin et al., 1991; Wiley et al., 2007).  
In humans and rodents, ∆9-THC is metabolised to a variety of oxidized 
derivatives by cytochrome P450 2C9 and 2C19 isoenzymes (Watanabe et al., 2007). 
The predominant metabolic pathway proceeds via hydroxylation to 11-hydroxy-∆9-
THC (11-OH-THC) and then further oxidation to 11-nor-9-carboxy-THC (THC-COOH) 
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(Huestis, 2007). Interestingly, 11-OH-THC is more potent at CB1 receptors than ∆
9-
THC, whereas THC-COOH lacks psychoactive effects (Lemberger et al., 1971; 
Watanabe et al., 1990). 11-OH-THC is more readily formed following oral 
administration of ∆9-THC, and as a major metabolite, 11-OH-THC likely contributes to 
the overall psychoactive effects usually ascribed to ∆9-THC (Huestis, 2007).  
∆9-THC produces rewarding effects, as demonstrated by user reports and by 
animal studies showing self-administration (Braida et al., 2004; Tanda, Munzar, & 
Goldberg, 2000). Approximately 10% of cannabis users develop dependence (Crean, 
Crane, & Mason, 2011). The rewarding effects of  ∆9-THC appear to be mediated by 
activation of dopaminergic reward circuitry involving the ventral tegmental area 
(VTA) and nucleus accumbens (NAc) (Gardner, 2014). In brief, dopaminergic neurons 
in the VTA innervate neurons in the NAc, and activation of this circuitry underlies the 
rewarding effects of a number of drugs of abuse (Fields & Margolis, 2015). ∆9-THC 
increases firing of dopaminergic VTA neurons, which may occur indirectly via 
inhibition of GABAergic projections onto those neurons (Gardner, 2014). However, 
excitatory glutamatergic neurons that express presynaptic CB1 also project onto 
dopaminergic neurons in the VTA (Lupica, Riegel, & Hoffman, 2004). Activation of 
these receptors would tend to decrease dopaminergic firing. Therefore, the effects of 
∆9-THC in the VTA are likely mediated by a complex interaction between competing 
neural circuitry. Nevertheless, antagonist studies provide some valuable mechanistic 
information. For example, the effects of ∆9-THC in the VTA can be blocked with CB1 
receptor antagonists, pointing to a CB1-dependent mechanism and involvement of the 
endocannabinoid system. Infusions of ∆9-THC directly into the NAc also increases 
NAc dopamine, which can be blocked not only by CB1 receptor antagonists but also by 
Chapter 1 12
 
 
opioid antagonist/inverse agonist naloxone (Tanda, Pontieri, & Chiara, 1997). Thus, 
multiple receptor systems are involved in mediating cannabinoid reward.  
Repeated ∆9-THC exposure can produce homeostatic compensations in the 
endocannabinoid system, leading to tolerance. Animal studies show that repeated ∆9-
THC administration decreases CB1 receptor density in hippocampal and striatal 
regions (Sim-Selley et al., 2006). Similarly, human cannabis users show down-
regulation of cortical CB1 receptors as measured by positron emission tomography, 
which positively correlates with the number of years of cannabis use (Hirvonen et al., 
2012). AEA concentrations in cerebrospinal fluid are also reduced by cannabis use in 
humans, in proportion to the amount of cannabis used (Morgan et al., 2013). However, 
these changes are reversible following cessation of ∆9-THC (Hirvonen et al., 2012; Sim-
Selley et al., 2006), and are less clearly characterised in other biological matrices. 
Although the precise mechanism underlying cannabinoid reward is not fully 
understood, it is noteworthy that abrupt cessation of cannabis use can produce a 
withdrawal syndrome (Allsop et al., 2011; Volkow et al., 2014). This is usually mild 
compared to opioid or alcohol withdrawal, but can present an obstacle to the 
reduction of cannabis use and impair normal daily activities (Allsop et al., 2012). 
Symptoms include irritability, cravings, decreased appetite, sleep disturbance, 
depression, anxiety, and headache (Allsop et al., 2015). These symptoms usually 
resolve after an extended period of cannabis/∆9-THC abstinence, perhaps related to 
the normalisation of receptor density and endocannabinoid concentrations as 
discussed above. 
∆9-THC can influence neuronal plasticity and associated learning, likely as a 
result of high CB1 receptor density in the prefrontal cortex and hippocampus. In 
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particular, ∆9-THC exposure can reduce neuron size and synaptic density in rat 
hippocampus (Scallet, 1991), and impairs episodic and working memory in infrequent 
cannabis users (Curran et al., 2002). This may occur via a reduction of blood flow to 
these brain regions (or conversely, inhibition of the prefrontal cortex and 
hippocampus may reduce blood flow). In rodents, these effects are more pronounced 
and enduring in adolescents (Higuera-Matas, Ucha, & Ambrosio, 2015). Adolescent 
rats show greater residual memory deficits than adults following chronic 
administration of ∆9-THC (Quinn et al., 2008).  
Peripherally, ∆9-THC produces tachycardia in humans via increases in diastolic 
blood pressure. Increases in resting heart-rate occur in a dose-dependent manner 
(Mittleman et al., 2001; Weiss et al., 1972). However, ∆9-THC can also produce 
bradycardia in tolerant human users. Moreover, in rodents, CB1 agonists including ∆
9-
THC produce bradycardia in non-tolerant animals (Banister et al., 2013). Thus, the 
effect of ∆9-THC and cannabinoids generally on heart-rate is not fully understood. 
∆9-THC can also bind to CB2 receptors, although the outcomes of CB2 
activation are less established than for CB1. However, the action of ∆
9-THC on CB2 
receptors with respect to immune and inflammatory responses has received some 
attention. For example, ∆9-THC can decrease the growth rate of CB1 and CB2 receptor 
expressing breast cancer tumors (Caffarel et al., 2010). This effect was blocked with 
CB2-selective antagonist SR144528, but not CB1-selective inverse agonist/antagonist 
rimonabant (SR141716A), indicating a specifically CB2 mediated mechanism. ∆
9-THC 
can also reduce signs of paw pain in a rat arthritis model, and this effect is reduced by 
SR144528. However, this effect is also partially CB1-dependent as it is also attenuated 
by rimonabant (Cox, Haller, & Welch, 2007).  
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∆9-THC does not exist in isolation within cannabis, and a variety of research 
focuses on potential interactions between ∆9-THC, other phytocannabinoids, and 
phytochemicals generally. These interactions are numerous and seem to occur via a 
number of indirect modulatory mechanisms. Because ∆9-THC is a CB1 receptor 
agonist, these interactions are potentially relevant to synthetic CB1 agonists, and are 
briefly reviewed in the following sections. 
 
1.2.4 Interactions between ∆9-tetrahydrocannabinol and cannabidiol 
Cannabis biosynthesises over one hundred phytocannabinoids beyond ∆9-THC 
(ElSohly & Gul, 2014). Of these, CBD has recently moved to the forefront of 
therapeutic cannabinoid research. Ongoing research has indicated applications in the 
treatment of anxiety (Blessing et al., 2015), epilepsy (Friedman & Devinsky, 2015), 
schizophrenia (Zuardi et al., 2012), pain (Notcutt et al., 2004), and cannabis 
withdrawal (Allsop et al., 2015). 
CBD is biosynthesied in a similar manner to ∆9-THC. CBGA (the precursor to 
THCA) is also a substrate for cannabidiolic acid (CBDA) synthase, which produces 
CBDA. Like THCA, CBDA is most concentrated in the glandular trichomes of 
cannabis, and can be decarboxylated to CBD via light and heat (Flores-Sanchez & 
Verpoorte, 2008). The molecular structure of CBD differs only slightly from ∆9-THC, 
yet this difference is sufficient to completely alter its pharmacology. Unlike ∆9-THC, 
CBD has poor binding affinity on both CB1 and CB2 receptors. CBD does not produce 
psychoactive effects in humans, and does not produce tetrad effects in rodents (Cascio 
& Pertwee, 2014). Instead, CBD appears to act via a range of mechanisms on several 
alternate molecular targets. It may indirectly modulate the effects of CB1 and CB2 
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agonists, is an antagonist at GPR55 (Ryberg et al., 2007), a partial agonist on serotonin 
(5-HT)1A receptors (Russo et al., 2005), and an allosteric modulator of µ and δ-opioid, 
dopamine D2, and γ-aminobutyric acid (GABA)A receptors (Kathmann et al., 2006).  
The interaction of CBD with ∆9-THC is an area of continuing research. Animal 
studies have suggested that CBD can both potentiate and attenuate the effects of ∆9-
THC (Cascio & Pertwee, 2014; Klein et al., 2011). CBD has been shown to dose-
dependently increase the effects of ∆9-THC on locomotor activity, rectal temperature, 
and spatial memory (Hayakawa et al., 2008; Reid & Bornheim, 2001). It can also 
potentiate ∆9-THC-produced inhibition of weight gain, anxiogenic effects, and 
decreases in social interaction in rats (Klein et al., 2011). Potentiation of ∆9-THC 
effects may occur through inhibition of enzymes belonging to the cytochrome P450 
2C and 3A subfamilies (Bornheim & Correia, 1989, 1990, 1991). On the other hand, 
CBD has been sometimes shown to attenuate the effects of ∆9-THC on operant 
behaviour (Zuardi et al., 1981), social interaction (Malone, Jongejan, & Taylor, 2009), 
and conditioned place aversion (Vann et al., 2008).  
In humans, a similar mix of potentiation and attenuation is observed. Studies 
have shown that CBD can attenuate some, but not all, of the psychoactive effects of 
∆9-THC. For example, CBD reduces anxiety and subjective ratings of intoxication 
produced by ∆9-THC in adults, but does not block tachycardic effects (Zuardi et al., 
1982). Studies have also shown that CBD can potentiate pleasurable ∆9-THC effects 
(Karniol et al., 1974), in addition to cardiac effects (Hollister & Gillespie, 1975). 
However, a more recent study found no difference in subjective or cardiac effects 
between ∆9-THC and a 50:50 mix of ∆9-THC and CBD (Sativex®) (Karschner et al., 
2011). The doses of ∆9-THC and CBD and the timing of dosing in the aforementioned 
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studies also vary widely. Thus, it appears that the relationship between CBD and ∆9-
THC is complex and can change based on the specific effect studied (e.g. anxiety vs 
heart-rate), on the dose of CBD and/or ratio of CBD to ∆9-THC, on the timing of 
dosing, and between species (e.g. human vs rat).  
It remains an interesting possibility that CBD could interact with other CB1 
agonists, including synthetic cannabinoids. If CBD can reduce some of the negative 
effects of ∆9-THC, then perhaps it can do the same for synthetic CB1 agonists, 
providing a possible intervention for synthetic cannabinoid intoxication. Conversely, 
the absence of CBD from synthetic cannabinoid preparations could possibly be 
detrimental. Continued research on the interaction between CBD and CB1 agonists 
could prove fruitful.  
 
1.2.5 Interactions between ∆9-tetrahydrocannabinol and other 
phytochemicals in Cannabis sativa 
 Beyond the phytocannabinoids, cannabis produces an extensive range of 
terpenoid compounds. Unlike phytocannabinoids, terpenoids are found in a wide 
variety of flowering plants. Interestingly, these compounds may pharmacologically 
interact with ∆9-THC, CBD, and other phytocannabinoids. By extension, they could 
also interact with synthetic cannabinoids. 
Terpenoids are diverse and abundant compounds that are largely responsible 
for the characteristic odours of most flowering plants (Knudsen et al., 1993), including 
cannabis. In addition to providing possible anti-fungal and pesticidal benefits for the 
plant (Gershenzon and Dudareva, 2007; Langenheim, 1994), terpenoid compounds 
have a variety of putative beneficial properties in humans and produce analgesic 
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(Lorenzetti et al., 1991), anxiolytic (Komiya et al., 2006), and sedative effects (do Vale 
et al., 2002). Like the phytocannabinoids, terpenoids are concentrated in the 
trichomes of the plant, and interestingly, phytocannabinoids and terpenoids are 
biosynthetically related. Terpenes are biosynthesised via combinations of five carbon 
isoprene units, and these same units are used in the biosynthesis of 
phytocannabinoids. Indeed, phytocannabinoids are “terpenophenolic” compounds; 
that is, they are synthesised via the combination of terpenes and phenols.  
Terpenoids may act directly or indirectly to modulate phytocannabinoid effects 
(Russo, 2011). For example, the terpene β-caryophyllene is a CB2 agonist in vitro 
(Gertsch et al., 2008). Direct action of terpenoids on CB1 receptors is unlikely, since a 
comparison of pure ∆9-THC and cannabis smoke (containing terpenoids) yielded no 
overall difference in CB1 binding in vitro (Fischedick et al., 2010a), and the subjective 
effects of pure ∆9-THC and cannabis are similar at low doses (Cooper et al., 2013; 
Wachtel et al., 2002). Nevertheless, interactions between terpenoids and 
phytocannabinoids via indirect mechanisms have been reported; for example, β-
linalool shows antinociceptive effects via adenosine A1 and A2A receptors (Peana et al., 
2006), as does β-myrcene via PGE-2 (Lorenzetti et al., 1991). These interactions have 
been collectively termed “the entourage effect” (Russo, 2011), although more research 
is needed to conclusively determine if terpenoids produce physiologically relevant 
interactive effects at concentrations found in cannabis. Nevertheless, if terpenoids can 
modulate the effects of ∆9-THC, then they may also modulate the effects of synthetic 
cannabinoids. Thus, as was the case for CBD, the total pharmacological effect of 
synthetic preparations may be influenced by the presence or absence of terpenoids. 
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1.3 The discovery and evolution of synthetic cannabinoids 
 
1.3.1 Early bicyclic synthetic cannabinoids 
 The structures of ∆9-THC and similar phytocannabinoids were used as 
templates for the first synthetic, i.e. human-designed, cannabinoids. These 
compounds were designed in order to investigate the endocannabinoid system, with 
the goals of building a mechanistic understanding of the system and discovering novel 
therapeutics. The earliest compounds were bicyclic synthetic cannabinoids that 
resulted from alterations to the chemical structure of ∆9-THC (Figure 1A). These 
include HU-210 and CP-47,497 (Figure 1B and 1C) which both possess greater affinity 
for CB1 and CB2 receptors than ∆
9-THC (Stern & Lambert, 2007; Titishov, Mechoulam, 
& Zimmerman, 1989; Weissman, Milne, & Melvin, 1982). Compounds of this type 
usually contain two six-membered rings and a hydrocarbon “tail” in a configuration 
similar to that of ∆9-THC. 
These compounds have been used with success in scientific investigations of 
cannabinoid pharmacology (Ottani & Giuliani, 2001). For example, competitive 
binding assays with radiolabelled CP-55,940 (a potent CB1 and CB2 receptor agonist) 
have been used to characterise the binding strength of a range of cannabinoid agonists 
(Thomas et al., 1998). Moreover, radiolabelled CP-55,940 was used to localise 
cannabinoid receptors in the central nervous system (Herkenham et al., 1990).  
The psychopharmacology of the early bicyclics has also been investigated, 
largely using rodent models. As expected, HU-210 and CP-55,940 produce tetrad 
effects in rats (Fox et al., 2001), which can be blocked by rimonabant (Chaperon & 
Thiébot, 1999). HU-210 can also impair rat learning in the water maze task when 
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administered daily at 50 µg/kg or higher (Ferrari et al., 1999), and can produce 
anxiogenic-like effects following sub-chronic treatment (Giuliani, Ferrari, & Ottani, 
2000). CP-55,940 can produce aversive effects in rats, as measured by conditioned 
place preference and conditioned taste aversion (McGregor, Issakidis, & Prior, 1996), 
although some studies have found mild rewarding effects, depending on dose and 
testing schedule (Braida et al., 2001). Chronic dosing with CP-55,940 can also produce 
lasting memory impairments in adolescent rats (O'Shea et al., 2004).  
Overall, the early bicyclic synthetic cannabinoids act similarly to ∆9-THC via 
action at CB1 receptors, although the available evidence suggests that some can 
produce more extreme effects, particularly on learning and memory (Higuera-Matas et 
al., 2015). This is presumably a result of the high potency of these compounds at CB1 
receptors. However, this relatively simplistic picture has since been complicated by 
the discovery of additional classes of cannabimimetic compounds that are structurally 
dissimilar to ∆9-THC and the early bicyclic synthetic cannabinoids. Such discoveries 
produced large increases in both the number and potency of synthetic cannabinoids, 
which has seemingly broadened the range of potential psychopharmacological and 
toxicological effects produced by these compounds.  
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Figure 1. Molecular structures of ∆9-THC and early synthetic cannabinoids. Note the 
structurally similarities between (A) ∆9-THC, (B) HU-210, and (C) CP-47,497, which 
each possess six-membered rings and hydrocarbon chains in similar configurations. 
Pravadoline (D) is also a cannabinoid receptor agonist, despite substantial structural 
differences from the early bicyclic synthetic cannabinoids. See Section 1.3.2 for further 
detail. 
 
1.3.2 Pravadoline and the aminoalkylindoles 
The synthetic cannabinoid landscape diversified with the development of 
pravadoline (WIN-48,098; (4-methoxyphenyl)[2-methyl]-1-[2-(4-morpholinyl)ethyl]-
1H-indol-3-yl]-methanone) in the 1980s. Pravadoline was developed as an anti-
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inflammatory cyclooxygenase inhibitor, but unexpectedly produced strong analgesic 
effects at doses ten times below its effective anti-inflammatory dose. Antagonist 
studies with naloxone and opioid receptor binding studies demonstrated that this 
analgesic effect was not opioid dependent (Haubrich et al., 1990). Further research 
revealed that pravadoline was in fact a CB1 receptor agonist (D'Ambra et al., 1992).  
The chemical structure of pravadoline differs substantially from that of the 
phytocannabinoids and phytocannabinoid-based synthetic cannabinoids (Figure 1D). 
Pravadoline is an aminoalkylindole, and further experimentation with variants of this 
structure revealed that many compounds of this class act on cannabinoid receptors as 
agonists or antagonists (Aung et al., 2000; D'Ambra et al., 1992; Huffman et al., 1994). 
An early example of this class is WIN-55,212-2 ([(3R)-2,3-dihydro-5-methyl-3-(4-
morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl-
methanone), an aminoalkylindole with strong cannabinoid receptor binding affinity 
(CB1 Ki = 1.9 nM, CB2 Ki = 0.28 nM) (Kuster et al., 1993). An important property of 
WIN-55,212-2 and many aminoalkylindole synthetic cannabinoids is that they are full 
agonists; that is, they have maximum efficacy at cannabinoid receptors (Fantegrossi et 
al., 2014). This is in contrast to ∆9-THC, which is a partial agonist that cannot activate 
CB1 receptors to the same extent regardless of concentration. It is therefore possible 
that aminoalkylindole synthetic cannabinoids may produce effects beyond or entirely 
different to that of ∆9-THC. 
This aminoalkylindole framework underwent extensive development in the 
1990s. Of particular note is the development of the “JWH” and “AM” series of synthetic 
cannabinoids, named after their creators John W. Huffman and Alexandros 
Makriyannis respectively (Huffman et al., 1994; Makriyannis & Deng, 2005). Together, 
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these series are comprised of over 200 unique compounds with varying cannabinoid 
receptor binding affinity. Of these compounds, JWH-018 (1-pentyl-3-(1-
naphthoyl)indole) possessed strong CB1 receptor affinity and was relatively easy to 
synthesise, and became the most well-known synthetic cannabinoid in recreational 
products. However, it should be noted from the outset that synthetic cannabinoid 
products contain an enormous variety of synthetic cannabinoids with diverse yet 
related molecular structures. 
 
1.3.3 Synthetic cannabinoids as recreational drugs 
By the mid-2000s, a large collection of synthetic CB1 agonists had been 
identified in scientific literature. Their syntheses were readily available, and were also 
straightforward for many aminoalkylindoles. Moreover, these compounds were largely 
unknown outside of the research community and were consequently legal, or at least 
not explicitly illegal, to possess or manufacture in most countries. In light of these 
factors, it is of little surprise that synthetic cannabinoids have been used recreationally 
as novel psychoactive substances. 
Synthetic cannabinoids experienced a spike in popularity in 2004, when the 
product “Spice” commenced sale in European markets. Initially, synthetic 
cannabinoids were sold in online marketplaces, often under the guise of “research 
chemicals”. In this setting, compounds could be ordered in a powdered or crystalline 
form, albeit with little to no testing of purity or confirmation of chemical identity. 
Alternatively, products were packaged and sold as “natural”, “herbal”, or “legal highs”. 
These products proved to be immensely popular, and profitable – the first company to 
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commence sale in Europe, “The Psyche Deli”, reportedly made profit of £700,000 
between 2006 and 2007 (Schifano et al., 2009). 
The packaging of early herbal products listed up to 14 different types of plants, 
two of which had potential psychoactive effects (Seely et al., 2011). However, the two 
plants - Pedicularis densiflora (indian warrior) and Leonotis leonuris (lion’s ear) – were 
not known to be able to produce the intense highs described by users. This prompted 
researchers to analyse the products for additionally psychoactive ingredients. It was 
quickly discovered that in reality, these “herbal” products contained a number of 
synthetic cannabinoids, primarily JWH-018 (EMCDDA, 2009). These products were 
produced by dissolving synthetic cannabinoid compounds of unknown purity in a 
volatile solvent and then spraying the mixture onto largely inert plant material. This 
process was not mentioned on the product packaging, nor was there any mention of 
synthetic cannabinoids. Often products were labelled “not for human consumption” in 
an attempt to circumvent legislation (Figure 2). 
After this discovery, recreational synthetic cannabinoid products were 
monitored by the European Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA). However, synthetic cannabinoid products quickly spread to other 
markets and were found in the USA in 2008, containing the older, phytocannabinoid 
derived HU-210. Similarly synthetic cannabinoids were detected in Japan in 2008, and 
in Australia in 2011, although it is possible that synthetic cannabinoid use began 
several years before they were detected (Barratt, Cakic, & Lenton, 2012).  
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Figure 2. Front and back of a typical synthetic cannabinoid product “Banana Cream 
Nuke”, as published by Schneir, Cullen, and Ly (2011). Note that a variety of ingredients 
are listed, none of which are synthetic cannabinoids, and that it displays the warning 
“NOT FOR HUMAN CONSUMPTION”. This particular product contained JWH-018 and 
JWH-073 ((1-butyl-1H-indol-3-yl)-1-naphthalenyl-methanone), and produced tachycardia 
and severe anxiety in two people admitted to an emergency department. 
 
During this time, the pharmacological and legal situation remained unclear, 
among both synthetic cannabinoid users and concerned members of the public. The 
pharmacology of synthetic cannabinoid use in humans was unknown until the 
publication of case studies focusing on acute toxicity, and some studies using animal 
models (reviewed in Section 1.3). The legislative and forensic responses to synthetic 
cannabinoid products varied widely between countries, and are reviewed in Section 
1.4.  
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1.3.4 Common structures and modifications 
Modern synthetic cannabinoids are comprised of a variety of chemical classes 
beyond the aminoalkylindoles. The complexity of synthetic cannabinoid nomenclature 
can be seen in their increasingly long abbreviations (for example, AB-CHMINACA is 
short for N-[(1S)-1-(aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-
indazole-3-carboxamide). However, the composition of most synthetic cannabinoids 
can be simplified, such that most structures can be decomposed into four broad 
components (EMCDDA, 2016; Figure 3): 
1) A core, typically an indole or indazole moiety 
2) A “bulky” structure that varies widely, often utilising ring structures, including 
but not limited to naphthyl, adamantyl, or cyclopropyl moieties 
3) A linker or “bridge”, often a carboxamide, carboxylate, or methanone moiety, 
connecting the core and bulky structure 
4) A tail, extending from the core, often an N-pentyl chain, which is frequently 
terminally halogenated 
These components can be combined in various configurations in order to 
generate large numbers of novel compounds. For example, JWH-018 is composed of 
an indole core, a naphthyl bulky structure, a methanone linker, and an N-pentyl tail 
(Figure 3A). Terminal fluorination of the N-pentyl chain yields AM-2201 (1-(5-
fluoropentyl)-3-(1-naphthoyl)indole; Figure 3B). Alternatively, the indole moiety of 
JWH-018 could be replaced with an indazole to yield THJ-018 (1-naphthalenyl(1-
pentyl-1H-indazol-3-yl)-methanone; Figure 3D), or the naphthyl moiety could be 
exchanged for an adamantyl group to give AB-001 (1-pentyl-3-(1-adamantoyl)indole; 
Figure 3C), a compound first detected in Irish recreational products in 2010 
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(Grigoryev, Kavanagh, & Melnik, 2012). Substitution of the methanone linker of AB-
001 for a carboxamide results in SDB-001 (also known as APICA; N-(1-adamantyl)-1-
pentyl-1H-indole-3-carboxamide; Figure 3E) found in Japan in 2012 (Uchiyama et al., 
2013). SDB-001 can then be modified; for example, swapping the adamantyl moiety for 
an α,α-dimethylbenzyl group yields CUMYL-PICA (N-(1-methyl-1-phenylethyl)-1-
pentyl-1H-indole-3-carboxamide; Figure 3F), which was detected in Europe in 2014 
(EMCDDA, 2014).  
Note that there are many alternate pathways and connections between the 
structures of these and other synthetic cannabinoids, and some exceptions to this 
general framework. For example, EG-018 (naphthalen-1-yl(9-pentyl-9H-carbazol-3-
yl)methanone) is an analogue of JWH-018, with a benzene ring directly attached to 
the aminoalkylindole group. This modification is rarely seen elsewhere. However, for 
the majority of synthetic cannabinoids, the above framework is useful in the 
conceptualisation of the relationships between large numbers of compounds, and for 
understanding of various structure-activity relationships (SARs) that exist within the 
many classes of synthetic cannabinoids. 
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Figure 3. Molecular structures of synthetic cannabinoids (A) JWH-018, (B) AM-2201, 
(C) AB-001, (D) THJ-018, (E) SDB-001, and (F) CUMYL-PICA. All structures have a core, 
linker, tail, and bulky structure, which can be altered to produce many diverse yet 
structurally related compounds (see text for further detail). 
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1.3.5 Structure-activity relationships 
 The use of SARs to predict the pharmacological properties of novel synthetic 
cannabinoids is an important area of research. Rather than individually testing each 
and every novel compound, it may be possible to predict the pharmacology of novel 
synthetic cannabinoids by understanding the effects of common structural alterations. 
Specifically, understanding how certain components of synthetic cannabinoids (e.g. 
tail length, bulky group composition) impact cannabinoid receptor binding strength 
and in vivo responses is an important area of research. 
 Some SARs have been established within specific classes of cannabinoids. 
Bicyclic synthetic cannabinoids (e.g. CP-47,497 and the early ∆9-THC –derived 
compounds) exhibit maximum binding affinity with a six or seven membered ring 
structure in place of the cyclohexyl ring of ∆9-THC (Melvin et al., 1993). Alkyl 
extensions from the cyclohexyl ring do not affect binding, but hydroxyalkyl extensions 
of three or four carbons improve binding strength at CB1 receptors (Figure 4). 
Additionally, bicyclic synthetic cannabinoids bind to cannabinoid receptors most 
strongly when their alkyl chains have seven or eight carbons (Melvin et al., 1993). In 
aminoalkylindoles, the length of the alkyl “tail” also profoundly affects cannabinoid 
receptor binding. A tail length of at least three carbons is necessary for high binding 
affinity at CB1 and CB2 receptors, and a length of five carbons is optimal (Aung et al., 
2000). Extension of the tail to seven or more carbons results in a sharp decrease in 
binding affinity at both cannabinoid receptors.  
 Other SARs are at present partly characterised or uncharacterised. For example, 
many synthetic cannabinoids with N-pentyl tails are terminally fluorinated, forming 
pairs of fluorinated and non-fluorinated compounds. AM-2201 is the 5-fluoropentyl 
Chapter 1 29
 
 
analogue of JWH-018, XLR-11 (1-(5-fluoropentyl)-1H-indol-3-yl)(2,2,3,3-
tetramethylcyclopropyl)methanone) is the 5-fluoropentyl analogue of UR-144 (1-
(pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-methanone), and 5F-PB-22 (1-
(5-fluoropentyl)-8-quinolinyl ester-1H-indole-3-carboxylic acid) is the 5-fluoropentyl 
analogue of PB-22 (1-pentyl-8-quinolinyl ester-1H-indole-3-carboxylic acid). Terminal 
bromination or iodination of the N-pentyl chain is known to increase cannabinoid 
receptor binding in ∆9-THC analogues (i.e. early bicyclic synthetic cannabinoids), and 
fluorination produces a smaller increase in affinity (Compton et al., 1993). This is less 
well characterised in aminoalkylindoles and it is unknown whether any such increases 
in binding affinity carry through to improve in vivo efficacy. Similarly, the effect of 
modification of the “bulky” groups of synthetic cannabinoids is also yet to be fully 
characterised. For example, the in vivo pharmacological effect of the substitution of 
the naphthyl group in JWH-018 for the adamantyl group in SDB-001 is unknown. 
Further research is needed to establish the in vivo and in vitro consequences of such 
structural alterations. 
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Figure 4. Structure-activity relationships for (A) aminoalkylindoles, with AM-2201 as 
an example, and (B) bicyclic synthetic cannabinoids, with CP-55,940 as an example. 
Structural components that improve cannabinoid receptor binding affinity are labelled. 
The effects of aminoalkylindole halogenation and bulky group composition on in vivo 
pharmacology are presently uncharacterised. 
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1.4 The psychopharmacology of synthetic cannabinoids 
  
1.4.1 Acute effects  
Recreationally used synthetic cannabinoids are usually strong CB1 receptor 
agonists, so it would be expected that they would produce effects similar to, or 
possibly exceeding, that of ∆9-THC. Indeed, the overall effects of synthetic 
cannabinoids in humans are typically described as being somewhat similar to that of 
cannabis, with additional, often negative, side effects (Winstock & Barratt, 2013). A 
global survey of synthetic cannabinoid users revealed that synthetic cannabinoid 
products reportedly had a shorter onset of effects as compared to cannabis (Winstock 
& Barratt, 2013). Moreover, users reported that synthetic cannabinoids produced more 
negative effects, hangover effects, and paranoia. Anecdotal online user reports 
describe similar effects, including anxiety and paranoia, vomiting, catalepsy, 
convulsions, agitation, and addiction. For example: 
 
“After about 10 minutes and only about 3 hits of the 'Smiley Dog' herbal incense 
we are so high we cannot stand or walk... I lose motor control and can no longer 
stand after 20 minutes. My heart feels as if it is going to explode, I become 
convinced I could die at any moment. A tingling feeling starts at the tips of my 
fingers and slowly works its way up to my hands, then up my arm… At this point I 
lose it, and have my friend call an ambulance… I'm vomiting and the tingling 
feeling has moved terrifyingly close to my heart. When the ambulance arrives 
they cannot bring me under control and I cannot stop my body from convulsing, 
shaking, and screaming … They had to strap me to a gurney and put me in an 
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ambulance… They administered 10 milligrams of [lorazepam] to try to calm me 
down but nothing really works until I'm at the emergency room and they put me 
down with [ziprasidone]. I'm convinced JWH-018 triggered a full psychotic break 
in me.” (Evilpoptart, 2011) 
 
This user seems to describe motor function impairment and tachycardia 
followed by a panic attack produced by a synthetic cannabinoid (which the user 
assumes to be JWH-018). Similar case reports are abundant across various internet 
forums, and closely mirror symptoms described in emergency room case studies 
(Schneir et al., 2011; Schwartz et al., 2015). 
In rodents, synthetic cannabinoids with high CB1 affinity produce classic 
“tetrad” effects, the same as those produced by ∆9-THC. Hypothermia can be reliably 
produced by JWH-018, SDB-001, UR-144, and XLR-11 in rodent models (Banister et al., 
2013; Wiley et al., 2015). This effect is dose-dependent, blocked by rimonabant, and 
absent in CB1 knockout mice. In general, recreationally abused synthetic cannabinoids 
are several times more potent than ∆9-THC in rodent models, as would be expected 
given their strong binding affinity and full agonism at CB1 receptors. The remaining 
three tetrad effects – analgesia, catalepsy, and hypomotility – are also observed in 
rodents following synthetic cannabinoid administration (Wiley et al., 2013). However, 
large numbers of synthetic cannabinoids have never been assessed for their in vivo 
effects. 
Tetrad assessment is a widely used screening tool, but it is limited in some 
aspects. Importantly, CB1 receptor agonism requires confirmation using antagonists or 
CB1 genetic knockouts, because all four tetrad measures are non-specific – that is, they 
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can be produced by other pharmacological mechanisms. Additionally, tetrad effects do 
not necessarily reflect psychoactivity – i.e. the cannabis “high”. To assess suspected 
psychoactive effects in rodents, drug discrimination paradigms have been utilised 
(Wiley et al., 2015; Wiley et al., 2013). In these paradigms, rodents are trained to 
respond in a certain way (e.g. lever press on a particular lever) when administered a 
drug (e.g. ∆9-THC). Drugs that produce similar subjective effects (e.g. synthetic 
cannabinoids) should elicit the same response. UR-144, XLR-11, AB-CHMINACA, AB-
PINACA ((S)-N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-
carboxamide), FUBIMINA ((1-(5-fluoropentyl)-1H-benzo[d]imidazol-2-yl)(naphthalen-
1-yl)methanone), JWH-018, and several 1-pentyl-3-phenylacetylindoles substitute for 
∆9-THC in drug discrimination assessments (Wiley et al., 2015; Wiley et al., 2013; 
Wiley et al., 2012).  
Another issue with the tetrad assessment is that measurement of each effect 
requires experimenter manipulation of the animal. For example, commonly used 
rectal temperature measurement can produce artifactual hyperthermic effects due to 
stress. In recent years, technological advancement in implantable radiotelemetric 
probes have permitted the measurement hypothermia in real time, allowing a high 
rate of sampling while avoid confounding effects from animal handling. Application of 
these radiotelemetric probes to synthetic cannabinoid screening has been 
demonstrated, and has shown that JWH-018 and SDB-001 produce hypothermic 
effects that last for at least 5 hours post-drug administration (Banister et al., 2013). 
Additionally, implantable radiotelemetric probes can measure heart-rate in real time. 
As reviewed in Section 1.2.3, the effect of cannabinoids on heart rate is undefined 
compared to standard tetrad effects. In humans, tachycardia is usually observed 
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following synthetic cannabinoid or ∆9-THC administration (Lapoint et al., 2011; 
Renault et al., 1971; Schneir et al., 2011), yet in rodents, CB1 receptor agonists produce 
bradycardia as measured via radiotelemetry probes (Banister et al., 2013). It is not 
clear whether this bradycardic effect is a direct action of CB1 activation or instead a by-
product of hypothermia or locomotor suppression. Nevertheless, these alternate 
measurement techniques are potentially useful for high throughput screening of the 
acute effects of novel synthetic cannabinoids in vivo. 
 
1.4.2 Acute toxicity  
In addition to the acute behavioural and physiological effects described in the 
previous section, severe toxicity has also been reported following synthetic 
cannabinoid administration. These include acute kidney injury, cardiotoxicity, 
cerebral ischemia, and seizures.  
Multiple case reports detail acute kidney injury following use of synthetic 
cannabinoids (Bhanushali et al., 2012; Buser et al., 2014; Pendergraft et al., 2014; 
Thornton et al., 2013). Generally, these cases concern individuals who have been 
admitted to emergency wards following the use of one or more synthetic cannabinoid 
products, often in conjunction with other drugs or alcohol. Histological examination 
has revealed acute injury to tubules in the renal cortex and increased inflammation in 
the renal medulla (Buser et al., 2014). It should be noted, however, that no case study 
has been able to confirm whether these injuries are produced by a synthetic 
cannabinoid in isolation, or an interaction of one or more synthetic cannabinoids with 
each other or other substances, by the product medium, or contaminants.  
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Cardiovascular side effects have been reported in numerous case studies 
reporting synthetic cannabinoid effects (Hermanns-Clausen et al., 2012; Mir et al., 
2011; Schwartz et al., 2015; Young et al., 2012). Tachycardia and hypertension seem 
particularly common, which might be expected given that ∆9-THC reliably increases 
heart rate in humans (Ashton, 2001). Beyond tachycardia and hypertension, 
palpitations have been reported (Schneir et al., 2011). It is unclear whether these 
palpitations are a direct pharmacological effect or if they are more closely linked to the 
anxiogenic features of synthetic cannabinoids. Most alarmingly, there is also evidence 
that suggests the involvement of synthetic cannabinoids in cases of acute myocardial 
infarction (Mir et al., 2011; Schwartz et al., 2015). 
Ischemic stroke following synthetic cannabinoid use has been reported on 
several occasions (Degirmenci, Kececi, & Olmez, 2016; Freeman et al., 2013; Inal et al., 
2014). For example, Bernson-Leung, Leung, and Kumar (2014) reported cases of 
ischemic stroke in two women, aged 22 and 26. Similarly, Dogan et al. (2016) reported 
the occurrence of strokes in two men aged 28 and 35 while using synthetic 
cannabinoids. In some cases, the locations of strokes indicate an embolic aetiology, 
such that hypertension, tachycardia and arrhythmia could expose a pre-existing 
vulnerability in certain people (Degirmenci et al., 2016; Dogan et al., 2016).  
Interestingly, to the author’s knowledge, there are no published studies that 
report acute toxicity in animals following synthetic cannabinoid administration. 
Moreover, in humans, only 3.5 % of synthetic cannabinoid users experience acute 
toxic effects requiring urgent medical care, although this statistic rises to 12.5 % for 
regular (weekly or more) users (GDS, 2016). That is, synthetic cannabinoid products as 
a whole do not seem to produce toxicity in a reliable manner. Reasons for this 
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variability may include unique toxidromes for each compound, specific drug 
interactions, dosage, user vulnerability, and product contamination. In some cases, 
specific compounds have been implicated in a number of poisoning cases. For 
example, a recent cluster of toxicity in New York has been attributed to AMB-
FUBINACA (methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate), which 
was found in both the suspected product and blood of several patients (Adams et al., 
2017). In other cases, contamination of a particular batch of products may be the root 
cause. Contamination of synthetic cannabinoid products with caffeine, O-
desmethyltramadol (an opioid analgesic), eugenol, and nicotine has been documented 
(Dresen et al., 2010). In sum, the available evidence indicates that some synthetic 
cannabinoid compounds or products may be substantially more toxic than others. 
Identification of toxic compounds before they reach large numbers of users is 
therefore a crucial area of research. 
 
1.4.3 Metabolism  
Synthetic cannabinoid metabolism appears to proceed in a similar manner to 
phytocannabinoids – predominantly undergoing oxidative transformations (e.g. 
hydroxylations) before phase II glucuronidation. These hydroxylations occur in most 
reports of synthetic cannabinoid metabolism (Sobolevsky, Prasolov, & Rodchenkov, 
2010; Takayama et al., 2014; Thomsen et al., 2014). Other phase II transformations 
(e.g. sulfation) are generally not observed.  
For synthetic cannabinoids containing a carboxamide or ester bulky group, 
metabolic transformations other than hydroxylation appear to be favourable. Available 
studies suggest that in these cases, hydrolysis is a primary metabolic pathway.  For 
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example, indazole carboxamides AB-PINACA and AB-FUBINACA are hydrolysed 
primarily by carboxylesterase 1 (Thomsen et al., 2014). A similar hydrolysis occurs for 
quinolinol synthetic cannabinoids PB-22 and 5F-PB-22 (Takayama et al., 2014; 
Thomsen et al., 2014). Hydroxylation then precedes on the hydrolysis products. 
Importantly, minor metabolic transformations can produce metabolites that 
retain CB1 binding affinity. For example, JWH-018 can be hydroxylated to form a 
metabolite that retains CB1 binding affinity (Seely, Brents, et al., 2012). 
Glucuronidation then forms a metabolite which is an antagonist at CB1 receptors. 
Thus, in vitro assessments of potency of the parent compound in isolation may not 
accurately reflect potency following metabolic transformations in vivo.  
Closely structurally related synthetic cannabinoids (e.g. fluorinated analogues) 
may produce identical metabolites (Andersson et al., 2016). This has the potential to 
thwart forensic attempts to identify a unique compound in biological samples. This 
problem may be compounded if the metabolic pathways that produce such 
metabolites are highly favoured. Thus, careful choice of forensic targets may be 
required, but for many new synthetic cannabinoids, these metabolic pathways are 
uncharacterised. 
Most studies that characterise synthetic cannabinoid metabolism do so using 
microsomal and hepatocyte incubations (Andersson et al., 2016; Takayama et al., 2014; 
Thomsen et al., 2014; Wohlfarth et al., 2014). Relatively few studies have been 
conducted using in vivo models (Carlier et al., 2016). Interestingly, metabolism often 
appears to be rapid in microsomal incubations, particularly for compounds possessing 
less stable functional groups like esters (Andersson et al., 2016; Takayama et al., 2014). 
Yet human case studies and radiotelemetric data indicate that the effects of synthetic 
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cannabinoids persist over several hours (Banister et al., 2013; Lapoint et al., 2011), and 
that in some cases, the parent compound remains detectible in adipose tissue for an 
extended period of time (Hasegawa et al., 2015). Therefore, there appears to be a 
discrepancy between in vivo and in vitro pharmacokinetic data. Future studies that 
directly compare in vivo and in vitro models of synthetic cannabinoid 
pharmacokinetics may prove valuable. 
 
1.4.4 Thermal degradation 
Smoking or vaporising synthetic cannabinoids involves heating to high 
temperatures. Burning a cigarette or joint produces temperatures of approximately 
700 °C, which can increase up to 900 °C during puffs (Baker, 1974). At these 
temperatures, there is emerging evidence that some synthetic cannabinoids thermally 
decompose, forming a variety of thermolysis products. For example, UR-144 and XLR-
11 contain a tetramethylcyclopropyl ring system that is sterically strained and opens 
when heated when burnt (Figure 5) (Adamowicz, Zuba, & Sekuła, 2013; Grigoryev et 
al., 2013). These ring-opened degradants retain affinity and efficacy at CB1, and can 
substitute for ∆9-THC in drug discrimination tests (Thomas et al., 2017). Thus, like 
synthetic cannabinoid metabolites, pyrolysis products may play a role in the total 
effect of synthetic cannabinoids. 
There is also the possibility that some synthetic cannabinoids could form toxic 
thermal degradants. For example, a common constituent of synthetic cannabinoids is 
a naphthyl group, which in isolation (i.e. naphthalene) is a suspected human 
carcinogen. If that group is thermally liberated from the remaining structure and 
inhaled, it could theoretically produce toxicity over and above that of the parent 
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Figure 5. (A) UR-144 and (B) UR-144 thermal degradant formed after heating to 800 °C. 
Note that the degradant not only retains cannabinoid receptor binding affinity, but binds 
more strongly to CB1 and CB2 receptors than the parent compound. Binding values 
determined via [3H]CP-55,940 displacement (Thomas et al., 2017). 
 
compound. Similarly, carboxamide synthetic cannabinoids could thermally 
decompose into a range of amides and nitriles (Davidson & Karten, 1956; Metcalfe et 
al., 1983). Even fluorinated degradants, including hydrofluoric acid, could theoretically 
be liberated from fluorinated synthetic cannabinoids (Hutter et al., 2013).  
Crucially, thermal degradants and their effects will not be detected in studies 
using other routes of administration (e.g. injections or infusions). If a synthetic 
cannabinoid produces thermal degradants that retain cannabinoid receptor affinity, as 
appears to be the case with UR-144 above, then the pharmacological impact of that 
compound may be under or overestimated. It is noteworthy that the thermal 
degradants of several classes of synthetic cannabinoids, such as the increasingly 
detected and potentially toxic carboxamides, are presently unknown.  
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1.4.5 Long-term effects and toxicity 
 As synthetic cannabinoid use is a relatively recent phenomenon, there are very 
few reports of the long-term effects of synthetic cannabinoid use in humans. Some 
users anecdotally report addiction, although a specific synthetic cannabinoid is rarely 
specified and multiple drug use is frequently reported, for example: 
 
“I have been clean for 14 days now from the synthetic weed. I was addicted to it 
for a year. The only way I got clean was when all smoke shops here … were raided 
and shut down. I was so angry when this happen cause the cravings were 
unbarable [sic]. This drug has turn [sic] me in to [sic] a depressed person with 
anxietx [sic]... I still get the urge every now and then to smoke but it usllay [sic] 
goes away within 10 min... I would say this addiction is up there in the crack 
addiction. I would know because I was addicted to crack from 2006 to 2007.” 
(brittney_burch, 2013) 
 
Tolerance and withdrawal following repeated use of synthetic cannabinoid 
products has also been reported in scientific literature (Macfarlane & Christie, 2015; 
Zimmermann et al., 2009). Common symptoms of synthetic cannabinoid withdrawal 
are irritability, agitation, anxiety, depression, and mood swings. This symptomology 
appears to be similar to cannabis withdrawal syndrome, which as mentioned in 
Section 1.1.2, can also produce irritability, agitation, and anxiety (Allsop et al., 2012). 
However users (as above) describe synthetic cannabinoid withdrawal as more severe 
than for cannabis (Winstock & Barratt, 2013), sometimes comparing it to cocaine or 
opiate withdrawal. 
Chapter 1 41
 
 
 Unfortunately, physiological and toxicological data are extremely limited 
beyond acute case reports. A very recent study has reported impairments to executive 
function in chronic synthetic cannabinoid users, compared to both cannabis and non-
cannabis users (Cohen et al., 2017). However, the authors could not focus on any one 
specific synthetic cannabinoid, nor could they rule out additional drug or medication 
use or the impact of socioeconomic status. Unfortunately, to the author’s knowledge, 
there are no controlled studies concerning long-term toxic outcomes of synthetic 
cannabinoid use using animal models.   
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1.5 Legislation, forensics, and treatments  
 
1.5.1 Reasons for synthetic cannabinoid use/abuse 
In spite of the apparent dangers discussed in the previous sections, people 
continue to use synthetic cannabinoids. Using products of unknown potency and 
composition with a number of negative side-effects, and a high possibility of toxicity 
or addiction, does not seem appealing. However, like other drugs of abuse, the use of 
synthetic cannabinoids appears to be mediated by a wide array of factors (Figure 6). 
Understanding these factors is important for the design of effective legislation and 
treatments. 
User surveys have found that the most commonly stated reason for using 
synthetic cannabinoids is simple curiosity, or as an alternative to cannabis use 
(Vandrey et al., 2012; Winstock & Barratt, 2013). Nearly all surveyed synthetic 
cannabinoid users report having used cannabis previously (Winstock & Barratt, 2013). 
However, most users do report a preference for cannabis over synthetic cannabinoid 
products (Winstock & Barratt, 2013), citing adverse side-effects as a dissuading factor.  
Workplace drug testing has been identified as a strong motivating factor for 
synthetic cannabinoid use (Gunderson et al., 2014). There is a delay between first 
detection of a novel synthetic cannabinoid, the development of forensic analyses, and 
the widespread implementation of these analyses. These delays create a period of time 
in which drug tests may fail to detect use of novel synthetic cannabinoids. These same 
tests are generally capable of detecting cannabis use, thereby encouraging synthetic 
cannabinoid use over cannabis, despite a higher risk of adverse side-effects. Although 
Chapter 1 43
 
 
 
Figure 6. Self-reported reasons for first using synthetic cannabinoids from 316 
Australian synthetic cannabinoid users (Barratt et al., 2012). 
 
blood and urine screens for synthetic cannabinoids have developed in recent years in 
response to increasing data regarding synthetic cannabinoid pharmacokinetics and 
metabolism (Hutter et al., 2012; Marino et al., 2016), newly discovered synthetic 
cannabinoids can remain undetected in drug screens for a substantial period of time. 
This is discussed further in Section 1.5.3. 
In places where synthetic cannabinoids are not yet banned, or where 
enforcement of legislation is lax or impractical, real or implied legality might be 
interpreted as a tacit guarantee of product safety. Products sold in physical “bricks and 
mortar” stores may be assumed to have met the product safety requirements of that 
jurisdiction. In reality, synthetic cannabinoid products have undergone no 
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toxicological testing. Additionally, in places where cannabis is illegal, so called “legal 
highs” provide an attractive alternate to illicit drug use. In a survey of Australian 
synthetic cannabinoid users, the second most common reason for use (behind 
curiosity) was that “synthetic cannabinoids are/were legal” (Barratt et al., 2012, p. 4). 
The legal status of synthetic cannabinoids is reviewed in Section 1.5.2. 
The ease with which products can be obtained through stores and online 
marketplaces also contributes to the popularity of synthetic cannabinoid products 
(Barratt et al., 2012). Synthetic cannabinoids, along with some other designer and 
non-designer drugs of abuse, can be packaged and shipped discreetly, because most 
can be powdered, stored at room temperature, and do not possess a strong odour. 
Users have reported that synthetic cannabinoids are easier to obtain than cannabis 
(Barratt et al., 2012). 
And finally, as reviewed in Section 1.4.5, addiction and withdrawal symptoms may 
contribute to the development of chronic synthetic cannabinoid use. This does not 
account for first use, but likely accounts for a substantial portion of total synthetic 
cannabinoid sales. Effective treatment of chronic users may therefore be particularly 
important for reducing the size of the synthetic cannabinoid market. 
 
1.5.2 Legislation and the “chemical arms race” 
In response to the psychoactive and potentially toxic effects reviewed in the 
previous sections, many countries have implemented legislation to curb the use of 
synthetic cannabinoids. International drug scheduling legislation (i.e. the UN 
Convention on Psychotropic Substances of 1971) contained no provisions concerning 
structural analogues of scheduled drugs, so the precise method of drug control fell to 
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individual jurisdictions. The scope and implementation of such legislation varies 
widely between and within countries. In many cases (e.g. Japan and the US) early 
legislation banned individual compounds, which triggered a “chemical arms race” that 
rapidly replaced banned compounds via structural alterations (Section 1.3.4). 
Subsequent laws attempted to ban substances based on chemical class (e.g. belonging 
to the aminoalkylindole class), effect (e.g. producing cannabimimetic effects), or 
action (e.g. binding to CB1), in order to capture novel synthetic cannabinoid variants. 
In Europe, a number of countries (Austria, Estonia, France, Germany, 
Lithuania, Luxembourg, Poland, Sweden, and the UK) implemented controls on 
synthetic cannabinoids in 2009, such that all synthetic cannabinoid products were 
banned from head shops and online stores (Seely, Lapoint, et al., 2012). Similar bans 
were expanded to Denmark, Ireland, Italy, Latvia, and Romania by 2011, and to 
Finland, Russia, and Switzerland by 2014 (Thomas et al., 2014). 
In the United States in 2011, the DEA placed JWH-018, JWH-200 ([1-[2-(4-
morpholinyl)ethyl]-1H-indol-3-yl]-1-naphthalenyl-methanone), JWH-073, CP-47,497, 
and cannabicyclohexanol into Schedule I for one year (Fattore & Fratta, 2011). This was 
followed by the Food and Drug Administration Safety and Innovation Act (2012) that 
banned substances via the placement of any CB1 agonist into Schedule I. Canada 
implemented similar controls on all “synthetic preparations of cannabis” (CCENDU, 
2014, p. 3).  
In 2013, Australia implemented a 3 month interim ban on the possession or sale 
of synthetic drug products in response to high-profile cases of toxicity produced by a 
range of synthetic drugs beyond synthetic cannabinoids. Following expiration of the 
ban, most Australian states implemented legislation regulating synthetic products. In 
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particular, New South Wales enacted “analogue laws” that banned substances based 
on chemical class or cannabimimetic activity. Additionally, Queensland, New South 
Wales, and South Australia  placed a blanket ban on possessing or selling any 
psychoactive substance other than alcohol, tobacco, and food (ADF, 2016). New 
Zealand originally allowed synthetic products to be sold if their safety could be 
demonstrated, but subsequently banned the sale and possession of designer drugs 
following concern about their addictive potential (The Guardian, 2014).  
The use of analogue laws such as those present in Australia or the United States 
are intended to counter circumvention via structural alterations, however loopholes 
remain. For example, if a structure falls outside established classes of CB1 agonists, 
binding studies must be performed to demonstrate CB1 efficacy before that structure 
can be legislated against. This takes time, during which a particular synthetic 
cannabinoid can be technically legal, or at least not explicitly illegal. In some cases, 
cannabimimetic activity may also need to be established before prosecutions can take 
place, even if the compounds belong to a known cannabimimetic class. Consequently, 
cases of poisoning caused by synthetic cannabinoid products sold from stores have 
persisted even after legislation has been enacted, and structural alterations are still 
used to circumvent legislation (Brook, 2016). Surveys of synthetic cannabinoid 
products show that over the last decade popular synthetic cannabinoids have emerged 
in waves as a result of legislative bans (Schwartz et al., 2015). In 2010-2012, JWH-018 
and AM-2201 were frequently detected in synthetic cannabinoid products, but their 
popularity declined sharply as they were specifically banned in several countries 
(NFILS, 2014). They were replaced by various indole carboxylates and indole or 
indazole carboxamides (Schwartz et al., 2015). Despite these legal difficulties, it should 
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be noted that legislation has been effective in reducing synthetic cannabinoid use. For 
example, synthetic cannabinoid use in New Zealand fell sharply following bans in 2014 
(GDS, 2016).  
 
1.5.3 Forensic detection and identification of synthetic cannabinoids 
 The frequently changing synthetic cannabinoid landscape has proven 
challenging for forensic chemists. Constantly emerging novel compounds necessitate 
the development of analytical methods that are broad, so as to detect as many 
compounds as possible, and adaptable, so that newly discovered compounds can be 
added to the method. Two common analytical approaches to the problem are 
immunoassay screens and mass spectrometric analysis (Thomas et al., 2014).  
Immunoassay screens involve mixing samples with solutions of antibodies that 
react to a specific drug or a class of drug (Cone et al., 2002). These screens can be 
designed to detect large numbers of structurally-related compounds, including 
synthetic cannabinoids. However, immunoassays require frequent updating and can 
be non-specific. False positives can occur with closely related structures, even though 
they may not have any CB1 affinity or produce any psychoactive effects. Therefore, 
confirmation with other methods and further testing for cannabimimetic activity is 
usually still required for enforcement of legislation (Mule & Casella, 1988). 
Mass spectrometric testing is increasingly used to detect and confirm the 
identity of synthetic cannabinoids. Mass spectra and retention time measurements in 
chromatographic systems can provide more specific information regarding compound 
identity than immunoassay screens. Recent years have seen the publication of generic 
methods designed to detect as many synthetic cannabinoids as possible (Hess et al., 
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2016; Scheidweiler, Jarvis, & Huestis, 2015). Both gas chromatography (GC)- and liquid 
chromatography (LC)-mass spectrometry (MS) have been implemented for the 
detection of synthetic cannabinoids and their metabolites in blood and urine (Hess et 
al., 2016; Paul & Bosy, 2015). However, analytical standards are still required to 
confirm compound identity.  
Advanced mass spectrometric techniques may be useful for screening novel 
synthetic cannabinoids. For example, mass defect filtering has been somewhat 
successful as a screening tool for detecting a wide range of synthetic cannabinoids 
(Grabenauer et al., 2012). A mass defect is the difference between a compound’s 
nominal mass and its exact mass; for example, PB-22 has a nominal mass of 358 Da 
and an exact mass of 358.1754 Da, yielding a mass defect of 0.1754 Da (Wohlfarth et 
al., 2014). This mass defect will tend to be similar to compounds of similar, but not 
necessarily identical, composition. Scanning a sample for compounds of similar mass 
defect to a known compound can potentially detect novel synthetic cannabinoids 
while excluding noise from irrelevant substances. This approach is particularly useful 
for analysing samples with complex biological matrices like blood or urine. 
Additionally, non-targeted mass spectrometric techniques have been 
implemented for detection of novel compounds and for characterisation of 
metabolites. These techniques usually involve using high resolution and mass accurate 
time of flight (TOF) or orbitrap instruments (Thomas et al., 2014). High mass accuracy 
instruments can, in some cases, be used to distinguish between isomers, and the high 
resolution of orbitrap instruments can improve identification of compounds in 
complex biological matrices. Ultimately however, all analytical methods require 
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frequent updates based on new research as novel compounds continue to be 
developed. 
  
1.5.4 Treatments for synthetic cannabinoid toxicity and dependence 
 While the acute effects of synthetic cannabinoid intoxication have been the 
subject of numerous reports, no specific antidotes for acute synthetic cannabinoid 
intoxication have been established. Theoretically, CB1 antagonists/inverse agonists 
could be used to reverse acute symptoms. However, the preeminent CB1 
antagonist/inverse agonist rimonabant is well known for its deleterious psychiatric 
side-effects, including depressed mood disorders and anxiety (Moreira & Crippa, 
2009; Sam, Salem, & Ghatei, 2011). Case studies report treatment of acute synthetic 
cannabinoid symptoms with close monitoring coupled with administration of fluids 
and sedatives as appropriate (Hermanns-Clausen et al., 2012; Lapoint et al., 2011; 
Schneir et al., 2011; Schwartz et al., 2015). 
 In case reports, withdrawal has been managed with benzodiazepines 
(diazepam) and antipsychotics (quetiapine) (Macfarlane & Christie, 2015). This 
approach is similar to treatment of cannabis withdrawal, which has been 
pharmacological treated with antidepressants, mood stabilizers, anticonvulsants, and 
anxiolytics (Allsop et al., 2015). However, these treatments produce minimal benefits 
in clinical populations (Marshall et al., 2014), and cannabis withdrawal symptoms are 
thought to increase the likelihood of relapse to cannabis use (Allsop et al., 2012). 
Similarly, it is conceivable that synthetic cannabinoid withdrawal, which appears to be 
more severe than cannabis withdrawal, may increase the likelihood of relapse to 
synthetic cannabinoid use.  
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  An alternative to the aforementioned treatments is agonist replacement 
therapy. Agonist replacement therapy has been used successfully in the treatment of 
opiate withdrawal, and involves replacing a hazardous agonist (e.g. heroin) with a less 
hazardous one (e.g. methadone).  The dose is gradually tapered downward until the 
user is free of both the drug and withdrawal symptoms. Alternatively, the agonist can 
be the same as the abused drug (e.g. nicotine patches or gum for treatment of nicotine 
addiction), and gradually reduced over time. This approach helps to control 
withdrawal symptoms and thereby reduces the likelihood of relapse caused by a desire 
to reduce withdrawal symptoms. In the case of cannabis dependence, ∆9-THC and 
nabiximols (Sativex®; a buccal spray consisting of equal parts ∆9-THC and CBD) have 
shown promise as an agonist substitution therapy (Allsop et al., 2015; Balter, Cooper, 
& Haney, 2014; Budney et al., 2007; Haney et al., 2013). Appropriate doses of 
nabiximols reduced withdrawal symptoms and rates of patient dropout in a double-
blind, inpatient study of cannabis dependent users (Allsop et al., 2014). 
A similar treatment might be viable for synthetic cannabinoid withdrawal 
symptoms. However, the viability of such an approach depends on being able to 
administer the treatment at appropriate concentrations, and being able to accurately 
monitor patient pharmacokinetics. Specifically, being able to accurately monitor 
concentrations of the replacement agonist (e.g. ∆9-THC) and the previously abused 
drug (a given synthetic cannabinoid) is essential. If daily monitoring is required, then 
urinalysis is also desirable as a less invasive alternative to repeated blood draws. At 
present, the trajectory of ∆9-THC concentrations during multiple days of agonist 
replacement therapy is uncharacterised. It is also unclear if urinalysis can be used as 
an accurate substitute for plasma analysis. These issues need clarification before the 
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widespread implementation of agonist replacement therapy for the treatment of 
cannabis withdrawal, and possibly synthetic cannabinoid withdrawal. 
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1.6 Thesis overview 
This thesis is comprised of investigations that were designed to build 
knowledge and understanding in several keys areas reviewed in this chapter. 
Specifically, the studies presented in this thesis aimed to: 
1. Characterise the in vivo potency and basic physiological effects of several 
synthetic cannabinoids that are in current use as recreational drugs (Chapter 2).  
2. Identify structure-activity relationships for aminoalkylindoles and related 
synthetic cannabinoids using in vivo measures (Chapter 2).  
3. Establish metabolic pathways and identify valid analytical targets among 
novel synthetic cannabinoids and their metabolites (Chapter 3). 
4. Identify and discuss the discrepancy between in vitro and in vivo synthetic 
cannabinoid pharmacokinetic data, where, for example, in vitro data predicts rapid 
clearance while in vivo data describes long durations of action (Chapter 3).  
5. Explore the long-term residual effects (e.g. cognitive effects, toxicological 
effects) arising from repeated synthetic cannabinoid exposure in rats (Chapter 4). 
6. Establish accurate and practical urinalysis techniques to accompany agonist 
replacement therapies (involving ∆9-THC) for cannabis and/or synthetic cannabinoid 
dependence and withdrawal (Chapter 5). 
Accordingly, Chapter 2 features in vivo physiological assessment of twelve 
synthetic cannabinoids of varying structure via biotelemetry. Hypothermic and 
bradycardic effects are characterised in vivo for the first time, and structure-activity 
relationships are established, addressing points 1 and 2.  
Chapter 3 examines the metabolism of two synthetic cannabinoids in vitro 
using rat and human liver microsomes and hepatocytes, in addition to in vivo 
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assessment in rats. Analytical methods for detecting these synthetic cannabinoids and 
their metabolites using LC-MS/MS are described. Relationships between compound 
structure and metabolism are identified, and in vitro and in vivo pharmacokinetic 
models are compared, addressing points 3 and 4. 
Chapter 4 details the acute and chronic effects of two synthetic cannabinoids in 
adolescent rats, addressing point 5. Acute increases in anxiety-like behaviour coupled 
with decreases in locomotor activity are observed. Long term impairment of object 
recognition memory, and down-regulation of cytokines are described. The effects 
produced by these synthetic cannabinoids are compared directly to ∆9-THC. 
Chapter 5 explores urinary monitoring of cannabinoids in humans, following 
inpatient treatment of cannabinoid withdrawal with nabiximols. Although this work 
did not focus on a synthetic cannabinoid using population, it establishes the viability 
of urinary monitoring of cannabinoids in clinical settings, addressing point 6. A 
similar approach, monitoring both phytocannabinoids and synthetic cannabinoids 
(using the metabolic data established in Chapter 4 and by other research groups) may 
be useful in treating synthetic cannabinoid dependence and withdrawal in the future. 
Finally, Chapter 6 contains a general discussion of the preceding work. The 
work presented in Chapters 2 – 5 is combined to illustrate the value of SARs and 
common metabolic pathways for predicting the crucial properties of novel synthetic 
cannabinoids, the potential impacts of chronic synthetic cannabinoid use, and the 
potential for agonist substitution therapy for treating synthetic cannabinoid 
dependence and withdrawal. 
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ABSTRACT: Synthetic cannabinoid (SC) designer drugs
featuring bioisosteric ﬂuorine substitution are identiﬁed by
forensic chemists and toxicologists with increasing frequency.
Although terminal ﬂuorination of N-pentyl indole SCs is
sometimes known to improve cannabinoid type 1 (CB1)
receptor binding aﬃnity, little is known of the eﬀects of
ﬂuorination on functional activity of SCs. This study explores
the in vitro functional activities of SC designer drugs JWH-018,
UR-144, PB-22, and APICA, and their respective terminally
ﬂuorinated analogues AM-2201, XLR-11, 5F-PB-22, and STS-
135 at human CB1 and CB2 receptors using a FLIPR
membrane potential assay. All compounds demonstrated
agonist activity at CB1 (EC50 = 2.8−1959 nM) and CB2
(EC50 = 6.5−206 nM) receptors, with the ﬂuorinated analogues generally showing increased CB1 receptor potency (∼2−5
times). Additionally, the cannabimimetic activities and relative potencies of JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-
PB-22, APICA, and STS-135 in vivo were evaluated in rats using biotelemetry. All SCs dose-dependently induced hypothermia
and reduced heart rate at doses of 0.3−10 mg/kg. There was no consistent trend for increased potency of ﬂuorinated SCs over
the corresponding des-ﬂuoro SCs in vivo. Based on magnitude and duration of hypothermia, the SCs were ranked for potency
(PB-22 > 5F-PB-22 = JWH-018 > AM-2201 > APICA = STS-135 = XLR-11 > UR-144).
KEYWORDS: Cannabinoid, THC, JWH-018, AM-2201, XLR-11, PB-22
Synthetic cannabinoids (SCs) are the most rapidly growingclass of recreational “designer drugs”. The European
Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
reports that, as of March 2015, 134 new SCs have been
identiﬁed in the European Union (EU) since 2008, with 30
novel SCs formally notiﬁed in 2014 alone.1 In the United States
(US) in 2010, the Drug Enforcement Administration’s National
Forensic Laboratory Information System (NFLIS) reported 19
distinct SCs across 3286 samples, but by 2012, there were 61
SC variants identiﬁed in 41 458 cases.2 In the EU in 2013, there
were over 21 000 seizures of SCs, a more than 200-fold increase
since 2008.1 Many SCs have no precedent in the scientiﬁc
literature yet bear hallmarks of rational design.
Like Δ9-tetrahydrocannabinol (Δ9-THC, 1; Figure 1), the
principal bioactive component of cannabis, SCs typically exert
agonist activity at both cannabinoid receptor subtypes, namely,
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CB1 and CB2 receptors, with psychoactivity attributed to
activation of the former.3 Generally, SCs are found as
adulterants in smoking mixtures of otherwise nonpsychoactive
herbal blends and are intended to substitute for the intoxicating
eﬀects of Δ9-THC. Although these products are disingenuously
marketed as incense and labeled “not for human consumption”,
consumers are aware of the psychoactivity of such products and
use them as technically legal cannabis substitutes. One of the
earliest SC products, branded “Spice”, was analyzed in 2008
and found to contain the C8-homologue of CP 47,497 (CP
47,497-C8, 2) and an (aminoalkyl)indole analogue of WIN
55,212-2 (3)4 known as JWH-018 (4), thereby accounting for
the anecdotal cannabimimetic eﬀects of this product.5 After the
active ingredients of Spice were identiﬁed, many governments
prohibited CP 47,497-C8 and JWH-018, forcing manufacturers
of Spice to circumvent restriction by substituting the active
constituents with other unregulated SCs. The iterative cycle of
SC identiﬁcation, prohibition, and substitution has produced
hundreds of diﬀerently branded products, with names like
“Kronic”, and “K2”, containing one or more SCs.
A popular design trend in the SC market currently is the
incorporation of a terminal ﬂuorine atom in variously
substituted N-pentylindoles.6 The terminally ﬂuorinated
analogue of JWH-018, AM-2201 (5), was one of several
nanomolar aﬃnity SCs (CB1 Ki = 1.0 nM; CB2 Ki = 2.6 nM)
reported by Makriyannis and colleagues in 2001,7 and was
identiﬁed in consumer products by forensic researchers in
several countries in 2011.8,9 Anecdotal reports that AM-2201
possesses psychoactivity at submilligram doses in humans likely
instigated the trend of bioisosteric ﬂuorine substitution in other
structurally related SC designer drugs. For example, South
Korea’s National Forensic Service reported no ﬂuorinated SCs
in 2010, but 90% of all seized SCs were ﬂuorinated by 2013.10
Several dozen terminally ﬂuorinated SCs have been reported by
forensic laboratories worldwide, and the rate of emergence
appears to be increasing.6
The SC sold as UR-144 (7, CB1 Ki = 150 nM; CB2 Ki = 1.8
nM) was ﬁrst reported by Abbott Laboratories in 2010 during
their exploration of CB2-selective ligands
11,12 and has since
been identiﬁed in numerous forensic samples.9,13−15 The 5-
ﬂuoro analogue of UR-144, sold as XLR-11 (8), has also been
identiﬁed in consumer products, despite no prior reports of its
structure in the scientiﬁc literature.16−19 In Korea, XLR-11 ﬁrst
appeared in 2012 and was the most frequently encountered SC
by 2013.10 XLR-11 use is associated with adverse health eﬀects,
including acute kidney injury (AKI)20,21 and cerebral
ischemia.22 Wiley and colleagues recently showed that XLR-
11 (CB1 Ki = 24 nM; CB2 Ki = 2.1 nM) has binding aﬃnities
Figure 1. Selected natural and synthetic cannabinoids.
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and functional activities at cannabinoid receptors that are
comparable to UR-144 (CB1 Ki = 29 nM; CB2 Ki = 4.5 nM)
and that both compounds show a preference for CB2
receptors.23 UR-144 and XLR-11 also showed similar
cannabimimetic potencies, greater than Δ9-THC, in mice.23
The indole-3-carboxylate derivative PB-22 (QUPIC, 10) and
its 5-ﬂuoropentyl analogue, 5F-PB-22 (11), were similarly
unprecedented when discovered by forensic scientists in
2013.24−26 Like AM-2201,27 PB-22 and 5F-PB-22 were
implicated in clinical reports of seizure,28,29 and the latter was
detected in several fatal intoxications in the USA.30 The
metabolism of PB-22 and 5F-PB-22 has been investigated, but
little else is known about the eﬀects of these SCs.31−33 The
adamantane-derived indole-3-carboxamide APICA (2NE1,
SDB-001, 12) was also unprecedented when discovered in
SC products,34 and 5-ﬂuoro-APICA (sold as STS-135, 13) was
identiﬁed shortly thereafter.26 The phase I metabolism of
APICA and STS-135 was recently published,35 and the
pharmacology of APICA was explored (CB1 IC50 = 175 nM;
CB2 IC50 = 176 nM),
17,36 but like PB-22 and 5F-PB-22, there
are no scientiﬁc reports regarding the activity of STS-135.
The increasing popularity of N-(5-ﬂuoropentyl)indole SCs is
concerning because of the limited information regarding their
pharmacology and toxicity, as well as those of their metabolites.
Oxidation of JWH-018 produces several bioactive hydroxylated
metabolites, some of which exhibit cannabinoid activity as
potent as the parent compound, raising concerns about their
toxicity and ultimate fate in the human body.37−40 Many
terminally ﬂuorinated N-pentylindole SCs undergo thermolytic
deﬂuorination due to the route of administration (smoking), as
well as metabolic oxidative deﬂuorination in vivo.33,41−44 For
example, the 5-hydroxylated metabolite 6 is common to both
JWH-018 and AM-2201.9,38,43,45 Similarly, UR-144 and XLR-11
share a common 5-hydroxylated metabolite (9).9,42 There is
also justiﬁable concern regarding the fate of N-dealkylated
metabolites of ﬂuorinated SCs, given their potential for
metabolism to toxic ﬂuorinated metabolites like ﬂuoroacetic
acid.
■ RESULTS AND DISCUSSION
The aim of the present study was to address the paucity of data
in the scientiﬁc literature regarding the pharmacology of
ﬂuorinated SCs. To this end, JWH-018, UR-144, PB-22, and
APICA were compared to the corresponding 5-ﬂuoropentyl
analogues AM-2201, XLR-11, 5F-PB-22, and STS-135,
respectively. The cannabinoid activity of 5-OH-UR-144, a
Scheme 1. Synthesis of Synthetic Cannabinoids 7−23a
aReagents and conditions: (a) 25, Me2AlCl, CH2Cl2, 0 °C to rt, 3 h, 82%; (b) NaH, Br(CH2)4X, DMF, 0 °C to rt, 1 h, 67−91%; (c) aq. NaOH,
MeOH,-THF, rt, 16 h, 94%; (d) NaH (2.0 equiv), Br(CH2)4X, DMF, 0 °C to rt, then (CF3CO)2O, 0 °Cto rt, 1 h; (e) KOH, MeOH, PhMe, reﬂux, 2
h, 79−88% (over 2 steps); (f) (COCl)2, DMF (cat.), CH2Cl2, rt, 1 h, quant.; (g) 32, Et3N, CH2Cl2, rt, 24 h, 78−86%; (h) R(CH2)nNH2, Et3N,
CH2Cl2, rt, 14 h, 73−90%.
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common metabolite of UR-144 and XLR-11, was also assessed.
To more fully examine the eﬀects of terminal ﬂuorination on
the cannabinoid activity of SCs, the 5-ﬂuoropentyl congeners of
previously described APICA analogues SDB-002 (14), -003
(16), -004 (18), -005 (20), and -006 (22) were also
synthesized and subjected to pharmacological evaluation.
Although there are no literature reports of the identiﬁcation
of 5F-SDB-002 (15), -003 (17), -004 (19), or -005 (21), both
SDB-006 and 5F-SDB-006 (23) were recently identiﬁed in
Finland.46
Figure 2. ORTEP diagram of the crystal structure of UR-144 (7) with thermal ellipsoids at the 50% probability level.
Table 1. Functional Activity of Δ9-THC and Indole SCs 4, 5, and 7−23 at CB1 and CB2 Receptors
hCB1 hCB2
compound pEC50 ± SEM (EC50, nM) max ± SEM (% WIN 55,212-2) pEC50 ± SEM (EC50, nM) max ± SEM (% WIN 55,212-2)
CB1
selectivitya
1 (Δ9-THC) 6.60 ± 0.11 (250) 51 ± 3 5.94 ± 0.57 (1157) 13 (at 10 μM) 4.6
3 (WIN 55,212-2) 6.55 ± 0.06 (284) 7.21 ± 0.09 (62) 0.2
4 (JWH-018) 6.99 ± 0.09 (102) 107 ± 6 6.88 ± 0.06 (133) 95 ± 5 1.3
5 (AM-2201) 7.43 ± 0.09 (38) 111 ± 6 7.23 ± 0.10 (58) 102 ± 7 1.5
7 (UR-144) 6.38 ± 0.06 (421) 94 ± 4 7.15 ± 0.05 (72) 104 ± 3 0.2
8 (XLR-11) 7.01 ± 0.07 (98) 110 ± 4 7.08 ± 0.15 (83) 117 ± 10 0.8
9 (5-OH-UR-144) 5.71 ± 0.12 (1959) 159 ± 11 8.18 ± 0.11 (6.5) 102 ± 5 0.003
10 (PB-22) 8.30 ± 0.06 (5.1) 114 ± 3 7.43 ± 0.08 (37) 101 ± 5 7.3
11 (5F-PB-22) 8.55 ± 0.10 (2.8) 108 ± 5 7.97 ± 0.07 (11) 101 ± 3 3.9
12 (APICA) 6.89 ± 0.11 (128) 100 ± 6 7.54 ± 0.11 (29) 91 ± 5 0.2
13 (STS-135) 7.29 ± 0.12 (51) 123 ± 8 7.88 ± 0.26 (13) 114 ± 13 0.3
14 (SDB-002) 6.58 ± 0.08 (264) 53 ± 3 7.24 ± 0.26 (57) 23 ± 4 0.2
15 (5F-SDB-002) 6.56 ± 0.16 (273) 87 ± 8 6.69 ± 0.12 (206) 39 ± 3 0.8
16 (SDB-003) 6.78 ± 0.06 (166) 82 ± 3 6.99 ± 0.08 (102) 95 ± 5 0.6
17 (5F-SDB-003) 7.13 ± 0.12 (75) 104 ± 7 7.53 ± 0.06 (29) 84 ± 3 0.4
18 (SDB-004) 6.68 ± 0.05 (207) 104 ± 3 6.67 ± 0.09 (216) 71 ± 5 1.0
19 (5F-SDB-004) 7.39 ± 0.06 (41) 107 ± 4 7.20 ± 0.12 (63) 62 ± 4 1.5
20 (SDB-005) 6.94 ± 0.07 (116) 99 ± 4 6.86 ± 0.12 (140) 74 ± 6 1.2
21 (5F-SDB-005) 6.83 ± 0.13 (148) 92 ± 7 6.87 ± 0.09 (136) 69 ± 4 0.9
22, SDB-006) 6.94 ± 0.09 (115) 96 ± 5 6.88 ± 0.22 (134) 68 ± 9 1.2
23, 5F-SDB-006 7.30 ± 0.09 (50) 87 ± 4 6.91 ± 0.11 (123) 61 ± 4 2.5
aCB1 selectivity expressed as CB2 EC50 divided by CB1 EC50.
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JWH-018 and AM-2201 were purchased from the National
Measurement Institute (NMI), Australia. The synthesis of 7 to
23 is shown in Scheme 1. The synthesis of 7−9 started from
indole (24), which was acylated with 2,2,3,3-tetramethylcyclo-
propyl-1-carbonyl chloride (25, freshly prepared from the
corresponding carboxylic acid) under Okauchi conditions47 to
give 26 in 82% yield. Alkylation of 26 with 1-bromopentane or
1-bromo-5-ﬂuoropentane gave 7 or 8, respectively. Attempts to
reverse the order of operations by performing the alkylation
and then acylation were successful for the preparation of 7 but
not 8, due to incompatibility of the ﬂuoroalkyl group with
Lewis acids. Alkylation of 26 with the 5-bromopentyl acetate
under the same conditions gave 27, and saponiﬁcation of the
ester cleanly furnished 9.
The synthesis of PB-22 and 5F-PB-22 started from indole,
which was alkylated with either 1-bromopentane or 5-ﬂuoro-1-
bromopentane in the presence of excess sodium hydride and
treated with triﬂuoroacetic anhydride to generate the
intermediate N-alkylated 3-(triﬂuoroacetyl)indole in one pot,
the hydrolysis of which provided either carboxylic acid 28 or
29, respectively. Treating 28 or 29 with oxalyl chloride gave
acid chlorides 30 and 31, respectively, each of which was
treated with 8-hydroxyquinoline (32) to yield esters 10 and 11.
Alternative, treating 30 and 31 with the appropriate amines
gave the desired carboxamides 12−23 in yields of 73−90%.
Several of these novel SCs formed large prismatic crystals
during recrystallization, especially the 2,2,3,3-tetramethylcyclo-
propanone derivatives 7 and 8. A single crystal of 7 was
obtained by slow evaporation of an isopropanol−water mixture,
and an X-ray crystal structure was obtained. An ORTEP
diagram of the crystal structure of 7 is shown in Figure 2. All
bond lengths and angles were as expected, with the pentyl chain
in a fully extended conformation. Full details of X-ray data
collection and tables of bond lengths and angles are available in
the Supporting Information.
All synthesized SCs were screened against CB1 and CB2
receptors in a ﬂuorometric imaging plate reader (FLIPR)
membrane potential assay to provide basic structure−activity
relationships for agonist activity at each CB receptor subtype
(see Table S8 of the Supporting Information for comparisons
to available binding aﬃnity data). Additionally, selected ﬂuoro/
des-ﬂuoro-SC pairs were evaluated in vivo to allow direct
comparison of the relative potency of JWH-018, AM-2201, UR-
144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135.
The cannabimimetic activity of indoles 4, 5, and 7−23 at
CB1 and CB2 receptors was compared with the activity of
established agonist Δ9-THC, and the results are shown in Table
1. Mouse AtT20 neuroblastoma cells were stably transfected
with human CB1 or CB2 receptors, and activities of Δ9-THC
and 7−23 were evaluated using a FLIPR membrane potential
assay whereby endogenously expressed G protein-gated
inwardly rectifying K+ channels (GIRKs) are activated by
agonists at the coexpressed CB1 or CB2 receptors.
48,49 The
maximum eﬀects of 4, 5, and 7−23 were compared with the
high eﬃcacy CB1/CB2 receptor full agonist WIN 55,212-2,
which produced a maximal decrease in ﬂuorescence, corre-
sponding to cellular hyperpolarization, of 29% ± 2% in AtT20-
CB1 cells and 31% ± 3% in AtT20-CB2 cells. None of the
compounds produced a signiﬁcant change in the membrane
potential of wild-type AtT-20 cells, which do not express CB1
or CB2 receptors.
All SCs activated CB1 and CB2 receptors and, with few
exceptions, did so with greater potency than Δ9-THC (250
nM) for CB1 receptor-mediated activation of GIRK (Table 1).
The psychoactivity of cannabinoid ligands is largely attributed
to activation of the CB1 receptor,
3 focusing our attention to
structure−activity relationships (SAR) for this series of SCs
around the CB1 receptor-mediated activation of GIRK. Δ9-
THC is a low eﬃcacy CB2 agonist, and in the assay of GIRK
activation in AtT20-CB2, its eﬀects at 10 μM were only 13% of
Figure 3. Hyperpolarization of CB1 receptors induced by (A) JWH-018 (4) and AM-2201 (5), (B) UR-144 (7) and XLR-11 (8), (C) PB-22 (10)
and 5F-PB-22 (11), and (D) APICA (12) and STS-135 (13) as a proportion of that produced by 1 μM WIN 55,212-2. Membrane potential was
measured using a ﬂuorescent dye, as outlined in the Methods. Each point represents the mean ± SEM of at least ﬁve independent determinations,
each performed in duplicate. Data was ﬁtted with a four parameter logistic equation in Graphpad Prism.
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CB1/CB2 agonist WIN 55,212-2. WIN 55,212-2 showed an
approximately 4-fold preference for stimulating a cellular
hyperpolarization in AtT-20-CB2 compared with AtT-20-CB1
cells.
The most potent compounds in the series were PB-22 (CB1
EC50 = 5.1 nM; CB2 EC50 = 37 nM) and 5F-PB-22 (CB1 EC50
= 2.8 nM; CB2 EC50 = 11 nM), both possessing nanomolar
potency at CB1 receptors. PB-22 and 5F-PB-22 were an order
of magnitude more potent at CB1 receptors than the next most
potent SCs AM-2201 (CB1 EC50 = 38 nM), STS-135 (CB1
EC50 = 51 nM), 5F-SDB-004 (CB1 EC50 = 41 nM), and 5F-
SDB-006 (CB1 EC50 = 50 nM). Most SCs in the series
demonstrated little selectivity for either CB receptor subtype,
with the exception of 5-OH-UR-144, a UR-144 metabolite,
which was a potent and selective CB2 receptor agonist (EC50 =
6.5 nM, 300-fold selectivity).
Excluding two des-ﬂuoro/ﬂuoro analogue pairs (14/15 and
20/21), for which there was little change, terminal ﬂuorination
Figure 4. Eﬀects of (A) JWH-018, (B) AM-2201, (C) UR-144, (D) XLR-11, (E) PB-22, (F) 5F-PB-22, (G) APICA, and (H) STS-135 on rat body
temperature. Dashed line denotes time of intraperitoneal injection. Each point represents the mean ± SEM for three animals.
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produced a roughly 2−5-fold increase in CB1 receptor potency.
This was most pronounced moving from UR-144 (EC50 = 421
nM) to XLR-11 (EC50 = 98 nM) and from 18 (EC50 = 207
nM) to 19 (EC50 = 41 nM). Interestingly, 14 possessed the
lowest eﬃcacy at CB1 and CB2 receptors in the series, and while
ﬂuorination to give 15 did not improve potency, it did increase
eﬃcacy at CB1 and CB2 receptors. The relative potency change
for des-ﬂuoro/ﬂuoro pairs JWH-018/AM-2201, UR-144/XLR-
11, PB-22/5F-PB-22, and APICA/STS-135 is depicted in
Figure 3.
Our results with UR-144, XLR-11, and common metabolite
5-OH-UR-144 are broadly consistent with previous studies. In
an assay of GTPγS binding in HEK 293 cell membranes, Wiley
and colleagues found that UR-144 showed a preference for
CB1, in contrast to our ﬁndings of a CB2 preference for UR-
144.23 Wiley and colleagues found that XLR-11 had a similar
potency at CB1 and CB2 receptors, consistent with XLR-11 in
our assay.23 A deﬁnitive explanation for these diﬀerences is not
possible, but it should be noted that HEK 293 cells are thought
to express a signiﬁcantly diﬀerent complement of G proteins
Figure 5. Eﬀects of (A) JWH-018, (B) AM-2201, (C) UR-144, (D) XLR-11, (E) PB-22, (F) 5F-PB-22, (G) APICA, and (H) STS-135 on rat heart
rate. Dashed line denotes time of intraperitoneal injection. Each point represents the mean ± SEM for three animals.
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from AtT-20 cells,50 and any signaling diﬀerences between
ligands might be magniﬁed by the cumulative nature of the
GTPγS binding assay when compared with the acute, peak
eﬀect measurements made for GIRK activation. Consistent
with our data from the GIRK assay, UR-144/XLR-11 common
metabolite 5-OH-UR-144 was previously reported to be highly
CB2 preferring in binding assays, signiﬁcantly more so than UR-
144 and XLR-11.12,23
Although the potency of any drug eﬀect depends on the
number of receptors expressed in the system under study, and
we have not directly measured the number of receptors in our
AtT-20-CB1 and -CB2 cells at the time of these assays, WIN
55,212-2 is recognized as having a higher aﬃnity for CB2
receptors than CB1 receptors in binding assays,
11,12 so it is
likely that CB2 preference of the SCs is genuine and not an
artifact of our expression systems.
Various Internet drug forums contain anecdotal reports by
SC consumers regarding the potency and psychoactivity of
these compounds. For more well-studied SCs, like JWH-018,
cross-substitution with Δ9-THC has been demonstrated.51−53
However, for the majority of SCs, there are little to no
pharmacological data or formal in vivo evaluations available.
The ability to induce hypothermia and bradycardia in rats is
common to phytocannabinoid Δ9-THC and newer, non-
classical synthetic cannabinoids such as JWH-018.23,36,54,55
The cannabimimetic activities of des-ﬂuoro/ﬂuoro SC pairs
JWH-018/AM-2201, UR-144/XLR-11, PB-22/5F-PB-22, and
APICA/STS-135 were therefore evaluated using biotelemetry
in male Wistar rats, and the eﬀects of various doses of JWH-
018/AM-2201, UR-144/XLR-11, PB-22/5F-PB-22, and
APICA/STS-135 on body temperature (Figure 4) and heart
rate (Figure 5) are presented.
Body temperature 1 h prior to intraperitoneal (ip) injection
and 6 h postinjection of JWH-018, AM-2201, UR-144, XLR-11,
PB-22, 5F-PB-22, APICA, and STS-135 are presented in 15
min bins in Figure 4. The dashed line on the ﬁgures represents
the time of SC injection. Doses were escalated from 0
(baseline) to 3 mg/kg for all compounds. If a large magnitude
eﬀect on body temperature was not evident at a 3 mg/kg dose
(deﬁned as an approximate mean maximal drop in body
temperature of 1.5 °C) then a further 10 mg/kg dose was
tested. Each SC was investigated in an ascending dose sequence
using a single cohort of three or four rats, with a new cohort of
rats used for each SC.
Results showed a dose-dependent hypothermia for all SCs,
with statistically signiﬁcant treatment or treatment by time
eﬀects at the speciﬁed doses (ANOVA, planned contrasts, SC
dose versus vehicle, P < 0.05). A large hypothermic eﬀect
(mean >1.5 °C) was evoked by 3 mg/kg of JWH-018, AM-
2201, PB-22, and 5F-PB-22. However, doses of 10 mg/kg of
APICA, STS-135, UR-144, and XLR-11 were required to
induce more modest hypothermia, indicating lower in vivo
potency of these compounds. Terminal ﬂuorination had no
obvious eﬀect on in vivo potency in any of the pairs of SCs
examined. This can be clearly seen in Figure S5, Supporting
Information, which displays the mean maximal decrease in
body temperature induced by diﬀerent doses of each
compound, and Figure S6, Supporting Information, which
shows the area under the curve (AUC) for body temperature
for each dose of each compound relative to baseline. Formal
statistical comparison of each pair of ﬂuorinated versus
nonﬂuorinated compounds showed no signiﬁcant statistical
diﬀerence between any of these pairs.
On the basis of the mean maximal hypothermia and AUC
obtained with a 3 mg/kg dose of each compound (Figures S5
and S6, Supporting Information), it is possible to rank SCs in
decreasing order of potency: PB-22 > 5F-PB-22 = JWH-018 >
AM-2201 > APICA = STS-135 = XLR-11 > UR-144.
Results for heart rate are presented in 30 min bins in Figure 5
with the dashed line on the ﬁgures again representing the time
of ip injection of each SC. Results were generally consistent
with body temperature data, although data were generally more
variable than with body temperature data, reﬂecting the
multiple determinants of heart rate including locomotor
activity, stress, and direct cardiovascular pharmacological
eﬀects. All doses shown produced a signiﬁcant decrease in
heart rate, with statistically signiﬁcant treatment or treatment
by time eﬀects at these doses (ANOVA, planned contrasts, SC
dose versus vehicle, P < 0.05).
There is variability in the duration of eﬀects for each SC, as
determined by hypothermic and bradycardic responses. A point
of interest is the potential two-stage hypothermic and
bradycardic response demonstrated by JWH-018 and AM-
2201. Given their several common metabolites, it is possible
that the second hypothermic and bradycardic reponse
oberserved for JWH-018 and AM-2201 around 4−5 h
postinjection may be due to the combination of active parent
compounds and active metabolites.
■ CONCLUSION
This study is the ﬁrst to pharmacologically characterize the
eﬀect of terminal ﬂuorination across structurally diverse classes
of 3-subsituted N-pentylindole SC designer drugs, exempliﬁed
by JWH-018/AM-2201, UR-144/XLR-11, PB-22/5F-PB-22,
and APICA/STS-135. A synthetic route to UR-144, XLR-11,
and their common metabolite 5-OH-UR-144 was established.
The synthesis of PB-22, 5F-PB-22, APICA, STS-135, and
several analogues of the latter was achieved. These routes may
prove useful to forensic chemists and pharmacologists
interested in the cannabinoid activity of novel N-alkyl-3-
acylindoles, N-alkylindole-3-carboxylates, and N-alkylindole-3-
carboxamides. All synthesized SCs acted as agonists of CB1 and
CB2 receptors in a FLIPR membrane potential assay and thus
are cannabinoids.
Preliminary structure−activity relationships suggest that
terminal ﬂuorination of the N-pentyl substituent of these SCs
generally enhances potency of CB1 receptor activation,
consistent with previously demonstrated improvements to
binding aﬃnity conferred by such a change, as well as anecdotal
reports of the potent psychoactive eﬀects of ﬂuorinated SCs.
However, in rats, although JWH-018/AM-2201, UR-144/XLR-
11, PB-22/5F-PB-22, and APICA/STS-135 were able to dose-
dependently decrease body temperature and heart rate at doses
of 0.3−10 mg/kg, depending on the SC, there was no obvious
eﬀect of ﬂuorination on in vivo potency. The reasons for the
discrepancy between in vitro and in vivo results is not entirely
clear but may reﬂect pharmacokinetic factors, species-related
diﬀerences in ligand aﬃnity and eﬃcacy, or an inability of body
temperature and heart rate measures to detect subtle
diﬀerences in overall potency. Nonetheless, the in vivo results
conﬁrm that all of the SCs explored have cannabimimetic
eﬀects that parallel those of Δ9-THC, albeit with a wide range
of diﬀering potencies across compounds.
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■ METHODS
General Chemical Synthesis Details. All reactions were
performed under an atmosphere of nitrogen or argon unless otherwise
speciﬁed. Toluene was dried over sodium wire and distilled from
sodium benzophenone ketyl. Dichloromethane and methanol were
distilled from calcium hydride. Anhydrous DMF (Sigma-Aldrich) was
used as purchased. Commercially available chemicals (Sigma-Aldrich)
were used as purchased. Analytical thin layer chromatography (TLC)
was performed using Merck aluminum-backed silica gel 60 F254 (0.2
mm) plates, which were visualized using shortwave (254 nm)
ultraviolet ﬂuorescence. Flash chromatography was performed using
Merck Kieselgel 60 (230−400 mesh) silica gel. Melting points were
measured in open capillaries using a Stuart SMP10 melting point
apparatus and are uncorrected. Nuclear magnetic resonance spectra
were recorded at 300 K using either a Bruker AVANCE DRX400
(400.1 MHz) or AVANCE III 500 Ascend (500.1 MHz) spectrometer.
The data are reported as chemical shift (δ ppm) relative to the residual
protonated solvent resonance, relative integral, multiplicity (s = singlet,
br s = broad singlet, d = doublet, t = triplet, q = quartet, sep = septet,
m = multiplet), coupling constants (J, Hz), and assignment.
Assignment of signals was assisted by COSY, DEPT, HSQC, and
HMBC experiments where necessary. Low resolution mass spectra
(LRMS) were recorded using electrospray ionization (ESI) on a
Finnigan LCQ ion trap spectrometer. Elemental analysis was obtained
from the Chemical Analysis Facility in the Department of Chemistry
and Biomolecular Sciences, Macquarie University, Australia.
General Procedure A: N-Alkylation of 1H-Indole-3-yl(2,2,3,3-
tetramethylcyclopropyl)methanone. A cooled (0 °C) solution of 26
(241 mg, 1.0 mmol) in DMF (2 mL) was treated portionwise with
sodium hydride (60% dispersion in mineral oil, 80 mg, 2.0 mmol, 2.0
equiv), stirred for 10 min, allowed to warm to ambient temperature,
and stirred for 1 h. The mixture was cooled to 0 °C and treated with
the appropriate bromoalkane (1.05 mmol, 1.05 equiv) in a single
portion, allowed to warm to ambient temperature, and stirred for 1 h.
The mixture was poured portionwise onto cooled (0 °C) half-
saturated aq. NH4Cl (40 mL) and extracted with EtOAc (3 × 10 mL).
The combined organic layers were washed with H2O (20 mL) and
brine (20 mL) and dried (MgSO4), and the solvent was evaporated
under reduced pressure to give crude products. The crude products
were puriﬁed using ﬂash chromatography or recrystallization.
(1-Pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)-
methanone (7). Treating 26 (241 mg, 1.0 mmol) with 1-
bromopentane (130 μL, 1.05 mmol) according to general procedure
A gave, following recrystallization from isopropanol, 7 (283 mg, 91%)
as prismatic colorless crystals. Rf 0.41 (hexane−EtOAc, 65:35); mp (i-
PrOH−H2O) 72−74 °C. 1H NMR (500 MHz, CDCl3): δ 8.42−8.40
(1H, m, ArH), 7.66 (1H, s, ArH), 7.35−7.33 (1H, m, ArH), 7.29−7.24
(2H, m, ArH), 4.14 (2H, t, J = 7.5 Hz, NCH2), 1.95 (1H, s, CH), 1.89
(2H, quin., J = 7.5 Hz, CH2), 1.40−1.33 (10H, m, 2 × CH2, 2 × CH3),
1.31 (6H, s, 2 × CH3), 0.91 (3H, t, J = 7.0 Hz, CH3).
13C NMR (125
MHz, CDCl3): δ 194.7 (CO), 136.8 (quat.), 133.6 (CH), 126.5
(quat.), 123.0 (CH), 122.8 (CH), 122.2 (CH), 119.8 (quat.), 109.8
(CH), 47.1 (NCH2), 41.8 (CH), 31.6 (Cquat.), 29.8 (CH2), 29.2
(CH2), 24.2 (CH3), 22.4 (CH2), 17.2 (CH3), 14.0 (CH3). LRMS
(+ESI) m/z 644.80 ([2M + Na]+, 80%), 622.40 ([2M]+, 55%), 312.07
([M + H]+, 100%). Anal. (C21H29NO) Calcd: C 80.98, H 9.38, N 4.50.
Found: C 80.99, H 9.54, N 4.49.
( 1 - ( 5 - F l u o r o p e n t y l ) - 1 H - i n d o l - 3 - y l ) ( 2 , 2 , 3 , 3 -
tetramethylcyclopropyl)methanone (8). Treating 26 (241 mg, 1.0
mmol) with 1-bromo-5-ﬂuoropentane (177 mg, 1.05 mmol) according
to general procedure A, followed by puriﬁcation using ﬂash
chromatography (hexane−EtOAc, 90:10), gave 8 (287 mg, 87%) as
a white crystalline solid. Rf 0.47 (hexane−EtOAc, 80:20); mp (i-
PrOH−H2O) 76−77 °C. 1H NMR (500 MHz, CDCl3): δ 8.41−8.39
(1H, m, ArH), 7.65 (1H, s, ArH), 7.33−7.32 (1H, m, ArH), 7.29−7.24
(2H, m, ArH), 4.43 (2H, dt, 2JH−F = 47.0 Hz,
3JH−H = 6.0 Hz, CH2F),
4.17 (2H, t, J = 7.3 Hz, NCH2), 1.97−1.91 (3H, m, NCH2CH2, CH),
1.77−1.69 (2H, m, CH2CH2F), 1.52−1.47 (2H, m, NCH2CH2CH2),
1.35 (6H, s, CH3), 1.30 (6H, s, CH3).
13C NMR (125 MHz, CDCl3):
δ 194.8 (CO), 136.7 (quat.), 133.5 (CH), 126.5 (quat.), 123.1 (CH),
122.9 (CH), 122.3 (CH), 119.9 (quat.), 109.7 (CH), 83.8 (d, 1JC−F =
165.0 Hz, CH2F), 47.0 (NCH2), 41.8 (CH), 31.8 (Cquat.), 30.1 (d,
2JC−F = 19.7 Hz, CH2), 29.8 (CH2) 24.2 (CH3), 23.0 (d,
3JC−F = 4.8
Hz, CH2), 17.2 (CH3). LRMS (+ESI) m/z 680.73 ([2M + Na]
+,
100%), 658.53 ([2M]+, 42%), 330.20 ([M + H]+, 98%). Anal.
(C21H28NOF) Calcd: C 76.56, H 8.57, N 4.25. Found: C 76.65, H
8.58, N 4.31.
( 1 - ( 5 - H y d r o x y p e n t y l ) - 1 H - i n d o l - 3 - y l ) ( 2 , 2 , 3 , 3 -
tetramethylcyclopropyl)methanone (9). A solution of 27 (185 mg,
0.5 mmol) in THF (2.5 mL) was treated dropwise with a solution of
NaOH (40 mg, 1.0 mmol, 2.0 equiv) in MeOH−H2O (80:20, 2.5
mL), and the mixture was stirred for 16 h. The solvent was evaporated
under reduced pressure, and the residue was partitioned between half-
saturated aq. NaHCO3 (10 mL) and CH2Cl2 (10 mL). The layers
were separated, and the aqueous layer was washed with CH2Cl2 (2 × 5
mL). The combined organic phases were washed with brine (10 mL)
and dried (MgSO4), and the solvent was evaporated. The crude
product was puriﬁed using ﬂash chromatography (hexane−EtOAc,
50:50, Rf 0.22) from 8 (154 mg, 94%) to give 9 as a white crystalline
solid. Mp 80−81 °C. 1H NMR (500 MHz, CDCl3): δ 8.41−8.39 (1H,
m, ArH), 7.66 (1H, s, ArH), 7.34−7.33 (1H, m, ArH), 7.28−7.24 (2H,
m, ArH), 4.16 (2H, t, J = 7.5 Hz, NCH2), 3.64 (2H, t, J = 6.5 Hz,
CH2OH), 1.95 (1H, s, CH), 1.92 (2H, quin., J = 7.5 Hz, CH2), 1.64−
1.58 (2H, m, CH2), 1.55 (1H, br s, OH), 1.47−1.43 (2H, m, CH2),
1.35 (6H, s, 2 × CH3), 1.31 (6H, s, 2 × CH3).
13C NMR (125 MHz,
CDCl3): δ 194.8 (CO), 136.7 (quat.), 133.6 (CH), 126.5 (quat.),
123.1 (CH), 122.8 (CH), 122.2 (CH), 119.8 (quat.), 109.7 (CH),
62.6 (CH2OH), 47.1 (NCH2), 41.8 (CH), 32.3 (CH2), 31.8 (Cquat.),
29.9 (CH2), 24.2 (CH3), 23.4 (CH2), 17.2 (CH3). LRMS (+ESI) m/z
676.73 ([2M + Na]+, 89%), 654.47 ([2M]+, 79%), 350.00 ([M + Na]+,
32%), 328.00 ([M + H]+, 100%). Anal. (C21H29NO2) Calcd: C 77.02,
H 8.93, N 4.28. Found: C 76.64, H 9.27, N 4.32.
General Procedure B: Esteriﬁcation of 1-Alkylindole-3-carboxylic
Acids. A suspension of the appropriate 1-alkylindole-3-carboxylic acid
(28 or 29, 1.0 mmol) in CH2Cl2 (2 mL) was treated with oxalyl
chloride (170 μL, 2.0 mmol, 2.0 equiv) followed by DMF (1 drop).
After stirring for 1 h, the solution was evaporated in vacuo. A solution
of the crude acid chloride and Et3N (490 μL, 3.5 mmol, 3.5 equiv) in
CH2Cl2 (5 mL) was slowly treated with a solution of 8-hydroxyquino-
line (32, 174 mg, 1.2 mmol, 1.2 equiv) in CH2Cl2 (5 mL). The
mixture was stirred for 24 h, the solvent was evaporated, and the
residue was partitioned between EtOAc (75 mL) and H2O (25 mL).
The layers were separated, and the organic phase was washed with sat.
aq. NaHCO3 (3 × 25 mL) and brine (25 mL) and dried (MgSO4),
and the solvent was evaporated under reduced pressure. The crude
products were puriﬁed using ﬂash chromatography.
Quinolin-8-yl 1-Pentyl-1H-indole-3-carboxylate (10). Treating 28
(230 mg, 1.0 mmol) with 8-hydroxyquinoline (174 mg, 1.2 mmol, 1.2
equiv) according to general procedure B gave, following puriﬁcation by
ﬂash chromatography (hexane−EtOAc, 50:50, Rf 0.50), 10 (280 mg,
78%) as an oﬀ-white crystalline solid. Mp 111−112 °C. 1H NMR (500
MHz, CDCl3): δ 8.92 (1H, dd, J = 4.1, 1.3 Hz), 8.33 (1H, dd, J = 7.7,
1.4 Hz), 8.19 (1H, dd, J = 8.4, 1.3 Hz), 8.17 (1H, s) 7.75 (1H, dd, J =
7.8, 1.3 Hz) 7.63−7.57 (2H, m), 7.43−7.40 (2H, m) 7.34−7.29 (2H,
m), 4.20 (2H, t, J = 7.3 Hz), 1.94 (2H, quin., J = 7.1 Hz), 1.40−1.37
(4H, m), 0.93 (3H, t, J = 6.7 Hz). 13C NMR (125 MHz, CDCl3): δ
163.4 (COO), 150.7 (CH), 147.8 (Cquat.), 142.2 (Cquat.), 136.9
(Cquat.), 136.1 (CH), 135.6 (CH), 129.7 (Cquat.), 127.5 (Cquat.), 126.4
(CH), 125.7 (CH), 123.0 (CH), 122.21 (CH), 122.19 (CH), 122.16
(CH), 121.7 (CH), 110.2 (CH), 106.1 (Cquat.), 47.3 (CH2), 29.8
(CH2), 29.2 (CH2), 22.4 (CH2), 14.0 (CH3). LRMS (+ESI) m/z
738.73 ([2M + Na]+, 53%), 716.73 ([2M]+, 100%), 358.93 ([M +
H]+, 60%), 214.07 (M − C9H7N − OH, 17%). Anal. (C23H22N2O2)
Calcd: C 77.07, H 6.19, N 7.82. Found: C 77.29, H 6.19, N 7.89.
Quinolin-8-yl 1-(5-Fluoropentyl)-1H-indole-3-carboxylate (11).
Treating 29 (249 mg, 1.0 mmol) with 8-hydroxyquinoline (174 mg,
1.2 mmol, 1.2 equiv) according to general procedure B gave, following
puriﬁcation by ﬂash chromatography (hexane−EtOAc, 50:50, Rf 0.38),
11 (324 mg, 86%) as an oﬀ-white/tan crystalline solid. Mp 116−117
°C. 1H NMR (500 MHz, CDCl3): δ 8.91 (1H, dd, J = 4.1, 1.5 Hz),
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8.33 (1H, dd, J = 6.9, 1.7 Hz), 8.19 (1H, dd, J = 8.3, 1.4 Hz), 8.17 (1H,
s) 7.75 (1H, dd, J = 7.8, 1.5 Hz), 7.63−7.57 (2H, m), 7.43−7.40 (2H,
m), 7.34−7.29 (2H, m), 4.45 (2H, dt, 2JCF = 47.3, 3JHH = 5.9 Hz,
CH2F), 4.22 (2H, t, J = 7.2 Hz), 1.99 (2H, quin., J = 7.5 Hz), 1.80−
1.70 (2H, m), 1.56−1.49 (2H, m). 13C NMR (125 MHz, CDCl3): δ
163.4 (COO), 150.7 (CH), 147.8 (Cquat.), 142.1 (Cquat.), 136.8
(Cquat.), 136.1 (CH), 135.5 (CH), 129.7 (Cquat.), 127.5 (Cquat.), 126.4
(CH), 125.7 (CH), 123.1 (CH), 122.29 (CH), 122.25 (CH), 122.16
(CH), 122.7 (CH), 110.1 (CH), 106.3 (Cquat.), 83.8 (d,
1JCF = 166.0
Hz, CH2F), 47.2 (CH2), 30.1 (d,
2JCF = 18.9 Hz, CH2CH2F), 29.8
(CH2), 23.0 (d,
3JCF = 5.0 Hz, CH2CH2CH2F). LRMS (+ESI) m/z
774.73 ([2M + Na]+, 66%), 752.60 ([2M]+, 100%), 399.00 ([M +
Na]+, 33%), 376.87 ([M + H]+, 99%), 232.00 (M − C9H7N − OH,
23%). Anal. (C23H21N2O2F) Calcd: C 73.39, H 5.62, N 7.44. Found:
C 73.46, H 5.46, N 7.37.
General Procedure C: Amidation of 1-Alkylindole-3-carboxylic
Acids. A suspension of the appropriate 1-alkylindole-3-carboxylic acid
(28 or 29, 2.0 mmol) in CH2Cl2 (5 mL) was treated with oxalyl
chloride (420 μL, 5.0 mmol, 2.0 equiv) followed by DMF (1 drop).
After stirring for 1 h, the solution was evaporated in vacuo. A solution
of the crude acid chloride in CH2Cl2 (5 mL) was added dropwise to a
solution of the appropriate amine (2.4 mmol, 1.2 equiv) and Et3N
(700 μL, 5.0 mmol, 2.5 equiv) in CH2Cl2 (20 mL). The mixture was
stirred for 14 h, the solvent was evaporated, and the residue was
partitioned between EtOAc (200 mL) and 1 M aq. HCl (50 mL). The
layers were separated, and the organic phase was washed with 1 M aq.
HCl (2 × 50 mL), sat. aq. NaHCO3 (3 × 50 mL), and brine (50 mL)
and dried (MgSO4), and the solvent was evaporated under reduced
pressure. The crude products were recrystallized from i-PrOH or i-
PrOH−H2O. The preparation of 12, 14, 16, 18, 20, and 22 was
described previously.36
N-(Adamantan-1-yl)-1-(5-ﬂuoropentyl)-1H-indole-3-carboxa-
mide (13). Treating (5-ﬂuoropentyl)indole-3-carboxylic acid (499 mg,
2.0 mmol, 1.0 equiv) with 1-aminoadamantane (363 mg, 2.4 mmol, 1.2
equiv) according to general procedure C gave 13 (663 mg, 87%) as
ﬁne white needles. Mp (i-PrOH−H2O) 138−140 °C. 1H NMR (500
MHz, CDCl3): δ 7.88 (1H, d, J = 7.5 Hz), 7.64 (1H, s), 7.36 (1H, d, J
= 7.5 Hz), 7.28−7.22 (2H, m), 5.69 (1H, br s, NH), 4.41 (2H, dt, 2JCF
= 47.0, 3JHH = 6.0 Hz, CH2F), 4.14 (2H, t, J = 7.2 Hz), 2.19 (6H, br s),
2.14 (3H, br s), 1.90 (2H, quin., J = 7.8 Hz), 1.78−1.62 (8H, m),
1.48−1.41 (2H, m). 13C NMR (125 MHz, CDCl3): δ 164.5 (CO),
136.7 (quat.), 131.3 (CH), 125.4 (quat.), 122.4 (CH), 121.3 (CH),
120.1 (CH), 112.6 (quat.), 110.3 (CH), 83.8 (d, 1JCF = 165.0 Hz,
CH2F), 52.2 (quat.), 46.7 (CH2), 42.4 (CH2), 36.7 (CH2), 30.1 (d,
2JCF = 19.9 Hz, CH2CH2F), 29.8 (CH2), 29.7 (CH), 23.0 (d,
3JCF = 5.0
Hz, CH2CH2CH2F). LRMS (+ESI) m/z 764.80 ([2M]
+, 100%),
383.13 ([M + H]+, 41%). Anal. (C24H31N2OF) Calcd: C 75.36, H
8.17, N 7.32. Found: C 75.37, H 8.43, N 7.42.
N-(Adamantan-1-ylmethyl)-1-(5-ﬂuoropentyl)-1H-indole-3-car-
boxamide (15). Treating (5-ﬂuoropentyl)indole-3-carboxylic acid
(499 mg, 2.0 mmol, 1.0 equiv) with 1-(aminomethyl)adamantane
(397 mg, 2.4 mmol, 1.2 equiv) according to general procedure C gave
15 (579 mg, 73%) as a white crystalline solid. Mp (i-PrOH−H2O)
148−150 °C. 1H NMR (500 MHz, CDCl3): δ 7.88 (1H, d, J = 7.5
Hz), 7.74 (1H, s), 7.39 (1H, d, J = 7.5 Hz), 7.29−7.26 (2H, m), 6.01
(1H, br s, NH), 4.42 (2H, dt, 2JCF = 47.5,
3JHH = 5.5 Hz, CH2F), 4.16
(2H, t, J = 7.0 Hz), 3.22 (2H, d, J = 6.0 Hz), 2.02 (3H, br s), 1.92 (2H,
quin., J = 7.0 Hz), 1.75−1.62 (14H, m), 1.49−1.43 (2H, m). 13C NMR
(125 MHz, CDCl3): δ 164.5 (CO), 136.8 (quat.), 131.8 (CH), 125.3
(quat.), 122.5 (CH), 121.5 (CH), 120.0 (CH), 111.6 (quat.), 110.5
(CH), 83.8 (d, 1JCF = 165.0 Hz, CH2F), 51.0 (CH2), 46.8 (CH2), 40.6
(CH2), 37.2 (CH2), 34.1 (quat.), 30.1 (d,
2JCF = 19.9 Hz, CH2CH2F),
29.8 (CH2), 28.5 (CH), 23.0 (d,
3JCF = 5.0 Hz, CH2CH2CH2F).
LRMS (+ESI) m/z 793.00 ([2M]+, 100%), 397.13 ([M + H]+, 60%).
Anal. (C25H33N2OF) Calcd: C 75.72, H 8.39, N 7.06. Found: C 75.46,
H 8.69, N 7.09.
N-Cyclohexyl-1-(5-ﬂuoropentyl)-1H-indole-3-carboxamide (17).
Treating (5-ﬂuoropentyl)indole-3-carboxylic acid (499 mg, 2.0
mmol, 1.0 equiv) with cyclohexylamine (275 μL, 2.4 mmol, 1.2
equiv) according to general procedure C gave 17 (488 mg, 74%) as
ﬁne white needles. Mp (i-PrOH) 145−147 °C. 1H NMR (500 MHz,
CDCl3): δ 7.89 (1H, d, J = 7.0 Hz), 7.69 (1H, s), 7.37 (1H, d, J = 7.0
Hz), 7.29−7.23 (2H, m), 5.82 (1H, d, J = 7.5 Hz, NH), 4.42 (2H, dt,
2JCF = 47.0,
3JHH = 6.0 Hz, CH2F), 4.15 (2H, t, J = 7.0 Hz), 4.10−4.02
(1H, m), 2.10−2.07 (2H, m), 1.91 (2H, quin., J = 7.6 Hz), 1.78−1.67
(5H, m), 1.50−1.42 (4H, m), 1.33−1.20 (3H, m). 13C NMR (125
MHz, CDCl3): δ 164.4 (CO), 136.7 (quat.), 131.4 (CH), 125.5
(quat.), 122.5 (CH), 121.4 (CH), 120.1 (CH), 111.6 (quat.), 110.4
(CH), 83.8 (d, 1JCF = 165.0 Hz, CH2F), 48.1 (CH), 46.8 (CH2), 33.7
(CH2), 30.1 (d,
2JCF = 19.7 Hz, CH2CH2F), 29.8 (CH2), 25.9 (CH2),
25.1 (CH2), 23.0 (d,
3JCF = 4.9 Hz, CH2CH2CH2F). LRMS (+ESI) m/
z 660.73 ([2M]+, 100%), 331.13 ([M + H]+, 78%). Anal.
(C20H27N2OF) Calcd: C 72.70, H 8.24, N 8.48. Found: C 72.38, H
8.46, N 8.42.
N-(Cyclohexylmethyl)-1-(5-ﬂuoropentyl)-1H-indole-3-carboxa-
mide (19). Treating (5-ﬂuoropentyl)indole-3-carboxylic acid (499 mg,
2.0 mmol, 1.0 equiv) with (aminomethyl)cyclohexane (310 μL, 2.4
mmol, 1.2 equiv) according to general procedure C gave 19 (578 mg,
84%) as ﬁne white crystals. Mp (i-PrOH) 114−116 °C. 1H NMR (500
MHz, CDCl3): δ 7.89 (1H, d, J = 7.0 Hz), 7.71 (1H, s), 7.38 (1H, d, J
= 7.0 Hz), 7.30−7.24 (2H, m), 6.00 (1H, br s, NH), 4.42 (2H, dt, 2JCF
= 47.0, 3JHH = 6.0 Hz, CH2F), 4.15 (2H, t, J = 7.0 Hz), 3.36 (2H, t, J =
6.5 Hz), 1.91 (2H, quin., J = 7.8 Hz), 1.85−1.82 (2H, m), 1.78−1.60
(6H, m), 1.48−1.42 (2H, m), 1.31−1.17 (3H, m), 1.04 (2H, ddd, J =
24.3, 12.3, 3.0 Hz). 13C NMR (125 MHz, CDCl3): δ 165.4 (CO),
136.7 (quat.), 131.6 (CH), 125.4 (quat.), 122.5 (CH), 121.5 (CH),
120.1 (CH), 111.5 (quat.), 110.4 (CH), 83.8 (d, 1JCF = 165.0 Hz,
CH2F), 46.8 (CH2), 45.8 (CH2), 38.4 (CH), 31.2 (CH2), 30.1 (d,
2JCF
= 19.9 Hz, CH2CH2F), 29.8 (CH2), 26.6 (CH2), 26.1 (CH2), 23.0 (d,
3JCF = 4.9 Hz, CH2CH2CH2F). LRMS (+ESI) m/z 710.93 ([2M +
Na]+, 95%), 688.73 ([2M]+, 100%), 345.07 ([M + H]+, 48). Anal.
(C21H29N2OF) Calcd: C 73.22, H 8.49, N 8.13. Found: C 72.97, H
8.62, N 8.01.
N-Phenyl-1-(5-ﬂuoropentyl)-1H-indole-3-carboxamide (21).
Treating (5-ﬂuoropentyl)indole-3-carboxylic acid (499 mg, 2.0
mmol, 1.0 equiv) with aniline (220 μL, 2.4 mmol, 1.2 equiv)
according to general procedure C gave 21 (584 mg, 90%) as a white
powder. Mp (i-PrOH) 116−119 °C. 1H NMR (500 MHz, CDCl3): δ
8.07−8.05 (1H, m), 7.79 (1H, s), 7.71 (1H, br s, NH) 7.67 (2H, d, J =
8.0 Hz), 7.42−7.36 (3H, m), 7.34−7.29 (2H, m), 7.13 (1H, t, J = 7.5
Hz), 4.42 (2H, dt, 2JCF = 47.0,
3JHH = 6.0 Hz, CH2F), 4.18 (2H, t, J =
7.0 Hz), 1.93 (2H, quin., J = 7.5 Hz), 1.76−1.68 (2H, m), 1.50−1.44
(2H, m). 13C NMR (125 MHz, CDCl3): δ 163.3 (CO), 138.6 (quat.),
136.8 (quat.), 131.8 (CH), 129.2 (CH), 125.6 (quat.), 124.0 (CH),
122.9 (CH), 121.9 (CH), 120.4 (CH), 120.2 (CH), 111.4 (quat.),
110.5 (CH), 83.8 (d, 1JCF = 165.0 Hz, CH2F), 46.9 (CH2), 30.1 (d,
2JCF = 19.9 Hz, CH2CH2F), 29.7 (CH2), 23.0 (d,
3JCF = 4.9 Hz,
CH2CH2CH2F). LRMS (+ESI) m/z 670.73 ([2M + Na]
+, 90%),
648.67 ([2M]+, 89%), 325.00 ([M + H]+, 100). Anal. (C20H21N2OF)
Calcd: C 74.05, H 6.53, N 8.64. Found: C 74.20, H 6.69, N 8.65.
N-Benzyl-1-(5-ﬂuoropentyl)-1H-indole-3-carboxamide (23).
Treating (5-ﬂuoropentyl)indole-3-carboxylic acid (499 mg, 2.0
mmol, 1.0 equiv) with benzylamine (260 μL, 2.4 mmol, 1.2 equiv)
according to general procedure C gave 23 (549 mg, 81%) as ﬁne white
needles. Mp (i-PrOH) 128−130 °C. 1H NMR (500 MHz, CDCl3): δ
7.94 (1H, d, J = 8.0 Hz), 7.72 (1H, s), 7.42−7.34 (5H, m), 7.31−7.22
(3H, m), 6.25 (1H, br s, NH), 4.71 (2H, d, J = 5.5 Hz), 4.41 (2H, dt,
2JCF = 47.5 Hz,
3JHH = 6.0 Hz, CH2F), 4.14 (2H, t, J = 7.5 Hz), 1.91
(2H, quin., J = 8.0 Hz), 1.76−1.64 (2H, m), 1.48−1.41 (2H, m). 13C
NMR (125 MHz, CDCl3): δ 165.2 (CO), 139.0 (quat.), 136.7 (quat.),
131.5 (CH), 128.9 (CH), 128.0 (CH), 127.6 (CH), 125.6 (quat.),
122.6 (CH), 121.6 (CH), 120.4 (CH), 111.0 (quat.), 110.3 (CH),
83.8 (d, 1JCF = 165.0 Hz, CH2F), 46.8 (CH2), 43.7 (CH2), 30.1 (d,
2JCF = 19.9 Hz, CH2CH2F), 29.8 (CH2), 23.0 (d,
3JCF = 4.9 Hz,
CH2CH2CH2F). LRMS (+ESI) m/z 698.73 ([2M + Na]
+, 100%),
676.87 ([2M]+, 31%), 339.13 ([M + H]+, 29). Anal. (C21H23N2OF)
Calcd: C 74.53, H 6.85, N 8.28. Found: C 74.59, H 6.94, N 8.36.
1H-Indole-3-yl(2,2,3,3-tetramethylcyclopropyl)methanone (26).
A solution of 2,2,3,3-tetramethylcyclopropanecarboxylic acid (25,
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1.19 g, 8.4 mmol) in CH2Cl2 (20 mL) was treated with (COCl)2 (1.4
mL, 2.4 mmol, 2.0 equiv) followed by DMF (1 drop). After stirring for
1 h, the solution was evaporated in vacuo, and the crude acid chloride
was used immediately in the following step.
A cooled (0 °C) solution of 24 (820 mg, 7.0 mmol) in CH2Cl2 (15
mL) was treated dropwise with a solution of 1 M Me2AlCl in hexane
(10.5 mL, 10.5 mmol, 1.5 equiv) and stirred for 30 min. To this
solution was added dropwise a solution of the freshly prepared acid
chloride in CH2Cl2 (15 mL), and the reaction was stirred for 3 h. The
reaction was quenched by dropwise addition to a solution of 1 M aq.
HCl (30 mL), the layers were separated, and the aqueous phase was
extracted with CH2Cl2 (2 × 30 mL). The combined organic layers
were washed with sat. aq. NaHCO3 (2 × 30 mL) and dried (MgSO4),
and the solvent was evaporated under reduced pressure. The crude
product was puriﬁed by ﬂash chromatography (CHCl3, Rf 0.26), to
give 26 as a pale yellow solid (1.38 g, 82%). 1H NMR (500 MHz,
CDCl3): δ 9.51 (1H, br s, NH), 8.44−8.41 (1H, m, ArH), 7.75 (1H, d,
J = 2.5 Hz, ArH), 7.39−7.37 (1H, m, ArH), 7.25−7.22 (2H, m, ArH),
1.97 (1H, s, CH), 1.37 (6H, s, CH3), 1.30 (6H, s, CH3).
13C NMR
(125 MHz, CDCl3): δ 196.1 (CO), 136.6 (quat.), 131.2 (CH), 125.5
(quat.), 123.4 (CH), 122.4 (CH), 122.2 (CH), 120.9 (quat.), 111.7
(CH), 41.9 (CH), 32.0 (quat.), 24.1 (CH3), 17.2 (CH3). All spectral
data were consistent with those published previously.11,12
( 1 - ( 5 - A c e t o x y p e n t y l ) - 1 H - i n d o l - 3 - y l ) ( 2 , 2 , 3 , 3 -
tetramethylcyclopropyl)methanone (27). Treating 26 (362 mg, 1.5
mmol) with 5-bromopentyl acetate (275 μL, 1.65 mmol, 1.1 equiv)
according to the general procedure gave, following puriﬁcation by ﬂash
chromatography (hexane−EtOAc, 65:35, Rf 0.30), 27 (371 mg, 67%)
as a white crystalline solid. Mp (i-PrOH−H2O) 57−59 °C. 1H NMR
(400 MHz, CDCl3): δ 8.42−8.39 (1H, m, ArH), 7.65 (1H, s, ArH),
7.35−7.31 (1H, m, ArH), 7.29−7.24 (2H, m, ArH), 4.17 (2H, t, J =
7.2 Hz, NCH2), 4.05 (2H, t, J = 6.6 Hz, CH2OAc), 2.02 (3H, s, Ac),
1.97−1.89 (3H, m, CH, CH2), 1.71-.164 (2H, m, CH2), 1.46−1.40
(2H, m, CH2), 1.35 (6H, s, 2 × CH3), 1.31 (6H, s, 2 × CH3).
13C
NMR (100 MHz, CDCl3): δ 194.7 (CO), 171.2 (C(O)OCH3) 136.7
(quat.), 133.4 (CH), 126.5 (quat.), 123.1 (CH), 122.9 (CH), 122.3
(CH), 119.9 (quat.), 109.7 (CH), 64.1 (CH2OAc), 47.0 (NCH2) 41.8
(CH), 31.8 (Cquat.), 29.8 (CH2), 28.3 (CH2), 24.2 (CH3), 23.5 (CH2),
21.1 (CH3), 17.2 (CH3). LRMS (+ESI) m/z 760.67 ([2M + Na]
+,
72%), 370.07 ([M + H]+, 100%). Anal. (C23H31NO3) Calcd: C 74.76,
H 8.46, N 3.79. Found: C 74.43, H 8.58, N 3.93.
General Procedure D: Synthesis of 1-Alkylindole-3-carboxylic
Acids. A cooled (0 °C) mixture of sodium hydride (60% dispersion in
mineral oil, 2.00 g, 50.0 mmol, 2.0 equiv) in DMF (30 mL) was
treated slowly with a solution of indole (2.93 g, 25 mmol) in DMF (3
mL), warmed to ambient temperature, and stirred for 10 min. The
mixture was cooled in an ice−water bath and then treated slowly with
the appropriate bromoalkane (26.3 mmol, 1.05 equiv). The mixture
was warmed to ambient temperature and stirred for 1 h, at which point
TLC analysis indicated complete consumption of indole. The solution
was cooled to 0 °C and treated slowly with triﬂuoroacetic anhydride
(8.70 mL, 62.5 mmol, 2.5 equiv). The resultant clear, red solution was
warmed to ambient temperature and stirred for 1 h, at which point
TLC analysis indicated the complete conversion of the 1-alkylindole to
1-alkyl-3-triﬂuoroacetylindole. The reaction was poured portionwise
onto stirred ice−water (500 mL), and the mixture was vigorously
stirred at 0 °C until complete solidiﬁcation of the oil layer had
occurred. The precipitate was collected by ﬁltration and air-dried to
give crude 1-alkyl-1H-3-triﬂuoroacetylindoles as pink solids.
A solution of crude 1-alkyl-1H-3-triﬂuoroacetylindole (25.0 mmol)
in toluene (22 mL) was slowly added to a reﬂuxing solution of KOH
(4.63 g, 82.5 mmol, 3.3 equiv) in MeOH (8 mL), and the mixture was
heated at reﬂux for 2 h. The mixture was cooled to ambient
temperature, and H2O (80 mL) was added. The layers were separated,
and the organic layer was extracted with 1 M aq. NaOH (25 mL). The
combined aqueous phases were acidiﬁed to pH 1 with 10 M aq. HCl,
extracted with Et2O (3 × 50 mL) or CH2Cl2 (3 × 50 mL), and dried
(MgSO4), and the solvent was evaporated. The crude products were
recrystallized from isopropanol to give analytically pure materials.
1-Pentylindole-3-carboxylic Acid (28). Treating indole with 1-
bromopentane according to general procedure D gave, after
recrystallization from i-PrOH, 28 as colorless crystals (4.57 g, 19.8
mmol, 79%). Mp (i-PrOH) 106−108 °C. 1H NMR (500 MHz,
CDCl3): δ 8.27−8.24 (1H, m), 7.93 (1H, s), 7.40−7.38 (1H, m),
7.33−7.29 (2H, m), 4.17 (2H, t, J = 7.2 Hz), 1.90 (2H, quin., J = 7.2
Hz), 1.39−1.32 (4H, m), 0.91 (3H, t, J = 7.0 Hz). 13C NMR (125
MHz, CDCl3): δ 170.7 (COOH), 136.9 (quat.), 135.6, 127.2 (quat.),
123.0, 122.3, 122.1, 110.2, 106.4 (quat.), 47.3 (CH2), 29.7 (CH2), 29.1
(CH2), 22.4 (CH2), 14.0. Anal. (C14H17NO2) Calcd: C 72.70, H
7.41, N 6.06. Found: C 72.67, H 7.77, N 5.93
1-(5-Fluoropentyl)indole-3-carboxylic Acid (29). Treating indole
with 1-bromo-5-ﬂuoropentane according to general procedure D gave,
after recrystallization from i-PrOH (twice), 29 as colorless crystals
(5.28 g, 21.2 mmol, 85%). Mp (i-PrOH−H2O) 120−122 °C. 1H
NMR (500 MHz, CDCl3): δ 8.29−8.25 (1H, m), 7.93 (1H, s), 7.40−
7.37 (1H, m), 7.34−7.30 (2H, m), 4.43 (2H, dt, 2JCF = 47.3, 3JHH = 5.9
Hz, CH2F), 4.18 (2H, t, J = 7.1 Hz), 1.98−1.92 (2H, m, CH2), 1.78−
1.68 (2H, m, CH2), 1.51−1.45 (2H, m, CH2). 13C NMR (125 MHz,
CDCl3): δ 170.9 (CO), 136.8 (quat.), 135.5 (CH), 127.1 (quat.),
123.1 (CH), 122.3 (CH), 122.1 (CH), 110.1 (CH), 106.6 (quat.),
83.8 (d, 1JCF = 166.0 Hz, CH2F), 47.1 (CH2), 30.0 (d,
2JCF = 20.1 Hz,
CH2CH2F), 29.6 (CH2), 22.9 (d,
3JCF = 5.0 Hz, CH2CH2CH2F). Anal.
(C14H16FNO2) Calcd: C 67.45, H 6.47, N 5.62. Found: C 67.31, H
6.60, N 5.46.
X-ray Data Collection. The solid was crystallized from i-PrOH−
H2O to give colorless crystals by slow evaporation at ambient
temperature.
The single-crystal X-ray diﬀraction experiments were carried out at
the Faculty of Pharmacy, University of Sydney, using a Bruker APEX-
II CCD-based diﬀractometer with an X-ray wavelength of 0.71073 Å
(Mo Kα) and at an experimental temperature of 150 K. The single
crystal of 7 was mounted on the tip of a thin glass ﬁber with a
minimum amount of Paratone N oil, which acted as both an adhesive
and a cryoprotectant, and inserted in the cold N2 stream of an Oxford
Cryosystem COBRA cooler. X-ray diﬀraction data were collected
using 0.3° Δω-scans, maintaining the crystal-to-detector distance at 6.0
cm. A total of 1588 frames were collected. The diﬀraction data were
integrated using SAINT+,56 which included corrections for Lorentz,
polarization, and absorption eﬀects. Unit cell parameters for 7 at 150 K
were reﬁned from 999 reﬂections.
The structure was solved using direct methods (SHELX-S)57 and
reﬁned using full-matrix least-squares (SHELXL).57 All non-hydrogen
atoms were treated as anisotropic, while hydrogen atoms were placed
in idealized positions, with Ueq set at 1.5 times that of the parent atom.
empirical formula C21H29NO
formula wt 311.45
temp (K) 150.15
cryst syst monoclinic
space group P21/n
unit cell dimensions
a (Å) 12.112
α (deg) 90
b (Å) 10.799
β (deg) 93.69
c (Å) 13.920
γ (deg) 90
Z 4
GOF on F2 1.050
ﬁnal R indices [I > 2σ(I)]
R1 0.0398
wR2 0.1019
R indices (all data)
R1 0.0478
wR2 0.1077
In Vitro Pharmacological Assessment of SCs. Mouse AtT-20
neuroblastoma cells stably transfected with human CB1 or human CB2
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have been previously described36 and were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS), 100 U of penicillin/streptomycin, and 300 μg/mL
G418. Cells were passaged at 80% conﬂuency as required. Cells for
assays were grown in 75 cm2 ﬂasks and used at 90% conﬂuence. The
day before the assay, cells were detached from the ﬂask with trypsin/
EDTA (Sigma) and resuspended in 10 mL of Leibovitz’s L-15 media
supplemented with 1% FBS, 100 U of penicillin/streptomycin, and 15
mM glucose (membrane potential assay and Ca5 calcium assay). The
cells were plated in volume of 90 μL in black-walled, clear bottomed
96-well microplates (Corning), which had been precoated with poly(L-
lysine) (Sigma, Australia). Cells were incubated overnight at 37 °C in
ambient CO2.
Membrane potential was measured using a FLIPR membrane
potential assay kit (blue) from Molecular Devices, as described
previously.49 The dye was reconstituted with assay buﬀer of
composition (mM): NaCl 145, 4-(2-hydroxyethyl)-1-piperazineetha-
nesulfonic acid (HEPES) 22, Na2HPO4 0.338, NaHCO3 4.17,
KH2PO4 0.441, MgSO4 0.407, MgCl2 0.493, CaCl2 1.26, glucose
5.56 (pH 7.4, osmolarity 315 ± 5). Prior to the assay, cells were loaded
with 90 μL/well of the dye solution without removal of the L-15,
giving an initial assay volume of 180 μL/well. Plates were then
incubated at 37 °C at ambient CO2 for 45 min. Fluorescence was
measured using a FlexStation 3 (Molecular Devices) microplate reader
with cells excited at a wavelength of 530 nm and emission measured at
565 nm. Baseline readings were taken every 2 s for at least 2 min, at
which time either drug or vehicle was added in a volume of 20 μL. The
background ﬂuorescence of cells without dye or dye without cells was
negligible. Changes in ﬂuorescence were expressed as a percentage of
baseline ﬂuorescence after subtraction of the changes produced by
vehicle addition, which was less than 2% for drugs dissolved in assay
buﬀer or DMSO. The ﬁnal concentration of DMSO was not more
than 0.1%.
Data were analyzed with PRISM (GraphPad Software Inc., San
Diego, CA), using four-parameter nonlinear regression to ﬁt
concentration−response curves. In all plates, a maximally eﬀective
concentration of WIN 55,212-2 was added to allow for normalization
between assays.
In Vivo Pharmacological Assessment of SCs. Eight cohorts of
three or four adult male Wistar rats (Animal Resources Centre, Perth,
Australia) initially weighing between 200 and 230 g were used for
biotelemetric assessment of each compound. The rats were singly
housed in an air-conditioned testing room (22 ± 1 °C) on a 12 h
reverse light/dark cycle (lights on from 21:00 to 09:00). Standard
rodent chow and water were provided ad libitum. All experiments were
approved by The University of Sydney Animal Ethics Committee.
Biotelemetry transmitters (TA11CTA-F40, Data Sciences Interna-
tional, St. Paul, MN) were implanted as previously described.36 Brieﬂy,
following anaesthetization (isoﬂurane, 3% induction, 2% mainte-
nance), a rostro-caudal incision was made along the midline of the
abdomen, and a biotelemetry transmitter (TA11CTA-F40, Data
Sciences International, St. Paul, MN) was placed in the peritoneal
cavity according to the manufacturers protocol. The wound was
sutured closed, and the rats were allowed 1 week of recovery before
data collection.
The rats were habituated over multiple days to injections of vehicle
(5% EtOH, 5% Tween 80, 90% physiological saline) at a set time of
day (11:00 am). Each cohort then received intraperitoneal injections
of each compound at the same time of day in an ascending dose
sequence (0.1, 0.3, 1, 3 mg/kg). This ascending sequence reduces the
risk posed to the animals in assessing hitherto untested compounds,
and the use of multiple cohorts limits the potential development of
tolerance to the compound. Two washout days were given between
each dose. If only a modest or negligible hypothermic response was
seen at 3 mg/kg, then a further 10 mg/kg dose of the compound was
given. Two washout days were given between each dose.
Data for heart rate and body temperature was gathered continuously
at 1000 Hz, organized into 15 or 30 min bins using Dataquest A.R.T.
software (version 4.3, Data Sciences International, St. Paul, MN), and
analyzed using PRISM (Graphpad Software Inc., San Diego, CA).
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ABSTRACT: Synthetic cannabinoid (SC) designer drugs based on
indole and indazole scaﬀolds and featuring L-valinamide or L-tert-
leucinamide side chains are encountered with increasing frequency by
forensic researchers and law enforcement agencies and are associated
with serious adverse health eﬀects. However, many of these novel SCs
are unprecedented in the scientiﬁc literature at the time of their
discovery, and little is known of their pharmacology. Here, we report
the synthesis and pharmacological characterization of AB-FUBINA-
CA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINA-
CA, 5F-ADB-PINACA, ADBICA, 5F-ADBICA, and several ana-
logues. All synthesized SCs acted as high potency agonists of CB1
(EC50 = 0.24−21 nM) and CB2 (EC50 = 0.88−15 nM) receptors in a
ﬂuorometric assay of membrane potential, with 5F-ADB-PINACA showing the greatest potency at CB1 receptors. The
cannabimimetic activities of AB-FUBINACA and AB-PINACA in vivo were evaluated in rats using biotelemetry. AB-FUBINACA
and AB-PINACA dose-dependently induced hypothermia and bradycardia at doses of 0.3−3 mg/kg, and hypothermia was
reversed by pretreatment with a CB1 (but not CB2) antagonist, indicating that these SCs are cannabimimetic in vivo, consistent
with anecdotal reports of psychoactivity in humans.
KEYWORDS: Cannabinoid, THC, JWH-018, FUBINACA, PINACA
Synthetic cannabinoids (SCs) are the most rapidly growingclass of recreational designer drugs. Since the identiﬁcation
of the ﬁrst SC designer drugs in 2008, more than 130 SCs have
been reported to the European Monitoring Centre for Drugs
and Drug Addiction (EMCDDA).1 Of the 101 new psycho-
active substances notiﬁed by the EMCDDA during 2014, 30
were SCs.1 Although these products are often mislabeled as
research chemicals or incense and include disclaimers stating
that the products are not for human consumption, SCs are
recreational designer drugs intended to mimic the eﬀects of Δ9-
tetrahydrocannabinol (Δ9-THC, 1, Figure 1) while circum-
venting the law.
The phytocannabinoid Δ9-THC is the principal bioactive
component of marijuana (Cannabis sativa), the most widely
used illicit substance in the world. Δ9-THC exerts its
psychoactive eﬀects by acting as a partial agonist at cannabinoid
type-1 (CB1) receptors,
2 although it is also a partial agonist at
type-2 (CB2) receptors. CB1 and CB2 receptors are classical G
protein-coupled receptors (GPCRs). While CB1 receptors are
found primarily at the terminals of central and peripheral
neurons, where they inhibit neurotransmitter release, CB2
receptors are mainly located in immune cells within and
outside the central nervous system (CNS).3,4 Due to the role of
the CB receptor system in numerous diseases, early
pharmaceutical drug discovery programs explored many
phytocannabinoid analogues like CP 47,497 (2) and CP
55,940 (3), disclosed by Pﬁzer in the 1970s and 1980s.5,6
Following structural leads from the pharmaceutical industry,
Huﬀman and co-workers at Clemson University have
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discovered many indole SCs with potent cannabimimetic
activity, including JWH-018 (4).
In 2008, a recreational herbal blend was found to contain the
C8 homologue of CP 47,497 and JWH-018.7 Following the
prohibition of CP 47,497-C8 and JWH-018 by many
governments, other structurally diverse indole SCs began to
appear.8−11 Recently, numerous SCs with clandestine design
origins and no precedent in the scientiﬁc literature have been
detected in forensic samples. For example, indole-3-carbox-
amide SC 2NE1 (APICA, SDB-001, 5) was identiﬁed along
with its indazole analogue AKB48 (APINACA, 6).12 Presum-
ably intended to mimic the alphanumeric format of compound
codes used throughout the pharmaceutical industry, 2NE1 and
AKB48 were named after Japanese and Korean female pop
music groups, respectively, by their clandestine designers.
Current popular design trends for modiﬁcation of the N-pentyl
group include terminal ﬂuorination and replacement with
cyclohexylmethyl or 4-ﬂuorobenzylic moieties.13,14
In 2013, novel indazole SCs AB-FUBINACA (7, Figure 2)
and ADB-FUBINACA (8) were identiﬁed in recreational
products by Japanese forensic scientists.10,15,16 Although many
recent SCs have no precedent in the scientiﬁc literature prior to
their identiﬁcation as designer drugs, 7 and 8 were both
described by Pﬁzer in a 2009 patent claiming CB1 ligands as
potential therapeutic agents.17 The binding aﬃnity and
functional activity in a GTPγS binding assay of 7 (Ki = 0.9
nM, EC50 = 23.2 nM) and 8 (Ki = 0.36 nM, EC50 = 0.98 nM) at
hCB1 receptors was reported, indicating that both compounds
are potent CB1 agonists, but no further pharmacology was
described. The stereochemistry of the isopropyl and tert-butyl
side chains of illicit 7 and 8, respectively, is unresolved.
However, the Pﬁzer patent reports activity exclusively for the
(S)-enantiomers, and it is likely that the Pﬁzer compounds and
the illicit SCs are (S)-enantiomers derived from the abundant
and inexpensive L-amino acids L-valine and L-tert-leucine.
AB-PINACA (9) was identiﬁed alongside 7, representing a
hybrid of 7 and N-pentyl SCs like 4 and 6.10,15 Although
previously unreported in the scientiﬁc literature, ADB-PINACA
(10) exposure was associated with severe adverse reactions,
including neurotoxicity and cardiotoxicity in the USA in late
2013,18−20 and was recently linked to a cluster of cases of
severe delirium.21 The 5-ﬂuorinated analogues of 9 and 10, 5F-
AB-PINACA (11) and 5F-ADB-PINACA (12), respectively,
have also been identiﬁed on the Japanese market.22,23 By 2014,
7−11 and 16 had been formally notiﬁed by the EMCDDA as a
result of seizures in Belgium, Germany, Turkey, the United
Kingdom, and Sweden.24
AB-FUBICA (13), ADB-FUBICA (14), AB-PICA (15), and
5F-AB-PICA (17) represent the indole analogues of indazoles
7, 8, 9, and 11 and have not appeared in the scientiﬁc literature.
However, the indole analogue of 10, ADBICA (16) was
identiﬁed in Japan,16 and its 5-ﬂuoro analogue, 5F-ADBICA
(18), was notiﬁed by the EMCDDA after law enforcement
agencies in the U.S. implicated 18 in a series of non-fatal
intoxications.24
Despite their widespread use and frequency of adverse
reactions requiring hospitalization, very little is known about
the activity of indole and indazole SCs comprising an L-
valinamide or L-tert-leucinamide subunit. In addition to reports
of the detection of SCs 7−11, 16, and 18 by forensic
researchers, the metabolic proﬁles of 7−9 and 11 were recently
published.25−28
Figure 1. Selected phytocannabinoids and synthetic cannabinoids.
Figure 2. Indole- and indazole-3-carboxamide synthetic cannabinoid
designer drugs.
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The aim of the present study was to address the paucity of
data regarding the pharmacology of indole and indazole SCs by
synthesizing 7−18, evaluating their activity at human CB1 and
CB2 receptors, and assessing the behavioral pharmacology of
these novel SCs in rats using biotelemetry.
■ RESULTS AND DISCUSSION
The original patent by Pﬁzer describing AB-FUBINACA and
ADB-FUBINACA utilized enantiopure amino acids L-valina-
mide (19, Figure 3) and L-tert-leucinamide (20) to give
products with (S) stereocenters.
While L-valinamide is available from numerous commercial
sources as its hydrochloride salt, L-tert-leucinamide is derived
from a non-natural amino acid, and the synthesis of 20 is shown
in Scheme 1. Treatment of L-tert-leucine (21) with benzyl
chloroformate gave Cbz-protected amine 22. The free acid of
22 was converted to the corresponding amide (23) using the
coupling reagents EDC and HOBt, and subsequent depro-
tection by catalytic hydrogenation aﬀorded 20. The three-step
procedure proved to be operationally convenient, and analyti-
cally pure L-tert-leucinamide was obtained on a multigram scale
following recrystallization.
The synthesis of indazole SCs 7−12 is shown in Scheme 2.
Fischer esteriﬁcation of indazole-3-carboxylic acid (24) gave 25,
which was deprotonated with potassium tert-butoxide and
alkylated with either 4-ﬂuorobenzyl bromide, 1-bromopentane,
or 1-bromo-5-ﬂuoropentane to aﬀord the corresponding N-
alkylindazole-3-carboxylic acid methyl esters 26−28. Alkylation
proceeded regioselectively to give 1-substituted 1H-indazoles as
the major products; however, small quantities of 2-alkylated
indazoles were obtained as minor products and separated by
ﬂash chromatography. Saponiﬁcation of the methyl ester of
26−28 to give free acids 29−31 was followed by amide
coupling with EDC-HOBt and either L-valinamide or L-tert-
leucinamide to give 7−12.
Access to the corresponding indole SCs (13−18) required
an alternative synthetic route, shown in Scheme 3. Excess
sodium hydride was added to indole (33), which was
subsequently alkylated with the appropriate bromoalkane and
then treated with triﬂuoroacetic anhydride to give the
corresponding N-alkyl-3-(triﬂuoroacetyl)indole (34−36) in a
one-pot process. Alkaline hydrolysis induced ﬂuoroform
elimination29 and furnished, upon workup and recrystallization,
the corresponding N-alkylindole-3-carboxylic acids (37−39) of
analytical purity. Coupling of 37−39 with 19 or 20 using EDC-
HOBt yielded 13−18. Indole SCs derived from L-valinamide
(13, 15, 17) were recrystallized from isopropanol to analytical
purity, whereas those comprising L-tert-leucinamide (14, 16,
18) were puriﬁed by ﬂash chromatography owing to their
superior solubility in a range of alcoholic solvents.
The activity of synthesized indazole (7−12) and correspond-
ing indole (13−18) SCs at CB1 and CB2 receptors was
evaluated using a ﬂuorometric imaging plate reader (FLIPR)
assay to provide structure−activity relationship (SAR) data
regarding the choice of heteroaromatic core, amino acid side-
chain, and alkyl substituent within this class of SCs.
Additionally, the in vivo activity of 7 and 9 was compared
using biotelemetry in rats to provide information regarding the
increasingly common 4-ﬂuorobenzyl motif in SCs.
The cannabimimetic activities of 7−18 were compared to
those of phytocannabinoid Δ9-THC (a partial agonist at CB1
and CB2) and indole SC JWH-018 (a full agonist at CB1 and
CB2), and the data is presented in Table 1. Murine AtT-20
neuroblastoma cells were stably transfected with human CB1 or
CB2 receptors, and activities of Δ9-THC, JWH-018, and 7−18
were evaluated using a FLIPR membrane potential assay
whereby endogenously expressed G protein-gated inwardly
rectifying K+ channels (GIRKs) are activated by agonists at the
expressed CB1 or CB2 receptors. The maximum eﬀects of Δ9-
THC, JWH-018, and 7−18 were compared to high eﬃcacy
CB1/CB2 receptor agonist CP 55,490, which produced a
maximal decrease in ﬂuorescence, corresponding to cellular
hyperpolarization, at a concentration of 1 μM in AtT-20-CB1
and AtT-20-CB2 cells. None of the compounds produced a
signiﬁcant change in the membrane potential of wild-type AtT-
20 cells, which do not express CB1 or CB2 receptors.
All indole and indazole SCs activated CB1 and CB2 receptors.
All compounds had greater potency (0.24−21 nM) than Δ9-
THC (172 nM) for CB1 receptor-mediated activation of GIRK.
Δ9-THC is a low-eﬃcacy CB2 agonist, and in the assay of GIRK
activation in AtT-20-CB2, its eﬀects at 30 μM were only 32 ±
1% of that mediated by CP 55,940. CP 55,940 was more potent
at stimulating a cellular hyperpolarization in AtT-20-CB2 cells
than AtT-20-CB1 cells, displaying an approximately 2-fold CB2
preference. All indazole and indole SCs had a similar maximal
eﬀect to CP 55,940 at CB1 and CB2 receptors, suggesting that
these SCs are also high eﬃcacy agonists. With the exception of
13, all novel SCs showed a mild preference for CB1 receptors,
and it is activation of CB1 receptors that is associated with the
psychoactive eﬀects of cannabinoids.2
The least potent compound in the series (indole 13) was 11-
fold more potent than Δ9-THC at CB1 receptors, and the most
potent compound (indazole 12) showed more than 1000 times
Figure 3. Amino acid derivatives L-valinamide (19) and L-tert-
leucinamide (20).
Scheme 1. Synthesis of L-tert-Leucinamidea
aReagents and conditions: (a) NaOH, BnOC(O)Cl, 0 °C to rt, 2 h, 99%; (b) NH4Cl, Et3N, HOBt, EDCI, DMF, rt, 16 h, 84%; (c) 10% Pd/C, THF,
48%.
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the potency of Δ9-THC, making 5F-ADB-PINACA one of the
most potent SC designer drugs reported to date. Excluding 7
and 8, indazoles and indoles containing the L-tert-leucinamide
group were more potent at both CB1 and CB2 receptors than
the corresponding SC featuring an L-valinamide substituent. In
the most dramatic example, the additional methyl group of 16
(EC50 = 0.68 nM) conferred a 17-fold increase in potency over
15 (EC50 = 12 nM) at CB1 receptors. The same trend was
observed for CB2 receptors, but potency enhancement was
more moderate, with 18 (EC50 = 1.2 nM) showing a 7-fold
improvement over 17 (EC50 = 1.2 nM).
Surprisingly, there were no clear trends for diﬀerences of
potency or eﬃcacy between indazole SCs 7−12 and the
corresponding indoles 13−18. Similarly, choice of N-alkyl
Scheme 2. Synthesis of Indazole SCs 7−12a
aReagents and conditions: (a) conc. H2SO4, MeOH, reﬂux, 4 h, 76%; (b) BrR
1, t-BuOK, THF, 0 °C to rt, 48 h, 67−77%; (c) NaOH, MeOH, rt, 24
h, 76−96%; (d) EDC·HCl, HOBt, DIPEA, 19 or 20, DMF, rt, 24 h, 31−63%.
Scheme 3. Synthesis of Indole SCs 13−18a
aReagents and conditions: (a) (i) NaH, BrR1, DMF, 0 °C to rt, 1 h, (ii) (CF3CO)2O, DMF, 0 °C to rt, 1 h; (b) KOH, MeOH, PhMe, reﬂux, 2 h
54−68% (over two steps); (d) EDC·HCl, HOBt, DIPEA, 19 or 20, DMF, rt, 24 h, 65−86%.
Table 1. Functional Activity of Δ9-THC, CP 55,940, JWH-018, and Novel SCs 7−18 at CB1 and CB2 Receptors
hCB1 hCB1 hCB2 hCB2
compound pEC50 ± SEM (EC50, nM) nax ± SEM (% CP 55,940) pEC50 ± SEM (EC50, nM) nax ± SEM (% CP 55,940) CB1 sel.
a
Δ9-THC (1) 6.76 ± 0.09 (172) 58 ± 3 32 ± 1 at 30 μM
CP 55,490 (3) 7.63 ± 0.09 (24) 7.88 ± 0.08 (13) 0.5
JWH-018 (4) 7.74 ± 0.16 (18) 116 ± 9 7.66 ± 0.16 (22) 87 ± 7 1.2
AB-FUBINACA (7) 8.76 ± 0.10 (1.8) 108 ± 7 8.50 ± 0.20 (3.2) 95 ± 12 1.8
ADB-FUBINACA (8) 8.92 ± 0.16 (1.2) 152 ± 11 8.46 ± 0.13 (3.5) 104 ± 7 2.9
AB-PINACA (9) 8.91 ± 0.09 (1.2) 103 ± 4 8.60 ± 0.16 (2.5) 104 ± 8 2.1
ADB-PINACA (10) 9.28 ± 0.08 (0.52) 117 ± 6 9.06 ± 0.31 (0.88) 107 ± 16 1.7
5F-AB-PINACA (11) 9.32 ± 0.10 (0.48) 94 ± 6 8.59 ± 0.25 (2.6) 110 ± 13 5.4
5F-ADB-PINACA (12) 9.61 ± 0.19 (0.24) 91 ± 7 8.68 ± 0.11 (2.1) 94 ± 5 8.8
AB-FUBICA (13) 7.67 ± 0.14 (21) 115 ± 7 7.84 ± 0.27 (15) 99 ± 10 0.7
ADB-FUBICA (14) 8.58 ± 0.15 (2.6) 113 ± 8 8.52 ± 0.16 (3.0) 96 ± 7 1.2
AB-PICA (15) 7.92 ± 0.07 (12) 99 ± 3 7.92 ± 0.21 (12) 94 ± 9 1.0
ADBICA (16) 9.16 ± 0.16 (0.69) 98 ± 7 8.75 ± 0.18 (1.8) 94 ± 7 2.6
5F-AB-PICA (17) 8.28 ± 0.21 (5.2) 123 ± 13 8.05 ± 0.53 (8.9) 121 ± 24 1.7
5F-ADBICA (18) 9.12 ± 0.14 (0.77) 110 ± 7 8.91 ± 14 (1.2) 92 ± 6 1.6
aCB1 selectivity expressed as the ratio of CB1 EC50 to CB2 EC50.
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group had little eﬀect on potency. However, indoles containing
the L-valinamide group (13, 15, 17), the least potent SCs
identiﬁed in this series, were each less potent than the
corresponding indazoles (7, 9, 11). Taken together, these
results suggest that the heteroaromatic core and indole nitrogen
substituent of these SCs contribute less to the activity of these
compounds than the pendant amide group. The diﬀerence in
CB1 activity between L-valinamide and L-tert-leucinamide
derivatives featuring a 1-pentyl group and containing an
indazole core (9 and 10, respectively) or an indole core (15
and 16, respectively) is depicted in Figure 4.
Very little is known about the potency and psychoactivity of
newer SCs in humans. Having demonstrated that 7−18 are
potent and eﬃcacious cannabimimetic agents in vitro, we
sought to demonstrate activity of some of these SCs in vivo.
Cross-substitution of older SCs, like JWH-018, with Δ9-THC
has been demonstrated.30−32 Cannabinoids are known to
induce hypothermia and bradycardia in rats, eﬀects that are
common to phytocannabinoids like Δ9-THC and heteroar-
omatic SCs such as JWH-018.33−35 We have previously
evaluated the hypothermic and bradycardic potencies of Δ9-
THC and numerous structurally diverse SCs including JWH-
018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA,
and STS-135.14,36 The cannabimimetic activities AB-FUBINA-
CA and AB-PINACA were evaluated using radiotelemetry in
male Wistar rats, and the eﬀects of these SCs on body
temperature (Figure 5) and heart rate (Figure 6) are presented
below.
Rat body temperature 1 h prior to intraperitoneal (i.p.)
injection and 6 h postinjection of AB-FUBINACA and AB-
PINACA are presented in 15 min bins in Figure 5. For each
drug, these data are presented for 1 h before (baseline) and 6 h
after injection of various doses. The dashed line on the ﬁgures
represents the time of SC injection. Each SC was investigated
using a cohort of 3−4 rats, with a diﬀerent cohort used for the
two compounds. Doses were escalated from 0 mg/kg (baseline)
to 0.1, 0.3, 1, and 3 mg/kg for each compound, with at least
two washout days between each dose. The 0.1 mg/kg doses of
each compound were without signiﬁcant eﬀects on body
temperature and heart rate, so data for these doses are not
presented.
A substantial hypothermic eﬀect was evoked by 0.3−3 mg/kg
of both drugs, with the peak reduction in body temperature
generally greater with AB-FUBINACA (>2 °C) than AB-
PINACA (>1.5 °C). As Figure 5 shows, the 4-ﬂuorobenzyl-
substituted AB-FUBINACA appeared to confer a hypothermic
eﬀect of greater magnitude and duration (∼4 h) than that
observed for the pentyl-substituted AB-PINACA (∼2 h) at the
same dose (3 mg/kg). This was veriﬁed by a statistical analysis
showing a signiﬁcantly greater area under the curve for body
temperature (relative to vehicle baseline) for AB-FUBINACA
doses compared to that for AB-PINACA at 3 mg/kg (P < 0.05).
Results for heart rate are presented in 30 min bins in Figure
6, with the dashed line on the ﬁgures again representing the
time of SC injection. Results were consistent with body
temperature data, although data were generally more variable
than they were with body temperature data, reﬂecting the
multiple determinants of heart rate including locomotor
activity, stress, and direct cardiovascular pharmacological
eﬀects. All doses shown produced a signiﬁcant decrease in
heart rate, with statistically signiﬁcant treatment or treatment
by time eﬀects at these doses (ANOVA, planned contrasts, SC
dose versus vehicle, P < 0.05).
To conﬁrm that the observed eﬀects were mediated through
CB1 or CB2 receptors, the reversibility of the eﬀects of AB-
PINACA and AB-FUBINACA on body temperature and heart
rate in rats following pretreatment with either CB1 receptor
antagonist rimonabant (SR141176, 40, Figure 7) or CB2
receptor antagonist SR144528 (41) was assessed. Rimonabant
is a potent, selective, CB1 receptor neutral antagonist that
reverses CB1-mediated cannabinoid agonist eﬀects in rodents
and humans,2,37,38 whereas SR144528 is selective CB2
antagonist/inverse agonist.39,40
Rat body temperatures after injection (i.p.) with vehicle, CB1
antagonist (rimonabant, 3 mg/kg), or CB2 antagonist
(SR144528, 3 mg/kg) 30 min prior to treatment with either
AB-FUBINACA (3 mg/kg) or AB-PINACA (3 mg/kg) are
presented in 15 min bins in Figure 8. For each treatment
condition, these data are presented for 1 h before (baseline)
and 6 h after injection of various doses. The ﬁrst dashed line on
the ﬁgure represents the time of vehicle/antagonist injection,
and the second dashed line represents time of SC injection.
Each SC was investigated using a cohort of 3−4 rats, with a
diﬀerent cohort used for the two compounds. The dose of each
antagonist was 3 mg/kg, and the dose of each SC was also 3
mg/kg.
Pretreatment with rimonabant was able to completely reverse
the hypothermic eﬀects of AB-FUBINACA, whereas pretreat-
ment with SR144528 had no eﬀect on the body temperature
decrease induced by AB-FUBINACA (Figure 8A). Similarly,
rimonabant partially reversed the decreased body temperature
eﬀected by AB-PINACA, but SR144528 had negligible eﬀect on
Figure 4. Hyperpolarization of CB1 receptors induced by (A) AB-PINACA (9) and ADB-PINACA (10) and (B) AB-PICA (15) and ADBICA (16)
as a proportion of that produced by 1 μM CP 55,940. Membrane potential was measured using a ﬂuorescent dye, as outlined in the Methods. Each
point represents the mean ± SEM of at least ﬁve independent determinations, each performed in duplicate. Data was ﬁtted with a four-parameter
logistic equation in GraphPad Prism.
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AB-PINACA-induced hypothermia (Figure 8B). These inter-
pretations are conﬁrmed by a statistical analysis of the areas
between each drug treatment and baseline (Figure S13,
Supporting Information). This suggests a CB1-mediated
hypothermic mechanism. Similar trends were observed for
the reversal of AB-FUBINACA- or AB-PINACA-induced
bradycardia by rimonabant but not SR144528; however, these
diﬀerences did not reach signiﬁcance (data not shown). This is
likely due to a combination of the relatively smaller magnitude
of SC-induced bradycardic eﬀects and high variability of the
heart rate data.
■ CONCLUSIONS
This study is the ﬁrst to pharmacologically characterize the
emergent class of recreational SC designer drugs based on
indole and indazole scaﬀolds and featuring L-valinamide or L-
tert-leucinamide side chains. Synthetic routes to identiﬁed SCs
of forensic interest (AB-FUBINACA, ADB-FUBINACA, AB-
PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA,
Figure 5. Eﬀects of (A) AB-FUBINACA and (B) AB-PINACA on rat body temperature. Dashed line denotes time of intraperitoneal injection. Each
point represents the mean ± SEM for three animals.
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ADBICA, 5F-ADBICA), as well as several undetected
analogues, were developed. These synthetic routes are general
for 1-alkyl-1H-indazole-3-carboxamides and 1-alkyl-1H-indole-
3-carboxamides and enable forensic chemists to proactively
develop reference standards for structurally related SCs
expected to appear in the future. All synthesized SCs acted as
agonists of CB1 and CB2 receptors in a FLIPR membrane
potential assay and thus are functional cannabinoids.
Preliminary SARs suggest that L-tert-leucinamide derivatives
possess greater potency at CB1 receptors in vitro than the
corresponding L-valinamide analogues. The most potent of
these was 5F-ADB-PINACA. In rats, AB-FUBINACA and AB-
PINACA were able to dose-dependently decrease body
temperature and heart rate at doses of 0.3−3 mg/kg, indicating
that these SCs are also cannabimimetic in vivo. AB-FUBINACA
had more potent eﬀects on body temperature than AB-
PINACA. The hypothermic eﬀects of AB-FUBINACA and AB-
PINACA appear to be mediated through CB1 receptors and
could be reversed by pretreatment with CB1 antagonist
rimonabant but not CB2 antagonist SR144528. Both in vitro
and in vivo results conﬁrm that all of the SCs explored have
Figure 6. Eﬀects of (A) AB-FUBINACA and (B) AB-PINACA on rat heart rate. Dashed line denotes time of intraperitoneal injection. Each point
represents the mean ± SEM for three animals.
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cannabimimetic eﬀects that parallel those of Δ9-THC, but with
greater potency.
■ METHODS
General Chemical Synthesis Details. All reactions were
performed under an atmosphere of nitrogen unless otherwise
speciﬁed. Commercially available chemicals were used as purchased.
Flash column chromatography was performed using Merck Kieselgel
60 (230−400 mesh) silica gel. Melting points were measured in open
capillaries using a Gallenkamp 5A 6797 melting point apparatus and
are uncorrected. Nuclear magnetic resonance spectra were recorded at
300 K using a Bruker 300, 400, or 500 MHz spectrometer. The data
are reported as chemical shift (δ ppm) relative to the residual
protonated solvent resonance, relative integral, multiplicity (s = singlet,
bs = broad singlet, d = doublet, t = triplet, q = quartet, quin. = quintet,
m = multiplet, dd = doublet of doublets, dt = doublet of triplets, qd =
quartet of doublets), coupling constants (J Hz), and assignment. Low-
resolution mass spectra (LRMS) were recorded using electrospray
ionization (ESI) recorded on a Finnigan LCQ ion trap spectrometer.
HPLC analysis of the organic purity of the compounds submitted for
in vivo testing (4−7) was conducted on a Waters e2695 separations
module using a Waters Sunﬁre C18 5 μm, 2.1 × 150 mm column and
detected using a Waters 2489 UV/vis detector set at 254 nm.
Separation was achieved using water with 0.1% formic acid (solvent A)
and acetonitrile with 0.1% formic acid (solvent B) at a ﬂow rate of 0.2
mL/min and a gradient of 5% B for 1 min, then 5−100% B over 30
min. Elemental analysis was obtained from the Chemical Analysis
Facility in the Department of Chemistry and Biomolecular Sciences,
Macquarie University, Australia.
General Procedure A: Amidation of 1-Alkyl-1H-indazole-3-
carboxylic Acids and 1-Alkylindole-3-carboxylic Acids. A
solution of the appropriate carboxylic acid 29, 30, 31, 37, 38, or 39
(7.5 mmol, 1.5 equiv) in DMF (50 mL) was treated with EDC (7.5
mmol, 1.5 equiv), HOBt (7.5 mmol, 1.5 equiv), DIPEA (25.5 mmol,
5.1 equiv), 19·HCl, or 20 (5 mmol) and stirred for 24 h. The mixture
was partitioned between and H2O (100 mL) and EtOAc (50 mL), the
layers were separated, and the aqueous layer was extracted with EtOAc
(2 × 50 mL). The combined organic phases were dried (MgSO4), and
the solvent was evaporated under reduced pressure. The crude
products were puriﬁed by ﬂash chromatography and/or recrystalliza-
tion.
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-ﬂuorobenzyl)-
1H-indazole-3-carboxamide (AB-FUBINACA, 7). Treating 29 (1.20 g,
4.4 mmol) with 19 (1.04 g, 6.8 mmol) according to general procedure
A gave, following puriﬁcation by ﬂash chromatography (hexane−
EtOAc, 10:90), 7 (0.94 g, 57%) as a white solid. Recrystallization from
i-PrOH−H2O yielded material of analytical purity. mp 151−152 °C;
1H NMR (500 MHz, CDCl3): δ 8.33 (1H, d), 7.54 (1H, d, J = 8.9
Hz), 7.37 (1H, m), 7.32 (1H, m), 7.27 (1H, m), 6.39 (1H, bs), 5.69
(1H, bs), 5.57 (2H, s), 4.58 (1H, dd, J = 8.9 Hz, 6.8 Hz), 2.35 (1H,
dq., J = 13.6 Hz, 6.8 Hz), 1.09 (6H, dd, J = 7.2 Hz, 5.1 Hz); 13C NMR
(125 MHz, CDCl3): δ 173.7 (CO), 162.9 (CO), 162.6 (d,
1JC−F =
249.1 Hz, quat.), 140.9 (quat.), 137.3 (quat.), 131.7 (d, 4JC−F = 3.4 Hz,
quat.), 129.2 (d, 3JC−F = 8.3 Hz, CH), 127.3 (CH), 123.4 (quat.),
123.1 (CH), 122.8 (CH), 116.0 (d, 2JC−F = 21.6 Hz, CH), 109.7
(CH), 58.0 (CH), 53.1 (CH2), 30.8 (CH), 19.6 (CH3), 18.4 (CH3);
19F NMR (470 MHz, CDCl3): δ −113.9 ppm; LRMS (+ESI): m/z
323.9 ([M − CONH3]+, 100%), 351.8 ([M − NH3]+, 50%), 368.8
([M + H]+, 20%); Anal. Calcd for C20H21N4O2F: C, 65.20; H, 5.75; N,
15.21. Found: C, 65.28; H, 5.73; N, 15.21; HPLC purity: 99.2%.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-ﬂuoroben-
zyl)-1H-indazole-3-carboxamide (ADB-FUBINACA, 8). Treating 29
(0.51 g, 1.9 mmol) with 20 (0.37 g, 2.8 mmol) according to general
procedure A gave, following puriﬁcation by ﬂash chromatography
(hexane−EtOAc, 10:90), 8 (0.22 g, 31%) as a white solid. mp 135−
137 °C; NMR (500 MHz, CDCl3): δ 8.21 (1H, d, J = 8.0 Hz), 7.72
(1H, d, J = 9.7 Hz), 7.27 (1H, m), 7.19 (1H, m), 7.14 (2H, dd, J = 8.3
Hz, 5.4 Hz), 6.99 (1H, bs), 6.93 (2H, t, J = 8.6 Hz), 6.16 (1H, bs),
5.52 (2H, s), 4.74 (1H, d, 9.6 Hz), 1.15 (1H, s), 1.11 (9H, s); 13C
NMR (125 Hz, CDCl3): δ 173.5 (CO), 162.6 (CO), 162.6 (d,
1JC−F =
245.8 Hz, quat.), 140.9 (quat.), 137.3 (quat.), 131.8 (d, 4JC−F = 3.1 Hz,
quat.), 129.1 (d, 3JC−F = 8.3 Hz, CH), 127.1 (CH), 123.4 (quat.),
123.0 (CH), 122.6 (CH), 115.9 (d, 2JC−F = 21.6 Hz, CH), 109.7
(CH), 59.7 (CH), 53.1 (CH2), 34.8 (quat.), 26.9 (CH3);
19F NMR
(470 MHz, CDCl3): δ −113.9; LRMS (+ESI): m/z 337.9 ([M −
CONH3]
+, 100%), 365.8 ([M − NH3]+, 50%), 382.7 ([M + H]+,
21%); Anal. Calcd for C21H23N4O2F: C, 65.95; H, 6.06; N, 14.65.
Found: C, 65.38; H, 6.08; N, 14.38.
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-inda-
zole-3-carboxamide (AB-PINACA, 9). Treating 30 (0.50 g, 2.2 mmol)
with 19 (0.50 g, 3.3 mmol) according to general procedure A gave,
following puriﬁcation by ﬂash chromatography (hexane−EtOAc,
50:50), 9 (0.44 g, 62%) as a white solid. Recrystallization from
EtOAc−hexane yielded material of analytical purity. mp 125−126 °C;
1H NMR (500 MHz, CDCl3): δ 8.30 (1H, d, J = 8.3 Hz), 7.51 (1H, d,
J = 8.8 Hz), 7.45−7.37 (2H, m), 7.26 (1H, m), 6.51 (1H, bs), 5.75
(1H, bs), 4.86 (1H, m), 4.38 (2H, t, J = 7.2 Hz), 2.36 (1H, dq., J =
13.6 Hz, 6.9 Hz), 1.94 (2H, quin., J = 7.4 Hz), 1.43−1.25 (4H, m),
1.08 (6H, m), 0.89 (3H, t, J = 7.1 Hz); 13C NMR (125 MHz, CDCl3):
δ 173.9 (CO), 163.2 (CO), 141.0 (quat.), 136.5 (quat.), 126.8 (CH),
123.0 (quat.), 122.8 (CH), 122.7 (CH), 109.5 (CH), 57.9 (CH), 49.7
(CH2), 30.7 (CH), 29.5 (CH2), 29.1 (CH2), 22.4 (CH2), 19.6 (CH3),
18.3 (CH3), 14.0 (CH3); LRMS (+ESI): m/z 258.9 ([M − CONH3]+,
100%), 313.9 ([M − NH3]+, 88%), 330.8 ([M + H]+, 46%) ; Anal.
Calcd for C18H26N4O2: C, 65.43; H, 7.93; N, 16.96. Found: C, 65.75;
H, 8.11; N, 16.98; HPLC purity: 97.6%.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-inda-
zole-3-carboxamide (ADB-PINACA, 10). Treating 30 (0.50 g, 2.2
mmol) with 20 (0.43 g, 3.3 mmol) according to general procedure A
gave, following puriﬁcation by ﬂash chromatography (hexane−EtOAc,
50:50), 10 (0.46 g, 63%) as a white solid. mp 135−137 °C; NMR (400
MHz, CDCl3): δ 8.27 (1H, m), 7.71 (1H, d, J = 9.5 Hz), 7.45−7.36
(2H, m), 7.29−7.22 (1H, m), 6.65 (1H, bs), 5.80 (1H, bs), 4.69 (1H,
d, J = 9.5 Hz), 4.38 (2H, t, J = 7.2 Hz), 1.95 (2H, quin., J = 7.2 Hz),
1.45−1.25 (4H, m), 1.16 (9H, s), 0.89 (3H, t, J = 7.0 Hz); 13C NMR
(100 MHz, CDCl3): δ 173.2 (CO), 162.8 (CO), 141.0 (quat.), 136.5
(quat.), 126.7 (CH), 123.0 (quat.), 122.7 (CH), 122.5 (CH), 109.5
(CH), 59.7 (CH), 49.6 (CH2), 34.8 (quat.), 29.5 (CH2), 29.0 (CH2),
26.9 (CH3), 22.3 (CH2), 14.0 (CH3); LRMS (+ESI): m/z 299.9 ([M
− CONH3]+, 100%), 327.9 ([M − NH3]+, 59%), 344.8 ([M + H]+,
19%) ; Anal. Calcd for C19H28N4O2: C, 66.25; H, 8.19; N, 16.27.
Found: C, 66.45; H, 8.40; N, 16.29.
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-ﬂuoropentyl)-
1H-indazole-3-carboxamide (5F-AB-PINACA, 11). Treating 31 (1.10
g, 4.4 mmol) with 19 (1.00 g, 6.7 mmol) according to general
procedure A gave, following puriﬁcation by ﬂash chromatography
(hexane−EtOAc, 10:90), 11 (0.56 g, 37%). Recrystallization from
EtOAc−hexane yielded material of analytical purity. mp 110−111 °C;
1H NMR (500 MHz, CDCl3): δ 8.30 (1H, m), 7.51 (1H, d, J = 8.9
Hz), 7.45−7.39 (2H, m), 7.27 (1H, m), 6.48 (1H, bs), 5.74 (1H, bs),
4.58 (1H, dd, J = 9.1 Hz, 6.7 Hz), 4.47 (1H, t, J = 6.0 Hz), 4.43−4.36
(3H, m), 2.35 (1H, dq, J = 13.6 Hz, 6.8 Hz), 2.00 (2H, m), 1.80−1.66
(2H, m), 1.51−1.41 (2H, m), 1.08 (6H, dd, J = 7.1 Hz, 5.2 Hz); 13C
Figure 7. Structures of selective CB1 receptor antagonist rimonabant
(SR141176, 40) and selective CB2 receptor antagonist SR144528
(41).
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NMR (125 MHz, CDCl3): δ 173.8 (CO), 163.0 (CO), 141.0 (quat.),
136.6 (quat.), 126.9 (CH), 122.99 (quat.), 122.91 (CH), 122.7 (CH),
109.4 (CH), 83.8 (CH2, d,
1JC−F = 164.0 Hz), 57.9 (CH), 49.3 (CH2),
30.7 (CH), 30.0 (CH2, d,
2JC−F = 20.1 Hz), 29.4 (CH2), 22.8 (CH2, d,
3JC−F = 5.1 Hz), 19.6 (CH3), 18.3 (CH3);
19F NMR (470 MHz,
CDCl3): δ −218.6; LRMS (ESI): m/z 303.9 ([M − CONH3]+,
100%), 331.9 ([M − NH3]+, 59%), 348.9 ([M + H]+, 48%); Anal.
Calcd for C18H25N4O2F: C, 62.05; H, 7.23; N, 16.08. Found: C, 61.96;
H, 7.26; N, 15.83.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-ﬂuoropen-
tyl)-1H-indazole-3-carboxamide (5F-ADB-PINACA, 12). Treating 31
(0.40 g, 1.6 mmol) with 20 (0.32 g, 2.4 mmol) according to general
procedure A gave, following puriﬁcation by ﬂash chromatography
(hexane−EtOAc, 10:90), 12 (0.27 g, 47%) as a white solid. mp 135−
137 °C; 1H NMR (400 MHz, CDCl3): δ 8.28 (1H, d, J = 8.2 Hz), 7.70
(1H, 9.4 Hz), 7.45−7.38 (2H, m), 7.30−7.23 (1H, m), 6.53 (1H, bs),
5.75 (1H, bs), 4.66 (1H, d, J = 9.6 Hz), 4.45−4.33 (3H, m), 2.18 (1H,
bs), 2.00 (2H, quin., J = 7.7 Hz), 1.84−1.64 (2H, m), 1.48 (2H, m),
1.16 (9H, s); 13C NMR (100 MHz, CDCl3): δ 173.1 (CO), 162.8
Figure 8. Eﬀects of 3 mg/kg of (A) AB-FUBINACA or (B) AB-PINACA on rat body temperature following pretreatment (30 min prior) with
vehicle, 3 mg/kg rimonabant (CB1 antagonist), or 3 mg/kg SR144528 (CB2 antagonist). The ﬁrst dashed line denotes time of intraperitoneal
injection of vehicle or antagonist. Second dashed line represents time of intraperitoneal injection of SC. Each point represents the mean ± SEM for
three animals.
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(CO), 141.0 (quat.), 136.8 (quat.), 126.9 (CH), 123.0 (quat.), 122.8
(CH), 122.7 (CH), 109.4 (CH), 83.9 (d, 1JC−F = 164.6, CH2), 59.8
(CH), 49.4 (CH2), 34.8 (quat.), 30.0 (d,
2JC−F = 19.7 Hz, CH2), 29.4
(CH2), 26.9 (CH3), 22.8 (d,
3JC−F = 5.1 Hz, CH2);
19F NMR (376
MHz, CDCl3): δ −218.3; LRMS (+ESI): m/z 317.9 ([M −
CONH3]
+, 100%), 345.9 ([M − NH3]+, 50%), 362.8 ([M + H]+,
17%); Anal. Calcd for C19H27N4O2F: C, 62.96; H, 7.51; N, 15.46.
Found: C, 63.12; H, 7.57; N, 15.29.
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(4-ﬂuorobenzyl)-
1H-indole-3-carboxamide (AB-FUBICA, 13). Treating 37 (1.20 g, 4.5
mmol) with 19 (1.03 g, 6.7 mmol) according to general procedure A
gave, following recrystallization from i-PrOH, 13 (1.28 g, 82%) as a
white solid. mp 212−214 °C; 1H NMR (300 MHz, DMSO-d6): δ 8.53
(1H, bs), 8.11 (1H, m), 7.64−7.50 (2H, m), 7.48 (1H, bs), 7.41−7.27
(2H, m), 7.24−7.10 (4H, m), 7.07 (1H, bs), 5.45 (2H, m), 4.36 (1H,
m), 2.09 (1H, m), 0.94 (6H, dd, J = 6.7 Hz, 2.7 Hz); 13C NMR (75
MHz, DMSO-d6): δ 173.5 (CO), 164.0 (CO), 161.6 (quat., d,
1JC−F =
243.18 Hz), 136.0 (CH), 133.7 (quat., d, 4JC−F = 2.87 Hz), 131.6
(quat.), 129.3 (d, 3JC−F = 8.1 Hz, CH), 126.7 (CH), 122.1 (CH),
121.1 (CH), 120.8 (CH), 115.5 (d, 2JC−F = 21.4 Hz, CH), 110.6
(quat.), 110.0 (CH), 57.4 (CH), 48.7 (CH2), 30.4 (CH), 19.5 (CH3),
18.5 (CH3);
19F NMR (282 MHz, DMSO-d6): δ −114.9 (m); LRMS
(+ESI): m/z 350.9 ([M − NH3]+, 100%), 367.8 ([M + H]+, 70%);
Anal. Calcd for C21H22N3O2F: C, 68.65; H, 6.04; N, 11.44. Found: C,
68.88; H, 6.15; N, 11.37; HPLC purity: 99.4%.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-ﬂuoroben-
zyl)-1H-indole-3-carboxamide (ADB-FUBICA, 14). Treating 37 (0.63
g, 2.3 mmol) with 20 (0.46 g, 3.5 mmol) according to general
procedure A gave, following puriﬁcation by ﬂash chromatography
(hexane−EtOAc, 10:90), 14 (0.76 g, 86%) as a white solid. mp 107−
108 °C; 1H NMR (400 MHz, CDCl3): δ 8.03 (1H, d, J = 7.7 Hz), 7.73
(1H, s), 7.31−7.20 (4H, m), 7.14−7.06 (2H, m), 6.99 (2H, t, J = 8.6
Hz), 6.77 (1H, d, J = 9.2 Hz), 6.54 (1H, bs), 5.71 (1H, bs), 5.27 (2H,
s), 4.71 (1H, d, J = 9.2 Hz), 1.14 (9H, s); 13C NMR (100 MHz,
CDCl3): δ 173.4 (CO), 165.0 (CO), 162.6 (d,
1JC−F = 247.2 Hz,
quat.), 136.8 (CH), 132.0 (d, 4JC−F = 3.2 Hz, quat.), 131.8 (quat.),
128.8 (d, 3JC−F = 8.1 Hz, CH), 125.8 (quat.), 123.1 (CH), 122.1
(CH), 120.5 (CH), 116.6 (d, 2JC−F= 21.6 Hz, CH), 111.4 (quat.),
110.7 (CH), 59.9 (CH), 50.1 (CH2), 34.9 (quat.), 27.0 (CH3);
19F
NMR (376 MHz, CDCl3): δ −113.9; LRMS (+ESI): m/z 363.9 ([M
− NH3]+, 100%), 381.8 ([M + H]+, 42%); Anal. Calcd C22H24N3O2F:
C, 69.27; H, 6.34; N, 11.02. Found: C, 69.68; H, 6.02; N, 10.95.
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indole-3-
carboxamide (AB-PICA, 15). Treating 38 (0.50 g, 2.2 mmol) with 19
(0.50, 3.3 mmol) according to general procedure A gave, following
puriﬁcation by ﬂash chromatography (hexane−EtOAc, 10:90), 15
(0.58 g, 81%) as a white solid. mp 214−215 °C; 1H NMR (400 MHz,
DMSO-d6): δ 8.25 (1H, s), 8.11 (1H, d, J = 7.7 Hz), 7.61−7.39 (3H,
m), 7.20 (1H, m), 7.13 (1H, t, J = 7.6 Hz), 7.06 (1H, bs), 4.35 (1H,
m), 4.19 (2H, m), 2.09 (1H, dq, J = 13.5 Hz, 6.8 Hz), 1.08 (2H, quin.,
J = 7.3 Hz), 1.39−1.19 (4H, m), 0.94 (6H, dd, J = 6.6 Hz, 3.1 Hz),
0.85 (3H, t, J = 7.0 Hz); 13C NMR (100 MHz, DMSO-d6): δ 173.6
(CO), 164.0 (CO), 136.1 (CH), 131.2 (quat.), 126.5 (quat.), 121.8
(CH), 121.0 (CH), 120.6 (CH), 110.3 (quat.), 109.3 (CH), 57.3
(CH), 45.8 (CH2), 30.3 (CH), 29.3 (CH2), 28.4 (CH2), 21.7 (CH2),
19.5 (CH2), 18.5 (CH3), 13.8 (CH3); LRMS (+ESI): m/z 312.87 ([M
− NH2]+, 100%), 329.80 ([M + H]+, 60%); Anal. Calcd for
C19H27N3O2: C, 69.27; H, 8.26; N, 12.76. Found: C, 69.21; H, 8.66;
N, 12.55; HPLC purity: 99.1%.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-in-
dole-3-carboxamide (ADBICA, 16). Treating 38 (0.57 g, 2.5 mmol)
with 20 (0.49 g, 3.7 mmol) according to general procedure A gave,
following puriﬁcation by ﬂash chromatography (hexane−EtOAc,
10:90), 16 (0.64 g, 75%) as a white solid. mp 138−139 °C; 1H
NMR (400 MHz,CDCl3): δ 8.01 (1H, m), 7.72 (1H, s), 7.38 (1H, m),
7.33−7.22 (2H, m), 6.74 (1H, d, J = 8.9 Hz), 6.60 (1H, bs), 5.71 (1H,
bs), 4.73 (1H, d, J = 8.9 Hz), 4.11 (2H, t, J = 7.2 Hz), 1.85 (2H, m),
1.42−1.25 (4H, m), 1,15 (9H, s), 0.89 (3H, t, J = 7.0 Hz); 13C NMR
(100 MHz, CDCl3): δ 173.5 (CO), 165.2 (CO), 136.8 (CH), 131.6
(quat.), 125.6 (quat.), 122.6 (CH), 121.8 (CH), 120.4 (CH), 110.6
(quat.), 110.4 (CH), 59.9 (CH), 47.1 (CH2), 34.9 (quat.), 29.8
(CH2), 29.1 (CH2), 27.0 (CH2), 22.4 (CH3), 14.0 (CH3); LRMS
(+ESI): m/z 326.9 ([M − NH3]+, 100%), 343.9 ([M + H]+, 31%);
Anal. Calcd for C20H29N3O2: C, 69.94; H, 8.51; N, 12.23. Found: C,
70.23; H, 8.65; N, 12.17.
(S)-N-(1-Amino-3-methyl-1-oxobutan-2-yl)-1-(5-ﬂuoropentyl)-
1H-indole-3-carboxamide (5F-AB-PICA, 17). Treating 39 (1.53 g, 6.5
mmol) with 19 (1.50 g, 9.8 mmol) according to general procedure A
gave, following recrystallization from i-PrOH, 17 (1.56 g, 69%) as a
white solid. mp 210−211 °C; 1H NMR (400 MHz, DMSO-d6): δ 8.25,
(1H, s), 8.11, (1H, d, J = 7.8 Hz), 7.61−7.39 (3H, m), 7.25−7.10 (2H,
m), 7.07 (1H, bs), 4.47 (1H, t, J = 6.0 Hz), 4.35 (2H, m), 4.21 (2H,
m), 2.09 (1H, dq, J = 13.5 Hz, 6.8 Hz), 1.84 (2H, m), 1.67 (2H, m),
1.35 (2H, m), 0.93 (6H, dd, J = 6.5 Hz, 2.9 Hz); 13C NMR (100 MHz,
DMSO-d6): δ 173.7 (CO), 164.1 (CO), 136.1 (CH), 131.3 (quat.),
126.5 (quat.), 121.9 (CH), 121.0 (CH), 120.7 (CH), 110.4 (quat.),
109.4 (CH), 83.7 (d, 1JC−F = 161.7 Hz, CH2), 57.4 (CH), 45.78
(CH2), 30.5 (CH), 29.5 (CH2), 29.3 (d,
3JC−F = 3.8 Hz, CH2), 22.2 (d,
2JC−F = 5.3 Hz, CH2), 19.5 (CH3), 18.5 (CH3);
19F NMR (376 MHz,
DMSO-d6): δ −216.86; LRMS (+ESI): m/z 330.9 ([M − NH3]+,
100%), 347.8 ([M + H]+, 67%); Anal. Calcd for C19H26N3O2F: C,
65.68; H, 7.54; N, 12.09. Found: C, 65.83; H, 7.66; N, 11.99.
(S)-N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-ﬂuoropen-
tyl)-1H-indole-3-carboxamide (5F-ADBICA, 18). Treating 39 (1.14 g,
4.9 mmol) with 20 (0.95 g, 7.3 mmol) according to general procedure
A gave, following puriﬁcation by ﬂash chromatography (hexane−
EtOAc, 90:10), 18 (1.14 g, 65%) as a white solid. mp 130−131 °C; 1H
NMR (400 MHz, CDCl3): δ 8.02 (1H, m), 7.71 (1H, s), 7.37 (1H,
m), 7.32−7.23 (2H, m), 6.76 (1H, d, J = 9.2 Hz), 6.67 (1H, bs), 5.74
(1H, bs), 4.74 (1H, d, J = 9.2 Hz), 4.47 (2H, dt, 2JH−F = 48,
3JH−H =
6.0 Hz), 4.13 (2H, t, J = 7.1 Hz), 1.90 (2H, m), 1.70 (2H, m), 1.45
(2H, m), 1.15 (9H, s) ppm; 13C NMR (100 MHz, CDCl3): δ 173.5
(CO), 165.1 (CO), 136.7 (CH), 131.5 (quat.), 125.7 (quat.), 122.7
(CH), 121.8 (CH), 120.5 (CH), 110.8 (quat.), 110.3 (CH), 83.8 (d,
1JC−F = 164.8 Hz, CH2), 59.9 (CH), 46.9 (CH2), 34.9 (quat.), 30.1 (d,
2JC−F = 19.9 Hz, CH2), 29.8 (CH2), 27.0 (CH3), 23.0 (d,
3JC−F = 5.1
Hz, CH2);
19F NMR (376 MHz, CDCl3): δ −218.53; LRMS (+ESI):
m/z 344.9 ([M − NH3]+, 100%), 361.8 ([M + H]+, 26%); Anal. Calcd
for C20H28N3O2F: C, 66.46; H, 7.81; N, 11.63. Found: C, 66.20; H,
7.94; N, 11.19.
L-tert-Leucinamide (20). To a solution of 23 (15.6 g, 59 mmol) in
THF (150 mL) was added 10% Pd/C (3.0 g), and the mixture was
stirred under an atmosphere of H2 for 12 h. The suspension was
ﬁltered through a pad of Celite, and the ﬁltrate was evaporated under
reduced pressure. The resulting solid was recrystallized from EtOAc−
hexane to yield 20 (4.74 g, 48%) as a white solid. mp 105−106 °C; 1H
NMR (500 MHz, DMSO-d6): δ 7.17 (1H, bs), 6.81 (1H, bs), 3.35
(1H, bs), 2.79 (1H, s), 1.5 (2H, bs), 0.88 (9H, s); 13C NMR (125
MHz, DMSO-d6): δ 176.17 (CO), 62.83 (CH), 33.56 (quat.), 26.53
(CH3); LRMS (+ESI): m/z 130.9 ([M + H]
+, 100%).
N-Cbz-L-tert-leucine (22). A cooled (0 °C) solution of L-tert-leucine
(21, 10.0 g, 76 mmol) and 5 M aq. NaOH (15 mL, 75 mmol, 1.0
equiv) in H2O (25 mL) was treated dropwise with benzyl
chloroformate (12 mL, 84 mmol, 1.1 equiv) and 2 M aq. NaOH
(42 mL, 84 mmol, 1.1 equiv), simultaneously. The mixture was
warmed to rt and stirred for 2 h, and the pH was adjusted to 10 by the
addition of sat. aq. NaHCO3. The aqueous layer was washed with Et2O
(3 × 50 mL), acidiﬁed to pH 3 with 2 M aq. HCl, and extracted with
Et2O (4 × 50 mL). The combined organic phases were dried
(MgSO4), and the solvent was evaporated under reduced pressure to
give a 22 (20 g, 99%) as a colorless oil. 1H NMR (400 MHz, CDCl3):
δ 7.43−7.29 (5H, m), 5.78 (1H, bs), 5.36 (1H, d, J = 9.5 Hz), 5.12
(2H, m), 4.21 (1H, d, J = 9.5 Hz), 1.02 (9H, s); 13C NMR (100 MHz,
CDCl3): δ 176.0 (CO), 156.4 (CO), 136.3 (quat.), 128.7 (CH), 128.4
(CH), 128.3 (CH), 67.4 (CH), 62.3 (CH2), 34.7 (quat.), 26.6 (CH3);
LRMS (−ESI): m/z 528.9 ([2M − H] −, 100%), 263.9 ([M − H]−,
76%).
N-Cbz-L-tert-leucinamide (23). To a solution of 22 (20.2 g, 76
mmol) in DMF (400 mL) were added NH4Cl (4.95 g, 93 mmol, 1.2
equiv), Et3N (32 mL, 229 mmol, 3.0 equiv), HOBt (13.2 g, 98 mmol,
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1.3 equiv), and EDC·HCl (18.8 g, 98 mmol, 1.3 equiv). After stirring
for 16 h, the reaction was quenched with sat. aq. NaHCO3 (100 mL),
and the aqueous phase was extracted with EtOAc (3 × 200 mL). The
combined organic phases were washed with H2O (3 × 200 mL) and
brine (100 mL) and dried (MgSO4), and the solvent removed under
reduced pressure. The obtained crude solid was recrystallized from
EtOAc−hexane to give 23 (16.9 g, 84%) as a white solid. mp 138−140
°C; 1H NMR (300 MHz, CDCl3): δ 7.40−7.29 (5H, m), 6.11 (1H,
bs), 5.75 (1H, bs), 5.62 (1H, d, J = 9.5 Hz), 5.08 (2H, m), 4.03 (1H, d,
J = 9.5 Hz), 1.01 (9H, s); 13C NMR (75 MHz, CDCl3): δ 175.1 (CO),
156.7 (CO), 136.4 (quat.), 128.7 (CH), 128.3 (CH), 128.1 (CH),
67.2 (CH), 62.4 (CH2), 34.4 (quat.), 26.6 (CH3); LRMS (+ESI): m/z
264.8 ([M + H]+, 100%).
Methyl 1H-Indazole-3-carboxylate (25). A solution of indazole-3-
carboxylic acid (24, 2.00 g, 12.3 mmol) in MeOH (30 mL) was treated
with conc. H2SO4 (2 mL) and heated at reﬂux for 4 h. The mixture
was concentrated in vacuo and dissolved in EtOAc (50 mL). The
organic phase was washed with sat. aq. NaHCO3 (20 mL), H2O (20
mL), and brine (20 mL) and dried (MgSO4), and the solvent was
evaporated under reduced pressure. The crude solid was recrystallized
from EtOAc−hexane to give 25 (1.65 g, 76%) as a white solid. mp
168−170 °C; 1H NMR (300 MHz, CDCl3): δ 8.23 (1H, m), 7.77
(1H, m), 7.49 (1H, m), 7.35 (1H, m), 4.08 (3H, s); 13C NMR (75
MHz, CDCl3): δ 163.41 (CO), 141.42 (quat.), 136.27 (quat.), 127.73
(CH), 123.60 (quat,), 122.50 (CH), 121.92 (CH), 111.35 (CH),
52.31 (CH3); LRMS (ESI): m/z 176.8 ([M + H]
+, 100%).
General Procedure B: Alkylation of Methyl 1H-Indazole-3-
carboxylate. To a cooled (0 °C) solution of 25 (2.17 g, 12.3 mmol)
in THF (60 mL) was added t-BuOK (1.52 g, 13.5 mmol, 1.1 equiv).
The mixture was warmed to rt, stirred for 1 h, and cooled (0 °C), and
the appropriate bromoalkane (19.7 mmol, 1.6 equiv) was added
dropwise. The mixture was warmed to rt and stirred for 48 h, and H2O
(60 mL) was added. The layers were separated, the aqueous layer was
extracted with EtOAc (2 × 50 mL), and the combined organic phases
were washed with H2O (3 × 50 mL) and brine (20 mL) and dried
(MgSO4), and the solvent was evaporated under reduced pressure.
Methyl 1-(4-Fluorobenzyl)-1H-indazole-3-carboxylate (26).
Treating 25 (2.30 g, 13.1 mmol) with 4-ﬂuorobenzyl bromide (1.78
mL, 14.3 mmol) according to general procedure B gave, following
puriﬁcation by ﬂash chromatography (hexane−EtOAc 70:30), 26
(2.50 g, 67%) as a clear glass-like solid. 1H NMR (300 MHz, CDCl3):
δ 8.24 (1H, dt, J = 8.1 Hz, 1.1 Hz), 7.44−7.27 (3H, m), 7.25−7.16
(2H, m), 7.03−6.93 (2H, m), 5.67 (2H, s), 4.05 (3H, s); 13C NMR
(75 MHz, CDCl3): δ 163.1 (CO), 162.6 (d,
1JC−F = 247.3 Hz, quat.),
140.6 (quat.), 135.3 (quat.), 131.6 (d, 4JC−F = 3.0 Hz, quat.), 129.2 (d,
3JC−F = 8.1 Hz, CH), 127.3 (CH), 124.3 (CH), 123.5 (quat.), 122.5
(CH), 116.0 (d, 2JC−F = 22.1 Hz, CH), 110.0 (CH), 53.5 (CH2), 52.3
(CH3);
19F NMR (282 MHz, CDCl3): δ −113.8 (m); LRMS (+ESI):
m/z 284.8 ([M + H]+, 100%).
Methyl 1-Pentyl-1H-indazole-3-carboxylate (27). Treating 25
(1.57 g, 8.9 mmol) with 1-bromopentane (1.75 mL, 14.1 mmol)
according to general procedure B gave, following puriﬁcation by ﬂash
chromatography (hexane−EtOAc 70:30), 26 (1.46 g, 77%) as a clear
glass-like solid. 1H NMR (400 MHz, CDCl3): δ 8.22 (1H, m), 7.50−
7.39 (2H, m), 7.30 (1H, m), 4.47 (2H, t, J = 7.4 Hz), 4.04 (3H, s),
1.97 (2H, quin., J = 7.2 Hz), 1.40−1.25 (4H, m), 0.88 (3H, m); 13C
NMR (100 MHz, CDCl3): δ 163.0 (CO), 140.7 (quat.), 134.9 (quat.),
126.8 (CH), 123.9 (quat.), 123.1 (CH), 122.5 (CH), 109.8 (CH),
61.1 (CH2), 50.1 (CH3), 29.7 (CH2), 29.1 (CH2), 22.4 (CH2), 14.0
(CH3); LRMS (+ESI): m/z 246.9 ([M + H]
+, 100%).
Methyl 1-(5-Fluoropentyl)-1H-indazole-3-carboxylate (28). Treat-
ing 25 (2.30 g, 13.1 mmol) with 1-bromo-5-ﬂuoropentane (2.42 g,
14.3 mmol) according to general procedure B gave, following
puriﬁcation by ﬂash chromatography (hexane−EtOAc 70:30), 28
(2.39 g, 69%) as a colorless glass-like solid. 1H NMR (400 MHz,
CDCl3): δ 8.24 (1H, m), 7.50−7.41 (2H, m), 7.32 (1H, m), 4.54−
4.43 (3H, m), 4.35 (1H, t, J = 5.9 Hz), 4.04 (3H, s), 2.03 (2H, quin., J
= 7.6 Hz), 1.80- 1.64 (2H, m), 1.52−1.41 (2H, m); 13C NMR (100
MHz, CDCl3): δ 163.2 (CO), 140.7 (quat.), 134.8 (quat.), 127.0
(CH), 123.9 (CH), 123.3 (quat.), 122.5 (CH), 109.7 (CH), 83.8 (d,
1JC−F = 165.1 Hz, quat.), 52.2 (CH2), 49.9 (CH3), 30.1 (d,
2JC−F =
19.7, CH2), 29.6 (CH2), 22.9 (d,
3JC−F = 5.1 Hz, CH2);
19F NMR (376
MHz, CDCl3): δ −218.7; LRMS (+ESI): m/z 264.8 ([M + H]+,
100%).
General Procedure C: Hydrolysis of Methyl 1-Alkyl-1H-
indazole-3-carboxylates. A solution of the appropriate methyl 1-
alkyl-1H-indazole-3-carboxylate (12.3 mmol) in MeOH (100 mL) was
treated with 1 M aq. NaOH (18.5 mL, 18.5 mmol, 1.5 equiv) and
stirred for 24 h. The solvent was reduced in vacuo, and the residue was
dissolved in H2O, acidiﬁed with 1 M aq. HCl, and extracted with
EtOAc (2 × 50 mL). The organic phase was dried (MgSO4), and the
solvent was evaporated under reduced pressure to aﬀord the free acid,
which was used in the subsequent coupling step without further
puriﬁcation.
1-(4-Fluorobenzyl)-1H-indazole-3-carboxylic Acid (29). Subjecting
26 (2.30 g, 8.1 mmol) to general procedure C gave 29 (2.10 g, 96%)
as a white solid. mp 200−203 °C; 1H NMR (300 MHz, DMSO-d6): δ
13.02 (1H, bs), 8.09 (1H, m), 8.47 (1H, m), 7.47 (1H, m), 7.39−7.27
(3H, m), 7.16 (2H, m), 5.76 (2H, s); 13C NMR (75 MHz, DMSO-d6):
δ 163.4 (CO), 161.7 (d, 1JC−F = 244.8 Hz, quat.), 140.4 (quat.), 135.1
(quat.), 132.9 (d, 4JC−F = 2.8 Hz, quat.), 129.7 (d,
3JC−F = 8.3 Hz,
CH), 126.9, 123.2, 123.0, 121.6, 115.5 (d, 2JC−F = 21.3 Hz, CH), 110.7
(CH), 51.8 (CH2);
19F NMR (282 MHz, CDCl3): δ −114.6; LRMS
(+ESI): m/z 270.9 ([M + H]+, 100%).
1-Pentyl-1H-indazole-3-carboxylic Acid (30). Subjecting 27 (0.96
g, 3.9 mmol) to general procedure C gave 30 (0.65 g, 72%) as a white
solid. mp 81−82 °C; 1H NMR (300 MHz, CDCl3): δ 9.85 (1H, bs),
8.26 (1H, m), 7.56−7.41 (2H, m), 7.34 (1H, m), 4.49 (2H, t, J = 7.3
Hz), 1.99 (2H, m), 1.45−1.25 (4H, m), 0.88 (3H, t, J = 6.9 Hz); 13C
NMR (75 MHz, CDCl3): δ 167.3 (CO), 140.9 (quat.), 134.0 (quat.),
127.0 (CH), 124.0 (quat.), 123.6 (CH), 122.5 (CH), 109.9 (CH),
50.2 (CH2), 29.6 (CH2), 29.0 (CH2), 22.4 (CH2), 14.0 (CH3); LRMS
(+ESI): m/z 323.9 ([M + H]+, 100%).
1-(5-Fluoropentyl)-1H-indazole-3-carboxylic Acid (31). Subjecting
28 (2.2 g, 8.3 mmol) to general procedure C gave 31 (1.9 g, 91%) as a
white solid. mp 80−82 °C; 1H NMR (300 MHz, CDCl3): δ 9.88 (1H,
bs), 8.27 (1H, m), 7.55−7.43 (2H, m), 7.36 (1H, m), 4.60−4.45 (3H,
m), 4.34 (1H, t, J = 5.9 Hz), 2.06 (2H, m), 1.86−1.62 (2H, m), 1.58−
1.39 (2H, m); 13C NMR (75 MHz, CDCl3): δ 167.4 (CO), 140.2
(quat.), 134.2 (quat.), 127.2 (CH), 124.0 (CH), 123.7 (CH), 122.5
(quat.), 109.8 (CH), 83.8 (d, 1JC−F = 165.1 Hz, CH2), 50.0 (CH2),
30.1 (d, 2JC−F = 19.8 Hz, CH2), 29.5 (CH2), 22.8 (d,
3JC−F = 4.9 Hz,
CH2);
19F NMR (282 MHz, CDCl3): δ −218.6; LRMS (+ESI): m/z
187.1 (100%), 250.9 ([M]+, 49%).
General Procedure D: One-Pot Synthesis of 1-Alkyl-3-
(triﬂuoroacetyl)indoles. A cooled (0 °C) suspension of NaH
(60% dispersion in mineral oil, 0.68 g, 17.1 mmol, 2.0 equiv) in DMF
(10 mL) was treated with a solution of indole (33, 1.00 g, 8.5 mmol)
in DMF (2 mL), warmed to rt, and stirred for 10 min. The mixture
was cooled to 0 °C, treated slowly with the appropriate bromoalkane
(1.05 equiv), warmed to rt, and stirred for 1 h. The solution was
cooled to 0 °C, treated with (CF3CO)2O (3.00 mL, 21.3 mmol, 2.5
equiv), warmed to rt, and stirred for 1 h. The mixture was poured onto
ice−water (120 mL) and stirred vigorously. The mixture was ﬁltered,
and the precipitate was dried to give the crude product as a red solid,
which was used in the following step without puriﬁcation.
1-(4-Fluorobenzyl)-3-(triﬂuoroacetyl)indole (34). Subjecting 4-
ﬂuorobenzyl bromide (1.13 mL, 9.0 mmol) to general procedure D
gave 34 as a red crystalline solid (2.72 g, 100%). mp 83−86 °C; 1H
NMR (400 MHz, CDCl3): δ 8.43 (1H, m), 7.96 (1H, m), 7.38 (1H,
m), 7.43−7.29 (2H, m), 7.22−7.12 (2H, m), 7.11−7.00 (2H, m), 5.38
(2H, s); 13C NMR (100 MHz, CDCl3): δ 175.1 (q,
2JC−F = 34.9 Hz,
CO), 162.9 (d, 1J C−F = 247.5 Hz, quat.), 137.5 (q,
3JC−F = 4.9 Hz,
CH), 136.9 (quat.), 130.7 (d, 3JC−F = 3.4 Hz, quat.), 129.7 (d,
2JC−F =
8.1 Hz, CH), 127.3 (quat.), 125.0 (quat.), 124.3 (CH), 123.0 (CH),
117.1 (q, 1JC−F = 291.8 Hz, quat.), 116.4 (d,
2JC−F = 22.2 Hz, CH),
110.8 (CH), 110.2 (CH), 50.8 (CH2);
19F NMR (282 MHz, CDCl3):
δ −112.9 (m), −72.3; LRMS (+ESI): m/z 321.9 ([M + H]+, 100%).
1-Pentyl-3-(triﬂuoroacetyl)indole (35). Subjecting 1-bromopentane
(1.11 mL, 8.96 mmol) to general procedure D gave 35 as a red
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crystalline solid (2.41 g, 100%). mp 56−57 °C; 1H NMR (400 MHz,
CDCl3): δ 8.42 (1H, m), 7.93 (1H, d, J = 1.5 Hz), 7.47−7.33 (3H, m),
4.20 (2H, t, J = 7.21), 1.93 (2H, quin., J = 7.16 Hz), 1.46−1.31 (4H,
m), 0.92 (3H, t, J = 7.02 Hz); 13C NMR (75 MHz, CDCl3): δ 174.9
(q, 2JC−F = 34.7 Hz, CO), 137.4 (q,
3JC−F = 4.9 Hz, CH), 136.8
(quat.), 127.3 (quat.), 124.6 (quat.), 124.0 (CH), 122.9 (CH), 117.3
(q, 1JC−F = 291.5 Hz, quat.), 110.5 (CH), 109.6 (CH), 47.8 (CH2),
29.6 (CH2), 29.0 (CH2), 22.3 (CH2), 14.0 (CH3);
19F NMR (376
MHz, CDCl3): δ −72.2; LRMS (ESI): m/z 284.0 ([M + H]+, 100%).
1-(5-Fluoropentyl)-3-(triﬂuoroacetyl)indole (36). Subjecting 1-
bromo-5-ﬂuoropentane (1.51 g, 9.0 mmol) to general procedure D
gave 36 as a red solid (2.59 g, 100%). mp 55−57 °C; 1H NMR (500
MHz, CDCl3): δ 8.41 (1H, m), 7.93 (1H, m), 7.46−7.32 (3H, m),
4.45 (2H, dt, 2JH−F = 45,
3JH−H = 5.8 Hz), 4.23 (2H, t, J = 7.2 Hz),
1.99 (2H, m), 1.75 (2H, m), 1.52 (2H, m); 13C NMR (125 MHz,
CDCl3): δ 174.9 (q,
2JC−F = 34.8 Hz, CO), 137.4 (q,
3JC−F = 5.0 Hz,
CH), 136.7 (quat.), 127.3 (quat.), 124.7 (CH), 124.1 (CH), 122.9
(CH), 117.2 (q, 1JC−F = 291.3 Hz, quat.), 110.4 (CH), 109.7 (quat.),
83.7 (d, 1JC−F = 165.1 Hz, CH2), 47.7 (CH2), 30.0 (d,
2JC−F 19.9 Hz,
CH2), 29.5 (CH2), 23.0 (d,
3JC−F = 4.5 Hz, CH2);
19F NMR (470
MHz, CDCl3): δ −72.2, −218.9; LRMS (+ESI): m/z 302.0 ([M +
H]+, 100%).
General Procedure E: Synthesis of 1-Alkylindole-3-carbox-
ylic Acids. To a reﬂuxing solution of KOH (1.57 g, 28.1 mmol, 3.3
equiv) in MeOH (3 mL) was added, portionwise, a solution of the
appropriate crude 1-alkyl-3-triﬂuoroacetylindole (8.5 mmol) in toluene
(7 mL). After heating at reﬂux for 2 h, the mixture was cooled to
ambient temperature, and H2O (30 mL) was added. The layers were
separated, and the organic layer was extracted with 1 M aq. NaOH (8
mL). The combined aqueous phases were acidiﬁed to pH 1 with 10 M
aq. HCl, extracted with Et2O (3 × 10 mL), and dried (MgSO4), and
the solvent was removed under reduced pressure. The crude solid was
recrystallized from i-PrOH to give the appropriate 1-alkylindole-3-
carboxylic acid as colorless crystals.
1-(4-Fluorobenzyl)indole-3-carboxylic Acid (37). Subjecting 34
(2.74 g, 8.5 mmol) to general procedure E gave 37 (1.51 g, 66%) as a
colorless crystalline solid. mp 205−208 °C; 1H NMR (400 MHz,
DMSO-d6): δ 8.22 (1H, s), 8.02 (1H, m), 7.54 (1H, m), 7.40−7.31
(2H, m), 7.24−7.11 (4H, m), 5.48 (2H, s); 13C NMR (100 MHz,
DMSO-d6): δ 165.5 (CO), 161.6 (d,
1JC−F = 243.3 Hz, quat.), 136.2
(CH), 135.4 (quat.), 133.4 (d, 3JC−F = 3.2 Hz, quat.), 129.5 (d,
3JC−F =
8.3 Hz, CH), 126.6 (quat.), 122.4 (CH), 121.4 (CH), 120.9 (CH),
115.4 (CH, d, 2JC−F = 21.7), 111.0 (CH), 107.0 (quat.), 48.7 (CH2)
ppm; 19F NMR (282 MHz, DMSO-d6) δ −114.80 (m) ppm; LRMS
(+ESI): m/z 283.9 (100%), 269.9 ([M + H]+, 10%).
1-Pentylindole-3-carboxylic Acid (38). Subjecting 35 (2.00 g, 7.1
mmol) to general procedure E gave 38 (0.88 g, 54%) as a colorless
crystalline solid. mp 101−102 °C (lit mp 106−108 °C);28 1H NMR
(300 MHz, CDCl3): δ 9.87 (1H, bs), 8.26 (1H, m), 7.93 (1H, s), 7.39
(1H, m). 7.35−7.27 (2H, m), 4.17 (2H, t, J = 7.1 Hz), 1.90 (2H, quin.,
J = 7.1 Hz), 1.46−1.25 (4H, m), 0.91 (3H, t, J = 6.8 Hz); 13C NMR
(75 MHz, CDCl3): δ 170.7 (CO), 136.9 (CH), 135.6 (quat.), 127.2
(quat.), 123.0 (quat.), 122.3 (CH), 122.1 (CH), 110.2 (CH), 106.4
(CH), 47.3 (CH2), 29.7 (CH2), 29.1 (CH2), 22.4 (CH2), 14.0 (CH3);
LRMS (+ESI): m/z 245.9 (100%), 231.9 ([M + H]+, 16%).
1-(5-Fluoropentyl)indol-3-carboxylic Acid (39). Subjecting 36
(2.57 g, 8.5 mmol) to general procedure E gave 39 (1.36 g, 68%) as
a colorless crystalline solid. mp 117−118 °C; 1H NMR (400 MHz,
CDCl3): δ 8.26 (1H, m), 7.93 (1H, s), 7.38 (1H, m), 7.35−7.28 (2H,
m), 4.43 (2H, dt, 2JH−F = 48,
3JH−H = 5.9 Hz), 4.19 (2H, t, J = 7.1 Hz),
1.95 (2H, m), 1.73 (2H, m), 1.48 (2H, m); 13C NMR (100 MHz,
CDCl3): δ 170.8 (CO), 136.8 (CH), 135.5 (quat.), 127.2 (quat.),
123.1 (CH), 122.3 (CH), 122.1 (CH), 110.1 (CH), 106.6 (quat.),
83.8 (d, 1JC−F = 164.9 Hz, CH2), 47.2 (CH2), 30.1 (d,
2JC−F = 20.0 Hz,
CH2), 29.7 (CH2), 23.0 (d,
3JC−F = 5.0 Hz, CH2);
19F NMR (376
MHz, CDCl3): δ −218.6; LRMS (+ESI): m/z 263.9 (100%), 249.9
([M + H]+, 18%).
In Vitro Pharmacological Assessment of SCs. Mouse AtT-20
neuroblastoma cells stably transfected with human CB1 or human CB2
have been previously described14,36,41 and were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS), 100 U penicillin/streptomycin, and 300 μg/mL G418.
Cells were passaged at 80% conﬂuence, as required. Cells for assays
were grown in 75 cm2 ﬂasks and used at 90% conﬂuence. The day
before the assay, cells were detached from the ﬂask with trypsin/
EDTA (Sigma) and resuspended in 10 mL of Leibovitz’s L-15 media
supplemented with 1% FBS, 100 U penicillin/streptomycin, and 15
mM glucose (membrane potential assay and Ca5 calcium assay). The
cells were plated in a volume of 90 μL in black-walled, clear-bottomed
96-well microplates (Corning) that had been precoated with poly-L-
lysine (Sigma, Australia). Cells were incubated overnight at 37 °C in
ambient CO2.
Membrane potential was measured using a FLIPR membrane
potential assay kit (blue) from Molecular Devices, as described
previously.42 The dye was reconstituted with assay buﬀer of the
following composition (mM): NaCl 145, HEPES 22, Na2HPO4 0.338,
NaHCO3 4.17, KH2PO4 0.441, MgSO4 0.407, MgCl2 0.493, CaCl2
1.26, and glucose 5.56 (pH 7.4, osmolarity 315 ± 5). Prior to the
assay, cells were loaded with 90 μL/well of the dye solution without
removal of the L-15, giving an initial assay volume of 180 μL/well.
Plates were then incubated at 37 °C at ambient CO2 for 45 min.
Fluorescence was measured using a FlexStation 3 (Molecular Devices)
microplate reader, with cells excited at a wavelength of 530 nm and
emission measured at 565 nm. Baseline readings were taken every 2 s
for at least 2 min, at which time either drug or vehicle was added in a
volume of 20 μL. The background ﬂuorescence of cells without dye or
dye without cells was negligible. Changes in ﬂuorescence were
expressed as a percentage of baseline ﬂuorescence after subtraction of
the changes produced by vehicle addition, which was less than 2% for
drugs dissolved in assay buﬀer or DMSO. The ﬁnal concentration of
DMSO was not more than 0.1%.
Data were analyzed with PRISM (GraphPad Software Inc., San
Diego, CA), using four-parameter nonlinear regression to ﬁt
concentration−response curves. In all plates, a maximally eﬀective
concentration of CP 55,940 was added to allow for normalization
between assays.
In Vivo Pharmacological Assessment of SCs. Four cohorts of
3−4 adult male Wistar rats (Animal Resources Centre, Perth,
Australia) initially weighing between 168 and 186 g were used for
biotelemetric assessment of body temperature and heart rate changes
following each compound or following either compound administered
with a CB1 and CB2 antagonist. The rats were singly housed in an air-
conditioned testing room (22 ± 1 °C) on a 12 h reverse light/dark
cycle (lights on from 21:00 to 09:00). Standard rodent chow and water
were provided ad libitum. All experiments were approved by The
University of Sydney Animal Ethics Committee.
Biotelemetry transmitters (TA11CTA-F40, Data Sciences Interna-
tional, St. Paul, MN) were implanted as previously described.14,36
Brieﬂy, following anesthetization (isoﬂurane, 3% induction, 2%
maintenance), a rostro-caudal incision was made along the midline
of the abdomen, and a biotelemetry transmitter (TA11CTA-F40, Data
Sciences International, St. Paul, MN) was placed in the peritoneal
cavity according to the manufacturer’s protocol. The wound was
sutured, and the rats were allowed 1 week of recovery before data
collection.
The rats were habituated over multiple days to injections of vehicle
(5% EtOH, 5% Tween 80, 90% physiological saline) at a set time of
day (11:00 am). The ﬁrst two cohorts then received injections of each
compound at the same time of day in an ascending dose sequence
(0.1, 0.3, 1, 3 mg/kg). This ascending sequence reduces the risk posed
to the animals in assessing hitherto untested compounds, and the use
of multiple cohorts limits the potential development of tolerance to
the compound. Two washout days were given between each dose. If
only a modest or negligible hypothermic response was seen at 3 mg/
kg, then a further 10 mg/kg dose of the compound was given. At least
two washout days were given between each dose.
For the antagonist studies (Figure 8), the third and fourth cohorts
of drug-naiv̈e rats were used for each compound, with a 48 h washout
period between each dose. Each cohort received injections of either
vehicle, CB1 antagonist (rimonabant, 3 mg/kg), or CB2 antagonist
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(SR144528, 3 mg/kg), followed by AB-FUBINACA (3 mg/kg) or AB-
PINACA (3 mg/kg). The vehicle or antagonist injections were given
to rats 30 min prior to the AB-FUBINACA or AB-PINACA injection.
Data for heart rate and body temperature was gathered continuously
at 1000 Hz, organized into 15 or 30 min bins using Dataquest A.R.T.
software (version 4.3, Data Sciences International, St. Paul, MN), and
analyzed using Prism (GraphPad Software Inc., San Diego, CA).
We calculated the area between baseline and drug-treatment body
temperature curves for each rat as a measure of compound potency.
Brieﬂy, for any time point, the area between baseline data points (Bt)
and drug-treatment data points (Dt) and the subsequent time points
(Bt+1 and Dt+1) forms a trapezoid, the area of which can be calculated
via the formula
= − + −+ +B D B Darea ( ) ( )
2
t t t t1 1
These areas were summed from the time of injection to 6 h
postinjection. This data was analyzed using a two-way mixed model
ANOVA with Bonferroni corrected contrasts comparing the
compounds at each dose.
For the antagonist studies, the area between the vehicle−vehicle
baseline and the vehicle−SC (i.e., vehicle−AB-FUBINACA or
vehicle−AB-PINACA), rimonabant−SC, and SR144528−SC treat-
ments was calculated over a 3 h time period postinjection of SC. These
areas were analyzed using a one-way repeated measures ANOVA with
planned Dunnet’s contrasts comparing the antagonist areas to the
vehicle−drug area.
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ABSTRACT: Indole and indazole synthetic cannabinoids
(SCs) featuring L-valinate or L-tert-leucinate pendant group
have recently emerged as prevalent recreational drugs, and
their use has been associated with serious adverse health
eﬀects. Due to the limited pharmacological data available for
these compounds, 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-
FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and
their analogues were synthesized and assessed for cannabimi-
metic activity in vitro and in vivo. All SCs acted as potent,
highly eﬃcacious agonists at CB1 (EC50 = 0.45−36 nM) and CB2 (EC50 = 4.6−128 nM) receptors in a ﬂuorometric assay of
membrane potential, with a general preference for CB1 activation. The cannabimimetic properties of two prevalent compounds
with conﬁrmed toxicity in humans, 5F-AMB and MDMB-FUBINACA, were demonstrated in vivo using biotelemetry in rats.
Bradycardia and hypothermia were induced by 5F-AMB and MDMB-FUBINACA doses of 0.1−1 mg/kg (and 3 mg/kg for 5F-
AMB), with MDMB-FUBINACA showing the most dramatic hypothermic response recorded in our laboratory for any SC (>3
°C at 0.3 mg/kg). Reversal of hypothermia by pretreatment with a CB1, but not CB2, antagonist was demonstrated for 5F-AMB
and MDMB-FUBINACA, consistent with CB1-mediated eﬀects in vivo. The in vitro and in vivo data indicate that these SCs act
as highly eﬃcacious CB receptor agonists with greater potency than Δ9-THC and earlier generations of SCs.
KEYWORDS: Cannabinoid, THC, JWH-018, AMB, MDMB
Synthetic cannabinoids (SCs) are the most rapidly growingclass of “designer drugs”, or new psychoactive substances
(NPSs).1 Consumer products available since about 2004 and
intended as “legal cannabis substitutes” were found in 2008 to
contain JWH-018 (1, Figure 1) and CP 47,497-C8 (2).2,3 In
2014, 177 diﬀerent SCs were reported to the United Nations
Oﬃce on Drugs and Crime (UNODC) Early Warning
Advisory (EWA).4 Many novel SCs have already been
discovered in 2016, and the structural diversity of these
substances is increasing.5−14
SCs are typically found to function as agonists of
cannabinoid receptor type 1 (CB1) and type-2 (CB2), with
activation of the former accounting for the psychoactivity of
these substances.15 However, many SCs are unknown prior to
ﬁrst detection by forensic chemists, and nothing is known of
their activity in humans. The scarcity of data regarding the
pharmacological and toxicological properties of emergent SCs
poses an ongoing challenge for scientists, healthcare workers,
and lawmakers across the globe.16−26
We have previously described the in vitro and in vivo
pharmacology of SCs based on 3-benzoylindoles (e.g., RCS-4,
3), 3-naphthoylindoles (e.g., AM-2201, 4), 3-alkanoylindoles
(e.g., XLR-11, 5), indole-3-carboxylates (e.g., 5F-PB-22, 6), and
indole-3-carboxamides (e.g., STS-135, 7).27−32 One of the most
prevalent, recent groups of SCs are 1-alkyl-1H-indazole-3-
carboxamides featuring pendant valinamide and tert-leucina-
mide groups, exempliﬁed by AB-FUBINACA (8) and ADB-
PINACA (9), respectively. Following the designation of several
members of this class as Schedule I substances by the Drug
Enforcement Administration (DEA) in the United States
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(US),33,34 newer indole- and indazole-3-carboxamide variants
have appeared featuring currently popular 5-ﬂuoropentyl, 4-
ﬂuorobenzyl, cyclohexylmethyl, or pentyl substituents at the 1-
position, and valinate and tert-leucinate methyl ester side chains
(10−25, Figure 2).
5F-AMB-PICA (MMB-2201, 5F-AMBICA, 10) was reported
to the European Monitoring Centre for Drugs and Drug
Addiction (EMCDDA) following its identiﬁcation in Hungary
and Sweden in 2014, and its indazole analogue, 5F-AMB-
PINACA (5F-AMB, 12), was found in Hungary contempora-
neously.35 The tert-leucinate analogue of 12, 5F-MDMB-
PINACA (5F-ADB, 13), was notiﬁed to the UNODC EWA
in Hungary and Japan in 2015. The indole derivative MDMB-
FUBICA (15) was discovered in Hungary and Sweden in 2015,
according to UNODC EWA, and AMB-FUBINACA (16) was
reported to the EMCDDA in Sweden around the same time.35
MDMB-FUBINACA (17) was identiﬁed following media
monitoring by EMCDDA after it was responsible for dozens
of deaths and hundreds of hospitalizations in the Russian
Federation in 2015.35,36 MDMB-CHMICA was ﬁrst identiﬁed
in Hungary in 2014, but has since been reported to the EWA in
France, Mauritius, Serbia, Turkey, and the UK.35
SC use is associated with serious adverse reactions,37−53 and
the most recent SCs appear to possess greater dependence
liabilities54−57 and toxicities58−64 than earlier examples. AMB-
FUBINACA was clinically conﬁrmed in a case of rhabdomol-
ysis,65 and fatal intoxications have been attributed to
consumption of 5F-AMB,44,66,67 5F-ADB,68 and MDMB-
CHMICA.69−71
Aspects of the spectral properties of selected members of this
class of SCs have been reported,72−76 and details of the
metabolism of AMB-PICA and 5F-AMB were recently
published,77 but little is known about the pharmacology of
these compounds in vitro or in vivo.
A systematic library of indole and indazole SCs featuring a
valinate or tert-leucinate functional group was prepared and
screened for cannabinoid activity in vitro and in vivo, in order
to elucidate the hitherto unknown structure−activity relation-
ships within this class.
■ RESULTS AND DISCUSSION
The synthesis of indole and indazole SCs required a diﬀerent
strategy for each heteroaromatic core. The synthesis of indole
SCs 10, 11, 14, 15, 18, 19, 22, and 23 is shown in Scheme 1,
and the synthesis of indazole SCs 12, 13, 16, 17, 20, 21, 24,
and 25 is shown in Scheme 2.
As shown in Scheme 1, indole was subjected to a one-pot
procedure in the presence of excess base whereby N-alkylation
with the appropriate alkyl bromide was followed treatment with
triﬂuoroacetic anhydride and gave triﬂuoroacetylindoles 27−
30. Base-mediated hydrolysis of the triﬂuoroacetyl groups of
27−30 gave the corresponding carboxylic acids 31−34. Finally,
amide bond formation was achieved by subjecting 31−34 to
HOBt/EDC coupling with methyl L-valinate or methyl tert-L-
leucinate to aﬀord 10, 11, 14, 15, 18, 19, 22, and 23.
As depicted in Scheme 2, the synthesis of indazole analogues
started from methyl 1H-indazole-3-carboxylate (35), which was
regioselectively alkylated with the suitable bromoalkane to give
the 1-alkyl-1H-indazole-3-carboxylate methyl esters 36−39.
Saponiﬁcation of esters 36−39 aﬀorded the corresponding
acids 40−43, which were coupled to methyl L-valinate or
methyl tert-L-leucinate using the HOBt/EDC method described
above, to furnish 1-alkyl-1H-indazole-3-carboxamides 12, 13,
16, 17, 20, 21, 24, and 25.
The activity of synthesized indole and indazole SCs 10−25 at
CB1 and CB2 receptors was assessed in a ﬂuorometric imaging
plate reader (FLIPR) assay to elucidate structure−activity
relationships (SARs) for this class. The activities of 10−25 at
CB1 and CB2 were compared to phytocannabinoid Δ9-THC (a
low eﬃcacy agonist at CB1 and CB2), and CP 55,940 (an
Figure 1. Selected synthetic cannabinoids.
Figure 2. Emergent indole and indazole SCs featuring pendant methyl
valinate and methyl tert-leucinate functional groups.
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Scheme 1. Synthesis of Indole SCs 10, 11, 14, 15, 18, 19, 22, and 23a
aReagents and conditions: (a) (i) NaH, BrR1, DMF, 0 °C−rt, 1 h; (ii) (CF3CO)2O, DMF, 0 °C−rt, 1 h, 72−94%; (b) 1 M aq. NaOH, MeOH,
reﬂux, 24 h, 67−92%; (c) methyl L-valinate or methyl L-tert-leucinate, EDC·HCl, HOBt, DIPEA, DMSO, rt, 24 h, 63−81%.
Scheme 2. Synthesis of Indazole SCs 12, 13, 16, 17, 20, 21, 24, and 25a
aReagents and conditions: (a) t-BuOK, BrR1, THF, 0 °C−rt, 48 h; 65−84%; (b) 1 M aq. NaOH, MeOH, reﬂux, 24 h, 76−91%; (c) methyl L-valinate
or methyl L-tert-leucinate, EDC·HCl, HOBt, DIPEA, DMSO, rt, 24 h, 60−77%.
Table 1. Functional Activity of Δ9-THC, CP 55,940, and Novel SCs 10−25 at CB1 and CB2 Receptors
hCB1 hCB2
compd pEC50 ± SEM (EC50, nM) max ± SEM (% CP 55,940) pEC50 ± SEM (EC50, nM) max ± SEM (%CP 55,940) CB1 sel.
a
Δ9-THC 6.77 ± 0.05 (171) 50 ± 11 20 ± 3 at 10 μM
CP 55,490 7.47 ± 0.05 (42) 7.17 ± 0.07 (68) 1.6
5F-AMBICA (10) 8.62 ± 0.06(2.4) 107 ± 4 8.34 ± 0.07 (4.6) 94 ± 3 1.9
5F-MDMB-PICA (11) 9.35 ± 0.07(0.45) 110 ± 4 8.13 ± 0.05 (7.4) 94 ± 3 16.4
5F-AMB (12) 8.71 ± 0.04(1.9) 109 ± 3 7.99 ± 0.13 (10) 103 ± 7 5.3
5F-ADB (13) 9.23 ± 0.11(0.59) 108 ± 5 8.12 ± 0.06 (7.5) 94 ± 3 12.7
AMB-FUBICA (14) 7.45 ± 0.05(36) 106 ± 3 7.85 ± 0.09 (14) 86 ± 4 0.4
MDMB-FUBICA (15) 8.57 ± 0.05(2.7) 109 ± 3 7.60 ± 0.12 (25) 92 ± 6 9.3
AMB-FUBINACA (16) 8.71 ± 0.10(2.0) 103 ± 5 7.75 ± 0.05 (18) 92 ± 3 9.0
MDMB-FUBINACA (17) 8.41 ± 0.04 (3.9) 108 ± 3 7.26 ± 0.14 (55) 101 ± 9 14.1
AMB-CHMICA (18) 8.45 ± 0.08(3.5) 114 ± 4 7.93 ± 0.07 (12) 88 ± 4 3.4
MDMB-CHMICA (19) 8.00 ± 0.05 (10) 112 ± 3 7.15 ± 0.05 (71) 103 ± 3 7.1
AMB-CHMINACA (20) 8.29 ± 0.07(5.1) 109 ± 4 7.54 ± 0.13 (29) 92 ± 7 5.7
MDMB-CHMINACA (21) 7.99 ± 0.04 (10) 111 ± 2 6.89 ± 0.04 (128) 96 ± 3 12.8
AMBICA (22) 7.74 ± 0.10(18) 111 ± 6 7.63 ± 0.08 (23) 90 ± 4 1.3
MDMB-PICA (23) 8.77 ± 0.06 (1.7) 109 ± 4 7.78 ± 0.13 (17) 90 ± 5 10
AMB-PINACA (24) 8.48 ± 0.05 (3.3) 110 ± 3 7.79 ± 0.11 (16) 96 ± 5 4.8
MDMB-PINACA (25) 8.84 ± 0.06 (1.4) 112 ± 4 7.56 ± 0.06 (28) 91 ± 4 20
aCB1 selectivity expressed as the ratio of CB1 EC50 to CB2 EC50.
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eﬃcacious agonist at CB1 and CB2), in an assay of CB receptor-
dependent membrane hyperpolarization (Table 1). The assay
used murine AtT20-FlpIn neuroblastoma cells stably expressing
human CB1 or CB2 receptors. Activation of CB receptors
resulted in opening of endogenous G protein-gated inwardly
rectifying potassium channels (GIRKs) that produced a
hyperpolarization of the cells which was reﬂected in a decrease
in the ﬂuorescence of a proprietary membrane potential dye.
The maximum eﬀects of Δ9-THC and 10−25 were compared
to the high eﬃcacy CB1/CB2 agonist CP 55,490. Data for each
experiment were normalized to the change in ﬂuorescence
produced by a maximally eﬀective concentration of CP 55,940
(1 μM). CP 55,940 (1 μM) decreased ﬂuorescence by 31 ± 1%
in CB1-expressing cells, and 26 ± 1% in CB2 expressing cells
(n = 18 each). None of 10−25 produced a signiﬁcant change in
the membrane potential of wild type AtT-20 cells (n = 5 each,
data not shown), which do not express CB1 or CB2 receptors.
Consistent with a predominant coupling of CB1 and CB2
receptors to Gi/Go family G proteins, the eﬀects of 10−25
were abolished by overnight treatment of the cells with
pertussis toxin (200 ng/mL), which blocks the coupling of
GPCR to Gi/Go family G proteins (n = 3 each, data not
shown).
All indole and indazole SCs 10−25 activated CB1 and CB2
receptors. All compounds had greater potency (0.45−36 nM)
than either Δ9-THC (171 nM) or CP 55,940 (42 nM) for CB1
receptor-mediated activation of GIRK. Consistent with our
previous studies using this assay, Δ9-THC was found to be a
low eﬃcacy agonist at CB2 receptors, and its eﬀects on GIRK
activation in AtT20-CB2 at 10 μM were only 20 ± 3% of that
mediated by a maximally eﬀective concentration of CP 55,940
(1 μM). Compounds 10−25 had a similar maximal eﬀect to CP
55,940 at CB1 and CB2 receptors, suggesting that these SCs are
also high eﬃcacy agonists. Excluding 14, all SCs showed a
preference for CB1 receptors over CB2 receptors, ranging from
low (e.g., 22; 1.3 times) to moderate (e.g., 25; 20 times). The
psychoactivity of cannabinoids is attributed to activation of CB1
receptors,15 and our data are consistent the anecdotally
reported psychoactive eﬀects of members of this class of SCs.
With the exception of several pairs of nearly equal potency
(16 and 17; 20 and 21), all tert-leucinate-functionalized SCs
were more potent CB1 agonists than the corresponding valinate
analogues, a trend that was also observed for tert-leucinimde
and valinamide analogues in our previous work.30
CB1 EC50 values for 10−25 ranged from 0.45 to 36 nM, but
only two of the 16 SCs had EC50 values greater than 10 nM (14
and 22), and two demonstrated subnanomolar potencies (11
and 13). The least potent SC in this class (AMB-FUBICA; 14)
was roughly 4 times more potent than Δ9-THC at CB1
receptors, while the most potent compound (5F-MDMB-
PICA; 11) was 380 times more potent than Δ9-THC.
Consistent with our previous work on other indole and
indazole SCs, there were no obvious trends for diﬀerences in
potency or eﬃcacy when moving between these heteroaromatic
cores for corresponding pairs of compounds. However, within
the tert-leucinate-ﬂunctionalized compounds, the nature of N-
alkyl substituent had a consistent eﬀect on CB1 potency for
compounds containing either an indole or indazole core.
For the tert-leucinate functionalized indoles, CB1 potency
decreased as a function of N-alkyl substituent in the order of 5-
ﬂuoropentyl (11), pentyl (23), 4-ﬂuorobenzyl (15), and
cyclohexylmethyl (19), and this trend is depicted in Figure
3a. The same trend was found for corresponding indazoles 13,
25, 17, and 21, respectively (Figure 3b). Although no such clear
trend was evident for valinate-containing SCs, it is notable that
three of the ﬁve least potent SCs contained a cyclohexylmethyl
group at the 1-position (19, 20, and 21), and three of the ﬁve
most potent SCs contained a 5-ﬂuoropentyl substituent (11,
12, and 13) regardless of heteroaromatic core or amino acid
ester side-chain.
Having demonstrated that 10−25 are potent and eﬃcacious
cannabimimetic agents in vitro, we sought to demonstrate
activity of several of the most prevalent and toxic SCs in vivo.
Both 5F-AMB and MDMB-FUBINACA have been linked with
numerous incidents of adverse eﬀects, including death, in
humans.35,36,44,66,67 The in vivo activity of 5F-AMB (12) and
MDMB-FUBINACA (17) were compared using biotelemetry
in rats to provide information regarding the activity of these
newer SCs in a living system. Biotelemetry provides a high
resolution, high ﬁdelity alternative to the classical cannabinoid
tetrad, and has the capacity to show both the magnitude and
time-course of cannabinoid eﬀects on rodent physiology.
In rodents, cross-substitution of older SCs, like JWH-018,
and Δ9-THC has been demonstrated, indicating that these
classes produce similar pharmacological eﬀects despite
structural dissimilarity.78−81 Cannabinoids induce hypothermia
and bradycardia in rats, and these physiological changes are
common to phytocannabinoids like Δ9-THC and structurally
distinct indole and indazole SCs.82−84 We have previously
determined the hypothermic and bradycardic potencies of Δ9-
THC and numerous structurally diverse SCs, including JWH-
018, AM-2201, UR-144, XLR-11, APICA, STS-135, PB-22, 5F-
Figure 3. Hyperpolarization mediated by CB1 receptors induced by diﬀerently 1-substituted (a) indoles 11, 15, 19, and 23, and the corresponding
(b) indazoles 13, 17, 21, and 25 as a proportion of that produced by 1 μM CP 55,940. Membrane potential was measured using a ﬂuorescent dye, as
outlined in the Methods. Each point represents the mean ± SEM of at least ﬁve independent determinations, each performed in duplicate. Data was
ﬁtted with a four-parameter logistic equation in GraphPad Prism.
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PB-22, AB-PINACA, and AB-FUBINACA in rats.27,28,30 The
cannabimimetic activities of 5F-AMB and MDMB-FUBINACA
were assessed using radiotelemetry in male Long Evans rats,
and the eﬀects of these SCs on body temperature (Figure 4)
and heart rate (Figure 5) are presented below.
Rat body temperatures 1 h prior to intraperitoneal (i.p.)
injection and 6 h post injection of 5F-AMB and MDMB-
FUBINACA are presented in 15 min bins in Figure 4. For each
drug, these data are presented for 1 h before (baseline) and 6 h
after injection of various doses. The dashed line on the ﬁgures
represents the time of SC injection. Each SC was investigated
using a cohort of 3−4 rats, with a diﬀerent cohort used for the
two compounds. Doses were escalated from 0 mg/kg (baseline)
to 0.1, 0.3, 1, and 3 mg/kg for each compound with at least 2
washout days with no injections between each dose.
Both 5F-AMB and MDMB-FUBINACA evoked a substantial
hypothermic eﬀect at doses of 0.1−1 mg/kg, and up to 3 mg/
kg in the case of 5F-AMB (Figure 4). The peak reduction in
body temperature was generally greater with MDMB-
FUBINACA (>3 °C) than 5F-AMB (>2 °C). The hypothermic
eﬀects of MDMB-FUBINACA were so dramatic at a dose of
0.3 mg/kg, and diﬀered so little from the increased dose of 1
mg/kg, that no higher doses were explored. These data indicate
that MDMB-FUBINACA is one of the most potent SCs
evaluated in rats in our laboratories thus far. Interestingly, the
0.1 mg/kg dose of MDMB-FUBINACA produced a strong
hypothermic response (>3 °C) in two of the four rats tested,
while the remaining pair did not respond. At higher doses, all
four rats responded consistently. When compared to 5F-AMB,
MDMB-FUBINACA induced a prolonged hypothermia at all
doses, with mean core body temperature returning to baseline
after more than 8 h at the smallest dose tested (0.1 mg/kg, data
shown in SI). This was veriﬁed by a statistical analysis showing
a signiﬁcantly greater area under the curve for body
temperature (relative to vehicle baseline) for MDMB-
FUBINACA doses compared to 5F-AMB at 0.3 mg/kg (P <
0.05) and 1 mg/kg (P < 0.05) (see Figure S33, Supporting
Information).
Data for heart rate changes eﬀected by 5F-AMB and MDMB-
FUBINACA are presented in 15 min bins in Figure 5, with the
dashed line on the ﬁgures representing time of SC injection. A
two-way mixed-model ANOVA with planned contrasts revealed
that 5F-AMB produced a signiﬁcant decrease in heart rate over
the 6 h immediately following dosing at 0.3 mg/kg (P < 0.05),
1 mg/kg (P < 0.05), and 3 mg/kg (P < 0.01) compared to
vehicle. MDMB-FUBINACA did not signiﬁcantly reduce heart
rate compared to vehicle at any dose over the same time period.
However, heart rate was reduced in the ﬁrst 2 h following
injection with 0.3 mg/kg MDMB-FUBINACA (P < 0.05). It
should be noted that heart rate data were generally more
variable than those for body temperature. Variability in heart
rate data is expected due to multiple determinants; locomotor
activity, stress, and direct pharmacological cardiovascular
eﬀects.
To conﬁrm that the observed eﬀects were mediated through
CB1 or CB2 receptors, the reversibility of the eﬀects of 5F-AMB
Figure 4. Eﬀects of (a) 5F-AMB and (b) MDMB-FUBINACA on rat
body temperature. Dashed line denotes time of intraperitoneal
injection. Each point represents the mean ± SEM for four animals.
Figure 5. Eﬀects of (a) 5F-AMB and (b) MDMB-FUBINACA on rat
heart rate. Dashed line denotes time of intraperitoneal injection. Each
point represents the mean ± SEM for four animals.
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and MDMB-FUBINACA on body temperature and heart rate
in rats following pretreatment with either CB1 receptor
antagonist rimonabant or CB2 receptor antagonist SR144528
was assessed. Rimonabant is a potent and selective CB1
receptor antagonist, and reverses CB1-mediated cannabinoid
agonist eﬀects in rodents85 and humans,15 while SR144528 is a
selective CB2 functional antagonist.
86
Rat body temperatures after injection (i.p.) with vehicle, CB1
antagonist (rimonabant, 3 mg/kg), or CB2 antagonist
(SR144528, 3 mg/kg) 30 min prior to treatment with either
5F-AMB (3 mg/kg) or MDMB-FUBINACA (1 mg/kg) are
presented in 15 min bins in Figure 6. For each treatment
condition, the data are presented for 1 h before (baseline) and
6 h after injection of various doses. The ﬁrst dashed line on the
ﬁgure represents the time of vehicle/antagonist injection, and
the second dashed line represents time of SC injection. Each
SC was investigated using a cohort of 3−4 rats, with a diﬀerent
cohort used for the two compounds.
Rimonabant pretreatment completely reversed the body
temperature decrease induced by 5F-AMB or MDMB-
FUBINACA, while pretreatment with SR144528 had no eﬀect
on the hypothermic eﬀects of 5F-AMB or MDMB-FUBINACA
(Figure 6a). These interpretations are conﬁrmed by a statistical
analysis of the areas between each drug treatment and baseline
(Figure S35, Supporting Information), and suggest a CB1-
mediated hypothermic mechanism. Similar trends were
observed for the reversal of 5F-AMB- or MDMB-FUBINA-
CA-induced bradycardia by rimonabant but not SR144528,
however, these diﬀerences did not reach signiﬁcance (data not
shown). This is likely due to a combination of the relatively
smaller magnitude of SC-induced bradycardic eﬀects and high
variability of the heart rate data.
■ CONCLUSION
The proactive pharmacological evaluation of emergent SCs is
essential to harm minimization and law enforcement eﬀorts
targeting these compounds. This study is the ﬁrst to
pharmacologically characterize the most recent, prevalent
class of SC designer drugs based on 1-alkylindole-3-
carboxamide and 1-alkyl-1H-indazole-3-carboxamide scaﬀolds
featuring pendant methyl L-valinate or methyl L-tert-leucinate
functional groups. Synthetic routes to identiﬁed SCs of forensic
interest (5F-AMBICA, 5F-AMB, AMB-FUBINACA, MDMB-
FUBINACA, MDMB-CHMICA), as well as several anticipated
but hitherto undetected analogues, were developed. These
synthetic routes are general for 1-alkyl-1H-indole-3-carbox-
amides and 1-alkyl-1H-indazole-3-carboxamides and facilitate
the proactive development of reference standards for SCs
expected to appear in future. All synthesized SCs acted as
agonists of CB1 and CB2 receptors in the nanomolar range in a
FLIPR membrane potential assay, and are potent, functional
cannabinoids. In rats, 5F-AMB and MDMB-FUBINACA dose-
dependently eﬀected hypothermia and bradycardia at doses of
0.1−1 mg/kg (and up to 3 mg/kg in the case of the former),
demonstrating that these SCs are potently cannabimimetic in
vivo. The dramatic reduction of body temperature induced by
MDMB-FUBINACA at doses as low as 0.1 mg/kg positions
this compounds as one of the most potent SCs explored in our
laboratories. The hypothermic eﬀects of 5F-AMB (3 mg/kg)
and MDMB-FUBNACA (1 mg/kg) could be reversed by
pretreatment with CB1 antagonist rimonabant (3 mg/kg), but
not CB2 antagonist SR144528 (3 mg/kg), and appear to be
mediated through CB1 receptors. Taken together, in vitro and
in vivo data conﬁrm that SCs 10−25 are cannabimimetic agents
of greater potency than Δ9-THC and earlier SCs.
■ METHODS
General Chemical Synthesis Details. All reactions were
performed under an atmosphere of nitrogen or argon unless otherwise
speciﬁed. Commercially available chemicals were used as purchased.
Analytical thin-layer chromatography was performed using Merck
aluminum-backed silica gel 60 F254 (0.2 mm) plates (Merck,
Darmstadt, Germany), which were visualized using shortwave (254
nm) UV ﬂuorescence. Flash chromatography was performed using
Merck Kieselgel 60 (230−400 mesh) silica gel. Melting point ranges
(m.p.) were measured in open capillaries using a Stuart SMP10
melting point apparatus (Bibby Scientiﬁc, Staﬀordshire, UK) and are
uncorrected. Nuclear magnetic resonance spectra were recorded at 300
K using either a Bruker AVANCE DRX400 (400.1 MHz) or AVANCE
III 500 Ascend (500.1 MHz) spectrometer (Bruker, Bremen,
Germany). The data are reported as chemical shift (δ ppm) relative
to the residual protonated solvent resonance, relative integral,
multiplicity (s = singlet, br s = broad singlet, d = doublet, t = triplet,
quart. = quartet, quin. = quintet, m = multiplet), coupling constants (J
Hz), and assignment. Assignment of signals was assisted by correlation
spectroscopy (COSY), distortionless enhancement by polarization
transfer (DEPT), heteronuclear single quantum coherence (HSQC),
and heteronuclear multiple-bond correlation (HMBC) experiments
where necessary. Low-resolution mass spectra (LRMS) was recorded
Figure 6. Eﬀects of (a) 3 mg/kg 5F-AMB or (b) 1 mg/kg MDMB-
FUBINACA on rat body temperature following pretreatment (30 min
prior) with vehicle (VEH), 3 mg/kg rimonabant (CB1 antagonist), or
3 mg/kg SR144528 (CB2 antagonist). The ﬁrst dashed line denotes
time of intraperitoneal injection of vehicle or antagonist. Second
dashed line represents time of intraperitoneal injection of SC. Each
point represents the mean ± SEM for three animals.
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using electrospray ionization (ESI) recorded on a Finnigan LCQ ion
trap mass spectrometer (ThermoFisher Scientiﬁc, Waltham, MA).
High-resolution mass spectra (HRMS) were run on a Bruker 7T Apex
Qe Fourier Transform Ion Cyclotron resonance mass spectrometer
equipped with an Apollo II ESI/APCI/MALDI Dual source by the
Mass Spectrometry Facility of the School of Chemistry at the
University of Sydney. IR absorption spectra were recorded on a Bruker
ALPHA FT-IR spectrometer as solid or thin ﬁlm from ethanol, and the
data are reported as vibrational frequencies (cm−1). Please see the
Supporting Information for 1H and 13C NMR spectra and Fourier
transform infrared (FTIR) spectra of all ﬁnal compounds.
General Procedure A: Amidation of 1-Alkylindole-3-carbox-
ylic Acids and 1-Alkyl-1H-indazole-3-carboxylic Acids. To a
solution of the appropriate 1-alkylindole-3-carboxylic acid or 1-alkyl-
1H-indazole-3-carboxylic acid (0.39 mmol), methyl L-valinate hydro-
chloride (69 mg, 0.41 mmol, 1.05 equiv) or methyl L-tert-leucinate
hydrochloride (75 mg, 0.41 mmol, 1.05 equiv), EDC·HCl (150 mg,
0.78 mmol, 2.0 equiv), and HOBt (119 mg, 0.78 mmol, 2.0 equiv) in
DMSO (5 mL) was added DIPEA (340 μL, 1.95 mmol, 5.0 equiv)
dropwise and the mixture was stirred for 14 h. The reaction was
quenched by the addition of sat. aq. NaHCO3 (75 mL) and extracted
with EtOAc (3 × 75 mL). The combined organic layers were washed
with brine (100 mL), dried (MgSO4), and evaporated under reduced
pressure. The pure amides were obtained following puriﬁcation by
ﬂash chromatography.
Methyl (S)-2-(1-(5-Fluoropentyl)-1H-indole-3-carboxamido)-3-
methylbutanoate (5F-AMB-PICA, 10). Subjecting 31 (100 mg, 0.40
mmol) and methyl L-valinate hydrochloride (70 mg, 0.42 mmol, 1.05
equiv) to general procedure A gave, following puriﬁcation by ﬂash
chromatography (hexane-EtOAc, 80:20), 10 (92 mg, 63%) as a white
solid. mp 146−148 °C; Rf. 0.30 (hexane/EtOAc, 80:20); 1H NMR
(300 MHz, CDCl3): δ 7.96 (1H, d, J = 8.1 Hz), 7.70 (1H, s), 7.34
(1H, d, J = 8.7 Hz), 7.25−7.22 (2H, m), 6.44 (1H, d, J = 8.7 Hz), 4.83
(1H, dd, J = 8.7, 4.8 Hz), 4.46 (1H, t, J = 5.7 Hz), 4.30 (1H, t, J = 6.0
Hz), 4.12 (2H, t, J = 6.9 Hz), 3.75 (3H, s), 2.27 (1H, m), 1.88 (2H,
quin., J = 7.5 Hz), 1.80−1.62 (2H, m), 1.42 (2H, quin., J = 8.4 Hz),
1.00 (6H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3): δ 173.3 (CO),
165.0 (CO), 136.7 (quat.), 131.8 (CH), 125.5 (quat.), 122.7 (CH),
121.8 (CH), 120.3 (CH), 110.8 (quat.), 110.4 (CH), 83.8 (CH2F, d,
1JCF = 163.5 Hz), 57.1 (CH), 52.3 (CH2), 46.9 (CH3), 31.9 (CH),
30.1 (CH2, d,
2JCF = 20.3 Hz), 29.8 (CH2), 23.0 (CH2, d,
3JCF = 5.3
Hz), 19.2 (CH3), 18.2 (CH3);
19F NMR (282 MHz, CDCl3): − 218.6
(1F, m); LRMS (+ESI): m/z 385.14 ([M + Na]+, 100%); HRMS
(+ESI): m/z calculated [M + Na]+ 399.2060, found 399.2054; IR
(diamond cell, thin ﬁlm) 3343 (w), 2977 (m), 2962 (m), 2877 (w),
1736 (s), 1625 (s), 1509 (s), 1465 (s), 1225 (s), 1198 (s), 1167 (s),
1147 (s), 751 (s).
Methyl (S)-2-(1-(5-Fluoropentyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate (5F-MDMB-PICA, 11). Subjecting 31 (100 mg,
0.40 mmol) and methyl L-tert-leucinate hydrochloride (76 mg, 0.42
mmol, 1.05 equiv) to general procedure A gave, following puriﬁcation
by ﬂash chromatography (hexane-EtOAc, 80:20), 10 (112 mg, 74%) as
a white solid. mp 82−84 °C; Rf. 0.35 (hexane/EtOAc, 80:20); 1H
NMR (300 MHz, CDCl3): δ 7.99 (1H, m), 7.74 (1H, s), 7.38 (1H,
m), 7.31−7.27 (2H, m), 7.52 (1H, d, J = 9.3 Hz), 4.78 (1H, d, J = 9.3
Hz), 4.40 (2H, dt, J = 41.4 Hz, 6.0 Hz), 4.15 (2H, t, J = 7.2 Hz), 3.76
(3H, s), 1.91 (2H, quin., J = 7.2 Hz), 1.81−1.62 (2H, m), 1.46 (2H,
quin., J = 6.3 Hz), 0.93 (9H, s); 13C NMR (75 MHz, CDCl3): δ 172.8
(CO), 164.8 (CO), 136.7 (quat.), 131.9 (CH), 125.4 (quat.), 122.6
(CH), 121.8 (CH), 120.1 (CH), 110.8 (quat.), 110.4 (CH), 83.7
(CH2F, d,
1JCF = 164.3 Hz), 59.9 (CH), 51.9 (CH2), 46.8 (CH3), 35.2
(quat.), 30.1 (CH2, d,
2JCF = 19.5 Hz), 29.7 (CH2), 26.9 (CH3), 22.9
(CH2, d,
3JCF = 5.3 Hz);
19F NMR (282 MHz, CDCl3): δ − 218.5 (1F,
m); LRMS (+ESI): m/z 399.14 ([M + Na]+, 100%); HRMS (+ESI):
m/z calculated [M + Na]+ 399.2060, found 399.2056; IR (diamond
cell, thin ﬁlm) 3437 (w), 2971 (m), 2959 (m), 1730 (s), 1639 (s),
1499 (s), 1234 (s), 1186 (s), 773 (m), 751 (s).
Methyl (S)-2-(1-(5-Fluoropentyl)-1H-indazole-3-carboxamido)-3-
methylbutanoate (5F-AMB-PINACA, 12). Subjecting 40 (100 mg,
0.42 mmol) and methyl L-valinate hydrochloride (75 mg, 0.45 mmol,
1.1 equiv) to general procedure A gave, following puriﬁcation by ﬂash
chromatography (hexane/EtOAc, 80:20), 12 (105 mg, 69%) as a white
solid. mp 68−70 °C; Rf. 0.50 (hexane/EtOAc, 60:40); 1H NMR (300
MHz, CDCl3): δ 8.35 (1H, d, J = 8.1 Hz), 7.47 (1H, d, J = 9.0 Hz),
7.42−7.39 (2H, m), 4.80 (1H, dd, J = 8.7, 5.1 Hz), 4.51 (1H, t, J = 5.7
Hz), 4.42 (2H, t, J = 6.9 Hz), 4.36 (1H, t, J = 5.7 Hz), 3.78 (3H, s),
2.30 (1H, m, J = 6.6 Hz), 2.05 (2H, quin., J = 7.5 Hz), 1.83−1.62 (2H,
m), 1.48 (2H, quin., J = 7.5 Hz), 1.04 (6H, t, J = 6.0 Hz); 13C NMR
(75 MHz, CDCl3): δ 172.8 (CO), 162.6 (CO), 141.0 (quat.), 136.9
(quat.), 126.9 (CH), 123.1 (quat.), 123.0 (CH), 122.8 (CH), 109.3
(CH), 84.0 (CH2, d,
1JCF = 149.3 Hz), 56.9 (CH), 52.3 (CH2), 49.3
(CH3), 31.7 (CH), 30.0 (CH2, d,
2JCF = 19.9 Hz), 29.5 (CH2), 22.8
(CH2, d,
3JCF = 5.0 Hz), 19.3 (CH3), 18.2 (CH3);
19F NMR (282
MHz, CDCl3): δ − 218.5 (1F, m); LRMS (+ESI): m/z 386.11 ([M +
Na]+, 100%); HRMS (+ESI): m/z calculated [M + Na]+ 386.1856,
found 386.1849; IR (diamond cell, thin ﬁlm): 3415 (w), 2960 (m),
1740 (s), 1667 (s), 1526 (s), 1491 (s), 1710 (m), 752 (m).
Methyl (S)-2-(1-(5-Fluoropentyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate (5F-MDMB-PINACA, 13). Subjecting 40
(150 mg, 0.63 mmol) and methyl L-tert-leucinate hydrochloride (97
mg, 0.67 mmol, 1.05 equiv) to general procedure A gave, following
puriﬁcation by ﬂash chromatography (hexane-EtOAc, 80:20), 13 (151
mg, 63%) as a white solid. mp 64−66 °C; Rf. 0.60 (hexane/EtOAc,
60:40); 1H NMR (300 MHz, CDCl3): δ 8.35 (1H, d, J = 8.1 Hz), 7.54
(1H, d, J = 9.6 Hz), 7.42−7.39 (2H, m), 4.73 (1H, d, J = 9.6 Hz), 4.52
(1H, t, J = 5.7 Hz), 4.42 (2H, t, J = 7.2 Hz), 4.36 (1H, t, J = 6.0 Hz),
3.76 (3H, s), 1.99 (2H, quin., J = 7.8 Hz), 1.84−1.67 (2H, m), 1.48
(2H, quin., J = 8.1 Hz), 1.09 (9H, s); 13C NMR (300 MHz, CDCl3): δ
172.3 (CO), 162.5 (CO), 141.0 (quat.), 137.0 (quat.), 126.9 (CH),
123.1 (quat.), 123.0 (CH), 122.8 (CH), 109.3 (CH), 83.9 (CH2, d,
1JCF = 163.5 Hz,), 59.6 (quat.), 51.9 (CH2), 49.3 (CH3), 35.2 (quat.),
30.3 (CH2, d,
2JCF = 19.5 Hz), 29.5 (CH2), 26.8 (CH3), 22.8 (CH2, d,
3JCF = 4.5 Hz);
19F NMR (282 MHz, CDCl3): δ − 218.5 (1F, m);
LRMS (+ESI): m/z 400.14 ([M + Na]+, 100%); HRMS (+ESI): m/z
calculated [M + Na]+ 400.2012, found 400.2007; IR (diamond cell,
thin ﬁlm): 3420 (w), 2960 (m), 2870 (w), 1737 (s), 1671 (s), 1524
(s), 1491 (s), 1262 (m), 1216 (s), 752 (m).
Methyl (S)-2-(1-(4-Fluorobenzyl)-1H-indole-3-carboxamido)-3-
methylbutanoate (AMB-FUBICA, 14). Subjecting 32 (100 mg, 0.37
mmol) and methyl L-valinate hydrochloride (65 mg, 0.39 mmol, 1.05
equiv) to general procedure A gave, following puriﬁcation by ﬂash
chromatography (hexane/EtOAc, 80:20), 14 (110 mg, 78%) as a white
solid. mp 151−153 °C; Rf. 0.30 (hexane/EtOAc, 80:20); 1H NMR
(300 MHz, CDCl3): δ 8.05 (1H, d, J = 7.8 Hz), 7.78 (1H, s), 7.35−
7.28 (3H, m), 7.15 (2H, t, J = 5.4 Hz), 7.03 (2H, t, J = 7.5 Hz), 5.33
(2H, s), 4.90 (1H, dd, J = 8.7, 4.8 Hz), 3.82 (3H, s), 2.33 (1H, m, J =
6.0 Hz), 1.07 (6H, t, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3): δ
173.3 (CO), 164.9 (CO), 162.6 (quat., d, 1JCF = 247.2 Hz), 136.9
(quat.), 132.0 (CH), 131.9 (quat., d, 4JCF = 3.1 Hz), 129.0 (CH, d,
3JCF
= 8.3 Hz), 125.7 (quat.), 123.0 (CH), 122.1 (CH), 120.4 (CH), 116.1
(CH, d, 2JCF = 21.9 Hz), 111.5 (quat.), 110.7 (CH), 57.1 (CH2), 52.3
(CH3), 50.1 (CH), 31.8 (CH), 19.2 (CH3), 18.2 (CH3);
19F NMR
(282 MHz, CDCl3): δ − 113.9 (1F, m); LRMS (+ESI): m/z 405.11
([M + Na]+, 100%); HRMS (+ESI): m/z 405.1590, found 405.1583;
IR (diamond cell, thin ﬁlm): 3327 (m), 2944 (m), 2875 (w), 1738 (s),
1630 (s), 1510 (s), 1125 (s), 766 (s), 566 (m).
Methyl (S)-2-(1-(4-Fluorobenzyl)-1H-indole-3-carboxamido)-3,3-
dimethylbutanoate (MDMB-FUBICA, 15). Subjecting 32 (50 mg, 0.19
mmol) and methyl L-tert-leucinate hydrochloride (42 mg, 0.23 mmol,
1.2 equiv) to general procedure A gave, following puriﬁcation by ﬂash
chromatography (hexane/EtOAc, 80:20), 15 (58 mg, 77%) as a white
solid. mp 132−134 °C; Rf. 0.40 (hexane/EtOAc, 80:20); 1H NMR
(300 MHz, CDCl3): δ 8.02 (1H, d, J = 7.8 Hz), 7.77 (1H, s), 7.32−
7.26 (3H, m), 7.14 (2H, t, J = 6.3 Hz), 7.01 (2H, t, J = 6.3 Hz), 6.55
(1H, d, J = 9.3 Hz), 5.32 (2H, s), 4.79 (1H, d, J = 9.6 Hz), 3.78 (3H,
s), 1.10 (9H, s); 13C NMR (75 MHz, CDCl3): δ 172.8 (CO), 164.7
(CO), 162.6 (quat., d, 1JCF = 246.0 Hz), 136.9 (quat.), 132.2 (CH),
131.9 (quat., d, 4JCF = 3.0 Hz), 128.9 (CH, d,
3JCF = 8.3 Hz), 125.6
(quat.), 123.0 (CH), 122.1 (CH), 120.2 (CH), 116.1 (CH, d, 2JCF =
21.8 Hz), 111.5 (quat.), 110.8 (CH), 59.9 (CH2), 52.0 (CH3), 50.1
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(CH), 35.2 (quat.), 26.9 (CH3);
19F NMR (282 MHz, CDCl3): δ −
113.9 (1F, m); LRMS (+ESI): m/z 419.13 ([M + Na]+, 100%);
HRMS (+ESI): m/z calculated [M + Na]+ 419.1747, found 419.1740;
IR (diamond cell, thin ﬁlm): 3440 (w), 2961 (w), 1725 (s), 1637 (s),
1537 (s), 1327 (s), 815 (m).
Methyl (S)-2-(1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido)-3-
methylbutanoate (AMB-FUBINACA, 16). Subjecting 41 (100 mg, 0.37
mmol) and methyl L-valinate hydrochloride (65 mg, 0.39 /EtOAc,
90:10), 16 (85 mg, 60%) as a colorless oil. Rf. 0.65 (hexane/EtOAc,
80:20); 1H NMR (300 MHz, CDCl3): δ 8.36 (1H, d, J = 7.8 Hz), 7.50
(1H, d, J = 9.0 Hz), 7.42−7.27 (2H, m), 7.23−7.19 (2H, t, J = 6.9 Hz),
7.01 (2H, t, J = 7.8 Hz), 5.61 (2H, s), 4.83 (1H, dd, J = 8.7, 5.1 Hz),
3.78 (3H, s), 2.30 (1H, m, J = 6.6 Hz), 1.05 (6H, t, J = 5.4 Hz); 13C
NMR (75 MHz, CDCl3): δ 172.7 (CO), 162.6 (quat.,
1JCF = 245.3
Hz), 162.5 (CO), 140.9 (quat.), 137.5 (quat.), 131.9 (quat., d, 4JCF =
3.1 Hz), 129.1 (CH, d, 3JCF = 8.3 Hz), 127.2 (CH), 123.5 (quat.),
123.1 (CH), 123.0 (CH), 116.0 (CH, d, 2JCF = 21.8 Hz), 109.6 (CH),
56.9 (CH), 53.1 (CH2), 52.3 (CH3), 31.8 (CH), 19.3 (CH3), 18.2
(CH3);
19F NMR (282 MHz, CDCl3): δ − 114.0 (1F, m); LRMS
(+ESI): m/z 406.08 ([M + Na]+, 100%); HRMS (+ESI): m/z
calculated [M + Na]+ 406.1543, found 406.1537; IR (diamond cell,
thin ﬁlm): 3415 (w), 2964 (m), 1740 (s), 1667 (s), 1527 (s), 1511 (s),
1492 (s), 1261 (s), 1172 (s), 1158 (s), 750 (m).
Methyl (S)-2-(1-(4-Fluorobenzyl)-1H-indazole-3-carboxamido)-
3,3-dimethylbutanoate (MDMB-FUBINACA, 17). Subjecting 41
(100 mg, 0.37 mmol) and methyl L-tert-leucinate hydrochloride (81
mg, 0.41 mmol, 1.1 equiv) to general procedure A gave, following
puriﬁcation by ﬂash chromatography (hexane/EtOAc, 80:20), 17 (96
mg, 65%) as a white crystalline solid. mp 120−122 °C; Rf. 0.60
(hexane/EtOAc, 60:40); 1H NMR (300 MHz, CDCl3): δ 8.21 (1H, d,
J = 7.8 Hz), 7.59 (1H, d, J = 8.4 Hz), 7.44 (1H, t, J = 7.8 Hz), 7.33−
7.27 (3H, m), 7.06 (2H, t, J = 8.4 Hz), 5.72 (2H, s), 4.61 (1H, s), 3.77
(3H, s), 1.09 (9H, s); 13C NMR (75 MHz, CDCl3): δ 172.3 (CO),
162.6 (quat., d, 1JCF = 245.3 Hz), 162.3 (CO), 140.9 (quat.), 137.5
(quat.), 131.9 (quat., d, 4JCF = 3.3 Hz), 129.1 (CH, d,
3JCF = 8.3 Hz),
127.2 (CH), 123.5 (quat.), 123.1 (CH), 123.0 (CH), 116.0 (CH, d,
2JCF = 21.8 Hz), 109.6 (CH), 59.7 (CH), 53.1 (CH2), 51.95 (CH3),
35.2 (quat.), 26.8 (CH3);
19F NMR (282 MHz, CDCl3): δ − 114.00
(1F, m); LRMS (+ESI): m/z 419.12 ([M + Na]+, 100%); HRMS
(+ESI): m/z calculated [M + Na]+ 420.1699, found 420.1694; IR
(diamond cell, thin ﬁlm): 3419 (w), 2966 (m), 1737 (s), 1670 (s),
1526 (s), 1511 (s), 1222 (s), 1166 (s), 749 (m).
Methyl (S)-2-(1-(Cyclohexylmethyl)-1H-indole-3-carboxamido)-3-
methylbutanoate (AMB-CHMICA, 18). Subjecting 33 (50 mg, 0.20
mmol) and methyl L-valinate hydrochloride (35 mg, 0.21 mmol, 1.05
equiv) to general procedure A gave, following puriﬁcation by ﬂash
chromatography (hexane/EtOAc, 90:10), 18 (60 mg, 81%) as a white
solid. mp 137−139 °C; Rf. 0.55 (hexane/EtOAc, 80:20); 1H NMR
(300 MHz, CDCl3): δ 7.99 (1H, m), 7.70 (1H, s), 7.38 (1H, m),
7.31−7.27 (2H, m), 6.47 (1H, d, J = 8.7 Hz), 4.87 (1H, dd, J = 8.7, 4.8
Hz), 3.96 (2H, d, J = 7.2 Hz), 3.77 (3H, s), 2.31 (1H, m, J = 5.1 Hz),
1.88 (1H, m), 1.74−1.60 (5H, m), 1.25−1.18 (3H, m), 1.06−0.98
(8H, m); 13C NMR (75 MHz, CDCl3): δ 173.3 (CO), 165.1 (CO),
137.1 (quat.), 132.7 (CH), 125.4 (quat.), 122.5 (CH), 121.6 (CH),
120.1 (CH), 110.8 (CH), 110.5 (quat.), 57.0 (CH), 53.5 (CH2), 52.3
(CH3), 38.7 (CH), 31.9 (CH), 31.2 (CH2), 26.3 (CH2), 25.8 (CH2),
19.3 (CH3), 18.3 (CH3); LRMS (+ESI): m/z 393.16 ([M + Na]
+,
100%); HRMS (+ESI): m/z calculated [M + Na]+ 393.2154, found
393.2147; IR (diamond cell, thin ﬁlm): 3327 (w), 2929 (m), 2849
(w), 1735 (s), 1618 (s), 1539 (s), 1518 (s), 1257 (s), 735 (s).
Methyl (S)-2-(1-(Cyclohexylmethyl)-1H-indole-3-carboxamido)-
3,3-dimethylbutanoate (MDMB-CHMICA, 19). Subjecting 33 (50
mg, 0.20 mmol) and methyl L-tert-leucinate hydrochloride (40 mg,
0.21 mmol, 1.05 equiv) to general procedure A gave, following
puriﬁcation by ﬂash chromatography (hexane/EtOAc, 90:10), 19 (55
mg, 72%) as a white solid. mp 136−138 °C; Rf. 0.70 (hexane/EtOAc,
80:20); 1H NMR (300 MHz, CDCl3): δ 8.09 (1H, d, J = 5.7 Hz), 8.00
(1H, s), 7.46 (1H, d, J = 8.1 Hz), 7.27−7.16 (2H, m), 4.64 (1H, s),
4.04 (2H, d, J = 6.9 Hz), 3.75 (3H, s), 1.89 (1H, m), 1.71−1.57 (5H,
m), 1.28−1.02 (14H, m); 13C NMR (75 MHz, CDCl3): δ 172.9 (CO),
164.9 (CO), 137.1 (quat.), 132.8 (CH), 125.3 (quat.), 122.5 (CH),
121.7 (CH), 120.0 (CH), 110.8 (CH), 110.5 (quat.), 59.8 (CH), 53.5
(CH2), 52.0 (CH3), 38.7 (quat.), 35.2 (CH), 31.1 (CH2), 26.9 (CH3),
26.3 (CH2), 25.8 (CH2); LRMS (+ESI): m/z ([M + Na]
+, 100%);
HRMS (+ESI): m/z calculated [M + Na]+ 407.2311, found 407.2304;
IR (diamond cell, thin ﬁlm): 3320 (w), 2928 (m), 2851 (w), 1738 (s),
1614 (s), 1536 (s), 1512 (s), 1141 (s), 739 (s).
Methyl (S)-2-(1-(Cyclohexylmethyl)-1H-indazole-3-carboxami-
do)-3-methylbutanoate (AMB-CHMINACA, 20). Subjecting 42 (75
mg, 0.29 mmol) and methyl L-valinate hydrochloride (56 mg, 0.31
mmol, 1.05 equiv) to general procedure A gave, following puriﬁcation
by ﬂash chromatography (hexane/EtOAc, 80:20), 20 (83 mg, 77%) as
a colorless oil. Rf. 0.75 (hexane/EtOAc, 60:40);
1H NMR (300 MHz,
CDCl3): δ 8.34 (1H, d, J = 8.1 Hz), 7.47 (1H, d, J = 9 Hz), 7.42−7.36
(2H, m), 4.80 (1H, dd, J = 9.1 Hz, 5.7 Hz), 4.22 (2H, d, J = 7.2 Hz),
3.78 (3H, s), 2.31 (1H, m), 2.04 (1H, m), 1.72−1.58 (5H, m), 1.30−
0.97 (11H, m); 13C NMR (300 MHz, CDCl3): δ 172.7 (CO), 162.7
(CO), 141.5 (quat.), 136.7 (quat.), 126.6 (CH), 122.83 (quat.),
122.77 (CH), 122.6 (CH), 109.6 (CH), 56.8 (CH), 55.8 (CH2), 52.2
(CH3), 38.8 (CH), 31.7 (CH), 31.0 (CH2), 26.3 (CH2), 25.7 (CH2),
19.2 (CH3), 18.2 (CH3); LRMS (+ESI): m/z 394.15 ([M + Na]
+,
100%); HRMS (+ESI): m/z calculated [M + Na]+ 394.2107, found
394.2100; IR (diamond cell, thin ﬁlm): 3411 (w), 2927 (s), 2852 (m),
1741 (s), 1670 (s), 1525 (s), 1491 (s), 1176 (m), 751 (m).
Methyl (S)-2-(1-(Cyclohexylmethyl)-1H-indazole-3-carboxami-
do)-3,3-dimethylbutanoate (MDMB-CHMINACA, 21). Subjecting 42
(100 mg, 0.39 mmol) and methyl L-tert-leucinate hydrochloride (69
mg, 0.41 mmol, 1.05 equiv) to general procedure A gave, following
puriﬁcation by ﬂash chromatography (hexane/EtOAc, 80:20), 21 (110
mg, 73%) as a colorless oil. Rf. 0.85 (hexane/EtOAc, 60:40);
1H NMR
(300 MHz, CDCl3): δ 8.34 (1H, d, J = 8.1 Hz), 7.55 (1H, d, J = 9.6
Hz), 7.40−7.36 (2H, m), 4.73 (1H, d, J = 9.9 Hz), 4.22 (2H, d, J = 7.2
Hz), 3.76 (3H, s), 2.03 (1H, m), 1.75−1.58 (5H, m), 1.30−1.04 (14H,
m); 13C NMR (300 MHz, CDCl3): δ 172.4 (CO), 162.6 (CO), 141.5
(quat.), 136.8 (quat.), 126.7 (CH), 122.91 (quat.), 122.87 (CH),
122.6 (CH), 109.6 (CH), 59.6 (CH), 55.8 (CH2), 51.9 (CH3), 38.9
(quat.), 35.2 (CH), 31.1 (CH2), 26.8 (CH3), 26.4 (CH2), 25.8 (CH2);
LRMS (+ESI): m/z 408.17 ([M + Na]+, 100%); HRMS (+ESI): m/z
calculated [M + Na]+ 408.2263, found 408.2257; IR (diamond cell,
thin ﬁlm): 3417 (w), 2927 (s), 2852 (m), 1738 (s), 1672 (s), 1524 (s),
1491 (m), 1164 (m), 1134 (m), 751 (m).
Methyl (S)-2-(1-(Pentyl)-1H-indole-3-carboxamido)-3-methylbu-
tanoate (AMB-PICA, 22). Subjecting 34 (100 mg, 0.43 mmol) and
methyl L-valinate hydrochloride (76 mg, 0.45 mmol, 1.1 equiv) to
general procedure A gave, following puriﬁcation by ﬂash chromatog-
raphy (hexane/ethyl acetate, 85:15), 22 (98 mg, 66%) as a white solid.
mp 148−150 °C; Rf. 0.50 (hexane/ethyl acetate, 80:20); 1H NMR
(300 MHz, CDCl3): δ 7.99 (1H, d, J = 6 Hz), 7.74 (1H, s), 7.38 (1H,
d, J = 8.7 Hz), 7.29−7.26 (2H, m), 6.48 (1H, d, J = 8.4 Hz), 4.86 (1H,
dd, J = 8.7, 4.8 Hz), 4.13 (2H, t, J = 6.9 Hz), 3.78 (3H, s), 2.31 (1H,
m), 1.86 (2H, quin., J = 6.9 Hz), 1.33 (4H, m), 1.04 (6H, t, J = 6.9
Hz), 0.89 (3H, t, J = 6.9 Hz); 13C NMR (75 MHz, CDCl3): δ 173.3
(CO), 165.1 (CO), 136.8 (quat.), 132.0 (CH), 125.5 (quat.), 122.6
(CH), 121.7 (CH), 120.2 (CH), 110.6 (quat.), 110.5 (CH), 57.0
(CH), 52.3 (CH3), 47.0 (CH2), 31.9 (CH), 29.8 (CH2), 29.1 (CH2),
22.4 (CH2), 19.2 (CH3), 18.2 (CH3), 14.0 (CH3); LRMS (+ESI): m/z
367.14 ([M + Na]+, 100); HRMS (+ESI): m/z calculated [M + Na]+
367.1998, found 367.1992; IR (diamond cell, thin ﬁlm) 3338 (w),
2952 (m), 2928 (m), 2868 (w), 1739 (s), 1630 (s), 1508 (s), 1195 (s),
1157 (s), 751 (s).
Methyl (S)-2-(1-(Pentyl)-1H-indole-3-carboxamido)-3,3-dimethyl-
butanoate (MDMB-PICA, 23). Subjecting 34 (75 mg, 0.32 mmol) and
methyl L-tert-leucinate hydrochloride (61 mg, 0.39 mmol, 1.2 equiv) to
general procedure A gave, following puriﬁcation by ﬂash chromatog-
raphy (hexane/EtOAc, 90:10), 21 (82 mg, 71%) as a white solid. mp
70−72 °C; Rf. 0.60 (hexane/EtOAc 80:20); 1H NMR (300 MHz,
CDCl3): δ 8.00−7.95 (2H, m), 7.75 (1H, s), 7.42−7.37 (1H, m),
7.31−7.26 (2H, m), 6.53 (1H, d, J = 9.3 Hz), 4.79 (1H, d, J = 9.4 Hz),
4.13 (2H, t, J = 7.2 Hz), 3.76 (3H, s), 1.86 (2H, quin., J = 7.1 Hz),
1.39−1.26 (4H, m), 1.09 (9H, s), 0.89 (3H, t, J = 6.8 Hz); 13C NMR
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(75 MHz, CDCl3): δ 172.9 (CO), 164.9 (CO), 136.8 (quat.), 132.1
(CH), 125.4 (quat.), 122.5 (CH), 121.7 (CH), 120.1 (CH), 110.6
(quat.), 110.5 (CH), 59.8 (CH), 51.9 (CH3), 47.0 (CH2), 35.2
(quat.), 29.8 (CH2), 29.1 (CH2), 26.9 (CH3), 22.4 (CH2), 14.0
(CH3); LRMS (+ESI): m/z 381.15 ([M + Na]
+, 100%); HRMS
(+ESI): m/z calculated [M + Na]+ 381.2154, found 381.2149; IR
(diamond cell, thin ﬁlm): 3434 (w), 2952 (m), 2927 (m), 2868 (w),
1732 (s), 1641 (s), 1530 (s), 1498 (s), 1214 (s), 1185 (s), 1157 (s),
1129 (s), 751 (s).
Methyl (S)-2-(1-(Pentyl)-1H-indazole-3-carboxamido)-3-methyl-
butanoate (AMB-PINACA, 24). Subjecting 43 (100 mg, 0.46 mmol)
and methyl L-valinate hydrochloride (80 mg, 0.48 mmol, 1.05 equiv)
to general procedure A gave, following puriﬁcation by ﬂash
chromatography (hexane/EtOAc, 85:15), 24 (108 mg, 68%) as a
colorless oil. Rf. 0.75 (hexane/EtOAc, 60:40);
1H NMR (300 MHz,
CDCl3): δ 8.35 (1H, d, J = 8.1 Hz), 7.47 (1H, d, J = 8.7 Hz), 7.44−
7.37 (2H, m), 4.81 (1H, dd, J = 9.0, 5.1 Hz), 4.39 (2H, t, J = 7.5 Hz),
3.78 (3H, s), 2.31 (1H, m), 1.40−1.26 (4H, m), 1.04 (6H, t, J = 6.0
Hz), 0.90 (3H, t, J = 6.0 Hz); 13C NMR (300 MHz, CDCl3): δ 172.8
(CO), 162.7 (CO), 141.0 (quat.), 136.7 (quat.), 126.7 (CH), 123.1
(quat.), 122.9 (CH), 122.7 (CH), 109.4 (CH), 56.9 (CH), 52.3
(CH3), 49.6 (CH2), 31.7 (CH), 29.6 (CH2), 29.1 (CH2), 22.4 (CH2),
19.3 (CH3), 18.2 (CH3), 14.1 (CH3); LRMS (+ESI): m/z 368.12 ([M
+ Na]+, 100%); HRMS (+ESI): m/z calculated [M + Na]+ 368.1950,
found 368.1944; IR (diamond cell, thin ﬁlm): 3419 (w), 2959 (m),
2932 (m), 2873 (w), 1742 (s), 1670 (s), 1526 (s), 1491 (s), 1181 (s),
752 (m).
Methyl (S)-2-(1-(Pentyl)-1H-indazole-3-carboxamido)-3,3-dime-
thylbutanoate (MDMB-PINACA, 25). Subjecting 43 (100 mg, 0.46
mmol) and methyl L-tert-leucinate hydrochloride (71 87 mg, 0.48
mmol, 1.05 equiv) to general procedure A gave, following puriﬁcation
by ﬂash chromatography (hexane/EtOAc, 85:15), 25 (125 mg, 76%)
as a colorless oil. Rf. 0.85 (hexane/EtOAc, 60:40);
1H NMR (300
MHz, CDCl3): δ 8.34 (1H, d, J = 8.1 Hz), 7.55 (1H, d, J = 9.6 Hz),
7.41−7.36 (2H, m), 4.73 (1H, d, J = 9.9 Hz), 4.39 (2H, t, J = 7.5 Hz),
3.76 (3H, s), 1.95 (2H, quin., J = 6.9 Hz), 1.41−1.30 (4H, m), 1.09
(9H, s), 0.90 (3H, t, J = 7.2 Hz); 13C NMR (300 MHz, CDCl3): δ
172.3 (CO), 162.5 (CO), 141.0 (quat.), 136.7 (quat.), 126.7 (CH),
123.1 (quat.), 122.9 (CH), 122.7 (CH), 109.4 (CH), 59.6 (CH), 51.9
(CH3), 49.6 (CH2), 35.2 (quat.), 29.6 (CH2), 29.1 (CH2), 26.8
(CH3), 22.4 (CH2), 14.1 (CH3); LRMS (+ESI): m/z 382.07 ([M +
Na]+, 100%); HRMS (+ESI): m/z calculated [M + Na]+ 382.2107,
found 382.2101; IR (diamond cell, thin ﬁlm): 3419 (bs), 2960 (m),
2873 (w), 1738 (s), 1672 (s), 1525 (s), 1492 (m), 1163 (m), 751 (m).
General Procedure B : Synthes is of 1-A lkyl -3-
(triﬂuoroacetyl)indoles. To a cooled (0 °C) suspension of sodium
hydride (60% dispersion in mineral oil, 137 mg, 3.42 mmol, 2.0 equiv)
in DMF (6 mL) was added indole (200 mg, 1.71 mmol) portionwise
and the mixture stirred for 10 min. The mixture was treated dropwise
with the appropriate bromoalkane (1.80 mmol, 1.05 equiv) and stirred
at ambient temperature for 1 h. The cooled (0 °C) mixture was treated
dropwise with triﬂuoroacetic anhydride (600 μL, 4.28 mmol, 2.5
equiv) and stirred at ambient temperature for 1 h. The reaction was
poured into ice water (75 mL) and extracted with CH2Cl2 (3 × 75
mL). The combined organic extracts were washed with H2O (100
mL), brine (100 mL), dried (MgSO4) and the solvent evaporated
under reduced pressure. The pure 1-alkyl-3-triﬂuoroacetylindoles were
obtained following puriﬁcation by ﬂash chromatography.
2,2,2-Triﬂuoro-1-(1-(5-ﬂuoropentyl)-1H-indol-3-yl)ethanone (27).
Subjecting indole (500 mg, 4.27 mmol) and 1-bromo-5-ﬂuoropentane
(560 μL, 4.48 mmol, 1.05 equiv) to general prcoedure B gave,
following puriﬁcation by ﬂash chromatography (hexane/EtOAc,
90:10), 27 as a red solid (920 mg, 72%). mp 42−44 °C; Rf 0.53
(hexane/EtOAc, 80:20); 1H NMR (300 MHz, CDCl3): δ 8.42−8.39
(1H, m), 7.93 (1H, s), 7.42−7.33 (3H, m), 4.43 (2H, dt, J = 47.1, 5.8
Hz), 4.21 (2H, t, J = 6.6 Hz), 1.97 (2H, quin., J = 6.0 Hz), 1.74 (2H,
dquin., J = 26.1 Hz, 5.2 Hz), 1.50 (2H, quin., J = 6.6 Hz); 13C NMR
(75 MHz, CDCl3): δ 174.8 (q,
2JCF = 34.5 Hz, quat.), 137.4 (q,
3JCF =
4.9 Hz, CH), 136.7 (quat.), 127.2 (quat.), 124.7 (CH), 124.0 (CH),
122.8 (CH), 117.2 (q, 1JCF = 289.5 Hz, CF3), 110.4 (CH), 109.6
(quat.), 83.7 (d, 1JCF = 164.3 Hz, CH2), 47.6 (CH2), 29.9 (d,
2JCF =
19.5 Hz, CH2), 29.5 (CH2), 22.9 (d,
3JCF = 4.5 Hz, CH2);
19F NMR
(282 MHz, CDCl3): δ − 72.2 (3F, s), − 218.7 (1F, m); LRMS
(+ESI): m/z 324.00 ([M + Na]+, 100%); IR (diamond cell, thin ﬁlm):
3154 (w), 2956 (m), 2922 (m), 2862 (w), 1658 (s), 1526 (s), 1280
(s), 1176 (s), 1133 (s), 876 (s), 759 (s), 726 (s).
2,2,2-Triﬂuoro-1-(1-(4-ﬂuorobenzyl)-1H-indol-3-yl)ethanone (28).
Subjecting indole (250 mg, 2.13 mmol) and 4-ﬂuorobenzyl bromide
(290 μL, 2.35 mmol, 1.1 equiv) to general prcoedure B gave, following
puriﬁcation by ﬂash chromatography (hexane/EtOAc, 90:10), 28 as a
red solid (518 mg, 76%). mp 82−84 °C; Rf 0.57 (hexane/EtOAc,
80:20); 1H NMR (300 MHz, CDCl3): δ 8.40 (1H, d, J = 7.7 Hz), 7.95
(1H, s), 7.38−7.29 (3H, m), 7.17−7.06 (2H, m), 7.06−7.00 (2H, m),
5.35 (2H, s); 13C NMR (75 MHz, CDCl3): δ 175.1 (q,
2JCF = 35.3 Hz,
CO), 162.8 (d, 1JCF = 246.8 Hz, quat.), 137.6 (q,
4JCF = 4.9 Hz, CH),
136.8 (quat.), 130.7 (d, 4JCF = 3.2 Hz, quat.), 128.9 (d,
3JCF = 8.2 Hz,
CH), 127.3 (quat.), 125.0 (CH), 124.3 (CH), 122.8 (CH), 117.1 (q,
1JCF = 291.1 Hz, quat.), 110.8 (CH), 110.1 (quat.), 50.8 (CH2);
19F
NMR (282 MHz, CDCl3): δ − 72.3 (3F, s), − 113.0 (1F, m); LRMS
(+ESI): m/z 344.01 ([M + Na]+, 100%); IR (diamond cell, thin ﬁlm):
3130 (w), 3080 (w), 2943 (w), 2866 (w), 1654 (s), 1525 (s), 1509 (s),
1392 (s), 1281 (m), 1157 (s), 1131 (s), 1046 (s), 876 (s), 747 (s), 728
(s).
2,2,2-Triﬂuoro-1-(1-(cyclohexylmethyl)-1H-indol-3-yl)ethanone
(29). Subjecting indole (200 mg, 1.71 mmol) and (cyclohexyl)methyl
bromide (250 μL, 1.80 mmol, 1.05 equiv) to general prcoedure B gave,
following puriﬁcation by ﬂash chromatography (hexane/EtOAc, 93:7),
29 as a pale brown solid (425 mg, 80%). mp 87−89 °C; Rf 0.79
(hexane/EtOAc, 80:20); 1H NMR (300 MHz, CDCl3): δ 8.42 (1H, d,
J = 4.1 Hz), 7.89 (1H, s), 7.45−7.32 (3H, m), 4.02 (2H, d, J = 6.9 Hz),
1.90 (1H, m), 1.74−1.62 (5H, m), 1.24−1.00 (5H, m); 13C NMR (75
MHz, CDCl3): δ 174.8 (q,
2JCF = 34.5 Hz, CO), 138.1 (CH), 137.1
(quat.), 127.1 (quat.), 124.5 (CH), 123.9 (CH), 122.7 (CH), 117.2
(quat.), 110.7 (CH), 109.3 (quat.), 54.2 (CH2), 38.3 (CH), 30.9
(CH2), 26.1 (CH2), 25.6 (CH2);
19F NMR (282 MHz, CDCl3): δ −
72.2 (3F, s); LRMS (+ESI): m/z 332.06 ([M + Na]+, 100%); IR
(diamond cell, thin ﬁlm): 3118 (w), 2925 (m), 2854 (w), 1650 (s),
1531 (s), 1397 (m), 1284 (m), 1179 (s), 1130 (s), 1048 (m), 875 (s),
748 (s), 725 (s).
2,2,2-Triﬂuoro-1-(1-(pentyl)-1H-indol-3-yl)ethanone (30). Subject-
ing indole (200 mg, 1.71 mmol) and 1-bromopentane (225 μL, 1.80
mmol, 1.05 equiv) to general prcoedure B gave, following puriﬁcation
by ﬂash chromatography (hexane/ethyl acetate 94:6), 30 as a yellow
oil (450 mg, 94%). Rf 0.81 (hexane-ethyl acetate 80:20);
1H NMR
(300 MHz, CDCl3): δ 8.43 (1H, d, J = 8.7 Hz), 7.93 (1H, s), 7.42−
7.36 (3H, m), 4.21 (2H, t, J = 6.9 Hz), 1.95 (2H, quin., J = 7.2 Hz),
1.43−1.32 (4H, m), 0.92 (3H, t, J = 6.6 Hz); 13C NMR (75 MHz,
CDCl3): δ 174.8 (q, CO,
2JCF = 34.5 Hz), 137.5 (d, CH,
4JCF = 4.5
Hz), 136.8 (quat.), 127.3 (quat.), 124.6 (CH), 124.0 (CH), 122.8
(CH), 117.3 (q, CF3,
1JCF = 289.5 Hz), 110.5 (CH), 109.5 (quat.),
47.8 (CH2), 29.5 (CH2), 29.0 (CH2), 22.3 (CH2), 14.0 (CH3);
19F
NMR (282 MHz, CDCl3): δ − 72.2 (3F, s); LRMS (+ESI): m/z
306.03 ([M + Na]+, 100%); IR (diamond cell, thin ﬁlm): 3124 (w),
2959 (m), 2933 (m), 2863 (w), 1662 (s), 1527 (s), 1397 (m), 1286
(m), 1181 (s), 1132 (s), 878 (m), 751 (m).
General Procedure C: Synthesis of 1-Alkyl-1H-indole-3-
carboxylic Acids and 1-Alkyl-1H-indazole-3-carboxylic Acids.
To a solution of the appropriate 1-alkyl-3-(triﬂuoroacetyl)indole or
methyl 1-alkyl-1H-indazole-3-carboxylate (2.58 mmol) in MeOH (20
mL) was added 1 M aq. NaOH (3.87 mL, 3.87 mmol, 1.5 equiv) and
the solution heated at reﬂux for 18 h. The mixture was cooled to
ambient temperature, solvent was evaporated in vacuo, and the
mixture was poured onto sat. aq. NaHCO3 (75 mL). The aqueous
phase was washed with Et2O (75 mL) and the pH adjusted to 2 with 1
M aq. HCl. The aquoeus phase was extracted with Et2O (3 × 75 mL)
and the combined organic layers were washed with brine (150 mL),
dried (MgSO4) and concentrated in vacuo to give the crude products.
Analytical purity for 1-alkyl-1H-indazole-3-carboxylic acids was
achieved by recrystallization from i-PrOH.
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1-(5-Fluoropentyl)-1H-indole-3-carboxylic Acid (31). Subjecting
27 (500 mg, 1.66 mmol) to general procedure C gave 31 (338 mg,
82%) as a white solid. mp 120−122 °C; 1H NMR (75 MHz, CD3OD):
δ 8.08 (1H, d, J = 7.8 Hz), 7.96 (1H, s), 7.48 (1H, d, J = 7.8 Hz),
7.28−7.17 (2H, m), 4.38 (2H, dt, J = 47.4, 6.0 Hz), 4.25 (2H, t, J = 6.9
Hz), 1.91 (2H, quin., J = 7.8 Hz), 1.77−1.63 (2H, dquin., J = 25.8, 7.2
Hz), 1.42 (2H, quin., J = 7.8 Hz); 13C NMR (75 MHz, CD3OD): δ
168.8 (CO), 138.1 (quat.), 136.3 (CH), 128.3 (quat.), 123.6 (CH),
122.6 (CH), 122.5 (CH), 111.4 (CH), 107.8 (quat.), 84.6 (d, 2JCF =
162.8 Hz, CH2), 47.6 (CH2), 31.1 (d,
3JCF = 9.5 Hz, CH2), 30.7
(CH2), 23.7 (CH2);
19F NMR (282 MHz, CD3OD): δ − 221.8 (1F,
m); LRMS (−ESI): m/z 248.29 ([M − H]−, 100%); IR (diamond cell,
thin ﬁlm): 3043 (w), 2962 (m), 2895 (w), 2704 (w), 2585 (w), 1635
(s), 1523 (s), 1467 (s), 1397 (s), 1272 (s), 1170 (s), 920 (s), 742 (s),
618 (s), 427 (s).
1-(4-Fluorobenzyl)-1H-indole-3-carboxylic Acid (32). Subjecting
28 (500 mg, 1.56 mmol) to general procedure C gave 32 (282 mg,
67%) as a white solid. mp 207−209 °C; 1H NMR (300 MHz,
CD3OD): δ 8.10 (1H, dd, J = 6.3, 3.3 Hz), 8.03 (1H, s), 7.39 (1H, dd,
J = 5.7, 2.1 Hz), 7.26−7.19 (4H, m), 7.05 (2H, t, J = 8.4 Hz), 5.43
(2H, s); 13C NMR (75 MHz, CD3OD): δ 168.7 (CO), 163.8 (d,
1JCF
= 243.8 Hz, quat.), 138.2 (quat.), 136.5 (CH), 134.2 (quat.), 130.2 (d,
3JCF = 8.3 Hz, CH), 128.5 (quat.), 123.8 (CH), 122.8 (CH), 122.5
(CH), 116.6 (d, 2JCF = 21.8 Hz, CH), 111.7 (CH), 108.5 (quat.), 50.6
(CH2);
19F NMR (282 MHz, CD3OD): δ − 118.3 (1F, m); LRMS
(−ESI): 268.22 ([M − H]−, 100%); IR (diamond cell, thin ﬁlm): 3108
(w), 2938 (w), 2587 (bs), 1652 (s), 1525 (m), 1508 (m), 1277 (m),
1225 (s), 1185 (s), 830 (s), 753 (s), 744 (s), 428 (s).
1-(Cyclohexylmethyl)-1H-indole-3-carboxylic Acid (33). Subject-
ing 29 (400 mg, 1.29 mmol) to general procedure C gave 33 (305 mg,
92%) as a white solid. mp 180−182 °C; 1H NMR (400 MHz, CDCl3):
δ 8.19−8.16 (1H, m), 7.81 (1H, s), 7.32−7.28 (1H, m), 7.25−7.20
(2H, m), 3.92 (2H, d, J = 7.2 Hz), 1.87−1.76 (1H, m), 1.68−1.56
(5H, m), 1.19−1.03 (3H, m), 1.00−0.90 (2H, m); 13C NMR (100
MHz, CDCl3): δ 170.6 (CO), 137.1 (quat.), 136.3 (CH), 127.1
(quat.), 122.9 (CH), 122.2 (CH), 122.0 (CH), 110.5 (CH), 106.2
(quat.), 53.8 (CH2), 38.5 (CH), 31.1 (CH2), 26.3 (CH2), 25.8 (CH2);
LRMS (−ESI): m/z 256.52 ([M − H]−, 100%); IR (diamond cell,
thin ﬁlm): 2926 (w), 2852 (w), 1652 (s), 1523 (m), 1467 (m), 1395
(m), 1236 (s), 754 (s), 744 (s).
1-(Pentyl)-1H-indole-3-carboxylic Acid (34). Subjecting 30 (450
mg, 1.59 mmol) to general procedure C gave 33 (323 mg, 88%) as a
white solid. mp 106−108 °C; 1H NMR (300 MHz, CD3OD): δ 8.09
(1H, dd, J = 6.5, 1.9 Hz), 7.93 (1H, s), 7.42−7.28 (3H, m), 4.17 (2H,
t, J = 7.2 Hz), 1.90 (2H, quin., J = 7 Hz), 1.40−1.32 (4H, m), 0.90
(3H, t, J = 6.6 Hz); 13C NMR (75 MHz, CD3OD): δ 168.8 (CO),
138.1 (quat.), 136.3 (CH), 128.3 (quat.), 123.6 (CH), 122.6 (CH),
122.4 (CH), 111.3 (CH), 107.7 (quat.), 47.7 (CH2), 30.7 (CH2), 30.0
(CH2), 23.3 (CH2), 14.2 (CH3); LRMS (−ESI): m/z 230.32 ([M −
H]−, 100%); IR (diamond cell, thin ﬁlm): 3106 (w), 2925 (m), 2856
(w), 2525 (bs), 1649 (s), 1526 (s), 1461 (m), 1273 (m), 1204 (s),
1117 (m), 940 (m), 731 (s).
1-(5-Fluoropentyl)-1H-indazole-3-carboxylic Acid (40). Subjecting
36 (750 mg, 2.84 mmol) to general procedure C gave 40 (580 mg,
81%) as a white solid. mp 89−91 °C; 1H NMR (300 MHz, CD3OD):
δ 8.36 (1H, d, J = 7.8 Hz), 7.52 (2H, m), 7.33 (1H, t, J = 7.5 Hz),
4.53−4.49 (3H, m), 4.34 (1H, t, J = 5.7 Hz), 2.03 (2H, quin., J = 7.2
Hz), 1.82−1.65 (2H, m), 1.50 (2H, quin., J = 6.9 Hz); 13C NMR (75
MHz, CD3OD): δ 165.5 (CO), 142.2 (quat.), 136.1 (quat.), 128.1
(CH), 124.7 (quat.), 124.2 (CH), 123.0 (CH), 111.2 (CH), 84.6 (d,
1JCF = 162.8 Hz, CH2), 50.3 (CH2), 31.0 (d,
2JCF = 20.3 Hz, CH2),
30.4 (CH2), 23.6 (d,
3JCF = 5.3 Hz, CH2);
19F NMR (282 MHz,
CD3OD): δ − 221.8 (1F, m); LRMS (−ESI): m/z 249.12 ([M − H]−,
100%); IR (diamond cell, thin ﬁlm): 3052 (bs), 2941 (m), 2866 (w),
1685 (s), 1480 (s), 1167 (s), 1120 (s), 751 (s).
1-(4-Fluorobenzyl)-1H-indazole-3-carboxylic Acid (41). Subjecting
37 (560 mg, 1.97 mmol) to general procedure C gave 41 (480 mg,
91%) as a white solid. mp 203−205 °C; 1H NMR (300 MHz,
CD3OD): δ 8.17 (1H, d, J = 8.1 Hz), 7.62 (1H, d, J = 8.7 Hz), 7.44
(1H, t, J = 7.5 Hz), 7.31 (3H, m), 7.04 (2H, t, J = 8.4 Hz), 5.71 (2H,
s); 13C NMR (75 MHz, CD3OD): δ 165.5 (CO), 163.9 (d,
1JCF =
244.5 Hz, quat.), 142.1 (quat.), 136.7 (quat.), 133.7 (d, 4JCF = 3 Hz,
quat.), 130.6 (d, 3JCF = 8.3 Hz, CH), 128.3 (CH), 125.0 (quat.), 124.3
(CH), 123.1 (CH), 116.5 (d, 2JCF = 21.8 Hz, CH), 111.4 (CH), 53.6
(CH2);
19F NMR (285 MHz, CD3OD): δ − 118.0 (1F, m); LRMS
(−ESI): m/z 269.07 ([M − H]−, 100%); IR (diamond cell, thin ﬁlm):
3058 (bs), 2926 (w), 1696 (s), 1510 (s), 1481 (s), 1224 (s), 1170 (s),
1157 (s), 749 (s).
1-(Cyclohexylmethyl)-1H-indazole-3-carboxylic Acid (42). Sub-
jecting 38 (475 mg, 1.74 mmol) to general procedure C gave 42 (388
mg, 86%) as a white solid. mp 124−126 °C; 1H NMR (300 MHz,
CD3OD): δ 8.16 (1H, d, J = 8.1 Hz), 7.66 (1H, d, J = 8.4 Hz), 7.47
(1H, t, J = 7.2 Hz), 7.31 (1H, t, J = 7.8 Hz), 4.34 (2H, d, J = 7.2 Hz),
2.05 (1H, m), 1.72−1.66 (3H, m), 1.56 (2H, d, J = 12.9 Hz), 1.26−
1.02 (5H, m); 13C NMR (75 MHz, CD3OD): δ 165.5 (CO), 142.6
(quat.), 135.9 (quat.), 128.0 (CH), 124.5 (quat.), 124.1 (CH), 123.0
(CH), 111.4 (CH), 56.5 (CH2), 40.0 (CH), 31.7 (CH2), 27.7 (CH),
26.7 (CH2); LRMS (−ESI): m/z 257.16 ([M − H]−, 100%); IR
(diamond cell, thin ﬁlm): 3060 (bs), 2926 (s), 2851 (m), 1707 (s),
1479 (s), 1230 (s), 1174 (s), 752 (s).
1-(Pentyl)-1H-indazole-3-carboxylic Acid (43). Subjecting 39 (600
mg, 2.58 mmol) to general procedure C gave 43 (510 mg, 85%) as a
white solid. mp 76−78 °C; 1H NMR (300 MHz, CD3OD): δ 8.26
(1H, d, J = 8.1 Hz), 7.52−7.44 (2H, m), 7.35 (1H, t, J = 7.8 Hz), 4.48
(2H, t, J = 7.2 Hz), 1.99 (2H, quin., J = 7.2 Hz), 1.34 (4H, m), 0.89
(3H, t, J = 6.0 Hz); 13C NMR (75 MHz, CD3OD): δ 165.4 (CO),
142.0 (quat.), 135.9 (quat.), 127.9 (CH), 124.5 (quat.), 124.0 (CH),
122.9 (CH), 111.0 (CH), 49.7 (CH2), 30.4 (CH2), 29.8 (CH2), 23.1
(CH2), 14.1 (CH3); LRMS (−ESI): m/z 231.12 ([M − H]−, 100%);
IR (diamond cell, thin ﬁlm): 3053 (bs), 2956 (m), 2931 (m), 2860
(w), 1687 (s), 1503 (s), 1218 (s), 1176 (s), 1121 (s), 752 (s).
General Procedure D: Synthesis of Methyl 1-Alkyl-1H-
indazole-3-carboxylates. To a cooled (0 °C) solution of methyl
1H-indazole-3-carboxylate (35, 500 mg, 2.84 mmol) in THF (15 mL)
was added potassium tert-butoxide (350 mg, 3.12 mmol, 1.1 equiv),
and the mixture warmed to ambient temperature and stirred for 1 h.
The cooled (0 °C) mixture was treated dropwise with the appropriate
bromoalkane (2.98 mmol, 1.05 equiv) and stirred for 48 h. The
reaction was quenched by pouring onto H2O (100 mL) and the layers
separated. The aqueous phase was extracted with EtOAc (3 × 100
mL), and the combined organic layers were washed with brine (150
mL), dried (MgSO4), and the solvent evaporated under reduced
pressure. The crude materials were puriﬁed by ﬂash chromatography.
Methyl 1-(5-Fluoropentyl)-1H-indazole-3-carboxylate (36). Sub-
jecting 35 (500 mg, 2.84 mmol) and 1-bromo-5-ﬂuoropentane (370
μL, 2.98 mmol, 1.05 equiv) to general procedure D gave, following
puriﬁcation by ﬂash chromatography (hexane/EtOAc, 80:20), 36 (560
mg, 75%) as a colorless oil. Rf 0.30 (hexane/EtOAc, 80:20);
1H NMR
(300 MHz, CDCl3): δ 8.24 (1H, d, J = 8.1 Hz), 7.49−7.45 (2H, m),
7.32 (1H, t, J = 6.3 Hz), 4.52−4.47 (3H, m), 4.33 (1H, t, J = 5.7 Hz),
4.04 (3H, s), 2.03 (2H, quin., J = 7.2 Hz), 2.00−1.63 (2H, m), 1.46
(2H, quin., J = 12.0 Hz); 13C NMR (75 MHz, CDCl3): δ 163.2 (CO),
140.6 (quat.), 134.8 (quat.), 127.0 (CH), 123.9 (quat.), 123.2 (CH),
122.4 (CH), 109.6 (CH), 83.8 (d, 1JCF = 163.5 Hz, CH2F), 52.1
(CH2), 49.8 (CH3), 30.0 (d,
2JCF = 19.5 Hz, CH2), 29.6 (CH2), 22.8
(d, 3JCF = 4.5 Hz, CH2);
19F NMR (282 MHz, CDCl3): δ − 218.6 (1F,
m); LRMS (+ESI): m/z 287.03 ([M + Na]+, 100%); IR (diamond cell,
thin ﬁlm): 2950 (m), 2867 (w), 1729 (s), 1710 (s), 1478 (s), 1163 (s),
1118 (s), 752 (s).
Methyl 1-(4-Fluorobenzyl)-1H-indazole-3-carboxylate (37). Sub-
jecting 35 (500 mg, 2.84 mmol) and 4-ﬂuorobenzyl bromide (371 μL,
2.98 mmol, 1.05 equiv) to general procedure D gave, following
puriﬁcation by ﬂash chromatography (hexane/EtOAc, 80:20), 37 (570
mg, 71%) as a white solid. mp 83−84 °C; Rf 0.35 (hexane/EtOAc,
80:20); 1H NMR (300 MHz, CDCl3): δ 8.25 (1H, d, J = 7.8 Hz),
7.42−7.29 (3H, m), 7.21 (2H, t, J = 6.9 Hz), 6.99 (2H, t, J = 8.1 Hz),
5.67 (2H, s), 4.06 (3H, s); 13C NMR (75 MHz, CDCl3): δ 163.1
(CO), 162.6 (d, 1JC−F = 245.3 Hz, quat.), 140.6 (quat.), 135.3 (quat.),
131.6 (d, 4JCF = 3.8 Hz, quat.), 129.2 (d,
3JCF = 8.3 Hz, CH), 127.3
(CH), 124.3 (quat.), 123.5 (CH), 122.5 (CH), 116.0 (d, 2JCF = 21.8
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Hz, CH), 53.5 (CH2), 52.2 (CH3);
19F NMR (282 MHz, CDCl3): δ −
113.8 (1F, s); LRMS (+ESI): m/z 307.00 ([M+ Na]+, 100%). IR
(diamond cell, thin ﬁlm): 3071 (w), 2952 (w), 1712 (s), 1510 (s),
1479 (s), 1268 (s), 1157 (s), 749 (s).
Methyl 1-(Cyclohexylmethyl)-1H-indazole-3-carboxylate (38).
Subjecting 35 (500 mg, 2.84 mmol) and (bromomethyl)cyclohexane
(415 μL, 2.98 mmol, 1.05 equiv) to general procedure D gave,
following puriﬁcation by ﬂash chromatography (hexane/EtOAc,
80:20), 38 (505 mg, 65%) as a colorless oil. Rf 0.60 (hexane/
EtOAc, 80:20); 1H NMR (300 MHz, CDCl3): δ 8.22 (1H, dt, J = 8.1,
0.9 Hz), 7.48−7.39 (2H, m), 7.33−7.28 (1H, m), 4.28 (2H, d, J = 7.5
Hz), 4.03 (3H, s), 2.08 (1H, m), 1.74−1.52 (5H, m), 1.32−0.98 (5H,
m); 13C NMR (75 MHz, CDCl3): δ 163.3 (CO), 141.3 (quat.), 134.6
(quat.), 126.8 (CH), 123.7 (quat.), 123.1 (CH), 122.3 (CH), 110.0
(CH), 56.1 (CH2), 52.1 (CH3), 38.9 (CH2), 31.7 (CH), 26.3 (CH2),
25.7 (CH2); LRMS (+ESI) m/z 295.05 ([M + Na]
+, 100%); IR
(diamond cell, thin ﬁlm): 2925 (s), 2851 (m), 1710 (s), 1477 (s),
1441 (m), 1224 (s), 1161 (s), 1121 (s), 751 (s).
Methyl 1-(Pentyl)-1H-indazole-3-carboxylate (39). Subjecting 35
(500 mg, 2.84 mmol) and 1-bromopentane (370 μL, 2.98 mmol, 1.05
equiv) to general procedure D gave, following puriﬁcation by ﬂash
chromatography (hexane/EtOAc, 80:20), 39 (585 mg, 84%) as a
colorless oil. Rf. 0.50 (hexane-EtOAc, 80:20);
1H NMR (300 MHz,
CDCl3): δ 8.24 (1H, d, J = 8.0 Hz), 7.50−7.44 (2H, m), 7.35−7.27
(1H, m), 4.47 (2H, t, J = 7.4 Hz), 4.04 (3H, s), 1.97 (2H, quin., J = 7.0
Hz), 1.32 (4H, m), 0.87 (3H, t, J = 6.6 Hz); 13C NMR (75 MHz,
CDCl3): δ 163.3 (CO), 140.6 (quat.), 134.6 (quat.), 126.8 (CH),
123.9 (quat.), 123.1 (CH), 122.3 (CH), 109.7 (CH), 52.1 (CH3), 50.1
(CH2), 29.7 (CH2), 29.0 (CH2), 22.4 (CH2), 14.0 (CH3); LRMS
(+ESI): m/z 269.03 ([M + Na]+, 60%), 515.16 ([2 M + Na]+, 100%);
IR (diamond cell, thin ﬁlm): 2954 (m), 2932 (m), 2860 (w), 1709 (s),
1477 (s), 1215 (s), 1159 (s), 1117 (s), 751 (s).
In Vitro Pharmacological Assessment of SCs. Mouse AtT-20
pituitary tumor cells engineered to express a FLP recombination site
were transfected with HA-tagged human CB1 or human CB2 receptors
(Genscript, Piscataway, NJ) as previously described for opioid
receptors in the same cells.87 Cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM) containing 10% fetal bovine
serum (FBS), 100 U penicillin/streptomycin ml−1, and 80 μg/mL
hygromycin. Wild type AtT-20 FlpIn cells were grown without
hygromycin. Cells were passaged at 80% conﬂuency as required. Cells
for assays were grown in 75 cm2 ﬂasks and used at 90% conﬂuence.
The day before the assay cells were detached from the ﬂask with
trypsin/EDTA (Sigma-Aldrich) and resuspended in 10 mL of
Leibovitz’s L-15 media supplemented with 1% FBS, 100 U
penicillin/streptomycin ml−1 and 15 mM glucose. The cells were
plated in volume of 90 μL in black walled, clear bottomed 96-well
microplates (Corning, Oneonta, NY). For experiments where cells
were treated with pertussis toxin (PTX), the cells were plated as
normal and PTX (200 ng/mL ﬁnal concentration, List Biological
Laboratories, Campbell, California) was added to the wells
immediately afterward. Cells were incubated overnight at 37 °C in
ambient CO2.
Membrane potential was measured using a FLIPR membrane
potential assay kit (blue) from Molecular Devices (Sunnyvale, CA), as
described previously.88 The dye was reconstituted with assay buﬀer of
composition (mM): NaCl 145, HEPES 22, Na2HPO4 0.338, NaHCO3
4.17, KH2PO4 0.441, MgSO4 0.407, MgCl2 0.493, CaCl2 1.26, glucose
5.56 (pH 7.4, osmolarity 315 ± 5). Prior to the assay, cells were loaded
with 90 μL/well of the dye solution without removal of the L-15,
giving an initial assay volume of 180 μL/well. Plates were then
incubated at 37 °C at ambient CO2 for 60 min. Fluorescence was
measured using a FlexStation 3 (Molecular Devices) microplate reader
with cells excited at a wavelength of 530 nm and emission measured at
565 nm. Baseline readings were taken every 2 s for 60−120 s, after
which either drug or vehicle was added in a volume of 20 μL. The
background ﬂuorescence of cells without dye or dye without cells was
negligible. Changes in ﬂuorescence were expressed as a percentage of
baseline ﬂuorescence after subtraction of the changes produced by
vehicle addition. Drug solutions were made up in assay buﬀer
containing 0.01% BSA (Sigma) and 1% DMSO, thus the ﬁnal
concentration of dimethyl sulfoxide was always 0.1%.
Data were analyzed with PRISM (GraphPad Software Inc., San
Diego, CA), using four-parameter nonlinear regression to ﬁt
concentration−response curves. In all plates, a maximally eﬀective
concentration of CP 55,940 (1 μM, Cayman Chemical, Ann Arbor,
MI) was added to allow for normalization between assays.
In Vivo Pharmacological Assessment of SCs. Two cohorts of
four adult male Long Evans rats (Animal Resources Centre, Perth,
Australia) initially weighing between 168 and 186 g were used for
biotelemetric assessment of body temperature and heart rate changes
following each compound. The rats were singly housed in an air-
conditioned testing room (22 ± 1 °C) on a 12 h reverse light/dark
cycle (lights on from 21:00 to 09:00). Standard rodent chow and water
were provided ad libitum. All experiments were approved by The
University of Sydney Animal Ethics Committee.
Biotelemetry transmitters (TA11CTA-F40, Data Sciences Interna-
tional, St. Paul, MN) were implanted as previously described.27 Brieﬂy,
following anesthetization (isoﬂurane, 3% induction, 2% maintenance)
a rostro-caudal incision was made along the midline of the abdomen,
and a biotelemetry transmitter (TA11CTA-F40, Data Sciences
International, St. Paul, MN) was placed in the peritoneal cavity
according to the manufacturers protocol. The wound was sutured
closed and the rats were allowed 1 week of recovery before data
collection.
The rats were habituated over multiple days to injections of vehicle
(5% EtOH, 5% Tween 80, 90% physiological saline) at a set time of
day (11:00 am). Each cohort then received injections of each
compound at the same time of day in an ascending dose sequence
(0.1, 0.3, 1, mg/kg). This ascending sequence reduces the risk posed
to the animals in assessing hitherto untested compounds, and the use
of multiple cohorts limits the potential development of tolerance to
the compound. Two washout days were given between each dose. If
only a modest or negligible hypothermic response was seen at 1 mg/
kg, then a further 3 mg/kg dose of the compound was given. At least
two washout days were given between each dose.
For the antagonist studies (Figure 6), the third and fourth cohort of
drug-naiv̈e rats were used for each compound, with a 48 h washout
period between each dose. Each cohort received injections of either
vehicle, CB1 antagonist (rimonabant, 3 mg/kg), or CB2 antagonist
(SR144528, 3 mg/kg), followed by 5F-AMB (3 mg/kg) or MDMB-
FUBINACA (1 mg/kg). The vehicle or antagonist injections were
given to rats 30 min prior to the 5F-AMB or MDMB-FUBINACA
injections.
Data for heart rate and body temperature was gathered continuously
at 1000 Hz and organized into 15 min bins using Dataquest A.R.T.
software (version 4.3, Data Sciences International, St. Paul, MN), and
analyzed using PRISM (Graphpad Software Inc., San Diego, CA).
We calculated the area between baseline and drug-treatment body
temperature curves for each rat as a measure of compound potency.
Brieﬂy, for any time point, the area between baseline data points (Bt)
and drug-treatment data points (Dt) and the subsequent time points
(Bt+1 and Dt+1) forms a trapezoid, the area of which can be calculated
via the formula:
= − + −+ +B D B Darea ( ) ( )
2
t t t t1 1
These areas were summed from the time of injection to 6 h
postinjection. MDMB-FUBINACA and 5F-AMB AUC data were
compared at each dose level with independent samples t tests.
For the antagonist studies, the area between the vehicle−vehicle
baseline and the vehicle−SC (i.e., vehicle−5F-AMB or vehicle−
MDMB-FUBINACA), rimonabant-SC, and SR144528-SC treatments
was calculated over a 3 h time period postinjection of SC. These areas
were analyzed using a one-way repeated measures ANOVA with
planned Dunnet’s contrasts comparing the antagonist areas to the
vehicle-drug area.
ACS Chemical Neuroscience Research Article
DOI: 10.1021/acschemneuro.6b00137
ACS Chem. Neurosci. 2016, 7, 1241−1254
1251
Chapter 2 115
■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acschemneur-
o.6b00137.
Table of compound names, CAS numbers, and relevant
references; selected 1H and 13C NMR spectra (PDF)
■ AUTHOR INFORMATION
Corresponding Author
*E-mail: michael.kassiou@sydney.edu.au.
Author Contributions
○S.D.B. and M.L. contributed equally.
Author Contributions
The synthesis, puriﬁcation, and chemical characterization of
compounds 10−25 was carried out by S.D.B., M.L., and
J.B.C.M., and overseen by M.K. M.C. and S.S. designed and
conducted all in vitro pharmacological studies, and data analysis
was performed by M.C., S.S., S.D.B., M.G., and J.S. M.S. made
and characterized the CB1 and CB2 cells. All behavioral
pharmacology was performed by R.K. with direction from
I.S.M. The manuscript was drafted by S.D.B. with contributions
from M.L., J.S. R.C.K., M.G., M.C., I.S.M., and M.K. All authors
have given approval to the ﬁnal version of the manuscript.
Funding
Work performed at The University of Sydney and presented
herein was supported in part by the European Union’s Seventh
Framework Programme [FP7/2007-2013] INMiND (Grant
Agreement No. HEALTH-F2-2011-278850). Work was also
supported by NHMRC Project Grant 1107088 awarded to
M.K., I.S.M., and M.C.
Notes
The authors declare no competing ﬁnancial interest.
■ ABBREVIATIONS
CB, cannabinoid; FLIPR, ﬂuorometric imaging plate reader;
GIRK, G-protein-gated inwardly rectifying K+ channels; ip,
intraperitoneal; NMR, nuclear magnetic resonance; pi, post-
injection; SAR, structure−activity relationship; SC, synthetic
cannabinoid; Δ9-THC, Δ9-tetrahydrocannabinol; TLC, thin
layer chromatography
■ REFERENCES
(1) Brandt, S. D., King, L. A., and Evans-Brown, M. (2014) The new
drug phenomenon. Drug Test. Anal. 6, 587−597.
(2) Auwarter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M.,
and Ferreiros, N. (2009) ’Spice’ and other herbal blends: harmless
incense or cannabinoid designer drugs? J. Mass Spectrom. 44, 832−837.
(3) Uchiyama, N., Kikura-Hanajiri, R., Kawahara, N., and Goda, Y.
(2009) Identification of a cannabimimetic indole as a designer drug in
a herbal product. Forensic Toxicol. 27, 61−66.
(4) United Nations Oﬃce on Drugs and Crime, World Drug Report
2015 (United Nations publication, Sales No. E.15.XI.6).
(5) Blakey, K., Boyd, S., Atkinson, S., Wolf, J., Slottje, P. M.,
Goodchild, K., and McGowan, J. (2016) Identification of the novel
synthet i c cannab imimet ic 8-qu ino l iny l 4 -methy l -3 -(1-
piperidinylsulfonyl)benzoate (QMPSB) and other designer drugs in
herbal incense. Forensic Sci. Int. 260, 40−53.
(6) Carlsson, A., Lindberg, S., Wu, X., Dunne, S., Josefsson, M., Astot,
C., and Dahlen, J. (2015) Prediction of designer drugs: synthesis and
spectroscopic analysis of synthetic cannabinoid analogues of 1H-indol-
3-yl(2,2,3,3-tetramethylcyclopropyl)methanone and 1H-indol-3-yl-
(adamantan-1-yl)methanone. Drug Test. Anal., DOI: 10.1002/
dta.1904.
(7) Kondrasenko, A. A., Goncharov, E. V., Dugaev, K. P., and
Rubaylo, A. I. (2015) CBL-2201. Report on a new designer drug:
Napht-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate. Forensic Sci.
Int. 257, 209−213.
(8) McLaughlin, G., Morris, N., Kavanagh, P. V., Power, J. D.,
Twamley, B., O’Brien, J., Talbot, B., Dowling, G., and Brandt, S. D.
(2015) The synthesis and characterization of the ’research chemical’
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-3-(4-flu-
orophenyl)-1H-pyrazole-5-carboxamide (3,5-AB-CHMFUPPYCA)
and differentiation from its 5,3-regioisomer. Drug Test. Anal.,
DOI: 10.1002/dta.1864.
(9) Uchiyama, N., Asakawa, K., Kikura-Hanajiri, R., Tsutsumi, T., and
Hakamatsuka, T. (2015) A new pyrazole-carboxamide type synthetic
cannabinoid AB-CHFUPYCA [N-(1-amino-3-methyl-1-oxobutan-2-
yl)-1-(cyclohexylmethyl)-3-(4-fluorophenyl)-1H-pyrazole-5-carboxa-
mide] identified in illegal products. Forensic Toxicol. 33, 367−373.
(10) Uchiyama, N., Shimokawa, Y., Kikura-Hanajiri, R., Demizu, Y.,
Goda, Y., and Hakamatsuka, T. (2015) A synthetic cannabinoid FDU-
NNEI, two 2-indazole isomers of synthetic cannabinoids AB-
CHMINACA and NNEI indazole analog (MN-18), a phenethylamine
derivative OH-EDMA, and a cathinone derivative dimethoxy-alpha-
PHP, newly identified in illegal products. Forensic Toxicol. 33, 244−
259.
(11) Westphal, F., Sonnichsen, F. D., Knecht, S., Auwarter, V., and
Huppertz, L. (2015) Two thiazolylindoles and a benzimidazole: Novel
compounds on the designer drug market with potential cannabinoid
receptor activity. Forensic Sci. Int. 249, 133−147.
(12) Jia, W., Meng, X., Qian, Z., Hua, Z., Li, T., and Liu, C. (2016)
Identification of three cannabimimetic indazole and pyrazole
derivatives, APINACA 2H-indazole analogue, AMPPPCA, and 5F-
AMPPPCA. Drug Test. Anal., DOI: 10.1002/dta.1967.
(13) Qian, Z., Hua, Z., Liu, C., and Jia, W. (2016) Four types of
cannabimimetic indazole and indole derivatives, ADB-BINACA, AB-
FUBICA, ADB-FUBICA, and AB-BICA, identified as new psycho-
active substances. Forensic Toxicol. 34, 133−143.
(14) Shevyrin, V., Melkozerov, V., Eltsov, O., Shafran, Y., and
Morzherin, Y. (2016) Synthetic cannabinoid 3-benzyl-5-[1-(2-
pyrrolidin-1-ylethyl)-1H-indol-3-yl]-1,2,4-oxadiazole. The first detec-
tion in illicit market of new psychoactive substances. Forensic Sci. Int.
259, 95−100.
(15) Huestis, M. A., Gorelick, D. A., Heishman, S. J., Preston, K. L.,
Nelson, R. A., Moolchan, E. T., and Frank, R. A. (2001) Blockade of
effects of smoked marijuana by the CB1-selective cannabinoid receptor
antagonist SR141716. Arch. Gen. Psychiatry 58, 322−328.
(16) Castaneto, M. S., Gorelick, D. A., Desrosiers, N. A., Hartman, R.
L., Pirard, S., and Huestis, M. A. (2014) Synthetic cannabinoids:
epidemiology, pharmacodynamics, and clinical implications. Drug
Alcohol Depend. 144, 12−41.
(17) Tuv, S. S., Krabseth, H., Karinen, R., Olsen, K. M., Oiestad, E.
L., and Vindenes, V. (2014) Prevalence of synthetic cannabinoids in
blood samples from Norwegian drivers suspected of impaired driving
during a seven weeks period. Accid. Anal. Prev. 62, 26−31.
(18) Andreeva-Gateva, P. A., Nankova, V. H., Angelova, V. T., and
Gatev, T. N. (2015) Synthetic cannabimimetics in Bulgaria 2010−
2013. Drug Alcohol Depend. 157, 200−204.
(19) Zawilska, J. B., and Andrzejczak, D. (2015) Next generation of
novel psychoactive substances on the horizon - A complex problem to
face. Drug Alcohol Depend. 157, 1−17.
(20) Langer, N., Lindigkeit, R., Schiebel, H.-M., Papke, U., Ernst, L.,
and Beuerle, T. (2016) Identification and quantification of synthetic
cannabinoids in “spice-like” herbal mixtures: update of the German
situation for the spring of 2015. Forensic Toxicol. 34, 94−107.
(21) Schifano, F., Orsolini, L., Duccio Papanti, G., and Corkery, J. M.
(2015) Novel psychoactive substances of interest for psychiatry. World
Psychiatry. 14, 15−26.
(22) Costain, W. J., Tauskela, J. S., Rasquinha, I., Comas, T., Hewitt,
M., Marleau, V., and Soo, E. C. (2016) Pharmacological character-
ACS Chemical Neuroscience Research Article
DOI: 10.1021/acschemneuro.6b00137
ACS Chem. Neurosci. 2016, 7, 1241−1254
1252
Chapter 2 116
ization of emerging synthetic cannabinoids in HEK293T cells and
hippocampal neurons. Eur. J. Pharmacol. 786, 234−245.
(23) Frinculescu, A., Lyall, C. L., Ramsey, J., and Miserez, B. (2016)
Variation in commercial smoking mixtures containing third-generation
synthetic cannabinoids. Drug Test. Anal., DOI: 10.1002/dta.1975.
(24) Gerostamoulos, D., Elliott, S., Walls, H. C., Peters, F. T., Lynch,
M., and Drummer, O. H. (2016) To Measure or Not to Measure?
That is the NPS Question. J. Anal. Toxicol. 40, 318−320.
(25) Hess, C., Schoeder, C. T., Pillaiyar, T., Madea, B., and Müller, C.
E. (2016) Pharmacological evaluation of synthetic cannabinoids
identified as constituents of spice. Forensic Toxicol. 34, 329.
(26) Odoardi, S., Romolo, F. S., and Strano-Rossi, S. (2016) A
snapshot on NPS in Italy: Distribution of drugs in seized materials
analysed in an Italian forensic laboratory in the period 2013−2015.
Forensic Sci. Int. 265, 116−120.
(27) Banister, S. D., Wilkinson, S. M., Longworth, M., Stuart, J.,
Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D. E., Glass, M.,
Connor, M., McGregor, I. S., and Kassiou, M. (2013) The synthesis
and pharmacological evaluation of adamantane-derived indoles:
cannabimimetic drugs of abuse. ACS Chem. Neurosci. 4, 1081−1092.
(28) Banister, S. D., Stuart, J., Kevin, R. C., Edington, A., Longworth,
M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Hibbs, D. E., Glass,
M., Connor, M., McGregor, I. S., and Kassiou, M. (2015) Effects of
Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-
018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-
135. ACS Chem. Neurosci. 6, 1445−1458.
(29) Banister, S. D., Stuart, J., Conroy, T., Longworth, M., Manohar,
M., Beinat, C., Wilkinson, S. M., Kevin, R. C., Hibbs, D. E., Glass, M.,
Connor, M., McGregor, I. S., and Kassiou, M. (2015) Structure−
activity relationships of synthetic cannabinoid designer drug RCS-4
and its regioisomers and C4 homologues. Forensic Toxicol. 33, 355−
366.
(30) Banister, S. D., Moir, M., Stuart, J., Kevin, R. C., Wood, K. E.,
Longworth, M., Wilkinson, S. M., Beinat, C., Buchanan, A. S., Glass,
M., Connor, M., McGregor, I. S., and Kassiou, M. (2015)
Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer
Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-
PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-
ADBICA. ACS Chem. Neurosci. 6, 1546−1559.
(31) Wilkinson, S. M., Banister, S. D., and Kassiou, M. (2015)
Bioisosteric Fluorine in the Clandestine Design of Synthetic
Cannabinoids. Aust. J. Chem. 68, 4−8.
(32) Longworth, M., Banister, S. D., Mack, J. B. C., Glass, M.,
Connor, M., and Kassiou, M. (2016) The 2-alkyl-2H-indazole
regioisomers of synthetic cannabinoids AB-CHMINACA, AB-
FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible
manufacturing impurities with cannabimimetic activities. Forensic
Toxicol. 34, 286.
(33) Drug Enforcement Administration, Department of Justice
(2014) Schedules of controlled substances: temporary placement of
four synthetic cannabinoids into Schedule I. Final order. Fed. Reg. 79,
7577−7582.
(34) Drug Enforcement Administration, Department of Justice
(2015) Schedules of controlled substances: temporary placement of
three synthetic cannabinoids into schedule I. Final order. Fed. Reg. 80,
5042−5047.
(35) European Monitoring Centre for Drugs and Drug Addiction
(2015), EMCDDA−Europol 2014 Annual Report on the implemen-
tation of Council Decision 2005/387/JHA, Implementation reports,
Publications Oﬃce of the European Union, Luxembourg.
(36) European Monitoring Centre for Drugs and Drug Addiction
(2015), New psychoactive substances in Europe. An update from the
EU Early Warning System (March 2015), Publications Oﬃce of the
European Union, Luxembourg.
(37) Von Der Haar, J., Talebi, S., Ghobadi, F., Singh, S., Chirurgi, R.,
Rajeswari, P., Kalantari, H., and Hassen, G. W. (2016) Synthetic
Cannabinoids and Their Effects on the Cardiovascular System. J.
Emerg. Med. 50, 258−262.
(38) Louh, I. K., and Freeman, W. D. (2014) A ’spicy’
encephalopathy: synthetic cannabinoids as cause of encephalopathy
and seizure. Crit. Care. 18, 553.
(39) Besli, G. E., Ikiz, M. A., Yildirim, S., and Saltik, S. (2015)
Synthetic Cannabinoid Abuse in Adolescents: A Case Series. J. Emerg.
Med. 49, 644−650.
(40) Gerostamoulos, D., Drummer, O. H., and Woodford, N. W.
(2015) Deaths linked to synthetic cannabinoids. Forensic Sci., Med.,
Pathol. 11, 478.
(41) Hermanns-Clausen, M., Kneisel, S., Szabo, B., and Auwarter, V.
(2013) Acute toxicity due to the confirmed consumption of synthetic
cannabinoids: clinical and laboratory findings. Addiction. 108, 534−
544.
(42) Hermanns-Clausen, M., Kneisel, S., Hutter, M., Szabo, B., and
Auwarter, V. (2013) Acute intoxication by synthetic cannabinoids–
four case reports. Drug Test. Anal. 5, 790−794.
(43) Hermanns-Clausen, M., Kithinji, J., Spehl, M., Angerer, V.,
Franz, F., Eyer, F., and Auwarter, V. (2016) Adverse effects after the
use of JWH-210 - a case series from the EU Spice II plus project. Drug
Test. Anal., DOI: 10.1002/dta.1936.
(44) Hess, C., Stockhausen, S., Kernbach-Wighton, G., and Madea, B.
(2015) Death due to diabetic ketoacidosis: Induction by the
consumption of synthetic cannabinoids? Forensic Sci. Int. 257, e6−e11.
(45) Lovett, C., Wood, D. M., and Dargan, P. I. (2015)
Pharmacology and toxicology of the synthetic cannabinoid receptor
agonists. Reánimation. 24, 527−541.
(46) Mills, B., Yepes, A., and Nugent, K. (2015) Synthetic
Cannabinoids. Am. J. Med. Sci. 350, 59−62.
(47) Muller, H. H., Kornhuber, J., and Sperling, W. (2015) The
behavioral profile of spice and synthetic cannabinoids in humans. Brain
Res. Bull., DOI: 10.1016/j.brainresbull.2015.10.013.
(48) Obafemi, A. I., Kleinschmidt, K., Goto, C., and Fout, D. (2015)
Cluster of Acute Toxicity from Ingestion of Synthetic Cannabinoid-
Laced Brownies. J. Med. Toxicol. 11, 426−429.
(49) van Amsterdam, J., Brunt, T., and van den Brink, W. (2015) The
adverse health effects of synthetic cannabinoids with emphasis on
psychosis-like effects. J. Psychopharmacol. 29, 254−263.
(50) Winstock, A., Lynskey, M., Borschmann, R., and Waldron, J.
(2015) Risk of emergency medical treatment following consumption
of cannabis or synthetic cannabinoids in a large global sample. J.
Psychopharmacol. 29, 698−703.
(51) Castellanos, D., and Gralnik, L. M. (2016) Synthetic
cannabinoids 2015: An update for pediatricians in clinical practice.
World J. Clin. Pediatr. 5, 16−24.
(52) Tait, R. J., Caldicott, D., Mountain, D., Hill, S. L., and Lenton, S.
(2016) A systematic review of adverse events arising from the use of
synthetic cannabinoids and their associated treatment. Clin. Toxicol.
54, 1−13.
(53) Schifano, F., Orsolini, L., Papanti, D., and Corkery, J. (2016)
NPS: Medical Consequences Associated with Their Intake. In Current
Topics in Behavioral Neurosciences, pp 1−30, Springer International
Publishing, Berlin.
(54) Nacca, N., Vatti, D., Sullivan, R., Sud, P., Su, M., and Marraffa, J.
(2013) The synthetic cannabinoid withdrawal syndrome. J. Addict.
Med. 7, 296−298.
(55) Macfarlane, V., and Christie, G. (2015) Synthetic cannabinoid
withdrawal: a new demand on detoxification services. Drug Alcohol Rev.
34, 147−153.
(56) Cooper, Z. D. (2016) Adverse Effects of Synthetic
Cannabinoids: Management of Acute Toxicity and Withdrawal. Curr.
Psychiatry Rep. 18, 52.
(57) Van Hout, M. C., and Hearne, E. (2016) User Experiences of
Development of Dependence on the Synthetic Cannabinoids, 5f-
AKB48 and 5F-PB-22, and Subsequent Withdrawal Syndromes. Int. J.
Ment. Health Addict., DOI: 10.1007/s11469-016-9650-x.
(58) Sasaki, C., Saito, T., Shinozuka, T., Irie, W., Murakami, C.,
Maeda, K., Nakamaru, N., Oishi, M., Nakamura, S., and Kurihara, K.
(2015) A case of death caused by abuse of a synthetic cannabinoid N-
ACS Chemical Neuroscience Research Article
DOI: 10.1021/acschemneuro.6b00137
ACS Chem. Neurosci. 2016, 7, 1241−1254
1253
Chapter 2 117
1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide. Forensic Toxicol.
33, 165−169.
(59) Chung, H., Lee, J., and Kim, E. (2016) Trends of novel
psychoactive substances (NPSs) and their fatal cases. Forensic Toxicol.
34, 1−11.
(60) Kasper, A. M., Ridpath, A. D., Morrison, M., Olayinka, O.,
Parker, C., Galli, R., Cox, R., Preacely, N., Anderson, J., Kyle, P. B.,
Gerona, R., Martin, C., Schier, J., Wolkin, A., Dobbs, T., Arnold, J. K.,
and Chatham-Stephens, K. (2015) Notes from the Field: Severe Illness
Associated with Reported Use of Synthetic Cannabinoids 
Mississippi, April 2015 MMWR Morb. Mortal. Wkly Rep. 64, 1121−
1122.
(61) Law, R., Schier, J., Martin, C., Chang, A., and Wolkin, A. (2015)
Increase in Reported Adverse Health Effects Related to Synthetic
Cannabinoid Use  United States, January−May 2015. MMWR
Morb. Mortal. Wkly. Rep. 64, 618−619.
(62) Trecki, J., Gerona, R. R., and Schwartz, M. D. (2015) Synthetic
Cannabinoid-Related Illnesses and Deaths. N. Engl. J. Med. 373, 103−
107.
(63) Labay, L. M., Caruso, J. L., Gilson, T. P., Phipps, R. J., Knight, L.
D., Lemos, N. P., McIntyre, I. M., Stoppacher, R., Tormos, L. M.,
Wiens, A. L., Williams, E., and Logan, B. K. (2016) Synthetic
cannabinoid drug use as a cause or contributory cause of death.
Forensic Sci. Int. 260, 31−39.
(64) Klavz,̌ J., Gorenjak, M., and Marinsěk, M. (2016) Suicide
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Abstract CUMYL-PICA [1-pentyl-N-(2-phenylpropan-2-
yl)-1H-indole-3-carboxamide] and 5F-CUMYL-PICA [1-
(5-ﬂuoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-car-
boxamide] are recently identiﬁed recreationally used/
abused synthetic cannabinoids, but have uncharacterized
pharmacokinetic proﬁles and metabolic processes. This
study characterized clearance and metabolism of these
compounds by human and rat liver microsomes and hep-
atocytes, and then compared these parameters with in vivo
rat plasma and urine sampling. It also evaluated
hypothermia, a characteristic cannabimimetic effect.
Incubation of CUMYL-PICA and 5F-CUMYL-PICA with
rat and human liver microsomes suggested rapid metabolic
clearance, but in vivo metabolism was prolonged, such that
parent compounds remained detectable in rat plasma 24 h
post-dosing. At 3 mg/kg (intraperitoneally), both com-
pounds produced moderate hypothermic effects. Twenty-
eight metabolites were tentatively identiﬁed for CUMYL-
PICA and, coincidentally, 28 metabolites for 5F-CUMYL-
PICA, primarily consisting of phase I oxidative transfor-
mations and phase II glucuronidation. The primary meta-
bolic pathways for both compounds resulted in the
formation of identical metabolites following terminal
hydroxylation or dealkylation of the N-pentyl chain for
CUMYL-PICA or of the 5-ﬂuoropentyl chain for 5F-
CUMYL-PICA. These data provide evidence that in vivo
elimination of CUMYL-PICA, 5F-CUMYL-PICA and
other synthetic cannabinoids is delayed compared to
in vitro modeling, possibly due to sequestration into adi-
pose tissue. Additionally, the present data underscore the
need for careful selection of metabolites as analytical tar-
gets to distinguish between closely related synthetic
cannabinoids in forensic settings.
Keywords Synthetic cannabinoid  Pharmacokinetics 
Metabolism  CUMYL-PICA  5F-CUMYL-PICA 
Delayed clearance in vivo
Introduction
Synthetic cannabinoid receptor 1 (CB1) agonists comprise
a large and growing class of recreationally used novel
psychoactive substances. These synthetic chemicals pro-
duce psychoactive ‘‘cannabimimetic’’ effects in humans
and rodents [1–5], and their use as recreational drugs has
been linked to a number of adverse health effects [6–9].
The molecular structures of these compounds are regularly
altered in an attempt to evade drug detection and legisla-
tion [10], and consequently users of synthetic cannabinoids
are frequently exposed to novel substances with unknown
pharmacokinetic and pharmacodynamic properties.
Two such novel synthetic cannabinoids are CUMYL-
PICA [1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-car-
boxamide] and its ﬂuorinated analogue 5F-CUMYL-PICA
[1-(5-ﬂuoropentyl)-N-(2-phenylpropan-2-yl)-1H-indole-3-
carboxamide]. These synthetic cannabinoids are a,a-
dimethylbenzyl analogues of SDB-006 and 5F-SDB-006,
which are in turn analogues of SDB-001 (APICA) and
STS-135 (Fig. 1). They are also structurally related to a
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number of other carboxamide synthetic cannabinoids such
as AMB and 5F-AMB. CUMYL-PICA was detected ﬁrst in
European synthetic cannabinoid products in 2014 [11], and
5F-CUMYL-PICA was recently detected in toxicological
analyses of blood samples in Germany [12].
To our knowledge, the pharmacokinetics of CUMYL-
PICA and 5F-CUMYL-PICA have not been characterized.
A thorough understanding of these processes is important
for determining drug toxicology and for identifying these
compounds in biological matrices where they are likely
extensively metabolized [13–15]. A precise understanding
of metabolic pathways is necessary, because closely
structurally related synthetic cannabinoids can produce
identical metabolites, which can increase the difﬁculty of
forensic identiﬁcation of a unique compound [13, 15]. In
addition, some synthetic cannabinoid metabolites retain
cannabinoid receptor efﬁcacy and therefore may be rele-
vant to the overall pharmacological proﬁle following drug
administration [16, 17].
Thus, the present study aimed to characterize the phar-
macokinetics related to metabolism and clearance of
CUMYL-PICA and 5F-CUMYL-PICA. First, these com-
pounds were assessed in vitro using rat and human liver
microsomes and hepatocytes, in order to measure clearance
and to establish metabolic pathways. These assays were
followed by in vivo kinetic assessment in rat blood and
urine sampled at several time points following drug
administration and measurement of body temperature.
These data were used to propose metabolic pathways for
CUMYL-PICA and 5F-CUMYL-PICA in rats and humans,
to examine the predictive utility of in vitro approaches to
synthetic cannabinoid metabolic studies, and to suggest
viable analytical targets for forensic analysis.
Materials and methods
Chemicals and reagents
CUMYL-PICA and 5F-CUMYL-PICA were obtained from
Cayman Chemicals (Ann Arbor, MI, USA). Acetonitrile
and formic acid were purchased from Fisher Scientiﬁc
(Raleigh, NC, USA). Rat and human liver microsomes and
hepatocytes were obtained from XenoTech (Kansas City,
KS, USA). Polysorbate 80 was purchased from Fisher
Scientiﬁc (Pittsburgh, PA, USA) and saline from Patterson
Veterinary Supply (Devens, MA, USA). All chemicals and
solvents were at least ACS or high-performance liquid
chromatography grade, respectively.
In vitro incubations
Rat and human liver microsomes
CUMYL-PICA and 5F-CUMYL-PICA were incubated at
1 lM with male human (pooled) or rat (pooled IGS
Sprague–Dawley) liver microsomes at 37 C, in triplicate,
with gentle shaking. A solution of each compound was
prepared in acetonitrile at a concentration of 0.1 mM. An
assay mixture containing microsomes (1 mg protein/mL
ﬁnal concentration), nicotinamide adenine dinucleotide
phosphate reduced form (NADPH; 1 mM ﬁnal) and a
buffer consisting of 50 mM potassium phosphate buffer,
pH 7.4, with 3 mM MgCl2 was prepared and pre-incubated
at 37 C for 5 min. Ten microliters of the 0.1 mM drug
solutions was added to 990 lL of assay mixture in a glass
test tube in a 37 C water bath to initiate the assay; 100-lL
samples were removed at 0, 5, 10, 30, and 60 min and
added to 100 lL acetonitrile. Samples were centrifuged
and stored at -80 C until analysis.
Fig. 1 Structures of CUMYL-PICA and 5F-CUMYL-PICA com-
pared to benzyl analogues SDB-006 and 5F-SDB-006 and to
adamantyl analogues SDB-001 and STS-135
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Rat and human hepatocytes
Incubation of CUMYL-PICA and 5F-CUMYL-PICA at
10 lM with male human or rat hepatocytes was performed
in triplicate, with 1 mL cell suspension (rat: 0.86 9 106
cells/mL, 80% viability; human: 0.80 9 106 cells/mL,
81.6% viability) in 24-well polystyrene cell culture plates
in a 37 C incubator with 5% CO2 atmosphere. Both
compounds were formulated in acetonitrile at 10 mM and
further diluted to 1 mM in acetonitrile so that the ﬁnal
concentration of acetonitrile in the incubation was 1% after
the addition of 10 lL drug solution to 990 lL of hepato-
cyte suspension. Incubation was conducted simultaneously
using 1 mL incubation cell blank containing live cells and
solvent blank; this incubation was treated exactly as the
cell incubations. At 0, 10, 60, and 180 min, a 100-lL
sample was removed and terminated with 100 lL ace-
tonitrile, vortexed (11,000 g for 1 min) and stored at
-80 C until analysis.
In vivo dosing and sampling in rats
Animals
Twelve 49-day-old male Long–Evans rats (226.8–286.7 g)
with jugular vein catheters were purchased from Charles
River Laboratories (Raleigh, NC, USA). Different groups
of rats (n = 4 per group) were used to test each compound
and vehicle control. Prior to testing, all animals were kept
in a temperature-controlled environment (20–22 C) on a
12-h light–dark cycle (lights on at 6 a.m.), with access to
food and water ad libitum. All in vivo work was carried out
in accordance with guidelines published in the Guide for
the Care and Use of Laboratory Animals (National
Research Council 2011), and were approved by the RTI
International Institutional Animal Care and Use
Committee.
Procedures
The animals were placed individually into glass metabolic
cages (Prism Research Glass, Raleigh, NC, USA). Ani-
mals were administered intraperitoneal injections, in case
of 3 mg/mL CUMYL-PICA or 3 mg/mL 5F-CUMYL-
PICA dissolved in vehicle solution comprising 7.8%
polysorbate 80 NF (Fisher Scientiﬁc, Pittsburgh, PA,
USA) and 92.2% saline USP (Patterson Veterinary Sup-
ply, Devens, MA, USA), with an injection volume of
1 mL/kg of rat body weight. Blood samples (200 lL)
were drawn 15 min pre-injection and 15 min, 30 min,
1 h, 2 h, 4 h, 8 h, and 24 h post-injection, put into chilled
K3EDTA collection tubes, and centrifuged at 2800 g for
10 min at 4 C. The plasma supernatant was decanted and
stored at -80 C until further analysis. Rectal tempera-
ture was also recorded at these time points using a digital
thermometer (Physitemp Instruments Inc., Clifton, NJ,
USA). Urine was collected at 8 and 24 h post-injection.
At 24 h post-injection, rats were euthanized via CO2
asphyxiation, and blood was rapidly collected and stored
as speciﬁed above.
Analyte extraction
Extractions of all analytes (parent compounds and
metabolites) from all matrices (microsomes, hepatocytes,
plasma, and urine) was performed as follows. Acetonitrile
was added in a 3:1 ratio to the sample volume (micro-
somes/hepatocytes sample volume 50 lL; plasma 25 lL;
urine 100 lL) and centrifuged at 4000 g for 15 min at
4 C. Supernatants were transferred to vials for immediate
analysis via liquid chromatography–tandem mass spec-
troscopy (LC–MS/MS).
LC–MS/MS analyses
Parent compounds CUMYL-PICA and 5F-CUMYL-PICA
in the media following incubation with rat and human liver
microsomes and in rat plasma were quantiﬁed using LC–
MS/MS. The LC–MS/MS system consisted of a Waters
Acquity UPLC system, equipped with a Waters BEH C18
column (100 mm 9 2.1 mm i.d., particle size 1.7 lm;
Waters Corp., Milford, MA, USA), coupled to an API 5000
tandem mass spectrometer (AB Sciex, Framingham, MA,
USA). Gradient elution was used with mobile phase solu-
tions 0.1% formic acid in water (A) and acetonitrile (B),
which started at 10% B for 0.5 min and was then ramped to
95% B over 10 min, held until 12.5 min and then returned
to 10% B for 2.5 min, with a total run time of 15 min. The
mass spectrometer was operated in positive electrospray
ionization mode with multiple reaction monitoring. The
monitored transitions were m/z 349.1 ? 231.1 for
CUMYL-PICA and m/z 367.1 ? 249.1 for 5F-CUMYL-
PICA.
Metabolites were also identiﬁed using LC–MS/MS, with
a Thermo Fisher LTQ Orbitrap Velos mass spectrometer
(Thermo Fisher Scientiﬁc, Waltham, MA, USA) coupled to
a Waters Acquity UPLC system (Waters Corp.). Chro-
matographic conditions were identical to those speciﬁed
above. The mass spectrometer was operated in positive
electrospray ionization mode, with scan range of m/z
100–910 and capillary temperature of 250 C. Because
during method development, poor fragmentation was
observed across a range of collision energies, higher-en-
ergy collisional dissociation was implemented, with a
collision energy at 35 eV.
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Data analysis
Hypothermic effects were statistically analyzed using a
two-factor mixed ANOVA with drug treatment (vehicle,
3 mg/kg CUMYL-PICA, or 3 mg/kg 5F-CUMYL-PICA)
as the between-subject factor and time (pre-dose, 15 min,
30 min, 1 h, 2 h, 4 h, 8 h, and 24 h) as the within-subject
factor. Simple effects of drug treatment were then analyzed
using Dunnett’s tests (a = 0.05), which compared the
CUMYL-PICA or 5F-CUMYL-PICA cohort to the vehicle
cohort at each time point.
Microsomal intrinsic clearance (CLint,micr) and half-life
were calculated from plots of chromatographic peak areas
against time. Intrinsic clearance (CLint) was calculated by
scaling CLint,micr to whole-liver dimensions for rats and
humans [18, 19]. Hepatic clearance (CLH) and extraction
ratios (ER) were estimated based on the corresponding rat
and human CLint values and estimates of liver blood ﬂow
rate (rat 13.8 mL/min; human 1400 mL/min) [20]. Plasma
concentrations of CUMYL-PICA and 5F-CUMYL-PICA
were calculated via a standard curve of the corresponding
calibrator samples using a reference standard. Plasma kinetic
parameters were then computed from plasma concentrations
of each compound via non-compartmental analysis per-
formed with WinNonlin (Certara, Princeton, NJ, USA).
Metabolites were identiﬁed in hepatocyte incubations,
rat plasma, and rat urine using Compound Discoverer 2.0
software (Thermo Fisher Scientiﬁc) and manual inspection
and interpretation of mass spectra.
Results
Body temperature
Compared to vehicle injection, 3 mg/kg CUMYL-PICA
and 5F-CUMYL-PICA produced hypothermic effects in
rats (Fig. 2). The mean rectal body temperature was sig-
niﬁcantly reduced following treatment with CUMYL-PICA
at 15 and 30 min and 1, 2, and 4 h post-injection. Simi-
larly, signiﬁcant hypothermic effects were observed fol-
lowing 5F-CUMYL-PICA treatment at 15 and 30 min and
1, 2, and 4 h post-injection.
Liver microsome clearance
Clearance of CUMYL-PICA and 5F-CUMYL-PICA was
rapid in rat and human liver microsome incubations
(Fig. 3a–d; Table 1). However, both compounds were still
detectible after 3 h incubations. Kinetic parameters were
similar across all incubations except for CUMYL-PICA in
human liver microsomes, which had a substantially longer
half-life and correspondingly reduced extraction ratio.
Plasma kinetics
Following intraperitoneal administration of 3 mg/kg
CUMYL-PICA or 5F-CUMYL-PICA, plasma concentra-
tions of the parent compounds rose quickly, followed by
gradual and incomplete elimination over the following 24 h
(Fig. 3e, f). Table 1 contains parameters generated from
non-compartmental analysis of the pharmacokinetic data.
Overall, the pharmacokinetics of both compounds in rat
plasma were similar, although the maximum concentration
of CUMYL-PICA was greater and occurred earlier than that
of 5F-CUMYL-PICA. CUMYL-PICA had a shorter half-life
than 5F-CUMYL-PICA, and the apparent clearance (CL/F)
values for both compounds were lower than clearance values
predicted by microsome preparations.
CUMYL-PICA metabolism
Phase I metabolites
Phase I metabolism of CUMYL-PICA was extensive, with
oxidation occurring at numerous sites (Figs. 4a, 5;
Table 2). Parent CUMYL-PICA eluted at 8.94 min, and
was conﬁrmed by matching fragmentation and retention
times with an analytical standard (Fig. 4a). The [M?H]?
molecular ion of CUMYL-PICA was m/z 349.2258, and
produced product ions at m/z 231.1472, 214.1220, and
188.1449, corresponding to fragmentation along the car-
boxamide linking group, and 119.0848 and 91.0542, cor-
responding to fragmentation of the a,a-dimethylbenzyl
moiety and subsequent formation of a tropylium ion.
Six monohydroxylated metabolites (C21, C22, C24–C27)
with m/z 365.2210 were identiﬁed in rat hepatocytes.
Metabolites C26 and C27 were likely hydroxylated on the
benzene ring of the a,a-dimethylbenzyl moiety, as they
produced product ions at m/z 135.0791 and 107.0493,
15.99 Da higher than product ions at m/z 119.0848 and
91.0542 of the parent molecule, respectively. However, C26
and C27 were not observed in human hepatocyte incuba-
tions. Metabolites C21 and C22 produced an ion at m/z
161.0707, suggesting that hydroxylation did not occur on the
indole moiety, and also produced a product ion at m/z
119.0848, excluding the a,a-dimethylbenzyl moiety, leaving
the N-pentyl chain as the likely hydroxylation location. C24
and C25 lacked the ion at m/z 161; thus hydroxylation may
have occurred on the indole moiety for these metabolites,
although the expected product ions at m/z 160 and 177
(144 ? 16 and 161 ? 16) were not observed.
Although fragmentation was insufﬁcient to localize each
hydroxylation to the exact molecular site, corresponding
data from 5F-CUMYL-PICA incubations were informa-
tive. A metabolite (F22) with retention time and frag-
mentation identical to that of C21 was also formed
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following hepatocyte incubation or rat dosing with 5F-
CUMYL-PICA. Because this metabolite could only occur
following oxidative deﬂuorination of 5F-CUMYL-PICA,
we conclude that metabolite C21 is hydroxylated at the
terminal position of the N-pentyl chain. C21 was further
oxidized to form a carboxylic acid metabolite C20
([M?H]? m/z 379.2005). Product ions at m/z 200.1076 and
119.0848 exclude this transformation from the indole and
a,a-dimethylbenzyl moieties, strongly suggesting forma-
tion of the carboxylic acid on the N-pentyl chain. Similar
hydroxylation and carboxylation has been reported for
AMB, 5F-AMB, JWH-018, AM-2201, RCS-4, UR-144,
JWH-073, JWH-210, and others [15, 16, 21–24].
The monohydroxylated metabolites underwent further
hydroxylation to form two dihydroxylated metabolites
(C11 and C13) with m/z 381.2261 (Fig. 5; Table 2). Sim-
ilar to metabolites C26 and C27, metabolite C11 was
hydroxylated once on the a,a-dimethylbenzyl moiety based
on product ion at m/z 135.0791, while the ion at m/z
144.0444 suggests that the other hydroxylation occurred on
the N-pentyl chain. C13 produced product ions at m/z
263.1379 and 246.1144, 32 Da higher than CUMYL-PICA
product ions at m/z 231.1472 and 214.1220, respectively,
and also produced a product ion at m/z 119.0848, but not at
m/z 135.0791, indicating that both hydroxylations occurred
on the indole and/or N-pentyl moieties. In 5F-CUMYL-
PICA preparations, we observed a metabolite (F15) with
retention time and mass identical to those of C13; however
product ions differed substantially, suggesting formation of
a similar but non-identical dihydroxylated metabolite.
CUMYL-PICA was also carbonylated, forming
metabolite C23 with [M?H]? m/z 363.2056. The product
ions at m/z 245.1312 and 228.1023 were 13.98 Da larger
than the corresponding CUMYL-PICA product ions at m/z
231.1472 and 214.1220 (i.e., ?O–2H). Ions at m/z
119.0848 and 144.0444 indicate that this carbonylation did
not occur on the a,a-dimethylbenzyl or indole moieties,
respectively, while the product ion at m/z 85.0646 localized
this transformation to the N-pentyl chain. Metabolite C28
had a molecular ion at m/z 347.2103, 2.0155 Da less than
CUMYL-PICA, suggesting a dehydrogenation. Product
ions at m/z 229.1315, 212.1048, 186.1290, and 119.0848
indicate that dehydrogenation occurred on the indole or N-
pentyl moieties; however, this likely occurred on the N-
pentyl chain, given the lack of suitable sites for dehydro-
genation on the indole moiety, and in light of similar
reports of dehydrogenation on the N-pentyl chain for other
synthetic cannabinoids [15].
Additionally, CUMYL-PICA appears to undergo
dealkylation of the N-pentyl chain, producing metabolite
C18 with m/z 279.1978. The product ions at m/z 161.0707,
144.0444, 119.0848, 118.0642, and 91.0542 are consistent
with this interpretation. Similar dealkylation occurred in
some synthetic cannabinoids containing an N-pentyl or N-
ﬂuoropentyl chain [23, 25]. Four monohydroxylations of
this metabolite were identiﬁed (m/z 295.1429). Two of
these (C9 and C10) occurred on the indole moiety, evi-
denced by product ions at m/z 177.0669 and 160.0407,
16 Da higher than 161.0707 and 144.0444, respectively.
The other two hydroxylations (C7 and C8) lacked these
ions, and instead produced a product ion at m/z 135.0791
while retaining ions at m/z 161.0707 and 144.0444,
strongly indicating that hydroxylation occurred on the a,a-
dimethylbenzyl moiety.
Fig. 2 Mean rectal body
temperature of male rats
following administration of
vehicle solution or 3 mg/kg
CUMYL-PICA or 5F-CUMYL-
PICA (n = 4 per group).
Dashed line denotes time of
intraperitoneal (i.p.) injection.
The error bars represent
standard error of the mean
(SEM). *P\ 0.05, **P\ 0.01,
***P\ 0.001,
****P\ 0.0001, comparing
CUMYL-PICA to vehicle at
each time point. P\ 0.05,
P\ 0.01, P\ 0.001,
P\ 0.0001, comparing
5F-CUMYL-PICA to vehicle at
each time point. PD pre-dose,
15 min before injection; VEH
vehicle
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Phase II metabolites
No direct phase II transformations of CUMYL-PICA were
observed, but several phase I metabolites underwent
glucuronidation. Five discrete peaks at m/z 541.2510 were
identiﬁed in rat and human hepatocytes (C12, C14, C15,
C17, and C19), 176 Da greater than monohydroxylated
metabolites (m/z 365.2210), indicating glucuronidation. A
Fig. 3 Mean chromatographic peak areas of CUMYL-PICA and 5F-
CUMYL-PICA following incubation with rat and human liver
microsomes (panels a–d, n = 3), and mean plasma concentrations
of CUMYL-PICA and 5F-CUMYL-PICA following a 3-mg/kg i.p.
injection in male rats (panels e and f, n = 4). Error bars are SEM
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metabolite identical to C15 in mass, retention time, and
product ions was observed in 5F-CUMYL-PICA incuba-
tions (F19), indicating that this metabolite is the glu-
curonide of C21. C19 was found following incubation
with human hepatocytes, which likely excludes it as a
glucuronide of the a,a-dimethylbenzyl hydroxylated
metabolites (C26 and C27), because these metabolites
were not found in human hepatocyte incubations
(Table 2).
Dihydroxylated metabolites were glucuronidated to four
identiﬁable glucuronides (C3–C5, C16). Mass spectral data
were not sufﬁcient to assign each glucuronide to a speciﬁc
dihydroxylated metabolite. Interestingly, C16 was far more
abundant and eluted much later than C3–C5 (Fig. 4a),
indicating a substantially less polar structure. Carboxylic
acid metabolite C20 formed glucuronide C6 (m/z
555.2334). Either C7 or C8 formed glucuronidated
metabolite C1, which had a mass of m/z 471.1746 and
product ions at m/z 161.0707, 144.0444, and 135.0791.
Similarly, C9 or C10 was glucuronidated to C2 ([M?H]?
m/z 471.1746, product ions at m/z 177.0669, 160.0407, and
119.0848). No sulfation or other phase II transformations
were observed.
5F-CUMYL-PICA metabolism
Phase I metabolites
Similar to CUMYL-PICA, 5F-CUMYL-PICA was exten-
sively oxidized and glucuronidated (Fig. 6; Table 3). The
[M?H]? molecular ion was m/z 367.2161 for the unaltered
compound, and major product ions were m/z 249.1417,
232.1116, and 206.1317, all 17.99 Da higher than corre-
sponding CUMYL-PICA ions (i.e., ?F-H), in addition to
identical ions at m/z 119.0848 and 91.0542. Compound
identity was also conﬁrmed by matching retention time and
fragmentation to the reference standard (retention time
8.11 min; Fig. 4b).
Six monohydroxylations of 5F-CUMYL-PICA were
identiﬁed (F23–F28, m/z 383.2103, 15.99 Da larger than
parent). Metabolites F23–F25 and F27 produced a product
ion at m/z 119.0848, suggesting hydroxylation on the
indole or N-ﬂuoropentyl moiety, while metabolites F26 and
F28 produced an ion at m/z 135.0791, indicating hydrox-
ylation on the a,a-dimethylbenzyl moiety. Unfortunately,
metabolites F23–F25 and F27 did not produce product ions
that might be used to distinguish between indole or N-
ﬂuoropentyl chain oxidations (e.g., 144 vs 160, or 161 vs
177). However, we suggest that 5F-CUMYL-PICA
hydroxylation likely proceeds in a manner similar to
CUMYL-PICA, and that these metabolites are likely
5-ﬂuoropentyl analogues of CUMYL-PICA metabolites
C22, C24, and C25.
Dihydroxylated metabolites F14 and F17 were also
detected. F14 produced a product ion at m/z 135.0791
suggesting that one hydroxylation occurred on the a,a-
dimethylbenzyl moiety, while ions at m/z 265.1363 and
248.1018 indicate that the other hydroxylation occurred on
the indole or N-ﬂuoropentyl portion of the molecule. F17
produced ion at m/z 119.0848 instead of m/z 135.0791,
suggesting both hydroxylations occurred on the indole or
N-ﬂuoropentyl portion of the molecule. This interpretation
is supported by the presence of ions at m/z 281.1266 and
264.1018 (15.99 Da higher than ions at m/z 265.1363 and
248.1107, respectively).
Oxidative deﬂuorination was a predominant metabolic
pathway, forming metabolite F22 at m/z 365.2210 and
product ions at m/z 247.1448, 230.1149, 204.1378, and
119.0848, identical to CUMYL-PICA metabolite C21.
Similar dehalogenation has been reported as a major
metabolic pathway for AM-2201, 5F-AMB, XLR-11, and
AM-694 [15, 22, 26]. Additional hydroxylation of F22
produced dihydroxylated metabolite F15 ([M?H]? m/z
381.2169), which produced ions at m/z 263.1379,
246.1144, 202.1207, and 119.0848, indicating that the
second hydroxylation occurred on the pentyl chain or
indole moiety. Oxidation of F22 formed carboxylic acid
Table 1 Pharmacokinetic parameters of CUMYL-PICA and 5F-
CUMYL-PICA incubated in rat and human liver microsomes in vitro
and in rat plasma in vivo
Pharmacokinetic parameter CUMYL-PICA 5F-CUMYL-PICA
Rat liver microsomes
Half-life (min) 2.24 1.19
CLint,micr (mL/min/mg) 0.31 0.58
CLint (mL/min/kg body wt.) 556.88 1048.24
CLH (mL/min/kg body wt.) 50.22 52.44
ER 0.91 0.95
Human liver microsomes
Half-life (min) 5.92 1.77
CLint,micr (mL/min/mg) 0.12 0.39
CLint (mL/min/kg body wt.) 135.46 453.05
CLH (mL/min/kg body wt.) 17.43 19.15
ER 0.87 0.96
Rat plasma
Half-life (h) 7.26 12.00
CL/F (mL/min/kg body wt.) 43.31 147.88
Cmax (ng/mL) 130.50 65.25
Tmax (h) 0.50 0.50
AUC 0–24 h (h ng/mL) 1086.57 581.78
AUC 0–? (h ng/mL) 1214.85 843.28
AUC area under the curve, CL/F observed apparent clearance, CLH
estimated hepatic clearance, CLint estimated intrinsic clearance,
CLint, micr intrinsic microsome clearance, Cmax mean maximum
observed concentration, ER extraction ratio, Tmax mean time of Cmax
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metabolite F21, identical to CUMYL-PICA metabolite
C20. F21 was then hydroxylated, forming metabolites
F11 and F13 ([M?H]? m/z 395.1937). F11 produced
product ion at m/z 135.0791, indicating hydroxylation on
the a,a-dimethylbenzyl moiety, and ion at m/z 200.1076
further localized this modiﬁcation to the benzene ring.
F13 produced ions at m/z 277.1163, 260.0936, 216.1009,
and 119.0848, suggesting hydroxylation of the indole
Fig. 4 Combined extracted ion chromatograms of a CUMYL-PICA and b 5F-CUMYL-PICA metabolites after 3-h incubation with rat
hepatocytes, obtained by liquid chromatography–single-stage mass spectrometry
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moiety. Interestingly, these hydroxylation reactions were
not detected in CUMYL-PICA incubations. Oxidative
deﬂuorination may occur more readily than terminal
hydroxylation of the N-pentyl chain, thereby increasing
concentrations of subsequent metabolites. This is sup-
ported by our chromatographic data that show a larger
extracted ion peak (m/z 365.2) for F22 compared to C21
(Fig. 4).
Fig. 5 Proposed CUMYL-PICA metabolic pathways in rats and humans. Dashed arrows between compounds denote formation of metabolites
that were not observed in human hepatocyte incubations. Unlocalized transformations are shown as Markush structures
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Table 2 CUMYL-PICA metabolites following incubation with rat and human hepatocytes, and their presence in rat plasma and urine following
a 3-mg/kg intraperitoneal (i.p.) injection
Metabolite RT
(min)
Transformation Molecular ion
[M?H]? (m/z)
Major product
ion(s) (m/z)
Rat
hepatocyte
Human
hepatocyte
Rat
plasma
Rat
urine
C1 4.15 N-Pentyl dealkylation ? hydroxylation
(a,a-dimethylbenzyl) ? glucuronidation
471.17 177, 161, 135 4 4
C2 4.51 N-Pentyl dealkylation ? hydroxylation
(indole) ? glucuronidation
471.17 177, 119 4 4 4
C3 4.68 Dihydroxylation ? glucuronidation 557.24 381, 263 4 4
C4 4.83 Dihydroxylation ? glucuronidation 557.24 381, 263 4 4
C5 4.95 Dihydroxylation ? glucuronidation 557.24 381, 263 4 4
C6 5.01 Carboxylation ? glucuronidation 555.23 379 4 4 4
C7 5.11 N-Pentyl dealkylation ? hydroxylation
(a,a-dimethylbenzyl)
295.14 161, 144, 135 4 4 4
C8 5.17 N-Pentyl dealkylation ? hydroxylation
(a,a-dimethylbenzyl)
295.14 161, 144, 135 4 4
C9 5.30 N-Pentyl dealkylation ? hydroxylation
(indole)
295.14 177, 160 4 4
C10 5.34 N-Pentyl dealkylation ? hydroxylation
(indole)
295.14 177, 160 4 4 4
C11 5.65 Dihydroxylation (a,a-dimethylbenzyl, N-
pentyl)
381.22 247, 230, 144,
135
4 4
C12 5.78 Hydroxylation ? glucuronidation 541.25 365, 230 4 4
C13 5.87 Dihydroxylation (N-pentyl, indole) 381.22 263, 246, 220,
119
4 4 4
C14 5.92 Hydroxylation ? glucuronidation 541.25 365, 230 4
C15 6.02 Hydroxylation (N-pentyl,
terminal) ? glucuronidation
541.25 423, 247, 230,
204, 119
4 4 4
C16 6.12 Dihydroxylation ? glucuronidation 557.24 381, 263 4 4
C17 6.30 Hydroxylation ? glucuronidation 541.25 365, 230 4
C18 6.41 N-Pentyl dealkylation 279.19 161, 144, 119,
118, 91
4 4
C19 6.50 Hydroxylation ? glucuronidation 541.25 365, 230 4 4 4
C20 6.68 Carboxylation 379.20 261, 244, 218,
200, 119, 91
4 4 4
C21 6.76 Hydroxylation
(N-pentyl, terminal)
365.22 247, 230, 204,
119
4 4 4 4
C22 7.11 Hydroxylation (N-pentyl) 365.22 247, 230, 161,
119
4 4 4
C23 7.13 Carbonylation (N-pentyl) 363.21 245, 228, 144,
119, 85
4 4 4
C24 7.37 Hydroxylation (indole) 365.22 247, 230, 204,
119
4 4 4 4
C25 7.46 Hydroxylation (indole) 365.22 247, 230, 204,
119
4 4 4
C26 7.80 Hydroxylation (benzene ring) 365.22 231, 214, 135 4
C27 7.86 Hydroxylation (benzene ring) 365.22 231, 214, 135 4 4
C28 8.52 Dehydrogenation (N-pentyl) 347.21 229, 212, 186,
119, 91
4 4 4
CUMYL-
PICA
8.94 Parent compound 349.22 231, 214, 188,
119, 91
4 4 4
Ticks denote detection of compounds in a given matrix
RT retention time
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Similar to CUMYL-PICA, the N-ﬂuoropentyl chain of
5F-CUMYL-PICA was eliminated, leaving metabolite F20,
identical in retention time and fragmentation to CUMYL-
PICA metabolite C18. As was the case for C18, F20 was
further oxidized on the a,a-dimethylbenzyl moiety (F7 and
F8, product ions at m/z 161.0707, 144.0444, 135.0791) or
indole moiety (F9 and F10, product ions at m/z 177.0669,
160.0376, 119.0848).
Fig. 6 Proposed 5F-CUMYL-PICA metabolic pathways in rats and humans. Dashed arrows between compounds denote formation of
metabolites that were not observed in human hepatocyte incubations. Unlocalized transformations are shown as Markush structures
Forensic Toxicol
123
Chapter 3 130
T
a
b
le
3
5
F
-C
U
M
Y
L
-P
IC
A
m
et
ab
o
li
te
s
fo
ll
o
w
in
g
in
cu
b
at
io
n
w
it
h
ra
t
an
d
h
u
m
an
h
ep
at
o
cy
te
s,
an
d
in
ra
t
p
la
sm
a
an
d
u
ri
n
e
fo
ll
o
w
in
g
a
3
m
g
/k
g
i.
p
.
in
je
ct
io
n
M
et
ab
o
li
te
R
T
(m
in
)
T
ra
n
sf
o
rm
at
io
n
M
o
le
cu
la
r
io
n
[M
?
H
]?
(m
/z
)
M
aj
o
r
p
ro
d
u
ct
io
n
s
(m
/z
)
R
at
h
ep
at
o
cy
te
H
u
m
an
h
ep
at
o
cy
te
R
at
p
la
sm
a
R
at
u
ri
n
e
F
1
4
.1
5
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(a
,a
-
d
im
et
h
y
lb
en
zy
l)
?
g
lu
cu
ro
n
id
at
io
n
4
7
1
.1
7
1
7
7
,
1
6
1
,
1
3
5
4
4
F
2
4
.4
4
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
h
y
d
ro
x
y
la
ti
o
n
?
g
lu
cu
ro
n
id
at
io
n
5
5
7
.2
4
3
8
1
,
2
6
3
4
F
3
4
.5
1
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
)
?
g
lu
cu
ro
n
id
at
io
n
4
7
1
.1
7
1
7
7
,
1
1
9
4
4
4
4
F
4
4
.6
5
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
h
y
d
ro
x
y
la
ti
o
n
?
g
lu
cu
ro
n
id
at
io
n
5
5
7
.2
4
3
8
1
,
2
6
3
4
4
4
F
5
4
.8
0
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
h
y
d
ro
x
y
la
ti
o
n
?
g
lu
cu
ro
n
id
at
io
n
5
5
7
.2
4
3
8
1
,
2
6
3
4
4
F
6
4
.8
7
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
)
?
g
lu
cu
ro
n
id
at
io
n
4
7
1
.1
7
1
7
7
,
1
1
9
4
4
4
F
7
5
.1
1
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(a
,a
-d
im
et
h
y
lb
en
zy
l)
2
9
5
.1
4
1
6
1
,
1
4
4
,
1
3
5
,
1
1
8
4
4
4
F
8
5
.1
7
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(a
,a
-d
im
et
h
y
lb
en
zy
l)
2
9
5
.1
4
1
6
1
,
1
4
4
,
1
3
5
,
1
1
8
4
4
4
F
9
5
.3
0
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
)
2
9
5
.1
4
1
7
7
,
1
6
0
,
1
3
4
,
1
1
9
4
4
4
F
1
0
5
.3
4
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
)
2
9
5
.1
4
1
7
7
,
1
6
0
,
1
3
4
,
1
1
9
4
4
4
F
1
1
5
.5
8
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
ca
rb
o
x
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(a
,a
-
d
im
et
h
y
lb
en
zy
l)
3
9
5
.1
9
2
6
1
,
2
4
4
,
2
1
8
,
2
0
0
,
1
4
4
,
1
3
5
4
4
F
1
2
5
.6
1
H
y
d
ro
x
y
la
ti
o
n
?
g
lu
cu
ro
n
id
at
io
n
5
5
9
.2
4
3
8
2
,
2
4
8
4
F
1
3
5
.6
4
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
ca
rb
o
x
y
la
ti
o
n
?
h
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
)
3
9
5
.1
9
2
7
7
,
2
6
0
,
2
3
4
,
2
1
6
,
1
1
9
4
4
4
F
1
4
5
.6
6
D
ih
y
d
ro
x
y
la
ti
o
n
(a
,a
-d
im
et
h
y
lb
en
zy
l,
in
d
o
le
/ﬂ
u
o
ro
p
en
ty
l)
3
9
9
.2
1
2
6
5
,
2
4
8
,
1
3
5
4
4
F
1
5
5
.6
8
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
o
x
id
at
io
n
3
8
1
.2
2
2
6
3
,
2
4
6
,
2
0
2
,
1
1
9
4
4
F
1
6
5
.7
0
H
y
d
ro
x
y
la
ti
o
n
?
g
lu
cu
ro
n
id
at
io
n
5
5
9
.2
4
3
8
2
,
2
4
8
4
4
4
F
1
7
5
.7
2
D
ih
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
/ﬂ
u
o
ro
p
en
ty
l)
3
9
9
.2
1
2
8
1
,
2
6
4
,
2
3
8
,
1
1
9
4
4
4
F
1
8
5
.7
8
H
y
d
ro
x
y
la
ti
o
n
?
g
lu
cu
ro
n
id
at
io
n
5
5
9
.2
4
3
8
2
,
2
4
8
4
4
4
4
F
1
9
6
.0
1
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
g
lu
cu
ro
n
id
at
io
n
5
4
1
.2
5
2
4
7
,
2
3
0
,
2
0
4
,
1
8
6
,
1
1
9
4
F
2
0
6
.4
2
F
lu
o
ro
p
en
ty
l
d
ea
lk
y
la
ti
o
n
2
7
9
.1
5
1
6
1
,
1
4
4
,
1
1
9
4
4
4
F
2
1
6
.6
8
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
?
ca
rb
o
x
y
la
ti
o
n
3
7
9
.2
1
2
6
1
,
2
4
4
,
2
1
8
,
2
0
0
,
1
1
9
4
4
4
F
2
2
6
.7
4
O
x
id
at
iv
e
d
eﬂ
u
o
ri
n
at
io
n
3
6
5
.2
2
2
4
7
,
2
3
0
,
2
0
4
,
1
1
9
4
4
4
F
2
3
6
.7
9
H
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
,
ﬂ
u
o
ro
p
en
ty
l)
3
8
3
.2
1
2
6
5
,
2
4
8
,
2
2
2
,
1
1
9
4
4
4
F
2
4
6
.8
5
H
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
,
ﬂ
u
o
ro
p
en
ty
l)
3
8
3
.2
1
2
6
5
,
2
4
8
,
2
2
2
,
1
1
9
4
4
4
F
2
5
6
.9
2
H
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
,
ﬂ
u
o
ro
p
en
ty
l)
3
8
3
.2
1
2
6
5
,
2
4
8
,
2
2
2
,
1
1
9
4
4
F
2
6
7
.0
3
H
y
d
ro
x
y
la
ti
o
n
(b
en
ze
n
e)
3
8
3
.2
1
2
4
9
,
2
3
2
,
2
0
6
,
1
3
5
,
1
0
7
4
4
4
F
2
7
7
.3
1
H
y
d
ro
x
y
la
ti
o
n
(i
n
d
o
le
,
ﬂ
u
o
ro
p
en
ty
l)
3
8
3
.2
1
2
6
5
,
2
4
8
,
2
2
2
,
1
1
9
4
4
F
2
8
7
.5
5
H
y
d
ro
x
y
la
ti
o
n
(b
en
ze
n
e)
3
8
3
.2
1
2
4
9
,
2
3
2
,
2
0
6
,
1
3
5
,
1
0
7
4
5
F
-C
U
M
Y
L
-
P
IC
A
8
.1
1
P
ar
en
t
co
m
p
o
u
n
d
3
6
7
.2
1
2
4
9
,
2
3
2
,
2
0
6
,
1
1
9
,
9
1
4
4
4
T
ic
k
s
d
en
o
te
d
et
ec
ti
o
n
o
f
co
m
p
o
u
n
d
s
in
a
g
iv
en
m
at
ri
x
Forensic Toxicol
123
Chapter 3 131
Phase II metabolites
As was the case for CUMYL-PICA, 5F-CUMYL-PICA did
not undergo direct phase II metabolism. Monohydroxylated
metabolites formed three glucuronides of mass 559.2445
(F12, F16, and F18). Like monohydroxylated CUMYL-
PICA glucuronides, mass spectra were not sufﬁcient to
localize each glucuronidation to a speciﬁc monohydroxy-
lated metabolite.
Oxidatively deﬂuorinated metabolite F22 was glu-
curonidated to F19, which was identical in retention time
and fragmentation to CUMYL-PICA metabolite C12. F15,
the hydroxylated metabolite of F22, was also glu-
curonidated. Interestingly, three distinct glucuronidations
were identiﬁed (F2, F4, and F5). It is likely that glu-
curonidation occurred on either hydroxyl group of F15,
which accounts for two glucuronides, but the presence of a
third glucuronidated compound suggests that an additional
dihydroxylated metabolite may have been formed but not
detected.
F9 and F10 were glucuronidated to F3 and F6 ([M?H]?
m/z 471.1746, product ions at m/z 177.0669, 160.0407, and
119.0848), while either F7 or F8 was glucuronidated to F1
([M?H]? 471.1746, product ions at m/z 161.0707,
144.0444, and 135.0791). No sulfation or other phase II
transformations were observed.
Discussion
This study examined the metabolism and clearance of syn-
thetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA
in rat and human liver microsomes and hepatocytes
(in vitro), and in whole animals following administration of
each compound in adult male rats. Both compounds pro-
duced moderate hypothermic effects at an intraperitoneal
dose of 3 mg/kg. While rapid clearance for both compounds
was predicted by in vitro data, actual elimination in vivo
occurred slowly (Fig. 3). Both compounds were extensively
metabolized via oxidative transformations and subsequent
glucuronidation, and produced several identical metabolites.
CUMYL-PICA and 5F-CUMYL-PICA produced
hypothermic effects of similar magnitude across a 4–8-h
period (Fig. 2). For the most part, the magnitude of
hypothermia was mirrored by blood drug concentration,
although therewas somedelaybetweenpeakhypothermia and
peak blood concentration. Rats dosed with CUMYL-PICA
also returned to baseline body temperature more rapidly than
might be expected frombloodconcentration.This could be the
result of homeostatic mechanisms including rapid receptor
internalization or down-regulation. Analogous hypothermic
effects in rodents have been observed following administra-
tion of a wide variety of number of CB1 agonists, including
other synthetic cannabinoids [1, 2, 27–29] and phyto-
cannabinoids [30]. These effects are blocked by the CB1
antagonist rimonabant (SR141716), indicating a CB1-depen-
dent mechanism [2, 31]. Although we did not block
hypothermia with rimonabant in this study, it is likely that
CUMYL-PICA and 5F-CUMYL-PICA produce hypothermia
via CB1 given their structural similarity to several synthetic
cannabinoids assessed in previous reports.
Although rapid clearance of CUMYL-PICA and 5F-
CUMYL-PICA was observed in microsomal incubations, rat
plasma half-lives were 7 and 12 h, respectively, and both
untransformed compounds were detectible in plasma at 24 h
post-dosing (Fig. 3; Table 1). In addition, apparent in vivo
clearance was substantially slower than clearance values
predicted by microsomal incubations. Several factors may
account for this discrepancy; lipophilicity seems to be the
most likely contributor. These compounds, including D9-
tetrahydrocannabinol (D9-THC), are largely non-polar and
dissolve poorly in aqueous solutions. In rats and humans,
D9-THC is sequestrated into adipose tissue and appears to
passively and slowly diffuse back into blood during satiety
[32, 33], or more rapidly during periods of food deprivation
[34]. In a case of fatal poisoning involving synthetic
cannabinoids AB-CHMINACA and 5F-AMB, unaltered
parent compounds were found at higher levels in adipose
tissue than in blood [35]. Thus it is plausible that similar
sequestration of CUMYL-PICA and 5F-CUMYL-PICA in
adipose tissue, followed by slow passive diffusion back into
blood, could be at least partly responsible for the long half-
lives of these compounds in vivo. Analysis of adipose tissue
following synthetic cannabinoid administration may prove
fruitful in future studies. It should also be noted that our
in vitro calculations ignored protein binding, because it is
presently uncharacterized for CUMYL-PICA and 5F-
CUMYL-PICA. Regardless of the mechanisms, the rapid
clearance of synthetic cannabinoids in microsomal incuba-
tions observed in this and similar studies should be inter-
preted with caution in light of rodent data and human case
studies that point to long elimination periods in vivo.
A total of 28 metabolites of CUMYL-PICA and 28
metabolites of 5F-CUMYL-PICA were identiﬁed in hepa-
tocyte preparations. However, some metabolites produced
small peaks (Fig. 4), and subsets of 18 and 22 metabolites
were detectable in rat plasma or urine for CUMYL-PICA
and 5F-CUMYL-PICA, respectively (Tables 2, 3).
CUMYL-PICA and 5F-CUMYL-PICA were generally
metabolized similarly by rat and human hepatocytes,
although a notable exception was that hydroxylation of the
a,a-dimethylbenzyl moiety was rarely observed using
human hepatocytes. Unsurprisingly, a greater number of
phase I metabolites were detected in plasma than in urine,
and most metabolites detected in urine were glucuronides.
For urinalysis, glucuronide hydrolysis is recommended in
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order to increase urinary metabolite concentrations to aid
detection and identiﬁcation. Extensive glucuronidation
appears to be common in the metabolism of other synthetic
cannabinoids [14, 15, 36] and phytocannabinoids [37, 38].
The terminally hydroxylated metabolite of CUMYL-
PICA was abundant (as measured semi-quantitatively by
peak area; Fig. 4), but it was identical to the oxidatively
deﬂuorinated metabolite of 5F-CUMYL-PICA. Similarly,
the carboxylated metabolite of 5F-CUMYL-PICA was
abundant but identical to the corresponding CUMYL-PICA
metabolite. Consequently, CUMYL-PICA and 5F-CUMYL-
PICA cannot be distinguished from each other using either
of their most abundant metabolites. Additionally, elimina-
tion of the N-pentyl or 5-ﬂuoropentyl chains of CUMYL-
PICA and 5F-CUMYL-PICA, respectively, formed identical
metabolites. Similar metabolic convergence has been
observed with other pairs of structurally related compounds,
including AMB and 5F-AMB, JWH-018 and AM-2201, and
UR-144 and XLR-11 [15, 23].
Considering these data, analytical targets for forensic
purposes must be selected with care. Long elimination
periods in vivo suggest that screening for parent com-
pounds in blood may be sufﬁcient in cases of acute expo-
sure. For less recent exposure, monohydroxylated
metabolites are potentially useful analytical targets in these
matrices, because they (or their glucuronides) were
observed at levels well above detection thresholds. For
CUMYL-PICA, a reasonable strategy would be to target
monohydroxylations occurring on the indole moiety (con-
sidering that a,a-dimethylbenzyl hydroxylation was not
observed in human hepatocyte preparations). Such
hydroxylation was difﬁcult to distinguish from the termi-
nally hydroxylated metabolite, but the presence of more
than one monohydroxylated metabolite at m/z 365 would
be selective for CUMYL-PICA. For 5F-CUMYL-PICA,
monohydroxylated metabolites retaining the terminal ﬂu-
orine may be useful analytical targets.
Conclusions
CUMYL-PICA and 5F-CUMYL-PICA produced moderate
hypothermic effects in male rats, and both compounds were
metabolized primarily via oxidative transformations fol-
lowed by glucuronidation in both rat and human models.
In vivo clearance of CUMYL-PICA and 5F-CUMYL-
PICA was substantially longer than predicted by in vitro
incubations, possibly due to the high lipophilicity of these
compounds or blood-protein binding. As is the case for
other structurally related pairs of synthetic cannabinoids,
formation of identical metabolites necessitates careful
selection of analytical targets in order to differentiate
between CUMYL-PICA and 5F-CUMYL-PICA.
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Introduction
The emergence of synthetic cannabinoids (SCs) as recreational 
drugs over recent years is a significant health concern, with 
their increasing use linked to a variety of adverse health effects 
(Trecki et al., 2015). SCs comprise a large, growing family of 
compounds with efficacy for cannabinoid receptors (cannabi-
noid receptor 1 and 2; CB1 and CB2). Many different SCs have 
been detected in ‘herbal’ products sold worldwide (Seely et al., 
2012b). These compounds produce psychoactive effects similar 
to cannabis use or Δ9-tetrahydrocannabinol (THC) via actions at 
CB1 (Wiley et al., 2012).
SC use has been associated with a toxidrome that in some 
ways resembles that of herbal cannabis itself, with features such 
as panic attacks, elevated blood pressure, and tachycardia 
(Schneir et al., 2011). Of greater concern are reports of severe 
toxic features that go beyond those of cannabis, including acute 
kidney injury, acute myocardial infarction, and generalised sei-
zures (Brents and Prather, 2014). It is unclear at present whether 
such features reflect a more potent action of these compounds 
than THC at CB1 or if there is some additional mechanism 
involved. Many SCs are also potent CB2 agonists and this could 
also influence toxicity given the expression of the CB2 receptor 
on immune and other cells (Malfitano et al., 2014). SCs may 
additionally act on G protein-coupled receptor 55 (GPR55) and 
transient receptor potential channels (Pertwee, 2010). Although 
actions on CB1 and CB2 vary widely between different SCs 
(Huffman et al., 1994; Rajasekaran et al., 2013), SCs generally 
tend to be full agonists with greater efficacy than the partial ago-
nist THC (Spaderna et al., 2013).
Systematic research into the effects of SCs is complicated 
by their rapid evolution and the sheer number of compounds 
available (EMCDDA, 2016; UNODC, 2015). Identification of 
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specific SCs in illicit products leads to their prohibition, which 
in turn reduces their popularity and leads to replacement by 
novel uncharacterised compounds. Thus, over the past decade 
SC compounds have emerged in waves (Schwartz et al., 2015). 
For example, the naphthoylindole compounds JWH-018 and 
AM-2201 were popular from 2010 to 2012, but now appear in 
few SC products (NFILS, 2014). More recent waves of popular 
compounds include indole carboxylates and indazole carboxa-
mides (Schwartz et al., 2015). It cannot be assumed that newly 
developed SCs will have the same effects as the older com-
pounds in vivo, given substantial differences in chemical struc-
ture, cannabinoid receptor efficacy and metabolism (Takayama 
et al., 2014; Thomsen et al., 2014).
Existing reports of SC effects in humans mostly fall into three 
categories: case studies reporting acute toxicity, user self-reports, 
and large surveys of SC users (Castaneto et al., 2014). Such stud-
ies are useful for identifying usage trends and potential com-
pounds or products of particular concern, but many reports do not 
include verification of chemical identity (e.g. via toxicological 
analysis of blood serum or urine), and those that do often reveal 
that multiple SC compounds have been used simultaneously 
(Musshoff et al., 2014). Use of SCs in conjunction with other 
types of recreational drugs and alcohol is also common (Barratt 
et al., 2012; Wilkins et al., 2016). Consequentially, the adverse 
effects observed in these reports cannot always be unambigu-
ously attributed to any single compound.
A limited number of SCs have been examined in preclinical 
studies in rodents, using some or all of the classic ‘tetrad’ meas-
ures of CB1 activation (decreased locomotor activity, catalepsy, 
hypothermia, antinociception). Such studies have revealed clas-
sic cannabimimetic effects of JWH-018 (Brents et al., 2012; 
Macri et al., 2013; Wiebelhaus et al., 2012), UR-144 and XLR-
11 (Wiley et al., 2013), and recently AB-CHMINACA, 
AB-PINACA, and FUBIMINA (Wiley et al., 2015). Dose-
dependent hypothermia and bradycardia have also been reported 
by our group with JWH-018, UR-144, PB-22, APICA and their 
fluorinated analogues (Banister et al., 2015b), as well as a vari-
ety of indazole SCs including AB-PINACA and AB-FUBINACA 
(Banister et al., 2015a).
More enriched studies of behavioural and physiological 
responses to novel SCs are sparse, with the exception of the large 
number of studies involving the very early SCs from the 1990s 
such as WIN-55,212-2, CP 55,940 and HU-210. A consistent 
finding among this research is the vulnerability of adolescent rats 
to lasting residual adverse effects of SCs and THC (for review 
see Higuera-Matas et al., 2015). Adolescent rats show greater 
residual memory deficits than adults following chronic THC 
administration (Quinn et al., 2008), and rats chronically treated 
with CP 55,940 during adolescence exhibit impaired working 
memory and social interaction compared with rats treated during 
adulthood (O’Shea et al., 2004). Similarly, chronic administra-
tion of WIN55,212-2 impaired recognition memory in adolescent 
but not adult rats (Schneider and Koch, 2003). These findings are 
of particular concern because adolescents constitute a substantial 
portion of SC users, with the median age of a global sample of 
users reported as 23 years (Winstock and Barratt, 2013) and 
recent studies showing that 10% of USA teenagers have tried SCs 
at least once (Palamar and Acosta, 2015). The dearth of behav-
ioural and toxicological data regarding the effects of the most 
currently prevalent SCs means that potentially large numbers of 
people from a vulnerable population are being exposed to drugs 
with unknown long-term effects.
Therefore we sought here to examine in vivo data regarding 
the lasting residual effects of currently emerging SCs in adoles-
cent animals. Two widely used indazole carboxamide SCs are 
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-
3-carboxamide (AB-PINACA), and N-(1-amino-3-methyl-1-
oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide 
(AB-FUBINACA; NFILS, 2015). These two compounds were 
first identified in herbal products in Japan (Uchiyama et al., 
2013), have since been found in Sweden (Vikingsson et al., 
2015), Germany (Langer et al., 2016), the United States 
(Monte et al., 2014), and elsewhere. Both AB-PINACA and 
AB-FUBINACA are highly potent CB1 agonists, and also pos-
sess appreciable CB2 potency (Banister et al., 2015a). Compounds 
in this class of have been implicated in recent poisonings causing 
intense anxiety, psychosis, and aggression (Schwartz et al., 2015; 
Trecki et al., 2015), resulting in their scheduling in the United 
States and elsewhere (DEA, 2015). We selected these compounds 
for this study on the basis of their prevalence and also their 
known dose-response relationship relative to THC and other can-
nabinoids in causing hypothermia and bradycardia in rats 
(Banister et al., 2015a; NFILS, 2015).
Here we examined the effects of these SCs in adolescent rats 
during and following repeated exposure relative to THC. Because 
the behavioural effects of most SCs are poorly characterised, we 
adopted an exploratory approach that utilised a variety of general 
behavioural measures. In line with human case reports and the 
known anxiogenic effects and memory deficits produced by 
other cannabinoid compounds in rats (e.g. THC, CP 55,940), we 
targeted anxiety-like behaviours and memory performance. 
Given user reports of unpleasant effects (e.g. physical discom-
fort, nausea, anxiety; Schwartz et al., 2015) we also tested for 
conditioned place aversion and measured vocalisations following 
drug administration. Social behaviours were also examined 
because these behaviours show lasting residual reductions in 
adolescent rats following THC or CP 55,940 administration 
(O’Shea et al., 2004; Quinn et al., 2008).
We also examined changes in a number of biomarkers after 
chronic administration, again adopting an exploratory approach. 
Plasma cytokines were assessed on the basis that cannabinoids 
have been shown to modulate cytokine production, typically 
decreasing levels of cytokines involved in pro-inflammatory pro-
cesses while increasing levels of anti-inflammatory cytokines 
(Katchan et al., 2016; Klein et al., 2003). Corticosterone was ana-
lysed as a general marker of stress and immune response, with 
the hypothesis that this analyte might be elevated following SC 
treatment, based on reports of anxiety in addition to encephalopa-
thy, acute kidney and cardiac injury (Bhanushali et al., 2012; 
Louh and Freeman, 2014; Mir et al., 2011). In addition we ana-
lysed plasma and cerebellar ethanolamides to examine any last-
ing modulation of endocannabinoid tone, which is thought to be 
generally decreased by chronic cannabinoid administration (Di 
Marzo et al., 2000; Rubino et al., 2015). The cerebellum was also 
targeted because human case reports have described impairment 
of movement sequences and disruption of fine motor skills fol-
lowing recreational use of a variety of SCs (Musshoff et al., 
2014). Together, these measures provide a broad examination 
of systems which have previously shown sensitivity to cannabi-
noid receptor agonists. We also compared these effects with 
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equivalent treatment with THC, anticipating that the SCs might 
produce more severe behavioural and biochemical effects.
Materials and methods
Subjects
A total of 64 experimentally naïve outbred male albino Wistar 
rats (Rattus norvegicus; Animal Resources Centre, Perth, 
Australia) were used for this experiment. Following their arrival 
at the laboratory, all rats were handled daily for 5 min each for 7 
days before the commencement of testing on post-natal day 
(PND) 31, at which point they weighed an average of 147 g 
(range 130–178 g). Rats were housed in groups of four with food 
and water available ad libitum, on a 12 h reverse light cycle 
(lights off at 09:00) with temperature maintained at 21 ± 1°C. 
Rats were assigned to one of four drug-treatment conditions: 
vehicle, THC, AB-PINACA, or AB-FUBINACA (n = 16 per con-
dition). One rat in the vehicle treatment condition was excluded 
from the experiment due to illness. All procedures were approved 
by the University of Sydney Animal Ethics committee in accord-
ance with the Australian Code of Practice for the Care and Use of 
Animals for Scientific Purposes.
Dose selection and preparation
AB-PINACA and AB-FUBINACA were synthesised as previ-
ously reported (Banister et al. 2015a). A stock solution of 25 
mg/mL THC in ethanol was obtained from Sigma Aldrich 
(Castle Hill, NSW, Australia).
Our dosing regimen consisted of six ‘low’ doses followed by 
six ‘high’ doses of each drug, with one drug dose administered 
every second day. This regimen was designed to mimic the escala-
tion of dosage commonly observed during chronic drug use. All 
rats received vehicle injections on the days between drug treat-
ments. We first selected THC doses used by Quinn et al. (2008), (1 
and 5 mg/kg), and then selected approximately equivalent doses of 
AB-PINACA and AB-FUBINACA (0.2 and 1 mg/kg for both). 
These doses were selected based on in vivo biotelemetry data – 
specifically, the peak hypothermia and bradycardia following drug 
administration in adolescent rodents (Banister et al., 2013, 2015a).
Drugs were prepared in a vehicle solution consisting of ethanol, 
Tween 80, and physiological saline (5:5:90). For the low THC dose 
(1 mg/kg), ethanol was added to an appropriate amount of 25 mg/mL 
THC in ethanol stock solution before addition of the Tween 80 and 
saline. For the higher dose (5 mg/kg), the THC stock solution was 
first concentrated to 50 mg/mL by evaporation of excess ethanol 
under a stream of nitrogen then prepared as for the low dose. All 
drugs were injected intraperitoneally at a volume of 1 mL/kg.
Behavioural assessment
Behavioural assessment was conducted over two phases – an ‘on-
drug’ phase during repeated drug administration during adoles-
cence (PNDs 31–55), and a ‘residual’ phase following a 2-week 
washout during adulthood (PNDs 69–94). These ages are consist-
ent with the adolescent ontogenetic window of 28–55 days for 
rats (Spear, 2000). A schematic of the assessment sequence is 
presented in Figure 1. All on-drug behavioural assessments com-
menced 15 min following injection.
Figure 1. Schematic of behavioural assessment over the entire experiment.
CPP: conditioned place preference; LOC: locomotor; NOR: novel object recognition; EM: emergence test; PND: Post-natal day; SI: social interaction.
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On-drug measures
Locomotor activity (PNDs 31 and 53). Individual rats were 
placed into a dark chamber with acrylic walls and a grid floor 
measuring 600 × 250 × 350 mm (L × W × H) for 15 min where 
they could explore freely. An infrared camera was mounted 
above the chamber, and the distance travelled by each rat was 
recorded and scored using automated tracking software (Track-
matePro v1.01, Motion Mensura, NSW, Australia).
Emergence (PNDs 33 and 55). The emergence test, a test of 
anxiety-like behaviour (Crawley and Goodwin, 1980; Quinn 
et al., 2008), was conducted in a 1200 × 1200 × 900 mm wooden 
arena painted matte black. A black hide box (400 × 240 × 170 
mm) with a red Perspex lid was positioned against the centre of 
one wall. The arena was illuminated by two floodlights (150 W 
white globes). Rats were tested individually for 5 min after being 
placed into the hide box. A camera mounted above the arena 
allowed recording of the test session that was scored offline by 
a blinded experimenter. The scored behaviours were (1) risk 
assessment (head protruding from the hide box while centre of 
mass remained inside the box), (2) latency to emerge (centre of 
mass outside the hide box), and (3) time spent in the open field 
(outside of the hide box). After each test the arena was cleaned 
with 50% ethanol.
Place conditioning (PNDs 34–52). Place conditioning was 
performed as previously described with minor modification 
(Quinn et al., 2008). The place conditioning chambers (Med 
Associates, St Albans, VT) consisted of two large side compart-
ments (280 × 210 × 210 mm), separated by a smaller central com-
partment (120 × 210 × 210 mm). Each side compartment had 
different textural, visual, and olfactory cues. One had black and 
white striped walls, a grid mesh floor, and 1 mL white vinegar in 
the waste pan beneath the floor. The other side had black walls, a 
metal rod floor, and 1 mL vanilla essence beneath the floor. Com-
partments could be isolated with guillotine doors. Odours were 
refreshed between each session.
Testing consisted of five phases: Baseline (PND 34), low-
dose conditioning (PNDs 35–42), low-dose test (PND 43), high-
dose conditioning (PNDs 44–51), and high-dose test (PND 52). 
For the conditioning days, rats were given drug injections every 
second day (totalling four low-dose and four high-dose injec-
tions) and vehicle every other day (except for the vehicle group 
which always received vehicle injections). Rats were placed in 
alternate sides of the chamber for 15 min each day, such that one 
side (counterbalanced between and within drug conditions) was 
always paired with drug treatment and the other with vehicle 
treatment. For the baseline and test days, rats were placed in the 
central compartment and allowed to freely explore all compart-
ments for 15 min and the time spent in each was recorded and 
scored via a camera mounted above the chamber. Preference 
scores were calculated as the amount of time spent in the drug-
conditioned side minus the amount of time spent in the vehicle-
conditioned side.
In addition, rat vocalisations were recorded as a supplemen-
tary measure of drug aversion (Giuliani et al., 2000; Henriksson 
and Jarbe, 1971; Quinn et al., 2008). Specifically, a blinded 
experimenter recorded the number of rats per group that emitted 
any audible vocalisation while being picked up and placed into 
the chambers during conditioning days (i.e. 15 min following 
drug administration). Each rat received a score of 0 for no vocali-
sations or 1 for any vocalisation, generating a total score ranging 
from 0 to 16 for each group on each day.
Residual measures
Novel object recognition (PNDs 69–72). The novel object rec-
ognition (NOR) testing occurred in a circular black plastic tub 
(diameter = 750 mm, height = 550 mm), in which two objects 
could be placed and secured with Velcro. Rats were first individu-
ally habituated to the arenas without objects for 10 min on PNDs 
69 and 70. The following day, rats were placed in the arenas for 3 
min before two identical objects (matte black painted spray bot-
tles or sauce pourers) were placed in the arena and rats were 
allowed to explore for 3 min. Rats were removed from the arena 
for 2 min (the inter-trial interval, ITI) and returned to a holding 
cage while the one of the two identical objects was swapped for a 
novel one. Rats were then returned to the arena for 3 min and the 
time spent investigating each object was recorded. The short 
2-min ITI was selected to minimise working memory demand in 
order to detect possible severe impairment to object recognition 
memory caused by drug exposure. The following day this test was 
repeated with a new set of objects (matte black painted salt shak-
ers or blue egg-shaped object) using a longer 60-min ITI. This 
increased task difficulty allowed detection of more subtle impair-
ments to object recognition memory, if present.
Social interaction (PNDs 73–74). The social interaction test 
was performed as previously described (Ramos et al., 2013). 
Briefly, rats were individually habituated for 20 min in a black 
plastic arena (780 × 520 × 470 mm) on PND 73. The following 
day, they were returned to the arena with a novel conspecific from 
the same drug-treatment group, and allowed to explore and inter-
act freely. Anogenital sniffing (sniffing the anogenital region of 
the conspecific), general investigation (sniffing of non-anogenital 
regions of the conspecific), pinning (one rat lying on with its 
dorso-lateral surface to the floor with the other rat above it), and 
rearing (standing on hind legs, including leaning on the arena 
walls) was recorded via a camera mounted above the arena. These 
behaviours were selected because they are general behaviours that 
are frequently expressed by healthy animals, and are widely used 
in existing literature with similar social interaction tests including 
assessments of cannabinoid modulation of social behaviour (File 
and Seth, 2003; Trezza and Vanderschuren, 2008). Total interac-
tion was calculated as the sum of anogenital sniffing, general 
investigation, and pinning. These behaviours were scored by an 
experimenter blinded to the experimental conditions.
Locomotor activity (PND 77). As described above, without 
any drug treatment.
Emergence (PND 78). As described above, without any drug 
treatment.
Post-mortem plasma and cerebellum analyses
Sample collection (PND 103). Individual rats from each treat-
ment condition were taken to a separate room in a dark holding 
Chapter 4 139
Kevin et al. 5
box and killed by rapid decapitation without anaesthesia on PND 
103. The rats were extensively habituated to the handling proce-
dure up on the 3 days before decapitation to minimise any stress 
or novelty effects on steroid levels. Immediately following 
decapitation trunk blood was collected in a chilled EDTA-coated 
collection tube and immediately centrifuged at 4°C at 4000 g for 
10 min. Plasma was collected in 1 mL aliquots while cerebellum 
was dissected with a razor blade and flash frozen with liquid 
nitrogen, prior to storage at −80°C until analysis.
Steroids. Plasma corticosterone, testosterone, and progesterone 
were analysed via liquid chromatography-tandem mass spec-
trometry (LC-MS/MS) as previously described (Bowen et al., 
2014). Corticosterone was the primary analyte of interest, with 
testosterone and progesterone included because the method 
allows for simultaneous quantitation of these analytes. Briefly, 
steroids were extracted from 250 μL plasma (analysed in dupli-
cate) into 1 mL methyl tert-butyl ether and dried under a gentle 
stream of nitrogen. Steroid residue was then reconstituted in ini-
tial mobile phase (0.1% formic acid in 10% methanol and 90% 
water) and analysed via LC-MS/MS.
Ethanolamides. Cerebellar and plasma ethanolamides were 
assessed as a measure of endocannabinoid tone, and also in light 
of reports of impaired movement sequences in humans following 
SC use (Di Marzo et al., 2000; Musshoff et al., 2014; Rubino 
et al., 2015). Ethanolamides (anandamide, AEA; palmitoyletha-
nolamide, PEA; 2-arachidonoylglycerol, 2-AG; oleoylethanol-
amide, OEA; and linoleoyl ethanolamide, LEA) in cerebellum 
were extracted as follows, based on a previous method (Stuart 
et al., 2013). The right cerebellum was dissected from whole cer-
ebellum and weighed, then 6 mL of MeOH and 10 μL of internal 
standard 1 μm deuterium labelled anandamide (d4-AEA) was 
added. Left cerebellum was preserved for possible future assays. 
Tissue was homogenised and centrifuged at 19,000 g for 20 min 
at 4°C. The resultant supernatant was decanted and 24 mL milli-
Q water was added, forming a 20% organic final supernatant. 
Analytes were extracted from the supernatant using solid phase 
extraction (SPE) with 500 mg C18 columns preconditioned with 
5 mL MeOH followed by 2.5 mL milli-Q water. Supernatant 
solution was loaded onto each column, washed with 2.5 mL 
milli-Q water, then 2 mL 40% MeOH, and analytes were washed 
with a final 1.5 mL 85% MeOH and eluted with 100% MeOH.
Plasma ethanolamides were also analysed. Briefly, 8 mL of 
1:1 ice cold ACN/MeOH was added to 250 μL of plasma, 20 μL 
of d4-AEA was added, and samples were left covered in the dark 
for 2 h at 4°C. Following centrifugation, the supernatant was 
treated as described above for the cerebellar extraction, with 
washes of 2.5 mL milli-Q water, 2 mL 50% MeOH and 1.5 mL of 
60% MeOH before the analytes were eluted from the SPE col-
umn with 100% MeOH. The SPE eluates for all samples were 
analysed via LC-MS/MS.
Cytokines. Plasma cytokine levels (granulocyte macrophage 
colony-stimulating factor, GM-CSF; interferon gamma, IFNγ; 
interleukins (IL)-1α, IL-1β, IL-2, IL-4, IL-6, IL-12, and tumour 
necrosis factor alpha, TNF-α) were measured using a commer-
cially available multiplex bead immunoassay kit (Rat Cytokine 
10-Plex Panel kit, Invitrogen, Camarillo, CA). The assay was 
performed according to the manufacturer’s instructions, with 
minor modifications. In brief, all reagent and sample volumes 
were scaled down to 20% of recommended values, and washes 
were performed by centrifugation in a 96-well v-bottomed plate. 
The assay was read on an LSR Fortessa-X20 flow cytometer 
(Becton Dickinson, Sydney, NSW, Australia) and data were ana-
lysed using FlowJo software v9.8.5 (FlowJo, Ashland, OR).
Data analysis
Data were analysed using SPSS version 20 (IBM, Chicago, IL) 
with significance set at 0.05. Place conditioning was analysed 
using mixed-model ANOVA, with treatment group (vehicle-, 
THC-, AB-PINACA-, or AB-FUBINACA-treatment) as the 
between-subjects factor and dosing phase (baseline, low-dose 
test, and high-dose test) as the within-subjects factor. For the 
emergence test, latency to emerge data were not normally distrib-
uted as several rats remained inside the hidebox for the entire test 
duration. Similarly, vocalisation data were not normally distrib-
uted as it was a binary measure. In these cases, non-parametric 
Kruskal–Wallis H tests with Bonferroni-corrected Mann–
Whitney tests were used in place of one-way ANOVAs. In all 
other cases, treatment groups were compared using a one-way 
ANOVA. In cases where the ANOVA reached statistical signifi-
cance, the treatment groups were compared pairwise using 
Tukey’s HSD tests.
Results
‘On-drug’ measures
Locomotor activity. There was a significant overall effect of 
low-dose drug treatment on locomotor activity (F(3,59) = 3.65, p < 
0.05). Tukey’s HSD tests found that the distance travelled was 
reduced by AB-PINACA and AB-FUBINACA compared with 
vehicle (all p < 0.05), but not by THC (p > 0.05) although it pro-
duced a strong tendency towards reduced activity (Table 1). No 
other comparisons were significant (all p > 0.05).
Similarly, there was a significant overall effect of high-dose 
drug treatment on locomotor activity (F(3,59) = 12.16, p < 0.001). 
Post-hoc tests found that all drugs reduced distance travelled 
compared with vehicle (all p < 0.001; Table 1), and no other pair-
wise comparisons reached significance (all p > 0.05).
Emergence. There was no overall significant effect of low-dose 
treatment on the latency to emerge (χ2(3) = 6.05, p > 0.05). High 
doses produced a significant overall effect (χ2(3) = 30.47, p < 
0.001), with all drugs increasing latency relative to vehicle treat-
ment (all p < 0.05).
There was a significant overall effect of treatment on time 
spent in the open field for high (F(3,59) = 5.16, p < 0.01) but not 
low doses (F(3,59) = 0.97, p > 0.05). Tukey’s HSD tests showed 
that THC and AB-PINACA significantly reduced open field time 
at a high dose compared with vehicle (all p < 0.05).
Risk assessment was also significantly affected by low 
doses (F(3,59) = 10.76, p < 0.001), such that all drug treatments 
significantly decreased risk assessment behaviour compared 
with vehicle (all p < 0.05) at a low dose. The same was true for 
high doses (F(3,59) = 24.26, p < 0.001; all pairwise comparisons 
with vehicle p < 0.001). No other pairwise comparisons 
reached statistical significance.
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Place conditioning. The results of the place conditioning test 
are presented in Figure 2. Overall, there was no main effect of 
drug treatment on preference scores (time in drug-conditioned 
side – time in vehicle-conditioned side; F(3,59) = 0.61, p > 0.05) or 
dosing phase (F(2,118) = 1.51, p > 0.05), nor was there a significant 
interaction effect (F(6,118) = 1.04, p > 0.05). Although there was a 
strong trend towards a preference for the drug-conditioned side 
following low-dose AB-FUBINACA treatment compared with 
vehicle, this failed to reach statistical significance (p = 0.06). 
There was no significant baseline preference for striped compart-
ments over blank (t(62) = 1.52, p > 0.05), nor vanilla scented over 
vinegar scented (t(62) = 0.53, p > 0.05).
Vocalisations on ‘no drug’ vehicle injection days of place 
preference testing did not differ between treatment groups (χ2(3) 
= 2.82, p > 0.05). There were overall treatment effects on vocali-
sations for low (χ2(3) = 11.01, p < 0.01) and high-dose phases 
(χ2(3) = 13.02, p < 0.0001). Post-hoc tests showed that signifi-
cantly more rats vocalised following AB-FUBINACA low-dose 
treatment compared with vehicle (p < 0.01), as was the case for 
high-dose THC (p < 0.001), AB-PINACA (p < 0.05) and 
AB-FUBINACA (p < 0.05) compared with vehicle. No other 
pairwise comparisons reached statistical significance.
Residual measures
Novel object recognition. When tested with a 2-min ITI, there 
was an overall effect of drug pre-treatment (F(3,59) = 3.04, p < 0.05), 
and AB-FUBINACA pre-treated rats spent a smaller percentage of 
time investigating the novel object compared with vehicle (p < 
0.05). With a 60-min ITI there was a significant overall effect 
(F(3,59) = 9.43, p < 0.001) and the percentage of time spent investi-
gating the novel object was reduced by all three cannabinoid pre-
treatments compared with vehicle (all p < 0.01; Figure 3). No other 
comparisons reached statistical significance (all p > 0.05).
Social interaction. For the social interaction test, there were 
significant overall effects of drug pre-treatment on rearing (F(3,59) 
= 3.03, p < 0.05), general investigation (F(3,59) = 5.77, p < 0.05), 
total interaction (F(3,59) = 3.50, p < 0.05) but not for anogential 
sniffing (F(3,59) = 0.40, p > 0.05) or pinning (F(3,59) = 2.52, p > 
0.05; Table 2). THC pre-treated rats showed less total social 
interaction with novel conspecifics compared with vehicle pre-
treated rats (p < 0.05) and less general investigation than AB-
FUBINACA pre-treated rats (p < 0.05). No other pairwise 
comparisons were statistically significant (all p > 0.05).
Locomotion. There were no significant residual effects on loco-
motor activity as a function of drug pre-treatment (F(3,59) = 0.82, 
p > 0.05; Table 1).
Emergence. There were no significant differences in latency to 
emerge (χ2(3) = 1.14, p > 0.05), time spent in the open field (F(3,59) 
= 0.04, p > 0.05), or risk assessment (F(3,59) = 0.85, p > 0.05).
Body weight. Body weight data are summarised in Table 3. 
There were no significant differences between treatment condi-
tions in weight at the beginning (PND 31) of the study (F(3,59) = 
0.35, p > 0.05). Over the dosing phase (PNDs 31–55), there was 
a significant overall treatment effect (F(3,59) = 8.97, p < 0.001), 
and all cannabinoid treatment groups gained significantly less 
weight than vehicle-treated rats (all p < 0.01). No other pairwise 
comparisons reached significance (all p > 0.05). Over the resid-
ual testing phase (PNDs 56–103), there were no significant dif-
ferences in weight gain (F(3,59) = 1.52, p > 0.05), and at the end of 
residual testing (PND 103), there was no significant difference in 
weight (F(3,59) = 1.42, p > 0.05).
Steroids. There were no significant effects of drug pre-treatment 
on plasma corticosterone (F(3,44) = 0.22, p > 0.05), testosterone 
(F(3,44) = 0.20, p > 0.05), or progesterone (F(3,44) = 0.02, p > 0.05) 
levels (Table 4).
Cytokines. Levels of IL-1β, IL-4, GM-CSF, TFNα, and IFNg in 
all samples across all drug-treatment conditions fell below limits 
Table 1. Locomotor and emergence results for all experimental phases.
VEH THC AB-PINACA AB-FUBINACA
Low-dose effects  
Locomotor (m) 27.5 (1.2) 20.2 (2.4) 19.5 (2.1)* 20.0 (1.9)*
LTE (s) 140.9 (35.5) 217.1 (32.2) 191.4 (36.3) 264.1 (24.5)*
Risk assessment (s) 52.2 (5.6) 30.9 (3.8)* 22.3 (6.2)*** 15.7 (2.9)***
Open time (s) 48.8 (16.4) 30.4 (15.4) 34.8 (19.8) 11.0 (9.8)
High-dose effects  
Locomotor (m) 34.4 (1.5) 17.8 (3.2)*** 19.5 (2.6)*** 14.1 (2.4)***
LTE (s) 189.8 (23.4) 300.0 (0.0)*** 287.5 (12.5)*** 265.1 (23.7)*
Risk assessment (s) 62.2 (8.3) 4.4 (1.1)*** 14.0 (7.0)*** 6.4 (2.1)***
Open time (s) 57.5 (16.4) 0.0 (0.0)** 1.8 (1.8)** 22.9 (16.8)
Residual effects  
Locomotor (m) 44.4 (2.7) 39.9 (2.2) 41.2 (1.6) 41.1 (1.7)
LTE (s) 75.8 (24.5) 69.6 (18.7) 46.1 (11.6) 74.5 (20.7)
Risk assessment (s) 32.0 (4.5) 38.7 (6.7) 36.3 (4.6) 36.3 (5.0)
Open time (s) 160.7 (18.7) 161.1 (16.7) 165.6 (11.4) 158.3 (16.9)
Data represent means (SEM). LTE: Latency to emerge. *p < .05, **p < .01, ***p < .001 compared with vehicle. Locomotor data are given in metres (m); LTE, risk assess-
ment, and open time are given in seconds (s).
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Figure 2. (a) Place conditioning following six low then six high doses of THC, AB-PINACA, and AB-FUBINACA. (b) Mean number of rats vocalising 
during placement in the CPP chambers during each training day. Vocalisations were significantly elevated following low doses of AB-FUBINACA and 
high doses of THC, AB-PINACA, and AB-FUBINACA compared with vehicle injections. Data are means ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001 
compared with vehicle at the same dose level.
Figure 3. Mean ± SEM data for the novel object recognition test, 2 weeks post drug administration, with (a) a 2-min inter-trial interval (ITI) or (b) 
a 60-min ITI. AB-FUBINACA pre-treated rats spent significantly less time investigating the novel object compared with vehicle for the 2-min ITI 
test, and all cannabinoid treatments reduced novel investigation with a 60-min ITI. *p < 0.05, **p < 0.01, ***p < 0.001 compared with vehicle.
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of detection (Table 4). There was no overall group difference in 
levels of IL-2 (F(3,44) = 1.62, p > 0.05), IL-6 (F(3,44) = 0.40, p > 
0.05), or IL-10 (F(3,44) = 0.97, p > 0.05). However, there were 
overall treatment effects for IL-1α (F(3,44) = 3.32, p < 0.05) and 
IL-12 (F(3,44) = 4.91, p < 0.01), with AB-FUBINACA treated rats 
showing significantly lower plasma levels of IL-1α compared 
with vehicle (p < 0.05) and IL-12 compared with both vehicle 
and AB-PINACA (p < 0.05).
Ethanolamides. There were significant overall effects of drug 
pre-treatment on most cerebellar ethanolamides: AEA, F(3,44) = 
16.96, p < 0.0001; PEA, F(3,44) = 9.91, p < 0.0001; 2-AG, F(3,44) = 
2.85, p < 0.05; OEA, F(3,44) = 10.69, p < 0.0001, but not LEA 
F(3,44) = 2.57, p > 0.05.
Tukey’s HSD tests showed that THC pre-treatment reduced 
AEA, PEA, 2-AG, and OEA when compared with vehicle (all 
p < 0.05), and reduced AEA, PEA, and OEA compared with 
AB-FUBINACA (all p < 0.05; Table 4). AEA, PEA, and OEA 
were reduced by AB-PINACA pre-treatment compared with 
vehicle (all p < 0.05) and AB-FUBINACA (all p < 0.05). No 
other comparisons were significant (all p > 0.05).
There were no significant differences in plasma ethanolamide 
levels as a function of treatment group (AEA, F(3,44) = 0.64, p < 
0.05; PEA, F(3,44) = 1.16, p < 0.05; 2-AG, F(3,44) = 1.46, p < 0.05; 
OEA, F(3,44) = 0.55, p < 0.05; LEA, F(3,44) = 1.21, p < 0.05).
Discussion
The present study examined various acute and long-lasting 
impacts of AB-PINACA and AB-FUBINACA relative to the pro-
totypical cannabinoid THC in adolescent rats. During dosing, all 
three cannabinoids produced locomotor suppression, anxiogenic 
effects in the emergence test and inhibition of body weight gain. 
Following drug administration, a residual impairment of object 
recognition memory was detected with all three drug pre-treat-
ments at a timepoint of 2 weeks. Six weeks post drug, a reduction 
in some cytokines was observed in the plasma of AB-FUBINACA 
pre-treated rats and a reduction in cerebellar ethanolamides in 
THC and AB-PINACA pre-treated rats. To our knowledge, this is 
the first investigation of long-term behavioural and biochemical 
effects of emerging SCs. Somewhat contrary to our expectations, 
THC administration produced similar acute effects, and only sub-
tle differences in long-term effects, relative to the two SC com-
pounds. Indeed, THC produced residual reductions in social 
interaction, an effect not seen with either SC.
Acute behavioural effects of chronic AB-
PINACA and AB-FUBINACA
The acute responses to AB-PINACA and AB-FUBINACA were 
typical of those observed with other cannabinoid agonists such as 
THC, CP 55,940, and JWH-018. This included locomotor hypo-
activity, inhibition of weight gain, and increased anxiety-like 
behaviours (Arevalo et al., 2001; O’Shea et al., 2004; Quinn 
et al., 2008). AB-PINACA, AB-FUBINACA and THC caused 
dose-dependent reductions in locomotor activity, consistent with 
previous reports of locomotor suppression in rodents adminis-
tered indazole SC compounds including AB-PINACA (Wiley 
et al., 2015), and earlier SCs such as JWH-018 (Macri et al., 
2013). There have also been observations of impairment of 
movement sequences and disruption of fine motor skills follow-
ing human recreational use of SCs (Musshoff et al., 2014). 
Weight gain was inhibited by all three cannabinoid compounds 
in the present study, consistent with earlier reports involving 
Table 2. Behaviour in the social interaction test 19 days post drug administration.
Behaviour Vehicle THC AB-PINACA AB-FUBINACA
Exploratory behaviour  
 Rearing 133.0 (10.4) 130.3 (10.0) 105.8 (7.9) 103.6 (7.2)
Social behaviour  
 Anogenital sniffing 25.2 (5.2) 20.8 (2.3) 26.5 (3.9) 23.1 (4.3)
  General investigation 37.6 (3.1) 27.1 (1.7) 38.1 (4.3) 46.6 (3.8)
 Pinning 19.8 (4.2) 3.8 (1.6) 22.5 (9.0) 9.8 (4.1)
 Total social interaction 82.6 (9.3) 51.8 (3.3)*† 87.0 (12.4) 79.5 (6.9)
Data are means (SEM) in seconds; *p < 0.05 compared with vehicle, †p < 0.05 compared with AB-FUBINACA.
Table 3. Effects of chronic administration of THC, AB-PINACA, and AB-FUBINACA on rat body weight.
VEH THC AB-PINACA AB-FUBINACA
Initial weight (g; PND 31) 148.8 (3.8) 147.4 (2.8) 149.3 (2.8) 145.6 (1.6)
Dosing phase weight gain
(g; PNDs 31–55)a
186.1 (4.9) 155.2 (3.8)*** 164.5 (5.3)** 162.9 (3.1)**
Residual phase weight gain
(g; PNDs 56–103)a
122.7 (3.7) 131.0 (4.4) 118.8 (7.3) 133.4 (6.3)
Final weight (g; PND 103) 457.2 (8.9) 433.6 (8.5) 432.7 (11.4) 441.9 (8.6)
Data represent means (SEM). aWeight gain during the dosing phase was calculated by subtracting weights on PND 31 from PND 55, and weight gain during the residual 
phase was calculated by subtracting weights on PND 56 from PND 103. **p < 0.01, ***p < 0.001 compared with vehicle.
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chronic administration of THC or CBD/ THC to adolescent rats 
(Klein et al., 2011), or chronic administration of HU-210 in 
adults rats (Dalton et al., 2009).
All three cannabinoids increased anxiety-like behaviours in 
the emergence test, similar to the effects of CP 55,940 (Arevalo 
et al., 2001; Marco et al., 2004) and THC Quinn et al. (2008). 
There were also large increases in audible vocalisations follow-
ing drug administration, a measure previously used to index can-
nabinoid aversion (Giuliani et al., 2000; Henriksson and Jarbe, 
1971). We previously showed that rat vocalisations during han-
dling increases following administration of 5 mg/kg THC (Quinn 
et al., 2008), an effect replicated here. The acute anxiogenic and 
aversive effects of these compounds may be consistent with the 
anxiogenic effects of cannabinoids reported in some human case 
studies (Schwartz et al., 2015).
Despite these apparent increases in anxiety-like behaviours and 
vocalisations, neither SC nor THC produced conditioned place 
aversion. Quinn et al. (2008) found that only adult rats showed 
conditioned place aversion to THC, as has been described with 
other drugs such as nicotine (Wilmouth and Spear, 2004). These 
THC-treated adolescent rats also showed anxiety-like behaviours 
in the emergence test. Therefore adolescent rats may be less prone 
to acquiring conditioned aversion from cannabinoids even when 
they produce anxiety-like effects, and this could conceivably 
increase the abuse potential of SCs in adolescent populations. 
Adolescents appear to be more vulnerable to cannabinoid-induced 
memory impairments as compared with adults (Higuera-Matas 
et al., 2015; Quinn et al., 2008; Viveros and Marco, 2015), which 
may consequently impair the acquisition of place conditioning.
The development of preference and aversion to cannabinoids 
in the conditioned place preference paradigm depends to a large 
extent on dose (Tanda, 2016). Place preference data regarding 
recent SCs are limited, but JWH-073, JWH-81, and JWH-210 
produce a place preference at low doses (0.5 mg/kg for JWH-
073, and 0.1 mg/kg for JWH-81 and JWH-210) that is not present 
at 1 mg/kg (Cha et al., 2014). It is possible that our low doses 
were a little too high to demonstrate a place preference, although 
0.2 mg/kg AB-FUBINACA pre-treatment trended towards pro-
ducing such an effect. Future studies exploring a range of low 
doses may prove instructive in this regard.
Table 4. Plasma steroid, cytokine, and ethanolamides with cerebellar ethanolamides 6 weeks post drug administration.
VEH THC AB-PINACA AB-FUBINACA
Plasma  
 Steroids (ng/mL)  
  Corticosterone 117.9 (13.6) 131.9 (16.2) 118.4 (13.5) 123.7 (11.7)
  Testosterone 2.4 (0.3) 2.1 (0.4) 2.1 (0.3) 2.0 (0.3)
  Progesterone 1.2 (0.2) 1.2 (0.1) 1.2 (0.1) 1.2 (0.2)
 Cytokines (pg/mL)  
  IL-1D 71.7 (13.0) 51.2 (7.5) 57.8 (7.3) 30.4 (8.9)*
  IL-1E – – – –
  IL-2 66.7 (7.1) 75.7 (9.6) 72.0 (5.8) 54.3 (6.4)
  IL-4 – – – –
  IL-6 5.6 (0.7) 4.9 (0.4) 4.9 (0.4) 5.5 (0.8)
  IL-10 21.2 (0.8) 21.8 (1.0) 20.5 (0.5) 20.3 (0.3)
  IL-12 496.2 (58.8) 473.2 (41.2) 546.2 (38.9) 303.5 (48.8)*‡
  IFNJ – – – –
  GM-CSF – – – –
  TNFD – – – –
 Ethanolamides (ng/mL)  
  AEA 0.33 (0.03) 0.39 (0.03) 0.34 (0.04) 0.36 (0.04)
  PEA 13.4 (0.8) 13.2 (0.9) 14.0 (0.6) 15.1 (1.0)
  2-AG 21.8 (4.4) 15.6 (4.7) 13.7 (2.6) 23.5 (3.6)
  OEA 7.7 (0.8) 7.7 (0.5) 7.2 (0.5) 8.3 (0.7)
  LEA 1.2 (0.1) 1.5 (0.1) 1.3 (0.1) 1.3 (0.1)
Cerebellum  
 Ethanolamides (ng/g)  
  AEA 46.6 (2.5) 32.8 (0.6)****†††† 34.7 (1.1)****††† 45.0 (2.0)
  PEA 330.3 (20.2) 238.9 (12.0)***†† 258.1 (12.3)**† 320.1 (10.8)
  2-AG 3316.7 (196.0) 2642.4 (156.3)* 2961.5 (163.9) 3144.0 (164.1)
  OEA 351.1 (21.5) 246.3 (12.0)***††† 280.1 (13.2)*† 344.0 (13.4)
  LEA 26.1 (1.3) 22.8 (0.7) 23.2 (0.6) 24.3 (0.8)
Data are means (SEM).
* p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with vehicle; ‡p < 0.05 compared with AB-PINACA; †p < 0.05, ††p < 0.01, †††p < 0.001, ††††p < 0.0001 
compared with AB-FUBINACA; – all samples < limit of detection.
2-AG: 2-arachidonoylglycerol; AEA: anandamide; GM-CSF: granulocyte macrophage colony-stimulating factor; IFNJ: interferon gamma; IL: interleukin; LEA: linoleoyl 
ethanolamide; OEA: oleoylethanolamide; PEA: palmitoylethanolamide; TNFD: tumour necrosis factor alpha.
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Residual effects of chronic AB-PINACA and 
AB-FUBINACA administration
Residual recognition memory impairment was observed with 
all three cannabinoid pre-treatments 2 weeks following cessa-
tion of drug administration. Moreover, AB-FUBINACA pre-
treated rats showed impaired NOR performance even with a 
short 2-min ITI, suggesting a more substantial impairment with 
this compound. Since SC compounds appear to be quickly 
metabolised (Paul and Bosy, 2015; Wohlfarth et al., 2015) and 
biotelemetry data demonstrates a return to baseline body tem-
perature and heart rate approximately 3 and 5 h after drug 
administration for AB-PINACA and AB-FUBINACA, respec-
tively (Banister et al., 2015a), it is unlikely that these residual 
effects are due to SCs persisting in the body. Residual impair-
ment has been reported in previous studies of THC and CP 
55,940 (O’Shea et al., 2004, 2006; Quinn et al., 2008). The 
underlying mechanism is unclear, but reduced NOR perfor-
mance accompanies hippocampal (Barker and Warburton, 
2011), and perirhinal cortex insult (Bussey et al., 1999; Norman 
and Eacott, 2004).
AB-PINACA and AB-FUBINACA had no residual effects on 
social interaction. In contrast, THC produced a lasting residual 
impairment, consistent with previous findings with chronic THC 
and CP 55,940 (O’Shea et al., 2004; Quinn et al., 2008). The 
absence of lasting social impairment with AB-PINACA and 
AB-FUBINACA treatment in the presence of a clear impairment 
with THC was unexpected, and suggests that mechanisms other 
than those arising from simple CB1 activation may be involved. 
There is increasing evidence of an interaction between cannabi-
noids and oxytocin in social reward, which could play a role in 
the effects seen here. It is notable that chronic daily administra-
tion of 1.5 mg/kg THC to rats down-regulates expression of the 
prosocial neuropeptide oxytocin in nucleus accumbens and ven-
tral tegmental areas (Butovsky et al., 2006). Further, social inter-
action or pharmacological activation of the oxytocin receptor 
(OTR) stimulates AEA mobilisation in the nucleus accumbens, 
which enhances social reward, while blockade of the OTR 
prevents this effect (Wei et al., 2015). Consequentially, a com-
parison of endocannabinoid or oxytocin levels in the nucleus 
accumbens following SC pre-treatment to THC pre-treatment 
may prove fruitful.
It was predicted that cytokines involved in pro-inflamma-
tory processes (IL-1α, IL-1β, IL-2, IL-12, IFNγ, GM-CSF, 
TNFα; see Kopf et al. (2010) for review) might be decreased 
by SC pre-treatment, perhaps due to an influence on CB2 
receptors. This prediction was partially confirmed by reduc-
tions observed in plasma concentrations of cytokines IL-1α 
and IL-12 with AB-FUBINACA pre-treatment. CB2 receptors 
are commonly expressed on immune cells and play a major 
role in inflammation (Galiegue et al., 1995; McPartland et al., 
2015) and repeated stimulation with CB2 agonists tends to 
reduce inflammation and related neuropathic pain (Guindon 
and Hohmann, 2008). Cytokines associated with anti-inflam-
matory processes (IL-4, IL-6, IL-10) were unaffected, although 
we note that the concentrations of most cytokines were low, or 
below limits of detection, as might be expected in healthy ani-
mals assessed a long time after drug administration (Cannon, 
2000). Together with the lack of any long-term increase in 
corticosterone, these data indicate that the long-term impact 
of these SCs on immune or stress responses may be relatively 
minor, reflecting human case reports detailing acute injury fol-
lowed by good recovery (Hermanns-Clausen et al., 2012; 
Schwartz et al., 2015). An analysis of plasma during acute dos-
ing with SCs would be informative, particularly if combined 
with CB2 inverse agonist SR144528 to isolate CB2-mediated 
effects.
A lasting reduction of cerebellar ethanolamides following 
THC and AB-PINACA pre-treatment indicates some residual 
reduction in central endocannabinoid tone that is of potential 
concern. A similar reduction in AEA in the prefrontal cortex of 
female rats occurs following chronic THC administration in 
adolescence (Rubino et al., 2015), in the striatum of adult male 
THC-tolerant rats (Di Marzo et al., 2000), and in human cere-
brospinal fluid following frequent cannabis use by schizo-
phrenic patients (Leweke et al., 2007). The functional 
importance of such decreases are unclear but could potentially 
link to reported disruptions in fine motor skills reported in 
humans following SC use (Musshoff et al., 2014). Although 
the long-term effects of chronic cannabinoid treatment on the 
endocananbinoid system remain controversial (Higuera-Matas 
et al., 2015), a number of studies demonstrate a downregula-
tion of CB1 receptor expression in rodents (Breivogel et al., 
2003; Sim-Selley et al., 2006) following chronic cannabinoid 
administration. The decreases in ethanolamides in the present 
and previous studies could be a consequence of a similar 
homeostatic compensation in endocannabinoid signalling that 
persists in the long term.
It was surprising that AB-FUBINACA pre-treatment failed to 
decrease cerebellar endocannabinoids given the otherwise strong 
effects produced by this compound. Similarly, it is unclear 
why AB-FUBINACA alone reduced plasma cytokine levels. 
At this time, the mechanisms underlying these idiosyncrasies are 
unknown, particularly while possible non-cannabinoid receptor 
targets of these compounds remain uncharacterised. AB-PINACA 
and AB-FUBINACA are known to differ markedly in metabo-
lism despite their structural similarities. In human liver micro-
somes, hydroxylation occurs primarily at the 1-pentyl moiety for 
AB-PINACA, and at the N-(1-amino-alkyl-1-oxobutan) moiety 
for AB-FUBINACA (Takayama et al., 2014). Several metabo-
lites of JWH-018, AM-2201, and JWH-073 retain cannabinoid 
receptor activity (Rajasekaran et al., 2013; Seely et al., 
2012a). The cannabinoid receptor activity of AB-PINACA and 
AB-FUBINACA metabolites is presently uncharacterised, but it 
may be that some of these metabolites retain cannabinoid recep-
tor activity. The potency of these metabolites could differ 
markedly given the difference in hydroxylation location. 
Ongoing studies in our laboratory are aimed at addressing this 
hypothesis.
Effects of AB-PINACA and AB-FUBINACA 
compared with THC
SC case reports generally describe adverse outcomes and toxicity 
that are more severe compared with cannabis use, yet in this 
study AB-PINACA and AB-FUBINACA produced effects very 
similar to THC on most measures. Overall differences between 
THC and the two SCs were only evident on two residual meas-
ures: social interaction (where THC alone produced an adverse 
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residual effect on social interaction), and in cerebellar ethanola-
mide levels (where THC and AB-PINACA reduced cerebellar 
AEA, PEA, and OEA but AB-FUBINACA did not). Moreover, 
we observed no obvious illness in any drug-treated rat at any 
point during the study.
This general failure to separate SCs from THC, despite 
numerous case reports of greater adverse effects of SCs, might 
reflect the fact that these case reports arise from persons seeking 
hospital treatment and consequentially reflect the most extreme 
cases (Khan et al., 2016; Trecki et al., 2015). Alternatively, there 
could be interspecies differences in SC pharmacokinetics, phar-
macodynamics and toxicity. The co-use/abuse of other drugs 
with SCs is common; in particular tobacco, energy drinks, and 
alcohol could be relevant (Winstock and Barratt, 2013).
It is also possible that severe adverse reactions to SCs may be 
modulated by dose factors, with the high potency of SC compounds 
increasing the risk of accidental overdose and toxicity compared 
with cannabis. SC products have no established manufacturing 
standards, and dose may vary between batches or be unevenly dis-
tributed within the product (Musah et al., 2012). This makes it dif-
ficult for users to determine a safe dose, even if they have used that 
product previously. Moreover, contamination of SC products with 
other compounds including caffeine, nicotine, and eugenol has been 
reported (Dresen et al., 2010). Such contamination could account 
for some toxicity, particularly in the cases where toxicity is clus-
tered around a specific batch of products (Monte et al., 2014; 
Schwartz et al., 2015). Finally, because many SCs are full cannabi-
noid receptor agonists, an overdose could produce more severe and 
qualitatively different effects to a similarly large dose of a partial 
agonist such as THC (Spaderna et al., 2013). With these factors in 
mind, it is perhaps not surprising that SC toxicity occurs in some 
but not all users, and often in clusters (Bhanushali et al., 2012).
Conclusion
In summary, the present study identifies both short-term and last-
ing residual behavioural impairments arising from chronic 
administration of AB-PINACA and AB-FUBINACA. Acute 
responses to both SCs resembled those observed with THC, 
but there were some subtle differences in the long term. 
AB-FUBINACA reduced some cytokine levels and produced 
more marked recognition memory impairments, THC alone 
produced lasting social impairment, while cerebellar endocan-
nabinoids were reduced by THC and AB-PINACA, but not 
AB-FUBINACA. These results highlight that while acute 
responses to different cannabinoid agonists may be similar, the 
long-term behavioural or biochemical impacts effects may differ. 
This emphasises the need for ongoing assessment of long-term 
effects of emerging SCs, particularly in vulnerable adolescent 
populations where negative effects may be amplified.
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Abstract Nabiximols (Sativex) is a buccal spray con-
taining both D9-tetrahydrocannabinol (THC) and cannabid-
iol (CBD). It has shown promise as an agonist substitution
therapy for treating cannabis withdrawal and dependence.
Monitoring urinary cannabinoid levels during treatment is
important for determination of cannabinoid pharmacoki-
netics and for treatment adherence during clinical trials.
Here, we use a recently described hydrolysis method to lib-
erate urinary CBD from its glucuronide conjugate, and
describe the trajectory of urinary CBD, THC, 11-nor-9-car-
boxy-THC (THC-COOH), and 11-hydroxy-THC (11-OH-
THC) in patients receiving nabiximols treatment (or pla-
cebo) during cannabis withdrawal. Urine and plasma sam-
pleswere taken before and during a 6-day inpatient treatment
regime and during a 3-day drug-free washout. Urine was
hydrolysed with red abalone b-glucuronidase, and CBD,
THC, THC-COOH, and 11-OH-THC were quantiﬁed in
daily urine using liquid chromatography-tandem mass
spectrometry. Overall, urine and plasma cannabinoid levels
followed similar trajectories and closely reﬂected the dosing
schedule. During nabiximols treatment, CBD levels in urine
and plasma rose markedly, while concentrations of THC and
its metabolites remained at, or slightly above, pre-treatment
levels. Following hydrolysis, urinary CBD was detected at
levels 50 and 200 times as high as those in non-hydrolysed
plasma and non-hydrolysed urine, respectively. THC, THC-
COOH, and 11-OH-THC concentrations were also ampliﬁed
by urinary hydrolysis. This method allows sensitive assess-
ment of urinary CBD, and may prove useful in clinical
studies involving nabiximols or other cannabinoid therapies.
Keywords Nabiximols  Sativex  Cannabinoid 
Cannabidiol  Urine  Withdrawal
Introduction
Problems relating to cannabis dependence are a signiﬁcant
cause of drug and alcohol treatment episodes worldwide
[1]. Cannabis dependence is thought to affect approxi-
mately 10 % of all cannabis users, amounting to roughly 13
million people globally [2]. Sudden abstinence from can-
nabis in dependent users can lead to a withdrawal syn-
drome with symptoms such as irritability, insomnia,
restlessness, weight loss, tremors, depression, and anxiety
[3, 4]. This can present a major obstacle to the reduction or
cessation of cannabis use [5–7]. Attempts to manage these
symptoms using conventional pharmacotherapies such as
antidepressants and mood stabilisers have met with only
limited success [8, 9]. However, the use of agonist
replacement therapy involving a variety of cannabinoid
receptor agonists shows considerable promise [10–13].
Nabiximols (Sativex) is a buccal spray derived from
Cannabis sativa plants which provides an approximate 1:1
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ratio of D9-tetrahydrocannabinol (THC) and cannabidiol
(CBD), with additional trace phytocannabinoids and ter-
penoids. It was developed primarily for the treatment of
muscle spasticity and pain in multiple sclerosis [14]. Our
group recently reported that nabiximols was efﬁcacious in
treating cannabis withdrawal [11]. The THC component of
nabiximols provides an agonist substitution effect, while
the addition of CBD may functionally minimise some of
the negative effects of THC such as anxiety, cognitive
impairments, and memory deﬁcits, and provide intrinsic
anxiolytic, hypnotic, and antipsychotic effects [15–17].
This could afford an advantage over pure THC prepara-
tions. Although CBD has poor afﬁnity for cannabinoid
receptors, it may act as an allosteric modulator at CB1
receptors [18], can increase endocannabinoid levels [19]
and may act at non-cannabinoid receptors such as 5-HT1A,
PPARc, and TRP channels [20–22].
Measurement of CBD, THC, and THC metabolites
during and following nabiximols administration is impor-
tant for dose titration, safety, and for monitoring treatment
adherence, particularly over an extended treatment period.
THC is predominantly metabolised via cytochrome P450
2C9 and 2C19 isoenzymes to 11-hydroxyl-THC (11-OH-
THC) and 11-nor-9-carboxy-THC (THC-COOH) [23, 24].
These metabolites can undergo phase II glucuronidation by
various UDP-glucuronosyltransferases [25]. The metabo-
lism of CBD is less well understood, but CBD appears to
be a better substrate for human UDP-glucuronosyltrans-
ferases than THC, and is excreted both directly and in
glucuronidated form in urine, together with 7-hydroxy-
CBD (7-OH-CBD) and oxidised derivatives as major
metabolites [26, 27].
These compounds can be measured in plasma, but uri-
nalysis would provide easier and less invasive sampling in
clinical studies. Until recently, sensitive and accurate
analysis of CBD in urine has been challenging, due to
uncharacterised phase II metabolites. A method optimised
for analysing CBD and its secondary glucuronidated or
sulfated metabolites using enzymatic hydrolysis with red
abalone b-glucuronidase, followed by gas chromatogra-
phy–mass spectrometry analysis, has been described, pro-
ducing a 250-fold increase in urinary CBD levels compared
to non-hydrolysed samples [28]. This method has the
potential to greatly improve the viability of CBD
urinalysis.
Here, we employed this method, adapted to liquid
chromatography–tandem mass spectrometry (LC–MS/
MS), in a clinical study involving cannabis withdrawal.
It is unclear how well urine and plasma cannabinoid
levels correlate during multiple days of nabiximols
treatment, and how well this method detects THC and its
metabolites; thus the method requires further validation
in clinical settings. In addition, the levels of CBD, THC,
and its metabolites during multiple days of nabiximols
treatment are largely uncharacterised in terms of overall
time course and peak concentration. Therefore, the pre-
sent study demonstrates the trajectory of CBD levels, as
well as THC and its primary metabolites, during treat-
ment with nabiximols across an inpatient cannabis
withdrawal episode in a clinical population of cannabis-
dependent treatment-seekers [29]. We also examine the
relationship between urine and plasma cannabinoid levels
to validate the utility and sensitivity of urinary CBD
monitoring in a clinical setting, using an enzymatic
hydrolysis approach.
Materials and methods
Participants and dosing
Urine and blood samples were provided by 51 participants
from a double-blind randomised clinical inpatient trial of
nabiximols for cannabis withdrawal management (see Ref.
[29]). Brieﬂy, they were individuals aged 18–65 years who
had a desire to reduce or halt cannabis use and had a his-
tory of cannabis withdrawal, but no current alcohol or other
drug dependence except for nicotine or caffeine. Samples
from 22 patients were selected for analysis based on the
criterion that they had provided at least 5 daily urine
samples across the 9 days of inpatient treatment. Of these,
11 were placebo-treated and 11 were nabiximols-treated.
Patients were asked to abstain from cannabis use for at
least 6 h before admission.
The ﬁrst nabiximols dose was administered at 4 p.m. on
day 1 (eight sprays, for a total of 21.6 mg THC and 20 mg
CBD), and again at 10 p.m. (eight sprays). Maximal doses
(eight sprays four times daily, for a total of 86.4 mg of
THC and 80 mg CBD) were administered on days 2 and 3.
The dose was tapered on subsequent days to six sprays four
times daily on day 4 (64.8 mg THC and 60 mg CBD), four
sprays four times daily on day 5 (43.2 mg THC, 40 mg
CBD), and two sprays four times daily on day 6 (21.6 mg
THC, 20 mg CBD). Days 7–9 were drug-free washout
days. Placebo participants received a matched placebo (a
spray with similar smell and taste) developed by GW
Pharmaceuticals, Porton Down Science Park, UK. This
research was approved by the Hunter New England Human
Research Ethics Committee.
Plasma and urine sampling
Blood was taken on days 1 (pre-treatment), 3 (peak dose),
and 7 (14.5 h after last nabiximols dose). Blood samples
were was not taken daily, in order to limit the invasiveness
of the study. Blood was drawn at 12:30 p.m. into an EDTA-
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coated collection tube and centrifuged at 1500 g for
10 min. Plasma was stored at -20 C until analysis. We
obtained daily urine samples, collected at the ﬁrst void of
the day and stored at -20 C until analysis. The urine
sample on day 1 was taken before the ﬁrst nabiximols dose.
Reagents
Cannabinoid standards and deuterated internal standards
(THC, THC-d3, CBD, CBD-d3, 11-OH-THC, 11-OH-THC-
d3, THC-COOH, and THC-COOH-d9) were obtained from
Cerilliant (Round Rock, TX, USA); methanol, acetoni-
trile, n-hexane, aqueous ammonia, and anhydrous sodium
acetate from Merck Millipore (Bayswater, VIC, Australia);
monobasic/dibasic potassium phosphate from Ajax Fine
Chemicals (Sydney, NSW, Australia); glacial acetic acid
from Fisher Scientiﬁc (Melbourne, VIC, Australia); and red
abalone b-glucuronidase from PM Separations (Capalaba,
QLD, Australia). All chemicals and solvents were at least
ACS or HPLC grade, respectively.
Cannabinoid urinalysis
Urine samples (0.5 mL) were analysed in duplicate using a
previously described method [28], adapted to LC–MS/MS
as detailed in the following sections.
Enzyme hydrolysis
Following fortiﬁcation with internal standard solutions, the
samples were adjusted to pH 5 with 1 mL 0.2 M sodium
acetate buffer, then hydrolysed with 25 lL red abalone b-
glucuronidase ([100,000 units/mL) and incubated for 15 h
at 37 C. Calibrator and quality control samples, prepared
using blank urine spiked with cannabinoid standards, were
treated identically. Following incubation, protein precipi-
tation was performed via addition of 1 mL ice-cold ace-
tonitrile, followed by centrifugation and aspiration of the
supernatant. Samples were adjusted to pH 6 with 2 mL
0.1 M phosphate buffer in preparation for solid-phase
extraction.
Solid-phase extraction
Hydrolysed samples were directly loaded onto 3 mL UCT
Styre Screen SSTHC063 SPE columns (United Chemical
Technologies [UCT], Inc., Bristol, PA, USA), washed with
1 mL of water/acetonitrile/ammonia (84:15:1, v/v/v), and
then dried under a vacuum for 20 min. Cannabinoid ana-
lytes were eluted from the columns with 3 mL of n-hexane/
ethyl acetate/glacial acetic acid (49:49:2, v/v/v). Eluates
were evaporated to dryness under a stream of high-purity
nitrogen at 60 C, and then reconstituted in 1 mL initial
mobile phase (40 % methanol and 60 % 10 mM ammo-
nium acetate) for LC–MS/MS analysis.
LC–MS/MS analysis
A Shimadzu Nexera ultra-high-performance liquid chro-
matograph (Shimadzu Corp., Kyoto, Japan) with a Pinnacle
DB Biphenyl column (100 9 2.1 mm i.d., particle size
1.9 lm; Restek Corp., Bellefonte, PA, USA) was used for
chromatographic separation. This was performed via gra-
dient elution with methanol and 10 mM ammonium acetate
at a ﬂow rate of 0.3 mL/min at 40 C. A Shimadzu LCMS-
8030 triple quadrupole mass spectrometer, operated in
positive atmospheric pressure chemical ionisation mode
with multiple reaction monitoring, was used for analyte
identiﬁcation and quantiﬁcation.
Non-hydrolysed samples
To investigate the effect of hydrolysis with red abalone b-
glucuronidase on all cannabinoid analytes, the urine sam-
ples of a single nabiximols-treated patient were analysed
without the enzyme hydrolysis step. These results were
compared to the analysis of the same samples using
enzyme hydrolysis.
Validation
Although this hydrolysis method was validated previously
for GC–MS [28], we determined selectivity, linearity,
accuracy, precision, limits of quantiﬁcation (LOQ), and
limits of detection (LOD) for our LC–MS/MS adaptation.
Selectivity was veriﬁed by analysing blank urine samples
provided by an experimenter who had not used or been
exposed to any cannabis in the last year. Linearity was
assessed using calibrators at seven ascending concentration
levels. Accuracy was determined using quality control
(QC) samples at low and high concentrations relative to the
calibration range, with bias calculated as percent deviation
from the nominal analyte concentration. Precision was
calculated using the same low and high QC samples, with
percent relative standard deviation calculated from three
runs on the same day (intraday) and on three separate days
(interday). LOQ was selected on the basis of accuracy and
precision of QC samples, while LOD was set as the lowest
calibrator concentration, with a signal-to-noise ratio of C3.
Cannabinoid plasma analysis
Plasma was analysed as reported previously [29]. Brieﬂy,
cannabinoids were extracted from plasma using solid-phase
extraction following protein precipitation with acetonitrile,
dried under nitrogen, reconstituted in initial mobile phase,
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and analysed with LC–MS/MS as speciﬁed in the previous
section.
Data analysis
Raw chromatographic data were analysed using LabSolu-
tions version 5.60 software (Shimadzu Corp., Kyoto,
Japan). Quantiﬁed analytical data were analysed with SPSS
version 22 software (IBM Corp., Armonk, NY, USA). The
analysis considered the main effects of treatment (nabixi-
mols or placebo) and time (days 1–9), and their interaction
in a linear mixed model for repeated measures with ﬁrst-
order autoregressive covariance structure [30]. We exam-
ined signiﬁcant effects with two sets of planned contrasts.
The ﬁrst set of contrasts compared the levels of each analyte
between nabiximols and placebo patients on each day of the
inpatient study (e.g., day 3 nabiximols urine compared to
day 3 placebo urine). The second set compared the levels of
analytes on each day to day 1 levels within each treatment
group (e.g., day 3 nabiximols urine compared to day 1
nabiximols urine). All contrasts were adjusted for multiple
comparisons using the Bonferroni method. Effect sizes
were calculated using the bias-corrected Hedges g (raw
difference between two means divided by standard devia-
tion adjusted for population size [31]).
We also computed Pearson’s correlations between plasma
and hydrolysed urinary concentrations of each analyte to
investigate whether urinalysis, a less invasive procedure,
could be used as a proxy for plasma drug levels. All data
across placebo and nabiximols treatment groups on days 1, 3,
and 7 (plasma sampling days) were pooled to achieve sufﬁ-
cient statistical power. In addition, we computed correlations
between plasma on days 1, 3, and 7 with urinary data on the
days following plasma sampling (days 2, 4, and 8), in an
attempt to account for any delay in analyte excretion. In all
cases, data where either urine or plasma concentrations fell
below the limits of quantiﬁcation were excluded.
Finally, we calculated the ratios of hydrolysed urinary
THC to CBD, THC-COOH to CBD, and 11-OH-THC to
CBD at peak dosing (day 3) for nabiximols-treated par-
ticipants, to investigate the consistency of analyte ratios
during nabiximols treatment, theorising that deviation from
a consistent ratio could be useful for identifying relapse to
recreational cannabis use in outpatient settings.
Results
Patient demographics and prior substance use
Patient characteristics are presented in Table 1. Patients
were on average 39 years of age, had used cannabis for an
average of 24.4 years, and had used an average 19.3 g of
cannabis per week in the month preceding treatment. There
were no signiﬁcant differences between nabiximols- and
placebo-treated patients in demographics or substance use
history. A greater number of urine and plasma samples
were provided over the course of the study by nabiximols-
treated participants, corresponding to greater treatment
retention [29].
Table 1 Demographics and
substance use history by
treatment group
Characteristic Nabiximols
(n = 11)
Placebo
(n = 11)
Total
(n = 22)
P valuea
Demographics, no. (%)
Age, mean (SD) 38.4 (9.58) 39.6 (6.99) 39.0 (8.21) 0.73
Male 8 (72.7) 9 (81.8) 17 (77.2) 0.61
Aboriginal or Torres Strait Islander 0 (0) 1 (9.1) 1 (4.5) 0.31
Substance use history, mean (SD)
Cannabis use g/weekb 13.2 (6.92) 25.4 (32.2) 19.3 (23.6) 0.23
Years of cannabis use 23.7 (9.94) 25.0 (6.32) 24.4 (8.16) 0.72
Alcohol use, U/weekb 4.60 (10.8) 5.83 (7.21) 5.21 (8.99) 0.76
Cigarettes/weekb 69.8 (59.5) 50.8 (55.9) 60.3 (57.1) 0.29
Tobacco use g/weekb 9.54 (2.37) 11.2 (2.83) 10.4 (8.48) 0.67
Samples, no.
Urine samples provided 88 77 165 0.04
Plasma samples provided 31 24 55 \0.01
Remaining at day 9, no. (%) 7 (63.6) 5 (45.5) 12 (54.5) 0.41
SD standard deviation
a Statistical comparisons were independent samples t-tests for continuous variables, or v2 tests for cate-
gorical variables
b Weekly use in the month before entering the study, measured by modiﬁed timeline follow-back
Alcohol measured in units (1 U = 8 g ethanol)
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Method validation
Validation and quantiﬁcation parameters for the LC–MS/
MS urinary hydrolysis method are presented in the sup-
plementary material (Table S1). All analytes produced a
linear response in the appropriate range, and precision and
accuracy were within acceptable limits [32]. No interfering
signals were detected in blank samples.
CBD
All but one placebo participant had undetectable CBD
levels in plasma and urine for the duration of inpatient
treatment. In contrast, in those patients receiving nabixi-
mols treatment (Fig. 1a), plasma and urinary CBD
appeared upon commencement of medication, rising to
asymptote in urine on day 4. CBD levels decreased fol-
lowing reductions in dosing on day 4, and decreased
towards zero over days 7, 8, and 9 (Fig. 1a), when
nabiximols was withdrawn. Overall, CBD levels in
hydrolysed urine were approximately 50 times those of
plasma CBD.
In urine samples, levels of CBD were signiﬁcantly
higher in the nabiximols-treated group (treatment 9 time:
F8,102.93 = 3.285, P\ 0.01) across all 9 days, and con-
trasts demonstrated that CBD levels were higher in
nabiximols patients on days 2–6, with maximal differences
observed on day 4 (all P\ 0.05; Hedges g = 0.68;
Fig. 1a). On these days in nabiximols-treated patients,
CBD levels were signiﬁcantly elevated compared to pre-
treatment levels (all P\ 0.05), while no differences from
pre-treatment were observed in placebo-treated patients.
Similarly, overall plasma CBD levels were signiﬁcantly
greater in nabiximols-treated patients than in those treated
with placebo (treatment 9 time: F2,40.68 = 38.42,
P\ 0.0001), and contrasts revealed that CBD levels were
higher in nabiximols-treated patients on days 3 and 7 (all
P\ 0.05; Fig. 1a), with the greatest difference occurring
on day 3 (Hedges g = 2.99). Compared to day 1 levels,
plasma CBD levels were elevated in nabiximols-treated
patients on days 3 and 7 (all P\ 0.05), while no differ-
ences from pre-treatment levels were found in placebo-
treated patients. Day 1 adjusted data are presented in the
supplementary material (Fig. S1).
Fig. 1 Mean cannabidiol (CBD), D9-tetrahydrocannabinol (THC),
11-nor-9-carboxy-THC (THC-COOH), and 11-hydroxy-THC (11-
OH-THC) in plasma (non-hydrolysed) and urine of patients treated
with placebo (n = 11) and nabiximols (n = 11). Shaded background
area indicates the tapered nabiximols dosing schedule. Note that
samples were taken in the morning and that day 1 samples were taken
before the ﬁrst nabiximols or placebo dose. Peak dosing occurred on
days 2 and 3, and washout occurred on days 7–9. Asterisk (*)
indicates nabiximols urine concentration signiﬁcantly greater than
placebo urine concentration. Hash symbol (#) indicates nabiximols
plasma concentration signiﬁcantly greater than placebo plasma
concentration
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THC
THC levels in urine were low compared to the other ana-
lytes, and were variable on day 1 (Fig. 1b). Overall, urinary
THC was elevated across the inpatient period in nabixi-
mols-treated patients (treatment 9 time: F8,96.22 = 3.41,
P\ 0.01), and contrasts showed higher urinary THC in
patients treated with nabiximols compared to placebo on
day 4 (P\ 0.05; Hedges g = 0.82; Fig. 1b). Urinary THC
did not signiﬁcantly differ from day 1 levels on any day for
nabiximols-treated patients, but THC levels for placebo-
treated patients decreased below initial levels on all sub-
sequent days (all P\ 0.05).
Overall, plasma THC was elevated by nabiximols treat-
ment compared to placebo (treatment 9 time:
F2,29.56 = 10.517, P\ 0.001), and contrasts showed higher
THC in participants treated with nabiximols versus placebo
on day 3 (P\ 0.05; hedges g = 1.41; Fig. 1b). Compared
to day 1 levels, THC decreased on day 7 for nabiximols-
treated participants, and the THC levels for placebo-treated
participants decreased on days 3 and 7 (all P\ 0.05).
THC-COOH
THC-COOH urine levels rose steadily during nabiximols
treatment, before declining rapidly as treatment ceased
(Fig. 1c). In the placebo group, THC-COOH levels gen-
erally declined across all 9 days, but did not reach zero.
Contrasts revealed that nabiximols treatment signiﬁcantly
increased THC-COOH levels on days 3–7, with the
greatest difference occurring on day 5 (all P\ 0.05;
Fig. 1c; Hedges g = 0.54).
Plasma THC-COOH was higher in patients treated with
nabiximols compared to placebo over the course of the
study (treatment 9 time: F2,32.50 = 17.36, P\ 0.0001),
and contrasts showed that plasma THC-COOH was higher
in nabiximols-treated patients on days 3 and 7 compared to
those treated with placebo (all P\ 0.05; Fig. 1c). This
difference was greatest on day 3 (Hedges g = 1.40). Rel-
ative to day 1 levels, plasma THC-COOH increased on day
3 for nabiximols-treated patients, and THC-COOH in the
placebo-treated group decreased on days 3 and 7 (all
P\ 0.05).
11-OH-THC
11-OH-THC levels followed a pattern similar to those of
THC-COOH, albeit at lower concentrations (Fig. 1d).
Urinary 11-OH-THC was higher in nabiximols-treated
versus placebo-treated patients throughout the duration of
the inpatient study (treatment 9 time: F8,113.55 = 4.64,
P\ 0.0001), and contrasts showed higher 11-OH-THC in
patients treated with nabiximols compared to placebo on
days 3–5 (all P\ 0.05; Fig. 1d). The greatest increase
occurred on day 4 (Hedges g = 1.38). Compared to day 1
levels, urinary 11-OH-THC levels were elevated on days 3
and 4 in nabiximols-treated patients, while placebo levels
decreased relative to day 1 levels on all subsequent days
(all P\ 0.05).
Overall, plasma 11-OH-THC was signiﬁcantly higher
in nabiximols-treated compared to placebo-treated
patients (treatment 9 time: F2,33.63 = 31.79, P\ 0.0001).
Contrasts revealed that on day 3, plasma 11-OH-THC was
signiﬁcantly greater in nabiximols-treated patients relative
to those treated with placebo (P\ 0.05; g = 3.20;
Fig. 1d). Compared to pre-treatment levels, 11-OH-THC
increased on day 3 for nabiximols-treated participants,
and placebo levels decreased on days 3 and 7 (all
P\ 0.05).
b-Glucuronidase hydrolysis
Hydrolysis of urine samples with b-glucuronidase pro-
duced large increases in concentrations of all analytes
(Fig. 2). CBD levels were approximately 200 times greater
in hydrolysed urine, peaking at 245 ng/mL on day 3 in
hydrolysed urine, compared to 1.2 ng/mL in non-hydrol-
ysed urine on day 5. THC-COOH levels were several times
higher in hydrolysed urine across the 9 days. Without
hydrolysis, THC and 11-OH-THC levels fell below limits
of quantiﬁcation on all days.
Relationship between urine and plasma analyte
concentrations
Scatter plots of urinary and plasma analyte concentrations
are presented in Fig. 3. Urine–plasma Pearson correlations
for pooled data from plasma sampling days 1, 3, and 7 were
strong and statistically signiﬁcant for CBD (r = 0.87,
P\ 0.001; Fig. 3) and THC (r = 0.74, P\ 0.001), and
moderate and statistically signiﬁcant for THC-COOH
(r = 0.47, P\ 0.001) and 11-OH-THC (r = 0.44,
P\ 0.05). The urine–plasma correlation was improved for
THC-COOH by using urinary data from the days following
plasma sampling (i.e., days 2, 4, and 8; r = 0.67,
P\ 0.001), but CBD, THC, and 11-OH-THC correlations
fell compared to same-day plasma and urine correlations
(CBD: r = 0.03, P[ 0.05; THC: r = 0.30, P\ 0.05;
11-OH-THC: r = 0.29, P[ 0.05).
Analyte ratios
Ratios of THC to CBD, THC-COOH to CBD, and 11-OH-
THC to CBD for nabiximols-treated patients at peak dosing
(day 3) are presented in Table 2. Relative standard devi-
ations were high for all analyte ratios in both hydrolysed
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urine and non-hydrolysed plasma, indicating substantial
variability in analyte ratios between individual patients.
Discussion
The current study examined urine and plasma cannabinoid
concentrations during inpatient cannabis withdrawal,
where participants received 6 days of nabiximols or pla-
cebo treatment followed by 3 washout days. All cannabi-
noid analytes of interest (THC, THC-COOH, 11-OH-THC,
CBD) were detectable following b-glucuronidase hydrol-
ysis. The hydrolysis method utilised was particularly
effective in liberating urinary CBD.
CBD levels in urine were negligible before treatment,
reﬂecting the low or non-existent CBD content of typical
Australian street cannabis [33]. By contrast, THC, THC-
COOH, and 11-OH-THC were readily detectible initially,
although highly variable across individuals. Plasma THC-
COOH was more abundant than its parent compound THC,
consistent with cannabinoid pharmacokinetic studies
following smoking or oral administration [34, 35]. More-
over, in day 2 placebo urine, THC and 11-OH-THC levels
fell in comparison to day 1 levels, while THC-COOH did
not, possibly reﬂecting the conversion of THC and/or
11-OH-THC to THC-COOH [34]. The concentrations of all
cannabinoids in nabiximols-treated patients peaked shortly
after peak dosing, and declined steadily over multiple days
following cessation of dosing (Fig. 1), closely reﬂecting
the tapered dosing schedule. However, urinary THC and
THC-COOH was detectable in several patients on day 9,
even in the placebo group, concordant with the long period
of elimination of these analytes in heavy cannabis users
[36]. Slow elimination of cannabinoids has been well
characterised previously [37, 38], and may be partly due to
the long-term sequestration of cannabinoids in fat tissue
[36, 39, 40].
In participants receiving nabiximols treatment, CBD
was detected at high levels in urine subsequent to hydrol-
ysis of the urinary samples with red abalone b-glu-
curonidase. This produced urinary CBD at concentrations
50 times those seen in plasma, and approximately 200
Fig. 2 Effect of hydrolysis with red abalone b-glucuronidase on
urinary CBD, THC, THC-COOH, and 11-OH-THC in a single
nabiximols-treated patient. The background shaded area indicates the
tapered nabiximols dosing schedule. Note that samples were taken in
the morning and that day 1 samples were taken before the ﬁrst
nabiximols or placebo dose
Forensic Toxicol (2017) 35:33–44 39
123
Chapter 5 156
times those in non-hydrolysed urine, similar to the 250-fold
increase reported previously [28]. Given that CBD is
increasingly recognised as a potential treatment for a
variety of conditions, including schizophrenia [17], epi-
lepsy [41], and anxiety [42], this analytical technique could
be useful across a range of situations in which CBD itself,
or CBD-containing therapeutics such as nabiximols, are
being administered.
THC, THC-COOH, and 11-OH-THC concentrations
were also ampliﬁed by urinary hydrolysis (Fig. 2). We
observed a ﬁvefold increase in urinary THC-COOH fol-
lowing hydrolysis, and without the hydrolysis step, urinary
Fig. 3 Scatter plots of plasma (non-hydrolysed) and urine (hydrol-
ysed) concentrations of a CBD (n = 17), b THC (n = 51), c THC-
COOH (n = 51), and d 11-OH-THC (n = 24). Data were pooled
across treatment groups and across days 1, 3, and 7 (plasma sampling
days). White dots indicate data from placebo-treated patients; solid
black dots indicate data from nabiximols-treated participants. The e is
a THC-COOH scatter plot using urinary data from the days following
plasma sampling (days 2, 4, and 8; n = 47). Only data points where
both plasma and urine concentrations were above limits of quantiﬁ-
cation are included. Lines were ﬁtted via linear regression. *P\ 0.05,
***P\ 0.001
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THC and 11-OH-THC concentrations fell below limits of
quantiﬁcation. Hydrolysed concentrations of both THC-
COOH and 11-OH-THC in urine were approximately 10
times those in plasma (Fig. 1), potentially reﬂecting
improved sensitivity for these analytes compared to the
standard plasma assay. We also noted that THC-COOH
was more concentrated even in non-hydrolysed urine than
in plasma (Figs. 1c, 3c), as might be anticipated, given the
polarity and long urinary half-life of this metabolite
[43, 44]. Thus, although this method is optimised for CBD
sensitivity, it also improves the analysis of other major
cannabinoid analytes.
Importantly, urinary cannabinoid levels correlated with
plasma levels for all analytes (Fig. 3). These correlations
were stronger for CBD and THC than for metabolites
THC-COOH and 11-OH-THC. Our plasma samples did not
undergo hydrolysis; this variability in THC metabolites
might arise from differences in the proportion of free and
glucuronidated THC-COOH and 11-OH-THC in plasma
and urine for some patients, or a delay in excretion of
analytes from plasma into urine. Indeed, using urinary data
from the days following plasma sampling improved the
urine–plasma correlation for THC-COOH (Fig. 3e),
although this correction reduced correlations for all other
analytes. Creatinine normalisation might improve these
correlations overall, but urinary dilution cannot account for
the increased variability of THC metabolites compared to
CBD and THC, since all analytes would be similarly
impacted by dilution. Overall, these correlations suggest
that, following suitable hydrolysis procedures, urinary
cannabinoid measurement might ﬁnd use as a proxy for
plasma sampling in future clinical trials where CBD or
THC are administered, although some correction for a
delay in urinary excretion may be necessary for THC-
COOH. This may prove useful for a variety of clinical
trials where CBD and other cannabinoids are used, such as
pediatric epilepsy [45].
There is increasing interest in the use of nabiximols as
an agonist substitution therapy to treat persons who are
cannabis-dependent [11, 29, 46]. An important technical
issue thus arises as to whether any recreational use of
smoked or vaporised cannabis (i.e., relapse) taken in
addition to nabiximols treatment can be detected analyti-
cally, so that treatment efﬁcacy can be accurately dis-
cerned. In oral ﬂuid, analysis of cannabinoid ratios can
distinguish nabiximols treatment from stand-alone smoked
cannabis use via elevated CBD to THC ratios, but addi-
tional research is required to determine whether relapse to
cannabis smoking in addition to nabiximols treatment can
be accurately detected in oral ﬂuid [47]. We have similarly
considered the possibility of using urinary cannabinoid
ratios to detect such relapse to recreational use during
nabiximols treatment. In the current study, levels of CBD
on day 1 and in the placebo group across all 9 days were
low or negligible, reﬂecting the common lack of CBD in
recreational cannabis consumed by users in multiple
countries [33, 48–50]. Initiation of nabiximols therapy
corresponds to a sustained increase in urinary CBD levels.
It is possible that additional unsanctioned cannabis use
during nabiximols treatment may produce a sudden
Table 2 Urinary and plasma
analyte ratios in nabiximols-
treated patients at peak dosing
(on day 3)
Patient THC : CBD THC-COOH : CBD 11-OH-THC : CBD
Urine Plasma Urine Plasma Urine Plasma
1 0.06 1.54 19.8 28.0 0.00 1.31
2 0.02 3.07 9.56 116 0.19 3.83
3 0.05 3.35 9.52 72.4 0.36 3.09
4 0.05 2.38 12.0 71.2 0.39 1.83
5 0.13 2.01 20.0 37.9 1.02 1.71
6 0.05 2.11 4.57 67.7 0.62 2.73
7 0.05 2.17 6.11 51.3 0.33 1.56
8 0.27 2.15 31.9 23.1 3.17 1.94
9 0.04 1.84 3.34 17.8 0.39 1.54
10 0.04 4.84 11.4 135 0.40 3.53
11 –a 2.13 –a 90.5 –a 3.83
Range [0.02–0.27] [1.54–4.84] [3.34–31.9] [17.8–135] [0–3.17] [1.31–3.83]
Mean 0.08 2.51 12.8 64.6 0.69 2.45
RSD 9.37 0.37 0.68 0.59 1.33 0.40
THC D9-tetrahydrocannabinol, CBD cannabidiol, THC-COOH 11-nor-9-carboxy-THC, 11-OH-THC
11-hydroxy-THC, RSD relative standard deviation, calculated as the standard deviation divided by the
mean
a Urinary data for nabiximols-treated patient 11 on day 3 were unavailable
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increase in THC and its metabolites THC-COOH and
11-OH-THC relative to CBD in urine.
However, computation of urinary THC to CBD on day 3
(peak dosing) for nabiximols-treated patients produced a
large range of ratios, as was the case for ratios of THC-
COOH to CBD and 11-OH-THC to CBD (Table 2). Sim-
ilar variability was present to a smaller but still substantial
extent in ratios calculated from plasma concentrations.
These ranges may be too broad for detection of additional
cannabis use, although longer-term treatment (i.e., constant
nabiximols treatment over several additional days) might
produce more consistent ratios. Ongoing studies by our
group are aimed at addressing this hypothesis.
There are some caveats to consider. The lack of crea-
tinine-corrected estimates of urinary analytes is a limita-
tion, although the strong correlations between urinary and
plasma levels of CBD and THC suggest that the impact of
urinary dilution was minor. We were unable to collect
plasma every day, due to the invasiveness of daily sam-
pling; we could not calculate meaningful urine–plasma
correlations for individual participants. Placebo data were
impacted to a greater degree than nabiximols data by
patient dropout (Table 1), and while this underscores the
efﬁcacy of nabiximols treatment for cannabis withdrawal,
it reduced the reliability of placebo data and increased the
difﬁculty in obtaining statistically signiﬁcant results on
later days. It should be noted that the dosing regimen in this
study involved high doses of nabiximols, with peak doses
at 32 sprays per day (86.4 mg THC, 80 mg CBD), several
times higher than doses used in other clinical conditions
(e.g., pain, multiple sclerosis) in non-cannabis dependent
populations [51]. Replication of this study in patients using
lower doses of nabiximols may be warranted. Finally,
future studies could examine urinary levels of CBD
metabolites (e.g., 7-OH-CBD) in addition to THC
metabolites.
Conclusions
This study demonstrates a clinical application of urinary
hydrolysis to determine urinary CBD, THC, and THC
metabolites over multiple days of nabiximols treatment,
which may be applicable to a wide range of emerging
THC- and/or CBD-based treatments and clinical trials.
Urinary concentrations of CBD, 11-OH-THC, and THC-
COOH were greatly improved by hydrolysis with b-glu-
curonidase compared to the standard plasma assay and to
non-hydrolysed urine. Urine and plasma concentrations of
CBD, THC, THC-COOH and, to a lesser extent, 11-OH-
THC followed similar trajectories that reﬂected the dosing
schedule, suggesting that urine screening using this method
may be an appropriate and less invasive proxy for blood
testing.
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6.1 Chapter overview 
 The studies presented in this thesis were designed to build further knowledge 
and understanding in several key areas of cannabinoid research, as reviewed in 
Chapter 1. Specifically, these studies aimed to:  
1. Characterise the in vivo potency and basic physiological effects of several 
synthetic cannabinoids that are in current use as recreational drugs (Chapter 2).  
2. Identify structure-activity relationships for aminoalkylindoles and related 
synthetic cannabinoids using in vivo measures (Chapter 2).  
3. Establish metabolic pathways and identify valid analytical targets among 
novel synthetic cannabinoids and their metabolites (Chapter 3). 
4. Identify and discuss the discrepancy between in vitro and in vivo synthetic 
cannabinoid pharmacokinetic data, where, for example, in vitro data predicts rapid 
clearance while in vivo data describes long durations of action (Chapter 3).  
5. Explore the long-term residual effects (e.g. cognitive effects, toxicological 
effects) arising from repeated synthetic cannabinoid exposure in rats (Chapter 4). 
6. Establish accurate and practical urinalysis techniques to accompany agonist 
replacement therapies (involving ∆9-THC) for cannabis and/or synthetic cannabinoid 
dependence and withdrawal (Chapter 5). 
Overall, the studies presented in Chapters 2, 3, 4 and 5 successfully addressed 
these aims. The final chapter of the thesis provides a discussion of these studies, and is 
divided into two main sections. The first section provides a summary and discussion of 
the primary findings along with limitations and caveats from each experimental 
chapter. The latter section discusses the wider implications and significance of these 
findings and provides potential directions for future research. 
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6.2 Summary of findings 
 
6.2.1 Chapter 2: Physiological dose-response effects of synthetic 
cannabinoids as measured by biotelemetry 
The publications featured in Chapter 2 used adult male rats with surgically 
implanted radiotelemetric probes to measure the dose-response characteristics of 
twelve synthetic cannabinoids (JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, 
SDB-001, STS-135, AB-PINACA, AB-FUBINACA, 5F-AMB, and MDMB-FUBINACA) on 
body temperature and heart rate. The molecular structures of these compounds are 
diverse but interrelated; the list encompasses synthetic cannabinoids with fluorinated 
and non-fluorinated N-pentyl chains, indoles and indazoles, methanone, carboxylate 
and carboxamide linkers, and a variety of “bulky” groups (Section 1.3.4).  
There were several interesting outcomes of this work. First, dose-dependent 
hypothermia and bradycardia were established for all twelve compounds when 
delivered via the intraperitoneal route of administration. The in vivo dose-response 
relationships established in Chapter 2 proved useful in choosing doses for subsequent 
experiments (e.g. Chapter 4). Second, it was observed that bradycardic effects and 
hypothermic effects occurred over similar timeframes, although bradycardic effects 
were more subtle and were potentially masked by inherently noisy heart rate data. For 
screening purposes, body temperature appears to be the superior measure. Finally it 
was demonstrated that the CB1 receptor selective antagonist rimonabant, but not the 
CB2 receptor selective antagonist SR144528, blocked hypothermia produced by the 
small subset of these compounds that were subjected to antagonist testing (AB-
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PINACA, AB-FUBINACA, 5F-AMB, and MDMB-FUBINACA). This indicates a CB1 
receptor dependent mechanism of action in the hypothermic response.  
More generally, these studies enabled preliminary structure-activity 
relationships (SARs) to be established in vivo (Table 1). Of the twelve compounds 
studied, eight contained an indole core while four contained an indazole core. Overall, 
the indazoles were more potent both in vitro and in vivo, suggesting that this 
structural element confers an increase in efficacy, at least in terms of the classic 
“tetrad” component of hypothermia. Alternatively, all four indazoles also contained a 
carboxamide linker, which could also potentially account for their superior potency. 
However, of the eight indoles, two also contained a carboxamide linker (SDB-001 and 
STS-135), but neither of these compounds were particularly potent in vitro and both 
required relatively high doses to produce threshold hypothermia in vivo (3 and 1 
mg/kg, respectively). Thus, the carboxamide linker is probably not the key feature 
underpinning the greater potency of the indazole/carboxamide compounds in vivo. 
Instead, it is likely that the indazole substituent tends to increase potency compared 
to the indole moiety.  
Interestingly, the effect of fluorination of the N-pentyl chain was minimal in 
vivo. Although fluorination increased CB1 receptor binding activity in vitro, there were 
no consistent differences in elicited hypothermia for fluorinated versus non-
fluorinated ligands. Although the fluorinated compound XLR-11 was active at lower 
doses than its non-fluorinated analogue UR-144 in producing hypothermia, as was 
STS-135 compared to SDB-001, this was not the case for pairings of AM-2201 versus 
JWH-018 or 5F-PB-22 versus PB-22. Moreover, the maximal magnitude of 
hypothermia tended to be similar for fluorinated and non-fluorinated pairs (e.g. JWH-
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018 and AM-2201; Chapter 2). This indicates a discrepancy between predictions 
derived from in vitro binding studies and actual in vivo hypothermic responses.  
Explanation of this discrepancy may require consideration of some of the 
metabolism results presented in Chapter 3. Specifically, this chapter, and other 
published studies, indicate that many 5-fluoropentyl synthetic cannabinoids undergo 
rapid and extensive oxidative defluorination (Chapter 3; Section 6.2.3; Andersson et 
al., 2016; Grigoryev, Kavanagh, & Melnik, 2013; Sobolevsky, Prasolov, & Rodchenkov, 
2012; Wohlfarth et al., 2014). That is, while the 5-fluoropentyl compounds may bind 
more strongly to CB1 receptors than their N-pentyl counterparts, they may also 
undergo rapid biotransformation into the corresponding 5-hydroxy metabolite. These 
metabolites may themselves possess CB1 receptor binding activity greater than the 
parent compound (Seely et al., 2012), and are identical to the 5-hydroxy metabolites of 
the non-fluorinated N-pentyl analogues (Chapter 3). This metabolic convergence may 
contribute to the similarity in in vivo efficacy of fluorinated and non-fluorinated pairs. 
Direct assessment of the physiological effects of some of the 5-hydroxy metabolites 
using the biotelemetry paradigm could help to better substantiate this hypothesis. 
In any case, the effect of fluorination was clearly of smaller magnitude relative 
to alterations in the “bulky” group, which appears to be a major determinant of 
potency (Table 1). For example, substitution of the naphthyl group of JWH-018 and 
AM-2201 for the 2,2,3,3-tetramethylcyclopropyl group of UR-144 and XLR-11 
substantially reduced both in vitro and in vivo potency. Focusing on the indazole 
carboxamides, a (1S)-1-(aminocarbonyl)-2-methylpropyl group (present in AB-PINACA 
and AB-FUBINACA) confers a small potency increase compared to a methyl  
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isovalerate group (5F-AMB and MDMB-FUBINACA). Other relevant examples are 
provided in Table 1.  
Interestingly, JWH-018 and AM-2201 were more potent in vivo than might be 
expected given their in vitro binding profile at CB1 receptors. For example, JWH-018 
acts on human CB1 receptors with an EC50 of 102 nM, but only requires a dose of 0.3 
mg/kg to produce hypothermia in rats, and produces very substantial hypothermia at 
higher doses (Chapter 2; Table 1). Consider that AB-PINACA, which is far more potent 
at human CB1 (EC50 1.2 nM), also required a dose of 0.3 mg/kg to elicit hypothermia 
and produced a lesser maximal hypothermic effect compared to JWH-018 at 1 mg/kg.  
One possibility is that human CB1 receptors could differ markedly from rat CB1 
receptors in terms of binding activity for JWH-018 and AM-2201. However, human 
and rat CB1 receptors are 90% identical in terms of nucleotide sequence and are 98% 
identical in amino acid sequence (Gerard et al., 1990), indicating high receptor 
homology. Alternatively, JWH-018 metabolites are known to retain in vitro and in vivo 
affinity and activity at CB1 receptors (Brents et al., 2011). AM-2201 can also form some 
of these metabolites via oxidative defluorination (Hutter et al., 2013). These CB1 
receptor active metabolites could potentially contribute to the unexpected in vivo 
potency of JWH-018 and AM-2201. However, it should be noted that some JWH-018 
metabolites appear to be antagonists or neutral antagonists at CB1 receptors (Seely et 
al., 2012). So, to the extent that metabolites are responsible for this effect, it probably 
occurs via a complex interaction between several metabolites. 
 The 2,2,3,3-tetramethylcyclopropyl bulky group of UR-144 and XLR-11 was 
associated with a smaller magnitude hypothermia than that obtained with close 
analogues. Similarly, the human CB1 receptor potency of these two compounds was 
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low (UR-144 EC50: 421 nM; XLR-11 EC50: 98 nM), particularly for UR-144 which had an 
EC50 that was weaker than all of the other compounds tested in Chapter 2. This was 
surprising because UR-144 and XLR-11 have been very popular among users in recent 
years and are anecdotally reported as strongly efficacious (NFILS, 2015).  
This discrepancy may be explained by consideration of active metabolites or 
thermal degradants formed during consumption of UR-144 and XLR-11 (Section 1.4.4). 
In our biotelemetric assessments, we injected UR-144 and XLR-11 intraperitoneally, but 
human consumption occurs via inhalation after these compounds are heated to high 
temperatures. UR-144 and XLR-11 form ring-opened thermal degradants upon heating, 
which possess human CB1 binding 4.6– to 8-fold higher than the parent compounds, 
and substitute for JWH-018 as a discriminative stimulus in the drug discrimination 
paradigm in laboratory mice (Thomas et al., 2017). Therefore, future studies using 
intraperitoneal injection should consider thermal degradants before arriving at firm 
conclusions regarding the translation of results into human populations. 
A caveat worth noting is that the hypothermic and bradycardic effects observed 
in Chapter 2 do not necessarily correspond to human psychoactive effects. It is 
assumed that the CB1-mediated hypothermic effects in rats would strongly correlate 
with CB1-mediated intoxication in humans, but this remains an assumption and is an 
inherent limitation of this experimental approach. It is therefore encouraging to note 
that drug discrimination studies have indicated that mice appear to experience the 
effects of synthetic cannabinoids as being similar to those of ∆9-THC, or well-
established psychoactive synthetic cannabinoids like JWH-018. For example, AB-
PINACA substitutes for ∆9-THC at 3 mg/kg (Wiley et al., 2015), a dose at which we 
observed substantial hypothermia. Similarly, as mentioned above, UR-144 and XLR-11 
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ring-opened thermal degradants substitute for JWH-018 (Thomas et al., 2017), 
indicating a similar subjective effect.   
 To summarise, the work presented in Chapter 2: 
1. Established that a variety of modern synthetic cannabinoids are tolerated and 
efficacious in rats at an intraperitoneal dose between 0.1 and 3 mg/kg, but in some 
cases doses of up to 10 mg/kg are required for substantial hypothermia. 
2. Found that terminal fluorination of the N-pentyl chain of indole or indazole 
synthetic cannabinoids will generally increase CB1 receptor efficacy and potency in 
vitro. However, this is not always reflected in potency observed in vivo, at least in 
terms of hypothermic and bradycardic effects. This could be due to rapid and 
converging metabolic transformations, particularly oxidative defluorination. 
3. Showed that indazole synthetic cannabinoids appear to be more potent both 
in vitro and in vivo than indole synthetic cannabinoids. 
4. Established that the composition of the “bulky” group has a substantial 
influence on both in vitro and in vivo potency.  
5. Suggests that in some cases, consideration of thermal degradants may be 
necessary before translation of results into human populations. For example, the 
potency of UR-144 and XLR-11 may be underestimated by using intraperitoneal 
injection as the route of administration as opposed to heating and inhalation, which 
can produce thermolytic products that may bind strongly to CB1 receptors. 
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6.2.2 Chapter 3: In vitro and in vivo pharmacokinetics and metabolism of 
synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA 
 In Chapter 3, two carboxamide synthetic cannabinoids, CUMYL-PICA and 5F-
CUMYL-PICA, were incubated with rat and human liver microsomes and hepatocytes 
in vitro. These microsome and hepatocyte incubations were used to generate basic 
pharmacokinetic parameters including half-life and clearance rate of the parent 
compound, and to establish metabolic pathways, respectively, through identification 
of metabolites. Additionally, CUMYL-PICA and 5F-CUMYL-PICA were administered 
to rats (at 3 mg/kg, i.p.) in order to compare the results obtained in vitro with 
pharmacokinetic and metabolic results obtained in vivo. Hypothermia was also 
quantified as a characteristic cannabinoid effect using rectal body temperature. This 
study was performed with the aim of establishing valid analytical targets to allow 
detection of consumption of CUMYL-PICA and 5F-CUMYL-PICA in humans. This 
could be of use in future studies (e.g. characterisation of metabolites in other matrices 
like hair or adipose tissue), in emergency medicine (e.g. identification of these 
compounds following episodes of toxicity), in the forensic context (e.g. in deaths 
associated with synthetic cannabinoid use), or for confirming cessation of drug use 
during treatment programmes, discussed further in Section 6.3.3.  
Chapter 3 proposed specific metabolic pathways for CUMYL-PICA and 5F-
CUMYL-PICA which involved extensive phase I oxidative transformations followed by 
phase II glucuronidation. In particular, CUMYL-PICA was terminally hydroxylated on 
the N-pentyl chain (nominally forming 5-OH-CUMYL-PICA), while 5F-CUMYL-PICA 
was oxidatively defluorinated to form the same metabolite. 5-OH-CUMYL-PICA was 
then further oxidised to a carboxylic acid metabolite. This metabolic convergence may 
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cause difficulty in differentiating CUMYL-PICA and 5F-CUMYL-PICA in biological 
samples, so other hydroxylated metabolites were identified as potentially useful 
analytical targets. 
The metabolic transformations detailed in Chapter 3 are in agreement with 
metabolic data concerning other synthetic cannabinoids. For example, oxidative 
defluorination of the 5-fluoropentyl chain is also a major metabolic pathway for AM-
2201, XLR-11, 5F-PB-22, 5F-AMB, and AM-694 (Andersson et al., 2016; Grigoryev et al., 
2013; Sobolevsky et al., 2012; Wohlfarth et al., 2014). Additionally, it was noted that 
human and rat metabolic processes for CUMYL-PICA and 5F-CUMYL-PICA were 
similar, except that human hepatocytes generally failed to produce oxidations on the 
α,α-dimethylbenzyl moiety. Besides glucuronidation, no other phase II 
transformations, such as sulphation or acetylation, were observed in Chapter 3.  
It is noteworthy, although quite possibly coincidental, that metabolism of 
phytocannabinoids occurs in much the same way. For example, ∆9-THC is oxidised to 
11-OH-THC and then to THC-COOH, which is subsequently glucuronidated. In 
contrast to ∆9-THC metabolism, the specific metabolic enzymes responsible for 
synthetic cannabinoid metabolism remain largely uncharacterised. One exception is 
the case of the carboxamide synthetic cannabinoids (AB-PINACA, AB-FUBINACA, PB-
22, and 5F-PB-22) which are primarily metabolised by carboxylesterase 1. This is very 
different to the cytochrome p450 (CYP)-dominated (e.g. CYP 2C9 and 2C19 
isoenzymes) metabolism of ∆9-THC (Thomsen et al., 2014).  
The research presented in Chapter 3 focused on identification of metabolites in 
order to understand overall metabolic pathways and to identify useful analytical 
targets, rather than on identification of specific metabolic enzymes. Future studies 
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could focus on identifying relevant enzymes using specific microsomal isoforms. Such 
data could be used to better understand potential drug-drug interactions. For 
example, synthetic cannabinoids might inhibit or induce key enzymes responsible for 
the metabolism of other drugs (e.g. illicit drugs, prescription medications, natural 
products), potentially leading to toxicity in humans. In support of this hypothesis, a 
very recent study shows that AM-2201 can inhibit several CYP enzymes, specifically 
CYP 2C8, 2C9 and 3A4 (Kim et al., 2017), which are involved in the metabolism of a 
wide array of drugs and medications. Similar assessment of newer synthetic 
cannabinoids could prove valuable. 
A key finding from Chapter 3 was that the clearance rates predicted by 
microsomal incubations were substantially more rapid than the results obtained from 
actual in vivo experiments in rats. Prior studies using microsomal incubation to 
generate kinetic parameters have also reported rapid clearance: for example, the half-
lives of AMB and 5F-AMB were reported as 1.1 and 1.0 min, respectively (Andersson et 
al., 2016). As discussed in Chapter 3, sequestration of synthetic cannabinoids into 
adipose tissue and subsequent release into blood over time may delay elimination in 
vivo (Gunasekaran et al., 2009; Hasegawa et al., 2015; Johansson et al., 1989). 
Alternatively, or additionally, plasma protein binding may also account for this delay. 
Protein binding is presently uncharacterised for CUMYL-PICA, 5F-CUMYL-PICA, and 
most modern synthetic cannabinoids, and could be a key factor mediating long 
elimination times in vivo. Regardless of mechanism, these data highlight the need for 
careful comparisons of in vivo and in vitro pharmacokinetic data in ongoing studies 
with synthetic cannabinoids. 
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The hypothermic effects of CUMYL-PICA and 5F-CUMYL-PICA were largely as 
expected; a decrease of 2-3 °C and a return to baseline approximately 8 hours later. 
Compared to the biotelemetry data reported in Chapter 2, CUMYL-PICA and 5F-
CUMYL-PICA were approximately as potent in vivo as AB-FUBINACA, PB-22, and 5F-
PB-22. Further assessment of CUMYL-PICA and 5F-CUMYL-PICA at other doses (i.e. 
0.3 mg/kg and 1 mg/kg) using the biotelemetry paradigm could prove informative. 
In sum, the study presented in Chapter 3: 
1.  Identified the major and minor metabolic pathways for CUMYL-PICA and 
5F-CUMYL-PICA. 
2. Quantified the hypothermia produced by CUMYL-PICA and 5F-CUMYL-
PICA in rats at a dose of 3 mg/kg i.p. 
3. Established analytical methods for the measurement of CUMYL-PICA, 5F-
CUMYL-PICA, and metabolites in blood and urine, and identified useful analytes for 
future clinical and forensic purposes. 
4. Compared in vitro kinetic predictions with in vivo data, finding that in vitro 
data overestimated in vivo drug elimination, possibly due to sequestration of 
compounds in adipose tissue and/or due to protein binding. 
 
6.2.3 Chapter 4: Acute and residual effects in adolescent rats resulting 
from exposure to the novel synthetic cannabinoids AB-PINACA and AB-
FUBINACA 
 While Chapters 2 and 3 focused on the immediate physiological effects and 
metabolism of synthetic cannabinoids, Chapter 4 featured an exploratory study 
primarily concerned with identification of long-term (residual) effects produced by 
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repeated use of synthetic cannabinoids AB-PINACA and AB-FUBINACA. In this study, 
adolescent rats were employed in recognition of the predominance of the late 
adolescent/early adulthood age group among synthetic cannabinoid users  (Winstock 
& Barratt, 2013). The rats were dosed every second day for two weeks to partially 
mimic patterns of chronic or sub-chronic use in humans.  
The primary findings of this work were that AB-PINACA, AB-FUBINACA, and 
∆9-THC produced substantial and lasting recognition memory impairments. These 
impairments were most severe following AB-FUBINACA treatment. It was notable that 
a long-term residual deficit was seen in social interaction in rats following ∆9-THC 
pre-treatment, but not with either of the two synthetic cannabinoids.  Other findings 
included that AB-FUBINACA caused lasting changes in plasma cytokine 
concentrations, and that AB-PINACA and ∆9-THC caused lasting residual changes in 
cerebellar endocannabinoids. Overall, it was notable that the three cannabinoid 
compounds produced similar acute effects, and, as with Chapters 2 and 3, no serious 
or unique toxicity was observed with synthetic cannabinoids. 
 AB-PINACA and AB-FUBINACA produced typical cannabimimetic effects 
during acute administration, including reduced locomotor activity, increased anxiety-
like behaviour, and an inhibition of body weight gain. Similar effects have been 
observed following administration of ∆9-THC, CP-55,940, and JWH-018 (Arevalo, de 
Miguel, & Hernandez-Tristan, 2001; Macri et al., 2013). Locomotor suppression has 
also been reported with AB-PINACA, AB-CHMINACA and FUBIMINA in mice (Wiley 
et al., 2015). Although these acute effects were expected given previous reports, 
observation of these effects following AB-PINACA and AB-FUBINACA served as 
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preliminary confirmation that these compounds were representative of the wide 
variety of synthetic cannabinoids used by humans. 
 During acute dosing with the cannabinoids, perhaps the most intriguing 
finding was that although AB-PINACA, AB-FUBINACA, and ∆9-THC increased 
anxiety-like behaviours, none of the compounds produced conditioned place aversion. 
Several potential factors underlying this observation were identified in the discussion 
of Chapter 4 (Section 4.5). It is possible that adolescent rats are less sensitive to the 
aversive effects of cannabinoids, such that memory deficits could impair acquisition of 
conditioned place aversion, or that lower doses might have been more effective in 
producing aversion. Clearly, future studies that explore repeated synthetic 
cannabinoid administration using a more extensive dose range, or with adult rats for 
comparison with adolescents, could be enlightening. 
 Of the residual effects, of particular note were the lasting recognition memory 
impairments produced by AB-PINACA, AB-FUBINACA, and ∆9-THC. These 
impairments were most severe for AB-FUBINACA. Similar lasting residual impairment 
to recognition memory has been previously reported for CP-55,940 and ∆9-THC 
(O'Shea, McGregor, & Mallet, 2006; O'Shea et al., 2004; Quinn et al., 2008). Given 
that the hippocampus and perirhinal cortex have been implicated in recognition 
memory impairment (Barker & Warburton, 2011; Bussey, Muir, & Aggleton, 1999; 
Norman & Eacott, 2004), histological assessment of these areas following sub-chronic 
synthetic cannabinoid administration could prove instructive. Subtle 
endocannabinoid modulation was also observed following AB-PINACA and ∆9-THC 
administration, which may point to long-term homeostatic compensations in the 
endocannabinoid system resulting from the repeated use synthetic cannabinoids. 
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 Interestingly, neither AB-PINACA nor AB-FUBINACA produced any obvious 
toxicity in any animal. No animals showed signs of distress between drug doses (e.g. 
abnormal gait, coat abnormalities, seizures, etc). Indeed, no clear toxicity was 
observed in any animal tested with any of the compounds in Chapters 2, 3 or 4. This is 
in stark contrast with numerous case studies that detail toxicity arising from synthetic 
cannabinoid use (Adams et al., 2017; Bhanushali et al., 2012; Hermanns-Clausen et al., 
2012; Khan et al., 2016; Lapoint et al., 2011; Louh & Freeman, 2014; Mir et al., 2011; 
Schneir, Cullen, & Ly, 2011; Schwartz et al., 2015; Thornton et al., 2013). In the case of 
the biotelemetry assessments, the dosing regimen was selected to minimise potential 
harms (e.g. the ascending dose sequence), which may have reduced the likelihood of 
observing any toxic outcomes. Conversely, human case studies may reflect only the 
most severe cases following admittance to emergency departments, representing only 
a tiny and perhaps atypical minority of synthetic cannabinoid users in the community. 
It is also possible that animal toxicity is very transient, much as is reported in case 
studies where adverse symptoms in users often quickly dissipate, or are too subtle and 
hidden to observe (for example, minor kidney damage). Accordingly, to deconvolute 
these potential factors, an experiment examining kidney damage and neurotoxicity 
following AB-PINACA and AB-FUBINACA is presently ongoing in our laboratory. 
 In sum, the study presented in Chapter 4: 
1. Confirmed acute ∆9-THC-like cannabimimetic effects following 
administration of AB-PINACA and AB-FUBINACA. 
2. Identified lasting recognition memory deficits with all three cannabinoid 
pre-treatments, which were most severe for AB-FUBINACA pre-treated rats. 
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3. Identified subtle modulations in cytokine and endocannabinoid 
concentrations that persisted in the long-term (at least six weeks) and varied across 
treatments. The functional significance of these is unclear at present. 
4. Noted that the psychopharmacological effects of dose-matched ∆9-THC, AB-
PINACA, and AB-FUBINACA were largely similar, and that contrary to human case-
reports, no obvious toxicity was observed. A follow-up study concerning acute and 
residual toxic effects in brain and kidney may clarify this issue. 
 
6.2.4 Chapter 5: Urinary cannabinoid levels during nabiximols (Sativex®)-
medicated inpatient cannabis withdrawal 
 Chapter 5 presented an analysis of cannabinoid concentrations in the plasma 
and urine of twenty-two inpatients being treated for cannabis dependence and 
associated withdrawal symptoms with nabiximols (Sativex™) substitution therapy. 
Nabiximols comprises a 1:1 mix of ∆9-THC and CBD, and is administered as a buccal 
spray. The dosing protocol used in the study involved relatively strong doses (peaking 
at daily doses of 86.4 mg THC and 80 mg CBD on days 2 and 3) before tapering to 
zero by treatment day 7. Blood was taken from patients on treatment days 1, 3 and 7, 
while urine was sampled daily (days 1 – 9). Importantly, the study was conducted in an 
inpatient setting to obviate unsanctioned use of cannabis or other drugs.  
 The primary outcome of Chapter 5 was the clinical validation of a cannabinoid 
urinalysis method involving β-glucuronidase hydrolysis. Plasma and urinary CBD, ∆9-
THC, THC-COOH, and 11-OH-THC concentrations closely reflected the dosing 
schedule and could be used to monitor or titrate dosing. Indeed, the results indicated 
that doses of nabiximols could probably be reduced slightly in future studies, given 
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that concentrations of ∆9-THC and 11-OH-THC rose above initial values during the 
early stages of treatment (Appendix 2; Fig. S1). Additionally, the placebo group was 
useful for characterising elimination periods of analytes following heavy cannabis use, 
although elimination of ∆9-THC and THC-COOH was incomplete over the course of 
the study. Blood and urine concentrations of these ∆9-THC and THC-COOH remained 
above detection thresholds at the end of the inpatient period (day 9).  
A key finding was that plasma concentrations of CBD and ∆9-THC were 
positively and strongly correlated with urinary concentrations, providing evidence that 
cannabinoid urinalysis is a valid alternative to assays involving whole blood or plasma 
analysis. However, plasma and urinary ∆9-THC metabolite concentrations were less 
well correlated, and it was necessary to adjust results and interpose a urinary delay of 
one day in order to achieve a moderate urine-plasma correlation for THC-COOH. 
Nevertheless, urine sampling is potentially advantageous as it is less invasive than 
blood sampling, and urinary concentrations of all analytes were greater than in plasma 
following hydrolysis. Urinary sampling could enable cannabinoid analysis using less 
sensitive instruments, or analysis of trace cannabinoids where plasma concentrations 
fall below limits of detection or quantitation.  
The value of β-glucuronidase hydrolysis was also empirically demonstrated 
over several days of treatment. Without hydrolysis, concentrations of 11-OH-THC and 
∆9-THC often fell below limits of detection or quantitation. THC-COOH and CBD 
concentrations were also much lower. Given that synthetic cannabinoids are also 
extensively glucuronidated (Chapter 3; Andersson et al., 2016; Diao et al., 2016; 
Kavanagh, Grigoryev, & Krupina, 2017), this technique may prove valuable for 
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boosting detection of synthetic cannabinoids in urine. This possibility is discussed 
further in Section 6.3.3. 
 In sum, the study presented in Chapter 5: 
 1. Clinically validated a cannabinoid urinalysis method for monitoring 
nabiximols treatment of cannabis dependent inpatients 
2. Validated cannabinoid urinalysis as an alternative to blood analysis in a 
clinical population and inpatient setting, which could be used in conjunction with the 
methodology presented in Chapter 3 for the monitoring of patients undergoing 
synthetic cannabinoid withdrawal (see Section 6.3.3). 
3. Demonstrated that urinary cannabinoid concentrations (following 
hydrolysis) are substantially greater than plasma concentrations, such that urine may 
be useful for detecting trace concentrations of cannabinoids that may otherwise go 
undetected. 
4. Demonstrated the utility of β-glucuronidase hydrolysis for increasing analyte 
concentrations, which may be a similarly useful technique to apply to detection and 
quantification of synthetic cannabinoids and their metabolites in urine.  
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6.3 Wider implications and future directions 
6.3.1 Potency and metabolism prediction based on molecular structure 
 The rate at which novel psychoactive substances are being detected by 
monitoring agencies has arguably outstripped the rate at which regulators, researchers 
and forensic chemists can respond meaningfully to their threat. Between 2009 and 
2015, 157 novel synthetic cannabinoids were detected in recreational products in 
Europe alone, in addition to 93 novel cathinones, 58 novel phenethylamines, and over 
100 novel compounds belonging to several other drug classes (EMCDDA, 2016). The 
delay between when a compound is first discovered in recreational products and when 
that compound is characterised pharmacologically creates a window during which 
many people may be exposed to a compound with unknown potency, metabolism, and 
toxicity. Therefore, tools for predicting these key attributes may be of vital 
importance. Predictive tools could help to ease the burden of testing large numbers of 
newly discovered compounds, allowing researchers to focus on the most recent or the 
most toxic discoveries. 
For example, it may be possible to use SARs to predict potency of novel 
synthetic cannabinoids. Based on the results presented in Chapter 2, pairs of 5-
fluoropentyl and N-pentyl synthetic cannabinoids appear to produce similar 
physiological effects in vivo, at least in terms of body temperature and heart rate. In 
future, researchers could prioritise screening only one compound in each pair, 
predicting that in vivo efficacy will be similar for the remaining compound. Similarly, a 
newly discovered indazole synthetic cannabinoid could be predicted to possess 
somewhat higher potency in vivo compared to its indole analogue. Of course, in cases 
where a particular compound becomes popular in recreational products, or when a 
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compound appears anomalously potent compared to predictions, it could be 
prioritised for confirmatory screening. 
 The rate at which researchers can characterise the metabolites of novel 
synthetic cannabinoids also appears to be much slower than the rate of emergence of 
novel compounds. Therefore, predictive tools for synthetic cannabinoid metabolism 
and identification of likely metabolites of a parent molecule may be of value. 
Fortunately, metabolic pathways have already been identified for a variety of synthetic 
cannabinoids, as described in Chapter 3 and the broader literature (Table 2). Similar 
to the SARs identified in Chapter 2, structure-metabolism relationships (SMRs) are of 
potential future utility in clinical and forensic settings. 
For example, the primary metabolic pathway for synthetic cannabinoids with 
an N-pentyl chain tends to be terminal hydroxylation of that chain (Table 2). 
Similarly, synthetic cannabinoids possessing a 5-fluoropentyl chain are usually 
oxidatively defluorinated, forming an identical metabolite to their non-fluorinated 
counterparts. It seems reasonable to predict that these metabolic patterns will 
continue for newly identified synthetic cannabinoids with N-pentyl or 5-fluoropentyl 
moieties. In this case, these compounds could be forensically identified (although not 
necessarily differentiated from each other) using 5-hydroxyl metabolites even before 
they are characterised via metabolic studies. 
Similarly, synthetic cannabinoids with ester moieties are de-esterified to 
carboxylic acid metabolites (Table 2). This transformation is generally the 
predominant metabolic pathway, such that these carboxylic acid metabolites are 
potentially useful forensic markers. A practical example of this metabolite prediction 
can be found in a recent study that identified an AMB-FUBINACA metabolite in 
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multiple blood and urine samples following a mass intoxication in New York City 
produced by a specific synthetic cannabinoid product (Adams et al., 2017). This study 
used the de-esterified carboxylic acid metabolite of AMB-FUBINACA as a forensic 
target. At the time, this metabolite had not been identified in the scientific literature, 
but similar de-esterified carboxylic acid metabolites were known for AMB and 5F-AMB 
(Andersson et al., 2016). In this way, SMR-based prediction of synthetic cannabinoid 
metabolism has the potential to speed detection of novel synthetic cannabinoids in 
forensic and clinical settings, providing important information regarding novel 
products associated with a distinctive and localised toxidrome. 
However, in some cases complex interactions between structural elements may 
increase the difficulty of metabolite prediction. For example, when a carboxamide 
group is present as a linker (as in CUMYL-PICA and 5F-CUMYL-PICA, as opposed to 
when it is also located terminally, as in AB-PINACA), it is only converted to the 
corresponding amide in some circumstances (Figure 1). In Chapter 3, no such 
transformation was observed for CUMYL-PICA or 5F-CUMYL-PICA, nor has it been 
reported for AB-PINACA or AB-FUBINACA (Takayama et al., 2014; Thomsen et al., 
2014). However this transformation is observed for SDB-006, ADB-FUBINACA, and 
MDMB-FUBINACA (Diao et al., 2017; Kavanagh et al., 2017). Given that SDB-006 only 
differs from CUMYL-PICA in “bulky” group composition, it seems that an interaction 
between the bulky group and catabolic enzymes determines whether this specific 
transformation occurs on the linking group. This is presently difficult to predict for 
novel compounds, but further research into the metabolism of carboxamide synthetic 
cannabinoids may reveal the mechanism behind this selective pattern of metabolic 
transformation. 
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Figure 1. In some cases, metabolic biotransformations can be difficult to predict. The 
linking carboxamide group in (B) SDB-006 and (D) MDMB-FUBINACA is converted to 
the corresponding amide, but this transformation is not observed for (A) CUMYL-PICA 
and (C) AB-PINACA. Interactions between the “bulky” group and catabolic enzymes 
presumably produce this pattern. See text for further detail. 
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By combining the present understanding of SARs and SMRs, a simplified 
testing scheme can be proposed, as detailed in Figure 2. Under this scheme, rather 
than testing each and every novel compound, new compounds are first compared to  
existing ones. If SARs or SMRs are unknown, the new compound can be prioritised for 
testing. Otherwise, they are assumed to possess properties based on established SARs 
or SMRs and other more structurally unique or popular compounds can be prioritised.  
Further research that characterises or clarifies additional SARs/SMRs may be valuable 
in this regard. In cases where a compound is unexpectedly potent, has many 
thermolytic degradants, or presents potentially hazardous drug-drug interactions, it 
may require additional consideration.  
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Figure 2. Flow chart for the streamlined testing of novel synthetic cannabinoids. Under 
this scheme, the properties of new synthetic cannabinoids are predicted based on shared 
structural elements, unless discrepant data becomes available or a compound becomes 
particularly popular. Potential influences of thermolytic degradation or polydrug use 
may also require consideration. 
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 6.3.2 Implications of chronic use of synthetic cannabinoids 
 The long-term effects of synthetic cannabinoid administration identified in 
Chapter 4 persisted well beyond the period of drug administration. Therefore, 
treatment of chronic synthetic cannabinoid users may require consideration of lasting 
residual effects in addition to acute symptomology. Drug treatment and rehabilitation 
programs may need to consider the possibility that a person may test negative on drug 
screens (i.e. synthetic cannabinoids undetectable in blood or urine), yet suffer from 
lasting impairment or emotional disturbances resulting from prior use. 
Neuropsychological assessments during the treatment and rehabilitation of chronic 
synthetic cannabinoid users might determine whether cognitive function slowly 
improves with abstinence. 
 This of course assumes that the results of Chapter 4 will translate from rodent 
models into human populations. In this regard, it is worth noting that a very recent 
study found impaired executive function (assessed via the Stroop test, n-back task, and 
free-recall memory tasks) in synthetic cannabinoid users relative to both recreational 
cannabis users and non-users (Cohen et al., 2017). Thus, the preclinical findings 
concerning impaired recognition memory in Chapter 4 may well be an accurate 
portrait of impairments in human users. 
 A consistent finding from Chapter 4 and the wider cannabinoid literature is 
that adolescents are more vulnerable than adults to deleterious cognitive effects 
produced by synthetic cannabinoids and ∆9-THC. For example, chronic CP-55,940 or 
∆9-THC administration during adolescence impairs social interaction and working 
memory to a greater degree than in rats treated during adulthood (O'Shea et al., 2004; 
Quinn et al., 2008). Future studies that specifically include adolescent human 
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 populations of synthetic cannabinoid users could be particularly valuable in assessing 
potential long-term adverse effects of these drugs at this vulnerable developmental 
stage. 
 Additionally, the inhibitory effect of AB-FUBINACA (and possibly other 
synthetic cannabinoids) on pro-inflammatory cytokines uncovered in Chapter 4 is 
worthy of further investigation. In particular, it would be interesting to verify whether 
these cytokines are also elevated acutely, or whether a lasting downregulation is 
subsequent to acute upregulation following repeated drug administration. If cytokines 
are modulated acutely, then antagonist studies could quickly reveal systems (e.g. CB2 
receptors) that mediate the effect. Alternatively, transgenic rodents, specifically CB1 
and CB2 receptor null mice, could be utilised to elucidate underlying mechanisms.  
Future studies are also necessary to elucidate why AB-FUBINACA inhibited 
pro-inflammatory cytokines but the closely related AB-PINACA did not. AB-PINACA 
contains an N-pentyl chain in place of the N-(4-fluorobenzyl) group in AB-
FUBINACA. It may be interesting to determine if this relationship holds for similar 
pairings, like AMB (which contains an N-pentyl group) and AMB-FUBINACA (which is 
identical except for an N-(4-fluorobenzyl) group). 
Finally, it is important to acknowledge that some synthetic cannabinoids may 
have potential therapeutic applications. While the synthetic cannabinoids featured in 
this thesis were assessed with a view towards uncovering toxicological or deleterious 
effects, many early synthetic cannabinoids were developed by pharmaceutical 
companies as potential therapeutics. For example, the “CP” series of synthetic 
cannabinoids (e.g. CP-55,940) were developed by Pfizer as novel analgesics. The same 
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 is true for both AB-PINACA and AB-FUBINACA, which were both developed by Pfizer 
and patented in 2009 (Buchler et al., 2009).  
Moving forward, cytokine modulation and CB2 receptor agonist effects have 
potential applications in areas where modulation of inflammatory or immune 
responses is desired. In addition to their action on CB1 receptors, AB-PINACA and AB-
FUBINACA are also potent CB2 receptor agonists (Chapter 2). If these compounds 
were modified to reduce their CB1 receptor affinity (and consequently their 
hypothermic and psychoactive effects), they could feasibly find use as therapeutic 
agents with reduced potential for recreational use. As reviewed in Chapter 1, some 
studies have shown therapeutic applications for CB2 receptor selective agonists O-
3853 and O-1966 in decreasing cerebral infarction following ischemic stroke in mice 
(Zhang et al., 2007). The clinical efficacy of other CB2 receptor agonists in treatment 
of neuropathic pain is also being assessed, although in many cases encouraging 
preclinical findings have failed to translate into human populations (Dhopeshwarkar & 
Mackie, 2014). Continuing research using a variety of recently discovered CB2 agonists, 
ranging from bicyclic-based molecular structures to indole-,  benzimidazole-, γ-
carboline-, and 1,4-diazepane carboxamide-based structures may fuel further research 
and development into CB2 receptor mediated therapeutics (Nevalainen, 2014). 
 
 
6.3.3 Agonist substitution therapy for synthetic cannabinoid withdrawal 
 Chronic synthetic cannabinoid users report a withdrawal syndrome similar to, 
but exceeding, that of cannabis withdrawal. For example, consider a user’s self-report 
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 of synthetic cannabinoid withdrawal that occurred after the user’s daily supply was 
severed due to international travel: 
 
“That week was a nightmare. During the first 3 days I didn't sleep at all, I had 
insane cravings … and I thought I was going to die, on the 4th night I fell asleep 
from exhaustion only to dream about Spice for 2 hours and wake up with cold 
sweat and difficulty breathing, the worst thing was that I had nausea all the time, 
even when I made myself throw up the nausea would return in about 10 minutes 
to make me miserable, I couldn't talk to anyone … I wasn't sure I could hold down 
my food anyway. By the 5th day I was smoking some random flowers I picked 
outside in a bong … just to try and satisfy my cravings. Today I'm 2 months clean, 
I feel better than I did 2 months ago but still quite [bad]. I still get panic attacks, 
my stomach is still [expletive] and so I can't go outside my house, I still can't 
sleep properly and I still dream about Spice and crave it 24/7…” (MikePatton, 
2011) 
 
As reviewed in Section 1.5.4, specific treatments for synthetic cannabinoid 
dependence and withdrawal are limited and often non-existent. Users are generally 
forced to cease drug use without specific supportive medical interventions for 
withdrawal symptoms and craving. This may well increase the likelihood of relapse to 
synthetic cannabinoid use. As mentioned in earlier sections, agonist replacement 
therapy for synthetic cannabinoid withdrawal using nabiximols could be an efficacious 
intervention to assist with withdrawal and craving. However, before such efficacy can 
be assessed in clinical settings, basic monitoring techniques need to be established, 
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 such as the monitoring of synthetic cannabinoids, ∆9-THC, CBD, and metabolites in 
biological samples to allow tracking of treatment adherence and optimal dose 
titration. 
Chapter 5 primarily focused on urinalysis of phytocannabinoids and their 
metabolites in a clinical sample of treatment-seeking cannabis dependent users. 
However, synthetic cannabinoids could conceivably be analysed using a similar 
methodology. Certainly, synthetic cannabinoids can be measured in plasma, as was 
performed in Chapter 3, but for the same reasons that urinalysis is useful for 
monitoring agonist substitution therapy during cannabis withdrawal, urinalysis may 
be of use in monitoring synthetic cannabinoid withdrawal.  Both synthetic 
cannabinoids and phytocannabinoids tend to be metabolised similarly via extensive 
oxidations and glucuronidations (Chapters 4,  5; Andersson et al., 2016; Williams & 
Moffat, 1980; Wohlfarth et al., 2014), so it follows that similar analytical methods can 
be applied to each cannabinoid class. Moreover, urinary synthetic cannabinoid 
metabolites have been detected in prior studies (Grigoryev et al., 2012, 2013), and 
some urinary metabolites of CUMYL-PICA and 5F-CUMYL-PICA were elucidated in 
Chapter 3.  
 Therefore, by combining techniques from Chapters 3 and 5, and from other 
relevant publications (Table 2), urinary and plasma synthetic cannabinoid and 
phytocannabinoid concentrations could be measured accurately and simultaneously, 
allowing verification of the cessation of synthetic cannabinoid use while monitoring 
and titrating concentrations of agonist replacement (i.e. ∆9-THC and CBD). 
Application of glucuronidase hydrolysis using β-glucuronidase could also boost 
concentrations of key phase I metabolites for synthetic cannabinoids and 
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 phytocannabinoids simultaneously, potentially improving detection rates (Chapters 4, 
5; Wohlfarth et al., 2015). 
 Direct verification of the efficacy of agonist substitution therapy for synthetic 
cannabinoid dependence and withdrawal may be an important future step for 
progression of this area of research and treatment. A clinical validation focusing on 
synthetic cannabinoid dependent treatment-seeking inpatients would be an ideal 
follow-up study to the work presented in this thesis. 
 
  
Chapter 6 193
 6.4 Conclusions 
 The research presented in this thesis commenced with the characterisation of 
in vivo physiological effects (hypothermia and bradycardia) of a wide range of 
contemporary synthetic cannabinoids in rats. For the first time, in vivo dose-response 
relationships of these compounds were elucidated and doses ranges with functional 
effects were established for future experiments. The use of radiotelemetric probes in 
rats enabled collection of body temperature and heart rate data in real time without 
experimental artefacts associated with the stress of animal handling. This work 
enabled the identification of in vivo SARs, which may be used to predict potency of 
future novel synthetic cannabinoids. 
 The thesis then moved to the characterisation of metabolic pathways for the 
recently detected synthetic cannabinoids CUMYL-PICA and 5F-CUMYL-PICA. This 
study identified dozens of metabolites, providing useful analytical targets for future 
forensic and scientific investigations. Additionally, this study found that in vitro 
predictions of kinetic parameters, which have also been reported to be rapid for 
several other synthetic cannabinoids, overestimated the rate of actual in vivo 
elimination in rats. In vivo synthetic cannabinoid sequestration in adipose tissue and 
blood protein binding may be important factors to consider when interpreting in vitro 
synthetic cannabinoid kinetic data. 
 The long-term effects of repeated administration of AB-PINACA, AB-
FUBINACA and ∆9-THC were then assessed in adolescent rats. This revealed several 
well-established acute impacts (e.g. increases in anxiety-like behaviours, decreases in 
locomotor activity), but also revealed subtle long-term alterations to several 
biochemical and cognitive systems. AB-PINACA and ∆9-THC modulated 
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 endocannabinoid concentrations while AB-FUBINACA decreased concentrations of 
some pro-inflammatory cytokines. AB-PINACA, AB-FUBINACA, and ∆9-THC all 
produced recognition memory impairments in the long-term, which were notably 
more severe for AB-FUBINACA. These previously uncharacterised effects may have 
important implications in confronting the sequelae of synthetic cannabinoid use in 
humans, who may exhibit cognitive impairment even after cessation of drug use.  
 Finally, this thesis validated a cannabinoid urinalysis in a population of 
cannabis-dependent treatment-seeking users. It was found that cannabinoid urinalysis 
can substitute for plasma analysis, potentially reducing the invasiveness of sampling in 
future studies. Moreover, cannabinoid concentrations were greater in urine than in 
plasma, suggesting that cannabinoid urinalysis could be used for analysis of trace 
cannabinoids that may go undetected in blood. The utility of β-glucuronidase 
hydrolysis for increasing concentrations of phase I metabolites was demonstrated, 
which may also be useful for the analysis of urinary synthetic cannabinoid metabolites.  
 The work presented in this thesis culminated in the establishment of SARs and 
SMRs for the prediction of the pharmacological properties and metabolism of novel 
synthetic cannabinoids. It is hoped that a wider understanding of these processes will 
enable streamlined assessment of novel synthetic cannabinoids, allowing researchers, 
clinicians, and forensic chemists to prioritise the compounds that require the most 
attention from a public health perspective. Additionally, implications of chronic 
synthetic cannabinoid use for human users were identified - in particular, the lasting 
cognitive impact of synthetic cannabinoid use should be taken into account when 
designing treatments for chronic synthetic cannabinoid users. Finally, analytical 
methods were established for the future clinical validation of agonist replacement 
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 therapy using ∆9-THC and CBD for the treatment of synthetic cannabinoid 
withdrawal. Future studies are required to directly establish the efficacy of this 
approach, but it is hoped that the research presented here will constitute a first step 
towards the effective treatment of synthetic cannabinoid dependent populations.  
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)LJXUH60HDQPD[LPDOGHFUHDVHLQERG\WHPSHUDWXUH6(0IRUDOOFRPSRXQGVWHVWHGLQ
YLYR



7KH ERG\ WHPSHUDWXUH GDWD IRU LQGLYLGXDO UDWV GXULQJ WKH  K SRVWGUXJ ZDV H[DPLQHG WR
GHWHUPLQH WKH ORZHVW ERG\ WHPSHUDWXUH GDWDSRLQW UHFRUGHG 7KH ERG\ WHPSHUDWXUH UHFRUGHG
GXULQJ YHKLFOH WUHDWPHQW DW WKDW VDPH WLPH SRLQWZDV WKHQ XVHG WR FDOFXODWH ERG\ WHPSHUDWXUH
FKDQJH7KLVZDVDYHUDJHGDFURVVDOOWKHUDWVUHFHLYLQJWKHVDPHGUXJDQGGRVHWRSURGXFH)LJXUH
,QWKLV)LJXUHFRPSRXQGVDUHSUHVHQWHGLQSDLUVZLWKWKHQRQIOXRULQDWHGFRPSRXQGH[WHQGLQJ
XSZDUGVDQGWKHIOXRULQDWHGFRPSRXQGGRZQZDUGV
7KHGDWDREWDLQHGIRUPD[LPDOERG\WHPSHUDWXUHFKDQJHZHUHFRPSDUHGEHWZHHQHDFKGUXJSDLU
XVLQJWZRZD\PL[HGPRGHO$129$VZLWKGUXJWUHDWPHQWDVWKHEHWZHHQVXEMHFWVIDFWRUDQG
GRVHDVWKHZLWKLQVXEMHFWVIDFWRU7KHUHZDVDVLJQLILFDQWPDLQHIIHFWRIGRVHIRUHYHU\GUXJSDLU
DOOS+RZHYHUWKHUHZDVQRPDLQHIIHFWRIGUXJWUHDWPHQWIRUDQ\GUXJSDLUDOOS!
%RQIHUURQLFRQWUDVWVFRPSDULQJHDFKGRVH IRUHDFKSDLU HJ -:+PJNJ±$0
PJNJUHYHDOHGQRVLJQLILFDQWGLIIHUHQFHIRUDQ\GUXJSDLUDWDQ\GRVHDOOS!
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)LJXUH60HDQDUHDXQGHUWKHFXUYH$8&6(0IRUERG\WHPSHUDWXUHIRUHDFKFRPSRXQG
DQGGRVHWHVWHGH[SUHVVHGDVDSHUFHQWDJHRIWKDWREWDLQHGZLWK3%


7KHPHDQDUHDXQGHUHDFKGUXJWUHDWPHQWFXUYHUHODWLYHWREDVHOLQHXQGHUYHKLFOHWUHDWPHQWZDV
FDOFXODWHGDQGQRUPDOL]HGUHODWLYHWRWKHKLJKHVWREVHUYHG$8&REWDLQHGZLWKPJNJ3%
&RPSRXQGVDUHSUHVHQWHGLQSDLUVZLWKWKHIOXRULQDWHGFRPSRXQGH[WHQGLQJGRZQZDUGV
7KHVH DUHDV ZHUH FDOFXODWHG YLD WKH WUDSH]RLGDO PHWKRG %ULHIO\ IRU DQ\ WLPH SRLQW WKH DUHD
EHWZHHQEDVHOLQHGDWDSRLQWV %W DQGGUXJWUHDWPHQWGDWDSRLQWV 'W DQG WKHQH[W WLPHSRLQWV
%WDQG'WIRUPVDWUDSH]RLGWKHDUHDRIZKLFKFDQEHFDOFXODWHGYLDWKHIRUPXOD
ܣݎ݁ܽ ൌ ሺܤ௧ െ ܦ௧ሻ ൅ ሺܤ௧ାଵ െ ܦ௧ାଵሻʹ 
7KHVHDUHDVZHUHVXPPHGIURPWKHWLPHRILQMHFWLRQWRKRXUVSRVWLQMHFWLRQ
7KHPHDQDUHDIRUERG\WHPSHUDWXUHEHWZHHQEDVHOLQHDQGGUXJWUHDWPHQWIRUHDFKGUXJSDLUZDV
DQDO\VHG XVLQJ WZRZD\PL[HGPRGHO$129$VZLWK GUXJWUHDWPHQW DV WKH EHWZHHQ VXEMHFWV
IDFWRUDQGGRVHDVWKHZLWKLQVXEMHFWVIDFWRU6LPLODUO\WRSHDNERG\WHPSHUDWXUHGHFUHDVHWKHUH
ZDV D VLJQLILFDQWPDLQ HIIHFW RIGRVH IRU HYHU\GUXJSDLU DOO S +RZHYHU WKHUHZDVQR
PDLQ HIIHFW RI GUXJWUHDWPHQW IRU DQ\ GUXJ SDLU DOO S !  %RQIHUURQL FRQWUDVWV FRPSDULQJ
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HDFKGRVHIRUHDFKSDLUUHYHDOHGQRVLJQLILFDQWGLIIHUHQFHIRUDQ\GUXJSDLUDWDQ\GRVHDOOS!

7KHVHUHVXOWVVXJJHVWWKDWWHUPLQDOIOXRULQDWLRQKDVQRRYHUDOOHIIHFWRQSRWHQF\DVPHDVXUHGE\
ERG\ WHPSHUDWXUH +RZHYHU LW UHPDLQV SRVVLEOH WKDW RWKHU PHDVXUHV HJ FRJQLWLYH IXQFWLRQ
DQDOJHVLD DSSHWLWH PD\ EH GLIIHUHQWLDOO\ DIIHFWHG DV D IXQFWLRQ RI IOXRULQDWLRQ )XUWKHU
EHKDYLRXUDOWHVWLQJLVQHFHVVDU\WRFODULI\WKLVLVVXH
5DQNLQJ WKH$8&V IRU DOO HLJKW FRPSRXQGV DW WKH PJNJ GRVH JDYH WKH IROORZLQJ UDQNLQJ
3%!)3% -:+!$0!$3,&$ 676 ;/5!85

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±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AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, 
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Figure S33: AUC for hypothermic and bradycardic effects of 5F-AMB and MDMB-
FUBINACA (p. S37). 
 
Figure S34: 24 Hour body temperature data for MDMB-FUBINACA (p. S38). 
 
Figure S35: AUC for body temperature of 5F-AMB and MDMB-FUBINACA following 
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 T
able S1.  IU
PA
C
 nam
es, C
A
S num
bers, and selected references for valinate- and tert-leucinate-derived indole and indazole synthetic 
cannabinoids. 
 
IU
PA
C
 
C
A
S 
N
otified to 
EM
C
D
D
A
 
R
efs 
5F-A
M
B
-PIC
A
  
(10) 
m
ethyl (S)-2-(1-(5-fluoropentyl)-1H
-indole-3-
carboxam
ido)-3-m
ethylbutanoate 
1616253-26-9 
(racem
ate) 
5 D
ecem
ber 
2014, H
ungary 
1-3 
5F-M
D
M
B
-PIC
A
 
(11) 
m
ethyl (S)-2-(1-(5-fluoropentyl)-1H
-indole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
- 
- 
4 
5F-A
M
B
-PIN
A
C
A
 
(12) 
m
ethyl (S)-2-(1-(5-fluoropentyl)-1H
-indazole-3-
carboxam
ido)-3-m
ethylbutanoate 
1715016-74-2 
(racem
ate)  
1801552-03-3 
(S-enantiom
er) 
18 June 2014, 
H
ungary 
2-9 
5F-M
D
M
B
-
PIN
A
C
A
 (13) 
m
ethyl (S)-2-(1-(5-fluoropentyl)-1H
-indazole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
1715016-75-3 
(racem
ate) 
1838134-16-9 
(R-enantiom
er) 
- 
2, 4, 10 
A
M
B
-FU
B
IC
A
  
(14) 
m
ethyl (S)-2-(1-(4-fluorobenzyl)-1H
-indole-3-
carboxam
ido)-3-m
ethylbutanoate 
- 
- 
- 
M
D
M
B
-FU
B
IC
A
 
(15) 
m
ethyl (S)-2-(1-(4-fluorobenzyl)-1H
-indole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
- 
 
- 
A
M
B
-FU
B
IN
A
C
A
 
(16) 
m
ethyl (S)-2-(1-(4-fluorobenzyl)-1H
-indazole-3-
carboxam
ido)-3-m
ethylbutanoate 
1715016-76-4 
(racem
ate) 
- 
2, 4 
M
D
M
B
-
FU
B
IN
A
C
A
 ( 17) 
m
ethyl (S)-2-(1-(4-fluorobenzyl)-1H
-indazole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
1715016-77-5 
(racem
ate) 
O
ctober 2014, 
R
ussian 
Federation
a 
2-4 
A
M
B
-C
H
M
IC
A
  
(18) 
m
ethyl (S)-2-(1-(cyclohexylm
ethyl)-1H
-indole-3-
carboxam
ido)-3-m
ethylbutanoate 
- 
- 
- 
M
D
M
B
-C
H
M
IC
A
 
(19) 
m
ethyl (S)-2-(1-( cyclohexylm
ethyl)-1H
-indole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
1863065-84-2 
(racem
ate) 
12 Septem
ber 
2014, H
ungary
b 
2-3, 7, 11 
A
M
B
-C
H
M
IN
A
C
A
 
(20) 
m
ethyl (S)-2-(1-( cyclohexylm
ethyl)-1H
-indazole-
3-carboxam
ido)-3-m
ethylbutanoate 
1863066-03-8 
(racem
ate) 
- 
2 
M
D
M
B
-
C
H
M
IN
A
C
A
 (21) 
m
ethyl (S)-2-(1-(cyclohexylm
ethyl)-1H
-indazole-
3-carboxam
ido)-3,3-dim
ethylbutanoate 
1715016-78-6 
(racem
ate) 
- 
2, 4 
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1185888-32-7 
(S-enantiom
er) 
A
M
B
-PIC
A
  
(22) 
m
ethyl (S)-2-(1-(pentyl)-1H
-indole-3-
carboxam
ido)-3-m
ethylbutanoate 
- 
- 
- 
M
D
M
B
-PIC
A
 (23) 
m
ethyl (S)-2-(1-(pentyl)-1H
-indole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
- 
- 
- 
A
M
B
-PIN
A
C
A
 
(24) 
m
ethyl (S)-2-(1-(pentyl)-1H
-indazole-3-
carboxam
ido)-3-m
ethylbutanoate 
1863066-06-1 
(racem
ate) 
1890250-13-1 
(S-enantiom
er) 
10 D
ecem
ber 
2014, Sw
eden 
2-3, 9 
M
D
M
B
-PIN
A
C
A
 
(25) 
m
ethyl (S)-2-(1-(pentyl)-1H
-indazole-3-
carboxam
ido)-3,3-dim
ethylbutanoate 
- 
 
- 
aA
n alert w
as issued after the EM
C
D
D
A
 identified m
edia reports of tw
o outbreaks of serious adverse events associated w
ith 
consum
ption of M
D
M
B
-FU
B
IN
A
C
A
.  
bTw
o alerts w
ere issued in D
ecem
ber 2014 after the A
ustrian national focal point reported 7 non-fatal intoxications associated w
ith 
use of a product called ‘B
onzai citrus’ and/or ‘B
onzai W
inter B
oost’ (w
hich allegedly contained M
D
M
B
-C
H
M
IC
A
) and after the 
Sw
edish national focal point reported 4 deaths and 6 non-fatal intoxications associated w
ith the use of M
D
M
B
-C
H
M
IC
A
 that 
occurred betw
een Septem
ber and N
ovem
ber 2014. 
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 Figure S1. 1H
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C
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 Figure S2. 13C
 N
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M
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 Figure S3. 1H
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 Figure S4. 13C
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 spectrum
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 Figure S5. 1H
 N
M
R
 spectrum
 (300 M
H
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D
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M
B
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 Figure S6. 13C
 N
M
R
 spectrum
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H
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D
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l3 , 300 K
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M
B
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 Figure S7. 1H
 N
M
R
 spectrum
 (300 M
H
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D
M
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 Figure S8. 13C
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 spectrum
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H
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 Figure S9. 1H
 N
M
R
 spectrum
 (300 M
H
z, C
D
C
l3 , 300 K
) of A
M
B
-FU
B
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A
 (14). 
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 Figure S10. 13C
 N
M
R
 spectrum
 (75 M
H
z, C
D
C
l3 , 300 K
) of A
M
B
-FU
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IC
A
 (14). 
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 Figure S11. 1H
 N
M
R
 spectrum
 (300 M
H
z, C
D
C
l3 , 300 K
) of M
D
M
B
-FU
B
IC
A
 (15). 
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 Figure S12. 13C
 N
M
R
 spectrum
 (75 M
H
z, C
D
C
l3 , 300 K
) of M
D
M
B
-FU
B
IC
A
 (15). 
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 Figure S13. 1H
 N
M
R
 spectrum
 (300 M
H
z, C
D
C
l3 , 300 K
) of A
M
B
-FU
B
IN
A
C
A
 (16). 
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 Figure S14. 13C
 N
M
R
 spectrum
 (75 M
H
z, C
D
C
l3 , 300 K
) of A
M
B
-FU
B
IN
A
C
A
 (16). 
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 Figure S15. 1H
 N
M
R
 spectrum
 (300 M
H
z, C
D
C
l3 , 300 K
) of M
D
M
B
-FU
B
IN
A
C
A
 (17). 
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 Figure S16. 13C
 N
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R
 spectrum
 (75 M
H
z, C
D
C
l3 , 300 K
) of M
D
M
B
-FU
B
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A
C
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 (17). 
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 Figure S17. 1H
 N
M
R
 spectrum
 (300 M
H
z, C
D
C
l3 , 300 K
) of A
M
B
-C
H
M
IC
A
 (18). 
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 Figure S18. 13C
 N
M
R
 spectrum
 (75 M
H
z, C
D
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Figure S33. Mean normalized area under the vehicle baseline curve (AUC ± SEM) for (a) body 
temperature and (b) heart rate over the 6 hours immediately following doses of 0.1, 0.3, and 1 
mg/kg MDMB-FUBINACA and 5F-AMB. MDMB-FUBINACA produced a larger hypothermic 
response compared to 5F-AMB  at 0.3 and 1 mg/kg. * P < .05. 
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 Figure S34. B
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Figure S35. Mean area under the vehicle-vehicle baseline curve (AUC ± SEM) for body 
temperature for (a) 5F-AMB (3 mg/kg) and (b) MDMB-FUBINACA (1 mg/kg), following 
pretreatment with vehicle, rimonabant (CB1 antagonist, 3 mg/kg), or SR144528 (CB2 antagonist, 
3 mg/kg). The area was significantly reduced for both 5F-AMB and MDMB-FUBINACA by 
rimonabant but not SR144528. * p < .05 compared to vehicle. 
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Table S1 Method validation and quantification parameters for urinary cannabinoid analysis 
using LC-MS/MS 
          Parameter CBD THC THC-COOH 11-OH-THC 
          Internal Standard CBD-d3 THC-d3 THC-COOH-d9 11-OH-THC-d3 
          LOQ (ng/mL) 1.0 1.0 125 10.0 
          LOD (ng/mL) 0.5 0.5 20.0 1.0 
          Linearity 
                 Quantification range (ng/mL) 1-1000 1-100 125-5000 10-500 
             r2  .999 .996 .992 .993 
          Accuracy (%) 
                Low QC 102 96.4 95.0 92.7 
            High QC 91.0 100 99.1 90.0 
          Precision %RSD, intra-day (n=3) 
                Low QC 7.8 3.5 6.3 2.0 
            High QC 6.2 6.7 6.4 9.8 
          Precision %RSD, inter-day (n=3) 
                Low QC 7.3 3.0 5.4 9.9 
            High QC 1.3 9.2 6.6 11.5 
          LOQ Limit of quantification, LOD limit of detection, RSD relative standard deviation. QCs were  
samples spiked to concentrations of each analyte at the top (high QC) and bottom (low QC) of  
the quantification range  
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Fig. S1. Day 1 adjusted cannabidiol (CBD), Δ9-tetrahydrocannabinol (THC), 11-nor-9-
carboxy-THC (THC-COOH) and 11-hydroxy-THC (11-OH-THC) in plasma and urine of 
placebo (n=11) and nabiximols (n=11) treated patients. Shaded area indicates the tapered 
nabiximols dosing schedule, note that samples were taken in the morning and that day 1 
samples were taken before the first nabiximols or placebo dose. * nabiximols urine 
significantly different from day 1 levels; # nabiximols plasma significantly different from day 
1 levels; † placebo urine significantly different from day 1 levels; ‡ placebo plasma 
significantly different from day 1 levels.  
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